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The pathogenesis of chronic lymphocytic leukaemia (CLL) is inextricably linked 
to the tumour microenvironment, a ‘sanctuary site’ wherein CLL cells engage B 
cell receptor (BCR) signalling and form interactions with non-malignant 
accessory cells. ‘Crosstalk’ within the microenvironment elicits survival and 
proliferative signals that facilitate therapy resistance and outgrowth of 
malignant clones. Therefore, eliminating the signals that orchestrate these 
events is crucial to prevent disease progression. The advent of small molecule 
inhibitors targeting BCR signalling components have proven clinically effective. 
However, these treatments are not always available (or indeed suitable) for 
every patient and drug resistance has been reported. Thus, there is a need to 
identify novel treatment strategies that have the ability to improve CLL patient 
outcomes.  
Several oncogenic pathways emanating from microenvironment communication 
converge upon the PI3K-AKT-mTOR axis in CLL cells. Surprisingly, little is known 
about the functional importance of mTOR signalling in CLL pathogenesis. mTOR 
exists in two protein complexes, mTORC1 and mTORC2, which coordinate 
growth, survival and proliferation signals downstream of PI3K-AKT signalling. 
Despite encouraging preclinical data with the mTORC1-selective inhibitor 
rapamycin, the rapalogue everolimus only had modest anti-tumour activity in a 
CLL clinical trial. Clinical activity of mTORC1-selective inhibitors is limited due 
to abrogation of a S6K-mediated negative feedback loop modulating mTORC2 
activity, which results in activation of AKT-mediated pro-survival signalling. The 
development of ‘second generation’ ATP-competitive mTOR inhibitors avoid 
these issues by inhibiting both mTORC1 and mTORC2. As such, this investigation 
sought to address whether inhibition of mTORC1/2 with the dual mTOR kinase 
inhibitor AZD8055 would represent an effective therapeutic approach for CLL.  
The data presented in this thesis demonstrates that mTOR is an effector of BCR 
crosslinking in vitro, playing a role in the coordination cellular behaviours 
emanating from BCR engagement (BCR-PI3K-AKT) in CLL cells. mTORC1 (4E-
BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) activities were effectively targeted 
by the ‘second generation’ mTOR kinase inhibitor AZD8055 (and its clinical 
analogue AZD2014), which disabled pro-survival feedback loops associated with 
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rapamycin treatment. At the molecular level, AZD8055 inhibited mTOR signalling 
downstream of F(ab’)2-mediated BCR ligation and stromal cell (NT-L/CD40L) co-
cultures, highlighting the ability of this compound to disrupt various 
microenvironmental stimuli. On a functional level, AZD8055 elicited potent 
inhibitory effects on CLL growth and proliferation, but only moderately affected 
cell viability in vitro. For these reasons, AZD8055 anti-tumour activity appeared 
to be limited as a monotherapy. A synergistic combination of AZD8055 and the 
BTK inhibitor ibrutinib promoted cell death, augmented cell size contraction and 
arrested proliferation, indicating that simultaneous inhibition of mTOR kinase 
and BTK in CLL cells evokes anti-tumour activity via targeted inhibition of 
multiple oncogenic pathways and at different levels within the same pathway.  
In search of a mechanism of action, we proposed that the combination 
treatment conferred a more robust inhibition of AKT kinase activity. Among 
other methods, AKT promotes cell survival and proliferation via negative 
regulation of FOXO transcription factors. FOXOs are widely regarded as tumour 
suppressors, which regulate several cellular behaviours including cell cycle 
arrest and apoptosis. Our data demonstrated that BCR crosslinking negatively 
regulated FOXO1 (the most abundant FOXO in CLL cells) by AKT-dependent 
FOXO1T24 phosphorylation, subsequent nuclear export and reduced DNA-binding 
activity. Like normal B cells, these data suggested that FOXO1 inactivation was 
an important consequence of BCR engagement in CLL cells. For this reason, we 
hypothesised that inhibiting BCR signalling would unleash FOXO1 tumour 
suppressor activity. We showed that elimination of BCR signal transduction, via 
AZD8055 or ibrutinib mono- and combination therapy, re-engaged FOXO1 DNA-
binding activity by preventing FOXO1 nuclear export, which suggested that 
FOXO1 was an effector of BCR signalling inhibition that mediated treatment 
response. Through pharmacological FOXO1 inhibition, we demonstrated that 
FOXO1 activity contributed to the cytotoxic, cell-contracting and cytostatic 
effects of the combination treatment, indicating that FOXO1 functions as a 
tumour suppressor in this context.  
In conclusion, these studies highlight the potential for AZD8055/2014 as a drug 
partner for novel combination strategies in the treatment of CLL. Indeed, these 
data suggest that AZD8055/2014 could be combined with agents targeting 
IV 
 
proximal BCR signalling components (BTK, PI3K or SYK) or perhaps pro-survival 
signals (BCL2). Furthermore, reactivation of FOXO1 activity or other inactivated 
‘genetically intact’ tumour suppressors (via targeted inhibition of negative 
regulators) represents an interesting treatment strategy for CLL. Collectively, 
these data provide valuable information that has the potential to inform 
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1.1 Chronic lymphocytic leukaemia (CLL)  
A compartmentalised malignancy of mature B lymphocytes, CLL is characterised 
by the relentless expansion and progressive infiltration of CD19+ CD23+ CD5+ B 
cells in the blood, bone marrow (BM) and secondary lymphoid organs (SLOs) (1, 
2). CLL is a heterogenous disease with contrasting (and somewhat polarising) 
prognoses (2, 3). Clinical behaviour (and disease progression) largely mirrors the 
underlying complexity in disease biology (3), which informs prognosis and 
therapeutic strategies. For example, immunoglobulin heavy-chain variable 
region (IGVH) gene mutational status (4, 5), genetic aberrations (6) and the 
ectopic/aberrant expression of signalling molecules (7, 8) are implicated in CLL 
pathogenesis and represent essential markers for prognostic stratification. 
Disease progression is inextricably linked to the tumour microenvironment 
(TME), a ‘sanctuary site’ wherein CLL cells engage B cell receptor (BCR) 
signalling and form interactions with non-malignant accessory cells, which 
promotes cell survival and proliferation (9). The emergence of BCR signalling 
inhibitors (10) and BH3 mimetics (11) have demonstrated excellent clinical 
activity and transformed the treatment landscape for CLL patients. However, 
these treatments are not always available (or indeed suitable) for every patient 
(12) and drug resistance has been reported (13, 14). These observations have 
focussed the spotlight on the identification of novel treatment strategies that 
have the ability to improve progression-free (PFS) and overall survival (OS) rates 
for CLL patients with unmet clinical needs.  
1.1.1 CLL epidemiology 
With an ‘age-standardised’ incidence of 5.7/100,000 persons each year in the 
United Kingdom (UK) (15), CLL is frequently described as the most common adult 
leukaemia in the ‘Western’ world (2). In reference to the UK’s epidemiological 
data, there are ~3,800 newly diagnosed cases annually, which accounts for ~1 % 
of all new cancer diagnoses. CLL is predominantly a disease of the elderly, with 
the highest incidence in people aged between 85-89 (41 % of newly diagnosed 
cases are in people over the age of 75) (15). However, younger patients (≤55 




time to treatment compared to their ‘elderly’ (>55 years; median 67 years) 
counterparts, perhaps underscored by a disproportionate expression of poor 
prognostic disease biomarkers (16). Incidence rates are higher in males 
(7.9/100,000) than females (3.9/100,000), with 63 % of all newly diagnosed UK 
cases recorded in male patients (data correct as of 2017) (15). Interestingly, 
analysis of clinical data revealed that female CLL patients had reduced 
incidence of poor prognostic features, improved treatment responses and better 
survival rates (17). However, the reason(s) for this is not understood. The age-
adjusted mortality rate stands at 1/100,000 persons each year in the UK, 
accounting for less than 1 % (947 deaths recorded) of all cancer deaths in 2017 
(15). CLL patients with at least one family member (blood relative) with CLL, so-
called ‘familial CLL’, is observed in ~5-10 % of all CLL patients (18), indicating 
the presence of heritable and/or common genetic risk factors (2). Indeed, blood 
relatives of patients with CLL are 8.5-times more susceptible of developing the 
disease (and elevated risk of developing other lymphoma subtypes) (2, 19). CLL 
is less common (5 to 10-times) in people of Asian descent compared to those 
with mainly European backgrounds (20), further demonstrating the presence of a 
genetic predisposition and/or aetiology for this malignancy. Of note, incidence 
rates in Asian people are unaffected by emigration to ‘higher-risk’ countries, 
indicating geographical factors are less important in this context (20). Finally, 
environmental factors have been associated with elevated risk of CLL including 
exposure to ‘agent orange’ (21), insecticides (22) and certain hair dyes (23).  
1.1.2 CLL diagnosis, staging and prognostic stratification  
This section refers to the International Workshop on CLL (iwCLL) guidelines (12, 
24), which outlines ‘agreed’ recommendations for clinical diagnosis, staging and 
prognostic stratification.  
1.1.2.1 Diagnosis 
CLL is diagnosed via blood tests (including morphology) and immunophenotyping. 
An assessment of molecular genetics (cytogenetics and/or TP53 mutation) or 
IGVH mutational status may assist prognosis, but is less commonly adopted for 
diagnostic purposes (24). A diagnosis requires the detection of ≥5 x109/L B cells 




Morphologically (as assessed by blood smears), CLL cells are typically small in 
size with a large ‘dense’ nucleus and only a thin rim of cytoplasm (2). The 
presence of ‘smudge cells’ on blood smears is another feature associated with 
CLL (12, 24). A joint project by the European Research Initiative on CLL (ERIC) 
and European Society for Clinical Cell Analysis (ESCCA) recently established a 
consensus list of “required” and “recommended” disease markers for the 
diagnosis of CLL (adopted by the iwCLL guidelines). The immunophenotype 
CD19+, CD5+, CD20+, CD23+, κ and λ immunoglobulin (Ig) light (L) chains was 
“required” for CLL diagnosis, while a number of other markers (CD79b+, CD81+ 
and ROR1+, for example) were “recommended” for borderline cases (12, 25).  
1.1.2.2 Staging 
The Rai (26) and Binet (27) staging systems are widely adopted methods for 
stratifying CLL patients according to disease ‘risk’ following physical 
examination (2). The Rai staging system is largely based on lymphocytosis, which 
originally classified CLL patients into 5 stages (0 to IV) representing increased 
disease risk (26). This was later reduced to 3 ‘risk categories’ that combined the 
5 stages (28). In contrast, the Binet staging system is predominantly based on 
the number of affected lymphoid tissue groups (and the presence of anaemia or 
thrombocytopenia), which separates CLL patients into 3 stages (A, B and C) (27). 
CLL patients with Binet stage A disease are typically less likely to require 
therapy, whereas those with stage B or C (poorest prognosis) are associated with 
negative outcomes with reduced PFS and OS (Table 1.1) (Holroyd and MCCaig; 
personal communication). The Rai system is mainly applied in the United States, 
while the Binet system is more widely used in Europe (2, 29).  
Stage Clinical features Median life expectancy* 
A No anaemia/thrombocytopenia 
<3 lymphoid regions enlarged 
13 years 
B No anaemia/thrombocytopenia 
≥3 lymphoid regions enlarged 
8 years 
C Anaemia (<10 g/dL) 
Thrombocytopenia (<100 x109/L) 
2 years 





1.1.2.3 Prognostic stratification 
As a product of their time, the Rai and Binet staging systems do not account for 
the multitude of subsequently identified disease biomarkers that offer 
invaluable prognostic information (irrespective of clinical stage) (12). As such, 
various ‘prognostic scores’ have been devised (30-32). The CLL International 
Prognostic Index (CLL-IPI) combines clinical staging with essential prognostic 
variables (genetic and biological) to identify CLL patients in need of therapy 
(33). It uses a weighted system that ‘grades’ prognostic factors, including 
del(17p)/TP53 mutation, IGHV mutational status, serum β2-microglobulin (B2M), 
clinical stage and patient age (12), to generate a ‘risk score’ (Table 1.2). Risk 
scores ultimately translate into 4 ‘risk categories/prognostic subgroups’ that 
inform treatment decisions (33).  
Variable Adverse factor Grading 
del(17p)/TP53 Deleted/mutated 4 
IGHV mutational status Unmutated 2 
B2M (mg/L) >3.5 2 
Clinical stage Binet B/C or Rai I-IV 1 
Age >65 years 1 
 Risk score                            0-10 
Table 1.2 - The CLL-IPI (33, 233) 
 
The CLL-IPI has been validated in recent studies (34-36). Recently, Delgado et 
al. devised (and validated) an alternative prognostic model comprising only 2 
prognostic biomarkers (IGVH mutational status and cytogenetics), simplifying the 
CLL-IPI (37).  
1.1.3 CLL prognostic factors  
Over the last 30 years, our understanding of CLL pathophysiology has 
fundamentally changed with the identification of several prognostic biomarkers 
associated with disease progression. These factors have transformed risk 
stratification and underpinned management strategies for CLL patients (expertly 




1.1.3.1 IGVH mutational status and ‘stereotyped’ B cell receptors (BCRs) 
In normal B cell maturation, somatic hypermutation (SHM) of IGVH and Ig light-
chain variable region (IGVL) genes is essential for the generation of affinity-
enhanced antibodies in support of the adaptive immune response (39). In an 
early study, Fais et al. reported that approximately 51.6 % of CLL patients 
(cohort of 64 IgM+ patients) had undergone SHM of their IGVH genes (mutated; M-
CLL), whereas the others encoded IGVH genes corresponding to the most similar 
germline sequence (unmutated; U-CLL) (40). Two groups subsequently showed 
that these entities were implicated in disease progression and clinical outcome, 
with U-CLL patients (≥98 % sequence homology with germline) experiencing a 
more aggressive disease and poorer prognosis (irrespective of Binet stage) than 
their M-CLL counterparts (<98 % sequence homology with germline) (4, 5). These 
data were independently confirmed in a separate patient cohort (41) and 
recently validated (42). The presence or absence SHM in IGVH genes largely 
reflects the stage of maturation of the parent B cell (2), with U-CLL deriving 
from a pre-germinal centre (GC) CD5+ B cell (absent SHM) and M-CLL originating 
from a CD5+ B cell that has progressed through the GC reaction (Figure 1.1) (38, 
43).  
Analysis of IGVH gene sequences from 7,424 CLL patients revealed that nearly 
one-third of patients (30.4 %) displayed ‘quasi-identical’ or ‘stereotyped’ BCRs 
(44), i.e. the biased and, in some instances, identical usage of heavy 
complementarity determining region 3 (HCDR3) sequences (45). This study was 
preceded by several reports identifying BCR similarities among CLL patients (46-
50), which collectively supported the theory of a common antigenic determinant 
in CLL development (51). The identification of 19 “major” stereotyped subsets 
highlighted the clinical significance of BCR stereotypy in CLL disease course (44). 
Subsets #1 and #8, for example, typically confer poor prognosis and are 
associated with the expression of U-CLL. In contrast, subset #4 patients express 
M-CLL and experience a relatively indolent disease. Intriguingly, subset #2 have 
an aggressive disease course irrespective of IGVH mutational status, expressing 
both U-CLL (40 %) and M-CLL (60 %) (44, 50, 52). The significance of BCR 
stereotypy in CLL pathogenesis and clinical behaviour has been comprehensively 






Figure 1.1 - BCR maturation and cellular origins of CLL cells (modified from (45))   
 
1.1.3.2 Cytogenetic alterations and ‘complex karyotype’ 
In their seminal study, Döhner et al. identified a spectrum of cytogenetic 
aberrations and assessed their clinical implications in a cohort of 325 CLL 
patients. These data showed that 82 % of CLL patients harboured cytogenetic 
alterations (52 % possessed at least one alteration) at the time of enrolment 
(median 15 months from diagnosis), with the majority possessing at least one of 
the following aberrations: 13q14 (del(13q)), 11q22-q23 (del(11q)) and 17p13 
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cytogenetic aberration (55 % of patients), which conferred an indolent disease 
course (median survival time of 133 months) (2, 6). The deleted region in 
del(13q) encompasses the loci encoding the microRNAs (miRNAs) mir15A and 
mir16A (53), which negatively regulate the anti-apoptotic protein B cell 
lymphoma 2 (BCL2) (54). BCL2 overexpression as a consequence of 
mir15A/mir16A deletion favours survival in CLL cells (54-56), as evidenced by 
clinical activity of BH3 mimetic venetoclax in CLL clinical studies (38, 57, 58). 
Del(11q) is the next commonest cytogenetic aberration (~18 % of patients), 
which is associated with a more aggressive disease course (median survival time 
of 79 months) (6). Within this deleted region contains the locus encoding the cell 
cycle checkpoint kinase (DNA damage response) ataxia telangiectasia mutated 
(ATM) (59). Del(17p) occurs in ~7 % of patients and confers the poorest prognosis 
with rapid disease progression (median survival time of 32 months) (6). The 
deleted region encodes the tumour suppressor p53 (TP53) (60), which exhibits 
poor response to chemo- and chemoimmunotherapy (61, 62). Finally, trisomy 12 
appears in ~16 % of patients and confers a more favourable prognosis (median 
survival time of 114 months), akin to ‘normal karyotype’ (median survival time 
of 111 months) (6). In recent years, the hierarchical classification system 
formulated by Döhner et al. (6) was reassessed in a cohort of 1,585 CLL patients 
(63). These results are summarised in Table 1.3.  
 
(6) (63) 









Del(13q) 178 (55) 133 624 (39) not reached 
Del(11q) 58 (18) 79 187 (12) 7 
Trisomy 12 53 (16) 114 205 (13) 11 
Del(17p) 23 (7) 32 193 (12) 5 
Table 1.3 - Incidence of cytogenetic aberrations (including median survival): a comparison 
of the (6) and (63) studies 
 
 
Over the last 10 years, studies have implicated ‘complex karyotype’ (CK), 
defined as the presence of ≥3 chromosome alterations (64), as an independent 
prognostic marker associated with poor prognosis and inferior survival (65). 




was present in ~15% of patients and significantly associated with U-CLL, 
del(17p)/TP53 mutations and advanced clinical stage (66, 67). In line with these 
findings, CK was associated with worse response and/or disease progression 
(refractoriness) in patients treated with chemoimmunotherapy (68, 69) or 
targeted therapies (70, 71). More recently, the 5-year follow-up of single-agent 
ibrutinib-treated relapsed/refractory (R/R) CLL patients (phase 1b/2 study; 
#NCT01105247) showed that patients with CK had shorter PFS and OS compared 
with those without (72). Finally, Baliakas et al. recently postulated that CK is a 
heterogenous group with contrasting clinical behaviour. For example CK with ≥5 
chromosomal aberrations had poor prognosis irrespective of other prognostic 
factors, whereas patients with CK and trisomy 12 conferred a relatively indolent 
disease course (73).  
1.1.3.3 Recurrent somatic mutations and ‘clonal evolution’ 
Whole-exome sequencing (WES) and whole-genome sequencing (WGS) studies 
have transformed our understanding of the genomic landscape of CLL (74, 75). 
Building upon previous studies (76, 77), Landau et al. evaluated the genomic 
complexity and/or heterogeneity in 538 CLL patients from different “non-
overlapping” cohorts (76, 78). WES of this cohort identified >40 mutated CLL 
‘driver’ genes, which were implicated in a small group of signalling pathways: 
Notch signalling (NOTCH1, FBXW7), inflammatory pathways (MYD88, SAMHD1, 
RIPK1), BCR signalling (ITPKB), MAPK/ERK pathway (KRAS, NRAS, BRAF, MAP2K1), 
MYC-related (FBXW7), DNA damage/cell cycle regulation (ATM, TP53, POT1, 
CHEK2), chromatin modelling (ZMYM3, CHD2) and RNA processing (XPO1, SF3B1). 
From a clinical point of view, TP53 and SF3B1 inactivating mutations were found 
to confer reduced PFS and OS in 278 pre-treatment CLL patients derived from 
the CLL8 cohort (74). Furthermore, patients with TP53 mutations had reduced 
PFS and OS in response to chemotherapy (79, 80) and chemoimmunotherapy 
(81), based on the results of the CLL4 and CLL8 studies, respectively. 
Fortunately, BCR signalling inhibitors (ibrutinib, idelalisib) or BH3-mimetics 
(venetoclax) have improved PFS and OS for CLL patients with TP53 aberrations 
(82-84), highlighting the efficacy of these treatment strategies.   
‘Clonal evolution’, i.e. the adaptive ability of cancers to ‘selection pressures’ 




presence and/or complexity of sub-clonal ‘driver’ mutations (85). Studies have 
shown that intra-tumoral driver mutations (e.g. TP53, del(17p), IKZF3) are 
associated with progressive disease, treatment refractoriness and resistance (74, 
86), driven by the ‘intrinsic’ or ‘extrinsic’ expansion of sub-clones (85). Indeed, 
the evolution of subpopulations has posed numerous challenges for CLL 
therapeutic strategies (74, 76), particularly targeted therapies (87-89). Landau 
et al. assessed clonal evolution in 59 R/R patients from the CLL8 cohort. In 
almost all cases (~96 %), WES analysis uncovered treatment-induced ‘clonal 
shifts’ among patients before (pre-treatment) and after relapse. Interestingly, 
the relapsed clone was detectable in ~30 % of the pre-treatment samples, some 
of which already possessed a driver mutation (e.g. TP53) (74). More recently, 
reports have highlighted the ability of ibrutinib to confer a selective pressure 
that facilitates sub-clonal evolution (87-89). Burger et al. demonstrated that 
ibrutinib-resistant clones were present prior to ibrutinib initiation (87), while 
Landau et al. identified early clonal shifts (within first 12 months ibrutinib 
therapy; prior to relapse) that were associated with aggressive disease (88). In 
line with these findings, Ahn et al. identified ibrutinib-resistance mutations (BTK 
(C481S) or PLCG2 (R665W)) in single-agent ibrutinib-treated CLL patients up-to 
15 months before disease progression (89). These studies highlighted the highly 
dynamic nature of CLL, which manifests as a collection of genetically divergent 
diseases (subclones) within an individual patient that undergo ‘clonal 
competition’ influenced by selection pressures (90).  
1.1.3.4 Other prognostic parameters 
Damle et al. demonstrated that CD38 expression levels were elevated among U-
CLL patients and was associated with unfavourable treatment and/or disease 
outcome (4). A succession of studies subsequently confirmed CD38 as an 
important CLL prognostic marker with adverse disease progression, reduced 
treatment responsiveness and shorter OS (91-94). On a functional level, CD38 is 
a transmembrane glycoprotein that promotes CLL cell proliferation and survival 
via ligation to the adhesion molecule CD31. CD31 is expressed by non-malignant 
accessory cells of the CLL-TME (95).  
High expression of ζ chain associated protein kinase 70 (ZAP-70) is considered a 




and dismal survival (7, 8). Functionally, ectopic expression of ZAP-70 potentiates 
BCR signalling in CLL cells (96), analogous to its role in downstream of the T cell 
receptor (TCR) in T cells (97). 
1.1.4 Treatment of CLL  
The management of CLL has undergone significant changes in recent years with 
the advent of novel targeted therapies against signalling kinases and anti-
apoptotic proteins (98). This section outlines CLL management strategies and 
recent results from clinical trials. The treatment of CLL was recently reviewed in 
(12) and (98).  
1.1.4.1 CLL treatment algorithm 
With reference to ‘first line’ (1L) treatment options, several parameters are 
considered: clinical stage, patient symptoms, patient ‘fitness’ and genetic risk 
(TP53 mutational status). CLL patients with advanced (Binet stage C) or active 
disease will require some form of therapy (12). The 1L CLL treatment algorithm 





Fitness IGVH mut (M/U) Therapy 




Irrelevant Irrelevant Irrelevant None 
Active 
disease or 
Binet C or  
Rai III-IV 
Yes Irrelevant Irrelevant 
Ibrutinib/Acalabrutinib or 
Venetoclax + Obinutuzumab or 
Idelalisib + Rituximab 
No 
Go go 
M FCR (BR >65 years) or ibrutinib or Venetoclax + Obinutuzumab 
U Ibrutinib or FCR (BR >65 years) or Venetoclax + Obinutuzumab 
Slow go 
M 
Venetoclax + Obinutuzumab or 
Chlorambucil + Obinutuzumab or 
Ibrutinib/Acalabrutinib 
U 
Venetoclax + Obinutuzumab or 
Ibrutinib/Acalabrutinib or 
Chlorambucil + Obinutuzumab  




Fitness: patients in good physical condition (Go go) or those with impaired physical condition (Slow 
go). Updated treatment options are highlighted in red and refer to recent EMA approval of 




For many years, the alkylating agent chlorambucil remained the ‘go-to’ 1L 
treatment option for CLL patients (99). This was ultimately reassessed following 
the arrival of the purine analogue fludarabine (12, 100). Fludarabine 
demonstrated significantly higher complete response (CR) rates in previously 
untreated CLL patients compared to those who received chlorambucil (20 % and 
4 %, respectively) (101). Ensuing preclinical studies showed that combining 
fludarabine with the alkylating agent cyclophosphamide potentiated cytotoxicity 
in CLL patient samples (102), which subsequently enhanced overall response 
(OR) rates compared to single-agent fludarabine in phase II clinical trials 
(fludarabine-cyclophosphamide; FC) (103, 104). Later, randomised trials 
(including the UK LRF- and German CLL Study Group (GCLLSG) CLL4 trials) 
confirmed the superiority of FC over fludarabine monotherapy as 1L treatment, 
evoking higher OR/CR rates and improved PFS (61, 105, 106). Off the back of 
these studies, the foundations for new management strategies that incorporated 
anti-CD20 monoclonal antibodies (mAbs), such as rituximab (62) and 
obinutuzumab (107), were established.  
1.1.4.3 Chemoimmunotherapy 
The CD20 antigen has proved to be an effective target in the treatment of B cell 
malignancies, particularly in combination with chemotherapeutic agents (108). 
Single-agent rituximab was shown to have clinical activity in CLL patients, but 
was less efficacious compared to other B cell leukaemia (109, 110). Building 
upon promising preclinical (111) and phase II clinical data (112), the influential 
phase III GCLLSG CLL8 trial demonstrated that combining rituximab with FC had 
superior clinical activity as 1L treatment than FC alone (fludarabine-
cyclophosphamide-rituximab; FCR), with CR rates of 44.5 % and 22.9 %, 
respectively (62). Updated results from the CLL8 trial (median follow-up of 5.9 
years) revealed that patients receiving FCR had improved median PFS (56.8 
months vs. 32.9 months) and median OS (not reached vs. 86 months) compared 




enhanced PFS and OS in M-CLL patients, whereas U-CLL patients responded 
poorly. Inferior PFS and OS were associated with M-CLL patients harbouring 
del(17p), while those with favourable cytogenetic aberrations (del(13q) and 
trisomy 12) had better outcomes (113). Comparable results were obtained in a 
separate study of FCR vs FC in previously untreated CLL patients (median follow-
up of 12.8 years) from the MD Anderson Cancer Center (114). As such, FCR 
remains 1L therapy for physically ‘fit’ symptomatic CLL patients without TP53 
aberrations (12).  
Combining the alkylating agent bendamustine with rituximab (bendamustine-
rituximab; BR) similarly showed favourable response rates in R/R CLL patients 
(115) and as 1L therapy (116). In the proceeding phase III GCLLSG CLL10 trial, BR 
was compared to FCR in previously untreated physically ‘fit’ CLL patients with 
del(17p). Patients treated with FCR had a superior median PFS compared to 
those on the BR regimen (55.2 months vs. 41.7 months, respectively; median 
follow-up of 37.1 moths). However, FCR elicited more adverse and/or toxic 
effects, particularly in the over 65 age group (117). As a result, FCR remained 
standard 1L therapy for CLL patients, but BR was ‘green-lit’ as an alternative for 
physically ‘fit’ elderly patients (12).   
In preclinical studies, the anti-CD20 mAb obinutuzumab (GA101) demonstrated 
enhanced anti-cancer activity compared to rituximab in ex vivo CLL cells. 
Importantly, obinutuzumab augmented the cytotoxic effect of chlorambucil in 
combination (118). A subsequent phase I trial of single-agent obinutuzumab 
showed encouraging OR rates of 43 % in pre-treated R/R CLL patients (119). 
After phase II trials assessing the combination of rituximab with chlorambucil 
(120, 121), the phase III GCLLSG CLL11 trial compared obinutuzumab-
chlorambucil and rituximab-chlorambucil combination regimens with single-
agent chlorambucil in previously untreated CLL patients with underlying 
conditions. Here, obinutuzumab-chlorambucil extended PFS compared to 
rituximab-chlorambucil or chlorambucil alone (median PFS of 26.7 vs. 16.3 vs. 
11.1 months, respectively). Furthermore, obinutuzumab-chlorambucil resulted in 
superior CR rates than rituximab-chlorambucil (20.7 % vs. 7 %, respectively) 
(107). Obinutuzumab-chlorambucil is approved for 1L therapy in physically 




1.1.4.4 BCR signalling inhibitors  
BCR signalling is a central pathway in CLL pathogenesis (reviewed in (45, 122)). 
The advent of small-molecule BCR signalling inhibitors, such as ibrutinib and 
idelalisib, revolutionised the treatment landscape for CLL patients (and among 
patients with other B cell malignancies), particularly those with high-risk disease 
(45). BCR inhibitors typically antagonise TME communication, induce CLL cell 
death and arrest proliferation (123). From a clinical point of view, BCR inhibitors 
promote transient lymphocytosis alongside a concomitant reduction in 
lymphadenopathy (abnormal lymph node (LN) size) (45, 124). BCR signalling is 
described in more detail in section 1.2.     
Ibrutinib (PCI-32765) is an irreversible, orally administrable Bruton’s tyrosine 
kinase (BTK) inhibitor that covalently binds to a cysteine residue (C481) in the 
BTK active site (108, 125). In preclinical studies, Herman et al. showed that 
ibrutinib inhibited CpG oligonucleotide-induced CLL cell proliferation, 
antagonised ‘microenvironmental’ stimuli (CD40L, BAFF, TNF-α, IL-6, IL-4 and 
fibronectin) and overcame stromal cell survival signals in vitro (126). The same 
group later confirmed these findings in vivo, demonstrating that ibrutinib 
inhibited BCR and NF-κB pathways and diminished proliferation of LN- and BM-
resident CLL cells (127). In a parallel study, ibrutinib downregulated BCR-
induced chemokines CCL3 and CCL4 (in vitro and in vivo) and inhibited 
chemotaxis towards CXCL12 and CXCL13 (128). Later, de Rooij et al. further 
reported that ibrutinib thwarted BCR- and chemokine-induced adhesion and 
chemotaxis (129). In the Eµ-TCL1 CLL-like mouse model, ibrutinib delayed 
disease progression and induced lymphocytosis (128), similar to the observations 
in early phase I clinical trials (130). An ensuing multicentre phase Ib/II trial of 
ibrutinib monotherapy in poor prognostic R/R CLL patients demonstrated durable 
response rates, with PFS of 75 % and OS of 83 % (26 months follow-up), 
irrespective of high-risk genomic features (131). These findings led to clinical 
approval of ibrutinib for R/R CLL patients (108). At 5 years follow-up, the OR 
rate for single agent ibrutinib in previously untreated and R/R CLL patients was 
89 %, with CR rates of 29 % for treatment naïve and 10 % for R/R patients. The 
PFS rate was 92 % in treatment naïve (median PFS not reached) and 44 % in R/R 
patients (median PFS of 51 months). Importantly, this trial demonstrated long 




patients and those harbouring del(11q) (72). The efficacy of ibrutinib 
monotherapy over immunotherapy (RESONATE (132)), chemotherapy (RESONATE-
2 (133)) or chemoimmunotherapy (Alliance (134)) has recently been established 
among high-risk R/R patients and as 1L therapy. Additionally, combining 
ibrutinib with BR showed robust response rates in R/R patients (HELIOS (135)). 
More recently, the highly selective irreversible BTK inhibitor acalabrutinib (ACP-
196; calquence) has evoked encouraging response rates in R/R CLL patients, 
including those with del(17p) (136). Acalabrutinib has shown less off-target 
activity compared to ibrutinib (137). At a median follow up of 41 months, 
median PFS had not been reached (138).   
Idelalisib (CAL-101) is a selective inhibitor of phosphoinositide 3’-kinase (PI3K) 
isoform p110δ (PI3Kδ) (12). In preclinical studies, idelalisib inhibited cellular 
migration towards CXCL12 and CXCL13, overcame survival signals downstream of 
BCR engagement and downregulated BCR ligation-induced AKT and ERK 
activation in primary CLL cells (139). Idelalisib was assessed as a monotherapy in 
a small cohort of severely high-risk R/R CLL patients, which demonstrated OR 
rates of 72 % and a median PFS of 15.8 months (83). In a phase III study, 
combining idelalisib with rituximab significantly extended OS (92 % vs. 80 % at 12 
months) and median PFS (not reached vs. 5.5 months) compared to rituximab 
(plus placebo) in R/R CLL patients (140). Consequently, idelalisib and rituximab 
combination was approved for patients with refractory CLL (108). Final results 
from this trial reaffirmed the superior efficacy of idelalisib and rituximab over 
rituximab alone in R/R patients. Importantly, long-term idelalisib treatment was 
shown to be effective and devoid of unexpected adverse effects (141). 
Nevertheless, idelalisib is generally reserved for patients lacking alternative 
therapeutic options since it harbours a riskier safety profile than other targeted 
agents (108).  
Other studies have investigated targeted inhibition of additional BCR signalling 
components including spleen tyrosine kinase (SYK) using R406 (142) or 
PRT318/P505-15 (143) and the SCR-family protein-tyrosine kinases using 
dasatinib (144, 145), which antagonised CLL survival/chemotaxis under 




Despite excellent clinical activity (45), emerging evidence demonstrates that 
CLL cells engage in elaborate feedback mechanisms to overcome targeted 
inhibition of BTK (87, 88, 146) and PI3K (147). Furthermore, acquired resistance 
mutations (due to continuous therapy) have been reported (148). Ibrutinib 
resistance is often associated with cysteine-to-serine mutations (C481S) 
affecting the ibrutinib-binding site within BTK (149) or gain-of-function 
mutations in phospholipase Cɣ2 (PLCG2) (150). As such, targeted therapies 
(monotherapies) are rarely curative (12), highlighting the need to identify 
alternative targets and/or design rational drug combinations. ARQ-531 is a 
potent, reversible BTK inhibitor that has been shown to abrogate BCR signalling 
in ibrutinib-resistant (BTK (C481S) and PLCG2 mutants) CLL cells (151). In a 
phase I clinical trial, ARQ-531 showed anti-cancer activity as a monotherapy 
against ibrutinib-resistant R/R patients (152). Furthermore, the non-covalent 
BTK inhibitor vecabrutinib (SNS-062), which targets wild-type and mutated 
(C481S) BTK, has also demonstrated clinical activity in an ongoing phase Ib/II 
clinical trial in high-risk CLL patients relapsing on ibrutinib treatment (153).  
1.1.4.5 BCL2 inhibitors: BH3 mimetics 
The BCL2 protein family are critical regulators of the intrinsic apoptosis 
pathway, which contain shared BCL2 homology (BH) domains (154). BCL2 
proteins are functionally grouped into 3 subfamilies: anti-apoptotic (BCL2, BCL-
xL and MCL-1), pro-apoptotic multidomain (BAX and BAK) and pro-apoptotic BH3-
only (BIM, NOXA and PUMA). The balance of pro- and anti-apoptotic proteins, 
and subsequent binding therein, govern cellular life or death decisions (108). 
BH3 mimetics functionally mimic (and displace) pro-apoptotic BH3-only proteins 
via binding to the hydrophobic groove on anti-apoptotic BCL2 proteins, which 
tips the balance to induce apoptosis (154). BCL2 overexpression is key aspect of 
aberrant CLL cell survival (155).  
Following the inception of BH3 mimetics ABT-737 and navitoclax (ABT-263) 
(156), targeted inhibition of BCL2 by venetoclax (ABT-199) showed remarkable 
clinical activity in CLL, particularly in high-risk patients with del(17p)/TP53 
mutations, fludarabine refractoriness and/or U-CLL (57, 58, 84, 157). 
Furthermore, venetoclax performed favourably in CLL patients whose disease 




Nevertheless, acquired resistance to venetoclax has been reported via 
mechanisms including treatment-induced clonal evolution (160) or Gly101Val 
mutations (14, 161), which is often a consequence of continuous targeted 
treatment (108). As such, the phase III MURANO trial was designed to assess 
fixed-duration venetoclax-rituximab treatment, which resulted in excellent PFS 
rates that were sustained 2-years after venetoclax discontinuation (162). The 
GCLLSG CLL14 trial of fixed-duration venetoclax-obinutuzumab combination 
compared to chlorabucil-obinutuzumab in patients with previously untreated CLL 
(and coexisting conditions) showed the superiority of venetoclax-obinutuzumab 
over chlorabucil-obinutuzumab, with an estimated PFS of 88.2 % and 64.1 %, 
respectively (median follow-up 28.1 months). Importantly, this benefit was 
similarly evident in high-risk patients with del(17p)/TP53 mutations and U-CLL 
(163). As a result of this study, venetoclax-obinutuzumab was approved for 1L 
therapy (108). Following promising preclinical data (164), clinical studies are 
now assessing venetoclax combined with ibrutinib, such as the CLARITY (165), 
CAPTIVATE (166) and NCT02756897 (167) trials, in treatment naïve or R/R 
patients. These studies are ongoing and producing encouraging results.  
1.1.5 The CLL microenvironment (CLL-TME) 
CLL pathogenesis (and disease progression) is inextricably linked to the 
‘supportive’ CLL-TME, a ‘sanctuary site’ wherein CLL cells engage B cell receptor 
(BCR) signalling and form interactions with non-malignant accessory cells (also 
referred to as the BM and LN microenvironment) (expertly reviewed in (9)). CLL 
cells continually traffic between the PB compartment and lymphoid ‘sanctuary 
sites’ (168), lured to- and retained within the permissive niche by tissue-derived 
secreted chemokine gradients (CXCL12, CXCL13) (169, 170) recognised by 
chemokine receptors (CXCR4, CXCR5) on CLL cells (9, 95, 171). Upon entering 
the lymphoid tissue, CLL cells interact with TME bystander cells and engage BCR 
signalling, which largely facilitate resistance to cytotoxic agents, promote 
‘active’ disease and facilitate expansion of malignant clones (2, 122). On 
provision of adequate help, activated CLL cells proliferate in aptly named 
microanatomical sites known as ‘proliferation centres’ (also referred to as 
‘psuedofollicles’, given their distinct nature over normal B cell follicles) (9), 
where they turnover up to 2 % of their leukaemic clone per day (172). 




depends on inter-patient heterogeneity (for example IGVH mutational status, 
CD38 levels, NOTCH1 mutations), which extends to intra-patient genetic 
variability between cellular subclones (173). Indeed, the CLL-TME (LN 
microenvironment) has emerged as a driver of ‘clonal evolution’, wherein 
proliferating LN-resident CLL cells acquire additional genetic aberrations 
(distinct from their PB counterparts) and facilitate expansion of ‘dominant’ 
subclones (90, 174). More recently, interactions between non-malignant cellular 
components (173), TME-induced immune dysfunction (175) and hypoxia-driven 
cellular metabolic reprogramming (176, 177) have emerged as ‘hot topics’ in 
CLL-TME investigations. Given the importance of the LN microenvironment in 
CLL pathogenesis, the identification and targeted inhibition of pathways 
mediating TME crosstalk has become a key therapeutic strategy (9). Until 
recently, however, our understanding of the intricate cellular communication 
networks was surprisingly limited. Recent studies have made inroads into the 
complexity of the CLL-TME (for example (178) and (179)), which promise to 
unlock insights into CLL disease biology and identify novel therapeutic targets. In 
this section, key cellular components and pathways implicated in TME crosstalk 
are discussed.  
1.1.5.1 Cellular components of the CLL-TME 
Two-way communication between CLL cells and T cells represent a critical 
interaction at the level of the CLL-TME (9). Activated (and autologous) CD4+ T 
cells have been shown to sustain CLL cell survival and promote proliferation in 
vitro and in vivo (180, 181). Along these lines, Os et al. demonstrated that CLL 
cells operate as effective antigen presenting cells (APCs), akin to normal B cells 
(181). Importantly, immunohistochemical analysis demonstrated that 
proliferating (Ki-67+) CLL cells colocalised with CD4+ T cells in CLL patient LN 
biopsies (182, 183). Within the CLL-TME, Ghia et al. showed that a proportion of 
T cells expressed the costimulatory molecule CD40 ligand (CD40L/CD154) (182). 
CD40L engagement with CD40-expressing CLL cells in vitro promotes 
survival/proliferation (184, 185) via upregulation of anti-apoptotic proteins (186) 
and activation of PI3K-AKT, MAPK/ERK and NF-κB pathways (187, 188). 
Additionally, CD40L-triggered CD40 engagement has been shown to ‘sensitise’ 
CLL cells to further BCR signalling (189), retain CLL cells within the TME (190), 




interactions via CLL cell-mediated extracellular vesicle shedding (178). Other T 
cell factors similarly promote CLL survival/proliferation including interleukin-4 
(IL-4) (192) and interleukin-21 (IL-21) (180). In CLL patients, the circulating T 
cell population is increased (193) and phenotypically skewed towards increased 
proportions of CD8+ T cells (194), which correlate with advanced disease stage 
(195) and worse outcome (194). This being said, T cells derived from CLL 
patients appear to be functionally flawed (196, 197), which is perhaps indicative 
of increased expression of the exhaustion marker programmed cell death protein 
1 (PD-1) (198) and immune-inhibitory molecule cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) (199).  
 



























Of note, other cellular constituents of the CLL-TME similarly form elaborate 
communication networks that facilitate CLL disease progression (reviewed in 
(9)). In their study, Nishio et al. demonstrated that monocyte-derived nurse-like 
cells (NLCs) sustain CLL cell survival via expression of tumour necrosis factor 
(TNF) molecules B cell activating factor (BAFF) and a proliferation-inducing 
ligand (APRIL), which induce NF-κB signalling and upregulated MCL-1 expression 
in CLL cells (200). Perhaps most prominently, NLCs attract and preserve CLL 
cells within the LN niche via the production of CXCL12 and CXCL13 (170, 201) 
and expression of CD31 (202). Furthermore, NLC antigens trigger BCR activation 
in CLL cells, which supports CLL survival (203, 204). Integrated within the 
architecture of secondary lymphoid organs, stromal cells constitutively secrete 
chemokines, such as CXCL12, which lure CLL cells to the tissues via engagement 
with its cognate receptor CXCR4 on CLL cells (205). Moreover, stromal cells 
provide survival signals that protect CLL cells from cytotoxic agents (9), perhaps 
via activation of NOTCH signalling (206).  
1.1.5.2 BCR activation in the CLL-TME 
In their seminal study, Herishanu et al. identified the LN microenvironment as a 
key compartment in CLL pathogenesis (207), wherein CLL cells engage (auto-) 
antigens that activate BCR signalling resulting in enhanced survival, increased 
proliferation and ultimately disease progression (9). Gene expression profiling 
(GEP) was performed on CLL cells derived simultaneously from the PB, LN and 
BM compartments, which revealed marked differential expression between the 
distinctive niches. Gene set enrichment analysis (GSEA) subsequently 
demonstrated an overrepresentation of BCR-related genes (including BCR-
dependent NF-κB and nuclear factor of activated T cells (NF-AT) gene sets) in 
LN-derived CLL cells, suggestive of BCR activation in the LN microenvironment. 
This was confirmed following the generation of a ‘CLL-BCR gene signature’ from 
BCR-stimulated CLL cells in vitro, which were enriched for genes upregulated in 
LN-resident CLL cells. Importantly, the ‘BCR gene signature’ was more highly 
expressed in LN-resident cells derived from U-CLL patients than those from M-
CLL patients. The LN microenvironment was identified as the primary site of cell 
proliferation, wherein U-CLL cells expressed higher levels of proliferation-
promoting genes E2F1 and C-MYC compared to M-CLL cells, which was associated 




activation of BCR signalling in the LN microenvironment in vivo and reflected the 
contrasting functional behaviours among U-CLL and M-CLL in the context of the 
CLL-TME.  
The importance and/or relevance of BCR signal transduction (and participation 
of BCR signalling components in diverse pathways) in CLL-TME crosstalk was 
subsequently confirmed by preclinical in vitro and in vivo studies assessing BCR 
kinase inhibitors ibrutinib (126, 128, 129) and idelalisib (139, 208). Alongside the 
‘BCR-dependent’ impact of BCR inhibitors on survival and proliferation, these 
reports highlighted many ‘on-target, BCR-independent’ effects on 
chemotaxis/adhesion (122), owing to the promiscuity of BCR kinases (BTK and 
PI3Kδ) embedded within chemokine- and integrin-signalling networks (209). As 
discussed, these studies paved the way for clinical trials, which have 
transformed management strategies for CLL patients (45).   
1.1.5.3 Mimicking the CLL-TME in vitro 
Mimicking the CLL-TME in vitro has enabled investigators to glean mechanistic 
insights into the interactions (and signalling networks therein) promoting CLL 
cell survival, proliferation and drug resistance within the CLL-TME. In a similar 
vein, modelling TME crosstalk has illuminated the mechanism(s) of action of 
therapeutic agents in preclinical studies, offering insights into potential clinical 
efficacy (reviewed in (210)).  
For the first time, Bernal et al. demonstrated that BCR crosslinking using soluble 
F(ab’)2 fragments enhanced CLL cell survival via activation of NF-κB signalling 
and upregulation of anti-apoptotic protein MCL-1 (211). Furthermore, Nédellec 
et al. showed that CLL patients responded differently to F(ab’)2 fragments, with 
the functional consequence of BCR signalling being associated with prognostic 
subgroups (for example, ZAP-70 status, IGVH mutational status and CD38 
expression) (212). Thus, in vitro BCR stimulation continues to reveal novel 
insights into CLL-TME crosstalk. However, in the absence of a standardised 
protocol, Rombout et al. showed that immobilised anti-IgM conferred a more 
robust and reliable BCR stimulus than soluble F(ab’)2 fragments, indicating the 




In early studies, co-culturing CLL cells with stromal cells (214) or CD40L (CD154)-
expressing fibroblasts (187) prevented ‘spontaneous’ CLL apoptosis and initiated 
pro-survival pathways (210). These findings indicated that CLL-TME interactions 
(particularly with the stroma and T cells), could be recapitulated and/or 
mimicked in vitro. In their study, Willimott et al. demonstrated that co-
culturing CLL cells on mouse fibroblast L cells (NT-L) improved CLL cell survival 
via a mechanism dependent upon physical cellular contact. Furthermore, NT-L 
cells stably transfected with CD40L supplemented with interleukin-4 (IL-4) 
induced CLL cell proliferation, whereas those cultured on NT-L remained largely 
quiescent (215). In a parallel study, the same group showed that culturing CLL 
cells on CD40L (+IL-4) induced expression of anti-apoptotic proteins MCL-1, BCL-
xL and survivin, which reduced fludarabine-induced CLL cell apoptosis (186). An 
additional study showed that CD40L (+IL-4)-stimulated CLL cells were less 
sensitive to the BH3 mimetic ABT-737 due to upregulation of anti-apoptotic BCL-
xL and BCL2-A1 (216). Therefore, mimicking CLL-TME interactions using the NT-L 
and CD40L (+IL-4) co-culture systems are applicable to 1) investigate underlying 
growth and survival pathways, and 2) address the cytotoxic and cytostatic ability 
of therapeutic agents to overcome signals emanating from the LN 
microenvironment. Later, Hamilton et al. compared the functional and 
phenotypic responses of different co-culture systems mimicking interactions in 
the CLL-TME: NT-L cells transfected with CD40L (T cell) or CD31 (NLC) and the 
endothelial cell line HMEC-1 (vascular system). Given the effect on cell survival 
and proliferation, the authors concluded that the CD40L/IL-4 system was 
perhaps best-placed to mimic the LN microenvironment (217).  
It is important to note that this is not an exhaustive list. The CLL-TME has 
modelled by several distinct systems including co-cultures with activated T cells 
(180, 218), novel 3D co-culture systems of the BM niche (219), chemotaxis assays 
(128), CpG oligonucleotide stimulations (220) and in vitro models of hypoxia 
(177). Although highly relevant in CLL disease biology, they go beyond the scope 
of this thesis.  
1.2  BCR signalling  
BCR signalling plays a pivotal role in the growth, survival and proliferation of 




summarised the evidence that implicates BCR signal transduction in CLL 
pathogenesis (45). For example, the clinical importance of IGVH mutation status 
(4, 5), existence of BCR stereotypy (44) and activation of the BCR in the CLL-TME 
(207) all point towards the notion that CLL disease progression depends upon 
BCR signal transduction (45). In this section, we overview BCR signalling in 
‘normal’ B cells (BCR structure, development and signal propagation) and discuss 
the mechanisms, heterogeneity and functional importance of BCR activation in 
CLL cells.  
1.2.1 BCR signalling in ‘normal’ B cells 
BCR signalling is a key pathway in ‘normal’ B cell survival and development 
(221). In an early study, Lam et al. showed that deletion of the BCR (via 
inducible ablation of IGVH gene) resulted in apoptosis of mature B cells (222), 
demonstrating that a functioning BCR is required for B cell survival. Alongside a 
subsequent report (223), these data inferred that the maintenance of mature 
(and resting) B cells required ‘tonic’ signals, i.e. sustained ‘low-level’ signals 
emanating from the BCR in the absence of antigen-binding (224). Although the 
molecular events following ‘antigenic’ BCR activation are well characterised 
(225), the signalling pathways transmitting ‘tonic’ signals (and the cooperation 
with antigen-induced BCR stimulation) remain ill-defined (226, 227). 
Nevertheless, the prevailing dogma indicates that B cells are reliant upon both 
‘tonic’ and antigen-mediated BCR activation (122).   
1.2.1.1 V(D)J recombination 
The assembly of a functioning BCR occurs in a ‘stepwise’ manner along a 
continuum of strictly regulated developmental stages throughout B cell 
maturation (228). Occurring within the BM, Ig heavy- (H) chain ‘variable’ (V), 
‘diversity’ (D) and ‘joining’ (J) gene segments undergo functional 
rearrangements (facilitated by recombinase-activating gene (RAG) proteins) in 
an process known as V(D)J recombination (reviewed in (229)). Licensing the 
transition from progenitor B cells (pro-B) to precursor B cells (pre-B), this 
process generates an incredibly diverse Ig repertoire (specifically within HCDR3 
regions), which underpins the specificity and/or restricted affinity of BCR 




the ‘pre-BCR’ (i.e. the BCR expressed on pre-B cells) becomes a ‘complete’ BCR 
(expressing the IgM isotype) expressed on newly-promoted immature B cells. 
Following the rejection of self-reactive BCRs, immature B cells develop into 
mature B cells expressing both IgM and IgD isotypes. Further maturation occurs 
within the SLOs following antigen engagement in a process known as SHM, where 
multiple mutations (facilitated by activation-induced cytidine deaminase (AID)) 
are introduced into the IGVH and IGVL genes to create higher-affinity BCRs for 
the selected antigen (45).   
1.2.1.2 Structure of the BCR 
The BCR is transmembrane heteromultimeric complex comprising a membrane-
associated (and antigen-restricted) Ig (composed of two identical H- and two 
matching L-chains) non-covalently linked to the Igα (CD79A)/Igβ (CD79B) 
heterodimer (9). In mature B cells, the H-chain of surface Ig (sIg) is ordered into 
an assemblage of one V domain connected to three (IgD isotype) or four (IgM 
isotype) constant (C) domains (230), coupled with a short intracellular segment 
(231). The Ig can be subdivided into two functionally distinct portions: the 
‘fragment antigen-binding’ (F(ab)) and ‘fragment crystallisable’ (Fc) regions. 
The F(ab) region (containing V domains) is responsible for antigen-binding, 
whereas the Fc region defines the Ig isotype (230). The ‘reassembled’ V domain 
within the H-chain (i.e. IGVH genes) possesses marked sequence diversity 
(particularly within HCDR3 regions) dictating the BCRs antigen specificity (232). 
Because the Ig is devoid innate signalling capacity (231), signal propagation is 
achieved via immunoreceptor tyrosine-based activation motifs (ITAMs) on the 
cytoplasmic tails of CD79A/CD79B (9), which are essential for B cell survival 
(223). In a resting state, the BCR is presumed to exist as a monomer or small 
oligomer on the cell surface (although this is debated), awaiting antigenic 








Figure 1.3 - The structure of the BCR (modified from (233)) 
 
1.2.1.3 BCR signal transduction 
BCR signalling is initiated following antigen encounter, which triggers BCR 
‘clustering’ and the formation of the ‘signalosome’ (225). In the early events of 
antigen engagement and/or ‘signalosome’ formation, the Src-family kinase LYN 
phosphorylates ITAMs on Ig-linked CD79A/CD79B, which recruits and activates 
the BCR-proximal kinase SYK (via Src-homology 2 (SH2) domains) (234). SYK 
facilitates signal propagation from the BCR complex to downstream signalling 
kinases via its association and phosphorylation of the adaptor molecule B-cell 
linker protein (BLNK) (235). BLNK operates as a scaffold that bridges the 
interface between SYK and downstream effectors including BTK and its substrate 
PLCɣ2 (via SH2 domains) (236). Aberrations in BCR-associated kinases LYN (237), 
SYK (238, 239) and the TEC family kinase BTK (240) have deleterious effects on B 
cell development, signalling and function. Indeed, deficiencies in BTK function 


































Figure 1.4 - BCR signalling (modified from (45)) 
 
(XLA) (241, 242). LYN- or SYK-dependent activation of BTK (at BTKY551, followed 
by autophosphorylation at BTKY223) transmits signals via PLCɣ2 (via 
phosphorylation at multiple tyrosine residues e.g. PLCɣ2Y753) that ultimately 
leads to activation of downstream second messengers inositol-1,2,5-triphosphate 
(IP3) and diacylglycerol (DAG) (235). IP3 mobilises the release of intracellular 
Ca2+ and activates NF-AT-dependent transcription, while DAG (via activation of 
protein kinase Cβ (PKCβ)) leads to the activation of ERK1/2, Jun N-terminal 
kinase (JNK), p38 and NF-κB pathways (243). BCR engagement similarly promotes 
another ‘branching point’ facilitated by LYN-dependent phosphorylation of 
tyrosine residues (Y-X-X-M motifs) within the cytoplasmic tail of co-receptor 
molecule CD19, which creates docking sites for the p85 subunit (via the SH2 
domain) of PI3K (234). PI3K is necessary for BTK activation (244, 245) and, 
perhaps most prominently, initiates downstream AKT-mTOR signalling (246). BCR 















































addition to LYN’s role as a facilitator of ‘positive’ BCR signalling, LYN possesses 
the ability to negatively modulate BCR signal transduction via phosphorylation of 
immunoreceptor tyrosine-based inhibition motifs (ITIMs) on inhibitory co-
receptors FcɣRIIB, CD5 and CD22 (235). Phosphorylation of ITIMs promote 
docking of inhibitory phosphatases SH2 domain-containing tyrosine phosphatase-
1 (SHP-1) and SH2-domain-containing inositol 5’-phosphatase-1 and -2 (SHIP-1/-
2), which tightly regulate the duration and strength of BCR signal transduction 
(Figure 1.4) (234).  
1.2.2 BCR signalling in CLL cells 
Beyond the prevailing view that CLL cells merely hijack the innate functional 
properties of BCR signal transduction in ‘normal’ B cells (122), increasing 
evidence indicates that BCR signalling is dysfunctional in CLL cells (247). Recent 
studies identified constitutive ‘clustering’ of the BCR on ‘resting’ CLL cells, 
similar to that observed on anti-IgM stimulated ‘normal’ B cells (247, 248). 
These findings aligned with studies demonstrating the appearance of an 
‘activated’ phenotype (249) and support observations that upstream BCR 
signalling kinases LYN (250), SYK (251) and downstream PI3K (252) are 
constitutively activated (122). In their study, Ziegler et al. confirmed that CLL 
cells possess enhanced BCR responsiveness and demonstrated that BCR 
dysfunction (i.e. constitutive ‘clustering’) was strongly associated with disease 
severity (247). In the absence of mutations affecting the BCR (44) or downstream 
signalling modules (76) (as observed in activated B-cell-like (ABC) subtype-
diffuse large B-cell lymphoma (DLBCL) (253)), these data supported the 
paradigm that CLL cells possess the ability for cell-autonomous BCR activation 
(247). Indeed, Dühren-von Minden et al. showed that CLL-derived BCRs undergo 
‘antigen-independent’ activation via HCDR3-dependent binding of BCR-intrinsic 
epitopes located in the second framework region (FR2) (254). Binder et al. 
subsequently identified another ‘self-recognition’ epitope in the FR3 (255). 
Importantly, the capacity for cell-autonomous activation was restricted to BCRs 
from CLL cells (and not from other B cell malignancies) (122, 254). Although 
these studies highlighted the pathological importance of BCR stereotypy within 
HCDR3 regions, they did not explain the clinical heterogeneity associated with 
IGVH mutational status (122) and were unable to account for the contributions 





Figure 1.5 - Features of U-CLL and M-CLL patients (modified from (45)) 
 
While the underlying mechanisms remain obscure, surface IgM (sIgM) levels are 
often lower on CLL cells compared to ‘normal’ B cells, perhaps due to chronic 
activation (234). Nevertheless, the spatio-temporal dynamics of BCR activation 
represents a key determinant in CLL pathogenesis (9). Like mature B cells (222), 
Burger et al. postulated that CLL cell survival and expansion is reliant upon both 
‘tonic’ and antigen-triggered BCR activation (122). On a functional level, the 
heterogenous outcome of BCR activation in CLL cells is governed by the innate 
properties of the cell (e.g. IGVH mutational status), the degree of stimulation 
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IGVH mutational status, antigen engagement of cells derived from U-CLL 
patients generally leads to ‘positive’ BCR signalling i.e. increased proliferation 
and/or survival (256). Along these lines, U-CLL cells typically have increased 
responsiveness (albeit homogenous) to BCR stimulation (234), express higher 
levels of sIgM (257) and tend to be associated with ectopic ZAP-70 expression 
(258). In contrast, cells from M-CLL patients are usually forced into a state of 
unresponsiveness or ‘anergy’ (256), characterised on a molecular level by 
increased activity of ERK1/2 and NF-AT (259). These functional differences align 
with disease severity and prognosis (256). U-CLL cells are generally more 
‘polyreactive’, having been shown to recognise an array of autoantigens and 
microbial proteins (260-262), whereas M-CLL cells react to specific antigens with 
greater affinity (Figure 1.5) (9, 263). As mentioned earlier, the emergence of 
small-molecule BCR signalling inhibitors targeting BTK (ibrutinib) and PI3Kδ 
(idelalisib) have transformed outcomes for CLL patients, particularly those with 
high-risk disease (45). However, elaborate feedback mechanisms have been 
identified (13) and acquired resistance mutations have been reported (148). 
These observations have focussed the spotlight on the identification of novel 
treatment strategies directed towards ‘targetable’ BCR crosslinking-induced 
effectors that have the ability to improve CLL patient outcomes. 
1.3 The PI3K-AKT-mTOR axis 
Activated downstream of growth factor (GF) receptor stimulation (e.g. BCR, 
chemokine and adhesion molecules), the PI3K-AKT-mTOR signalling axis 
regulates (and coordinates) cellular behaviours including cell growth, 
proliferation, survival, metabolism and migration (264). With reference to the 
‘hallmarks of cancer’ (265), it is unsurprising that cancerous neoplasms 
frequently harbour dysregulation and/or hyperactivation of the PI3K-AKT-mTOR 
axis (266). Indeed, B cell malignancies are no stranger to upregulated and/or 
constitutively active PI3K-AKT-mTOR signalling (267). As such, pharmacological 
inhibition of PI3K-AKT-mTOR has garnered much attention as a treatment option 
for this indication (268). For example, the PI3Kδ inhibitor idelalisib (in 
combination with rituximab) has been approved by the US Food and Drug 
Administration (FDA) for R/R CLL patients (108). This section gives an overview 
of PI3K-AKT-mTOR axis in CLL cells (with an emphasis on mTOR signalling) 




investigations using current mTOR inhibitors. Of note, the PI3K-AKT-mTOR 
signalling axis was recently reviewed (246, 269, 270).  
1.3.1 PI3K-AKT signalling 
There are 3 classes of PI3Ks in humans (I, II and III). Class I PI3Ks express 4 
different isoforms (p110α (PI3Kα), p110β (PI3Kβ), p110δ (PI3Kδ) and p110ɣ 
(PI3Kɣ)), which form heterodimers with regulatory subunits (usually SH2-domain-
containing p85) that control PI3K activity and localisation (269, 271). In B cells, 
PI3Kα and PI3Kδ operate redundantly at the pre-B cell stage (272), while PI3Kδ 
plays an essential role in mature B cell development and function (271, 273). 
Although signals emanating from multiple cell surface receptors converge on the 
PI3K-AKT axis (9), perhaps the best characterised is following BCR engagement 
(especially in the context of ‘normal’ and malignant B cells) (274). Importantly, 
PI3K-AKT integrates signals emanating from both ‘tonic’ (275) and antigen-
induced BCR activation (235). BCR ligation-induced PI3K activation (via p85-
induced binding to CD19) phosphorylates and catalyses the conversion of 
phosphatidylinositol(4,5)P2 (PIP2) to phosphatidylinositol(3,4,5)P3 (PIP3), a 
cytoplasmic membrane-associated second messenger that recruits (and 
activates) pleckstrin homology (PH)-domain containing effectors including BTK, 
phosphoinositide-dependent kinase-1 (PDK1) and the AGC serine/threonine 
kinase AKT (235, 269). PIP3-mediated docking of PDK1 and AKT at the 
cytoplasmic plasma membrane promotes PDK1-dependent phosphorylation of 
AKT at T308 (AKTT308) within the catalytic domain. ‘Full’ activation of AKT 
requires additional mechanistic target of rapamycin (mTOR) complex 2 
(mTORC2)-dependent AKT phosphorylation at S473 (AKTS473) within the 
hydrophobic motif (246). It has been proposed that PDK1-dependent AKTT308 
phosphorylation enhances AKT kinase activity, which, in turn, phosphorylates 
mTORC2 component mSIN1 at T86 (mSINT86). Enhanced mTORC2 activity then 
phosphorylates AKTS473 in a positive feedback loop to ‘fully’ activate AKT (276). 
AKT promotes survival and proliferation via ‘positive’ and ‘negative’ regulation 
of downstream substrates, such as negative regulation of FOXO transcription 
factors (277), which control diverse cellular behaviours (246). PI3K-induced 
signal transduction is reduced by the activity of phosphatase and tensin homolog 
(PTEN), which dephosphorylates PIP3 to PIP2 thereby disabling recruitment of PH-




Evidence from Burkitt’s lymphoma (BL) and germinal centre B-cell (GCB) 
subtype-DLBCL indicate that ‘tonic’ BCR signalling-induced PI3K-AKT signal 
transduction is central to pathogenesis (264).  
1.3.1.1 PI3K-AKT signalling in CLL cells 
Engagement of BCR (278), CD40 (279), CXCR4 (169) receptors or intimate contact 
with stromal cells (280) within the CLL-TME have been shown to activate PI3K-
AKT signalling in CLL cells (122). PI3K-AKT activation in the context of CLL-TME 
communication has been reviewed (264, 271). Ringshausen et al. demonstrated 
that PI3K was constitutively active in CLL cells derived from the PB compartment 
(via detection of synthesised PI3P). Confoundingly, ‘basal’ activation of AKT 
(AKTS473) was not observed. Instead, PKCδ activity (PDK1-dependent PKCδT505 
phosphorylation) was readily detected in freshly isolated CLL samples. 
Importantly, inhibition of PI3K (LY294002) resulted in CLL cell apoptosis (252). 
Interestingly, U-CLL patients possess increased levels of PI3K expression 
compared to their M-CLL counterparts (281), perhaps indicative of enhanced BCR 
responsiveness in poor prognostic patients (234). More recently, genetic and 
pharmacological (CZC24832) inhibition of PI3Kɣ reduced CLL cell migration and 
adhesion, indicating that PI3Kɣ has a unique role (distinct from PI3Kδ) in CLL 
cells. Furthermore, expression of PI3Kɣ increased following CD40L (+IL-4) co-
culture (282). In line with these data, the PI3Kδ/ɣ inhibitor duvelisib (IPI-145) 
antagonised CLL-TME stimuli in vitro, induced apoptosis and prevented 
chemotaxis towards CXCL12 (283). Detection of basal AKT activity in CLL cells 
appears to be contentious, which probably highlights experimental limitations 
and/or differences. However, we (284) and others (285, 286) have observed 
varying levels of AKTS473 phosphorylation among PB-derived CLL patient samples, 
which could indicate constitutive AKT activation or a ‘functional snapshot’ of 
prior stimulation. Notably, however, Zhuang et al. showed that pharmacological 
AKT inhibition (A-443654; median LC50 = 0.71 µM) induced cell death in CLL 
patient samples devoid of external stimulation, whereas ‘normal PBMCs’ were 
less sensitive (285). Furthermore, studies have shown that AKT plays a key role 
in cell cycle progression and proliferation of CLL cells in response to CD40L (+IL-




Like many other cancers, growing evidence indicates that PTEN is functionally 
comprised in CLL cells (reviewed in (288)). Shehata et al. reported that PTEN 
tumour suppressor activity was reduced by casein kinase 2 (CK2)-dependent 
phosphorylation, inasmuch as the CK2 inhibitor apigenin diminished PTENS380 
phosphorylation and induced CLL cell apoptosis (290). Furthermore, others found 
that PTEN was downregulated by aberrant expression of PTEN-targeting miRNAs 
miR-26a, miR-214 (289) or miR-22 (291). More recently, Carra et al. 
demonstrated that inactivation of PTEN was instigated by upregulation of the 
de-ubiquitinase USP7, which resulted in aberrant cytoplasmic localisation of 
PTEN (288, 292). Collectively, these findings describe a pathophysiological state 
wherein aberrant PTEN inactivation could potentially lead to constitutive 
activation of PI3K-AKT-mTOR in CLL cells. 
1.3.2 mTOR signalling 
As an effector of PI3K activation (and a member of the PI3K-related protein 
kinases (PIKK) family), the serine/threonine protein kinase mTOR orchestrates 
diverse signals emanating from environmental inputs (e.g. GF receptor 
stimulation and nutrient sensing) to regulate many cellular behaviours including 
cell growth, metabolism, survival and proliferation (270). mTOR represents the 
catalytic subunit residing within 2 separate protein complexes: mTOR complex 1 
(mTORC1) and mTORC2. mTORC1 comprises three main components: mTOR, 
regulatory protein associated with mTOR (RAPTOR) and mLST8, alongside two 
inhibitory subunits PRAS40 and DEPTOR. In contrast, mTORC2 contains mTOR, 
rapamycin insensitive companion of mTOR (RICTOR), mLST8, DEPTOR and 
regulatory subunits mSIN1 and PROTOR1/2 (293). Although the complexes are 
differentiated by their constituent components (and response to rapamycin), 
downstream substrates and functional output (270), the concerted activities of 
mTORC1 and mTORC2 represent key signalling nodes coordinating PI3K-AKT 







Figure 1.6 - mTOR signalling (modified from (233) and (294)) 
 
1.3.2.1 mTORC1 
While mTORC1 plays a critical role integrating and modulating signalling 
pathways triggered by cellular stress (DNA damage, hypoxia and reduced ATP 













































focus on mTORC1 signalling in response to GF receptor stimulation (via PI3K-AKT 
signalling).  
AKT initiates mTORC1 activity via phosphorylation (and inactivation) of tuberous 
sclerosis complex 2 (TSC2), a tumour suppressor (and key negative regulator of 
mTORC1) functioning within the heterotrimeric TSC complex (TSC1, TSC2 and 
TBC1D7) (293). In the absence of stimulation, the TSC complex operates as a 
GTPase activating protein (GAP), which associates with (and functionally 
subdues) the GTPase Rheb. Upon AKT-dependent suppression of the TSC 
complex, the conversion of inactive Rheb-GDP to active Rheb-GTP permits 
binding and activation of mTORC1 (270). Furthermore, the activity of mTORC1 is 
controlled by AKT-dependent phosphorylation of mTORC1 inhibitory subunit 
PRAS40 at T246 (PRAS40T246), which facilitates its disassociation from RAPTOR, 
enabling activation of downstream mTORC1 substrates (295). Of note, crosstalk 
with the MAPK/ERK pathway (and its effector p90RSK) similarly activates mTORC1 
via suppression of the TSC complex (266).  
Within the mTORC1 complex, RAPTOR ensures correct mTORC1 localisation (293) 
and instigates the recruitment and association of mTORC1-specific substrates 
p70S6 Kinase 1 (S6K1) and eIF4E-Binding Protein 1 (4E-BP1) via their conserved 
TOR signalling (TOS) motifs (296). mTORC1-dependent phosphorylation of S6K1 
and 4E-BP1 plays a key role in the regulation of cell growth (for example, via 
translation of proteins implicated in cell cycle progression) (266). Together with 
PDK1-dependent phosphorylation at T229 (S6K1T229), mTORC1 directly 
phosphorylates (and activates) S6K1 at T389 (S6K1T389). Activated S6K1 
subsequently phosphorylates the 40S subunit component S6 ribosomal protein 
(S6) at S235/236 (S6S235/236) (270). Most prominently, S6K1 directly contributes to 
cap-dependent mRNA translation (and protein synthesis) via triggering eIF4B 
activation (a positive regulator of the eIF4F complex) and marking PDCD4 (an 
inhibitor of eIF4A RNA helicase activity) for degradation (S6K1-dependent 
PDCD4S67 phosphorylation) (293, 297). In the absence of stimulation, 4E-BP1 
suppresses cap-dependent mRNA translation via its association with eIF4E, which 
disables the assembly of the eIF4F complex (270). mTORC1-dependent 
phosphorylation of 4E-BP1 at T37/46 (4E-BP1T37/46) primes 4E-BP1 for further 




complex formation (298). Alongside its fundamental role in protein synthesis, 
mTORC1 functions to facilitate lipid/glucose metabolism (augmenting cell 
size/biomass) and repress autophagy/catabolism (protein turnover) (reviewed in 
(270)).    
Importantly, S6K1 is embedded within negative feedback loops that modulate 
mTORC2 activity (293). S6K1 directly reduces mTORC2 activity via 
phosphorylation of mTORC2 component RICTOR at T1135 (RICTORT1135) (299), 
while S6K1 similarly inactivates insulin receptor substrate 1 (IRS1) (and 
subsequent PI3K-AKT activation) via downregulation of IRS1 gene expression and 
phosphorylation-induced IRS1 depletion (300, 301). Finally, mTORC1 negates 
PI3K-AKT-mTORC2 signal transduction via phosphorylation (and stabilisation) of 
the mTORC1 negative regulator Grb10 (302, 303).  
1.3.2.2 mTORC2 
In the absence of PI3K-dependent generation of PIP3, the regulatory mTORC2 
subunit mSIN1 prevents mTORC2 activation via binding to its catalytic domain. 
Upon PI3K activation, the PH domain of mSIN1 interacts with PIP3, thereby 
releasing the inhibitory effect on mTORC2 kinase activity (293, 304). As 
mentioned earlier, AKT-dependent mSINT86 phosphorylation (and enhanced 
mTORC2 activity) reciprocates phosphorylation of AKTS473 in a positive feedback 
loop that results in maximum kinase activity (276, 293).  
Within the mTORC2 complex, RICTOR (the defining element of mTORC2) 
modulates the activity of downstream targets (305), akin to the function of 
mTORC1-specific (but unrelated) RAPTOR (293). Although AKT kinase activity 
does not require mTORC2-dependent AKTS473 phosphorylation to initiate effector 
functions, AKTS473 phosphorylation has been shown to stabilise PDK1-dependent 
AKTT308 phosphorylation (246, 306, 307). In this regard, mTORC2 modulates (in a 
substrate-specific manner (308)) AKT-dependent negative regulation of 
downstream substrates such as the FOXO transcription factors (277), glycogen 
synthase kinase 3 (GSK3) (309) and the TSC complex (310). Collectively, these 
‘nodes’ control diverse cellular behaviours including cell growth, proliferation 




PKC family, which regulate actin cytoskeleton remodelling, chemotaxis and cell 
migration (293).  
1.3.2.3 mTOR inhibitors 
mTORC1 and mTORC2 are functionally distinguished and/or characterised, in 
part, by their sensitivity to rapamycin (otherwise known as sirolimus in clinical 
settings) (293). Rapamycin forms a complex with FKBP12 that binds allosterically 
to the FKBP12-rapamycin binding (FRB) domain within mTOR kinase (specifically 
mTORC1), which prevents binding of substrate molecules (269). While mTORC2-
specific mTOR kinase equally possesses an FRB domain, mTORC2 is insensitive to 
rapamycin by virtue of RICTOR-mSIN1 complex, which creates a structural 
conformation that masks the ability of FKBP12-rapamycin to associate with the 
FRB domain (270). Although chronic exposure to rapamycin has been shown to 
reduce mTORC2 activity (via limiting the availability of mTOR kinase) (311), 
rapamycin is generally considered an allosteric mTORC1-selective inhibitor 
(293). Indeed, Choo et al. demonstrated that rapamycin differentially (and 
selectively) inhibits mTORC1 substrates, preferentially targeting S6K1 activity 
over 4E-BP1 (312). Although rapamycin is an effective cytostatic agent (313), its 
clinical derivatives (the ‘rapalogues’) CCI-779 (temsirolimus) and RAD001 
(everolimus) have evoked limited anti-cancer activity in clinical trial (293). 
Clinical activity of mTORC1-selective inhibitors is insufficient due to incomplete 
blockade of 4E-BP1 phosphorylation (thus enabling eIF4E-mediated translation) 
(312) and abrogation of negative feedback loops modulating mTORC2 activity, 
which results in activation of AKT-mediated pro-survival signalling (293, 314-
317). 
To circumvent the problems associated with selective-mTORC1 inhibitors 
(rapalogues), ‘second generation’ ATP-competitive dual mTOR kinase inhibitors 
(targeting mTORC1 and mTORC2) were developed (293). The dual mTOR kinase 
inhibitor AZD8055 (and it’s clinical analogue AZD2014 (vistusertib) (318)) has 
been shown to inhibit phosphorylation of mTORC1 (S6K1T389 and 4E-BP1T37/46) and 
mTORC2 (AKTS473) substrates and downstream proteins (S6S235/236 and FOXO1T24) 
(319). In pre-clinical studies, AZD8055 demonstrated in vitro activity against 
acute myeloid leukaemia (AML) (320), renal cell carcinoma (321) and breast 




clinical activity in lymphomas (323). However, dual mTOR kinase inhibition has 
been shown to upregulate expression of receptor tyrosine kinases (RTK) via 
elimination of inhibitory feedback mechanisms, resulting in pro-survival 
signalling mediated by PI3K-dependent AKTT308 phosphorylation (324). In an 
attempt to sidestep these drawbacks, dual PI3K/mTOR inhibitors, such as PF-
04691502 and SAR245409, have been developed, displaying positive results in 
pre-clinical investigations and phase I-II clinical trials (Table 1.5) (293).  
Compound  Target Phase Disease Reference 
AZD2014 
(Vistusertib) 











OSI-027 mTORC1/2 I AST, Lymphomas (327) 
CC-223 mTORC1/2 I-II NSCLC, NHL, MM (328) 
PF-04691502 PI3K/mTORC1/2 I-II Breast, Endometrial, 
AST 
(329) 





PI3K/mTORC1/2 I-II AST, GBM, Ovarian, 
Breast, NHL 
(331) 
CC-115 mTORC1/2/DNA-PK I-II AST, GBM, CLL, 
Prostate 
(332) 
Table 1.5 - mTOR kinase inhibitors in clinical trials (333) 
AST=Advanced Solid Tumours, GBM=Glioblastoma Multiforme, NSCLC=Non-Small Cell Lung 
Cancer, NHL=Non-Hodgkin Lymphoma, MCC=Merkel Cell Carcinoma, MM=Multiple Myeloma.  
 
1.3.2.4 mTOR signalling in CLL 
mTOR is aberrantly activated in various ‘solid’ and haematological cancers (294, 
334), albeit seldom as a result of activating mutations in mTOR (335). 
Pathological overactivation of PI3K-AKT or MAPK/ERK signalling hijacks mTOR 
activity (270), inasmuch as mTOR becomes detached from ‘normal’ physiological 
cues and sustains cancer cell growth (334). Despite a plethora of studies 
delineating PI3K-AKT signalling in CLL pathogenesis (264), mTOR (as an 
important node within the PI3K-AKT axis) has garnered surprisingly little 
attention as a potential therapeutic target for CLL.  
Early preclinical studies showed that pharmacological inhibition of mTORC1 




Indeed, Decker et al. demonstrated that rapamycin-induced G1 cell cycle arrest 
corresponded to decreased levels of cyclin D3, cyclin E and cyclin A, concluding 
that mTOR represents a putative therapeutic strategy to prevent accumulation 
of proliferative CLL cells within the LN microenvironment (313). Additionally, 
Åleskog et al. showed that CLL patient samples were vulnerable to rapamycin 
treatment, resulting in dose-dependent cell death irrespective of poor 
prognostic features (337). In line with these data, a recent drug-sensitivity 
screen demonstrated that a subset of M-CLL patients were particularly sensitive 
to everolimus treatment, with ~14 % of patients dependent upon mTOR signalling 
irrespective of BCR signalling capacity (338). In clinical trial, everolimus 
promoted redistribution of CLL cells from the tissues to the periphery in a subset 
of CLL patients, akin to the clinical manifestations observed with BCR signalling 
inhibitors. However, anti-cancer activity was modest, with only 18 % of patients 
achieving partial remission (339). Alongside the aforementioned limitations 
associated with prolonged mTORC1 inhibition (316, 317), an unpublished study 
showed that mTORC2 component RICTOR was overexpressed in CLL cells, which 
resulted in enhanced mTORC2 activity (340).  Collectively, these data suggest 
that selective-mTORC1 inhibitors would have limited efficacy in CLL. As such, 
dual mTOR kinase inhibitors (284) and dual PI3K/mTOR inhibitors PF-04691502 
(341) and SAR245409 (342) have been adopted in recent CLL pre-clinical 
investigations, which have resulted in enhanced CLL cell death and abrogation of 
CLL-TME stimuli. Moreover, the dual mTOR/DNA-dependent protein kinase (DNA-
PK) inhibitor CC-115 has equally demonstrated pre-clinical and clinical potency 
in CLL (343). Thus, the role of mTOR signalling in CLL pathogenesis (and targeted 
inhibition thereof) warrants further investigation.  
1.4 Forkhead Box (FOX) Class O (FOXO) transcription 
factors 
Reciprocal positive-feedback between AKT and mTORC2 influences AKT 
substrate specificity by maximising kinase activity (293). Among other methods, 
AKT promotes cell survival and proliferation via negative regulation of FOXO 
transcription factors (246). Mammalian FOXOs (belonging to the evolutionary 
conserved FOX transcription factor superfamily) consist of 4 family members: 
FOXO1, FOXO3, FOXO4 and FOXO6 (344), which possess similarities in their 




are widely (albeit differentially) expressed in a tissue-specific manner (for 
example, FOXO1 is abundantly expressed in adipose tissue), indicating individual 
FOXO family members have specific cellular functions (346). However, increasing 
evidence indicates that FOXOs can occupy similar expression patterns and fulfil 
overlapping (functionally redundant) roles (344). As context-dependent 
transcriptional activators and repressors, FOXOs operate as key regulators of 
diverse cellular processes including cell cycle arrest, apoptosis, metabolism, 
longevity and cell fate determination (347). FOXOs are unique among the FOX 
superfamily by virtue of an amino acid sequence (Gly-Asp-Ser-Asn-Ser) that 
flanks the DNA-binding domain, mediating interactions with the ‘forkhead 
response element’ (FHRE) or DNA consensus sequence 5′-(G/C)(T/A)AA(C/T)AA-3′ 
(346). FOXO subcellular localisation largely dictates transcriptional activity, 
which is influenced by multiple posttranslational modifications including FOXO 
nuclear export via AKT-dependent phosphorylation (345). Furthermore, nucleo-
cytoplasmic shuttling is regulated by conserved nuclear localisation sequences 
(NLS) and nuclear export sequences (NES), enabling interactions between FOXOs 
and nuclear export/import machinery (346). FOXOs are widely considered to be 
‘bona fide’ tumour suppressors, evoking transcriptional programmes resulting in 
potent inhibitory effects on cell growth and survival (348). However, emerging 
evidence points towards an alternative paradigm whereby FOXOs operate as 
mediators of cellular homeostasis and/or resistance in both ‘normal’ and 
pathophysiological scenarios (344). In any case, dysregulation of FOXOs can 
result in a broad spectrum of diseases including cancer (347). This section gives 
an overview of FOXO regulation and its functional importance in ‘normal’ and 
malignant B cells. Of note, the role of FOXOs in the context of cancer has been 
recently reviewed (344, 347).  
1.4.1 AKT-dependent FOXO regulation 
FOXO subcellular localisation is regulated by multiple posttranslational (and 
posttranscriptional) modifications, which largely influence FOXO transcriptional 
activity (reviewed in (345)). Perhaps most prominently, AKT negatively regulates 
FOXO DNA-binding and transactivation via phosphorylation at conserved 
RxRxxS/T residues (344, 348). AKT phosphorylates FOXOs at 3 serine/threonine 
sites (located at the N-terminus, NLS (flanking the DBD) and proximal to the NES) 




S253 and S315) and FOXO4 (T28, S193, S258) (347). FOXO6 transcriptional 
activity is abrogated by AKT-dependent phosphorylation (at T26 and S184), 
irrespective of inherent nucleo-cytoplasmic shuttling impairments (FOXO6 lacks 
the AKT phosphorylation site located at the C-terminus) (349). Importantly, 
Biggs et al. showed that FOXOs expressing mutant AKT phosphorylation sites 
were resistant to AKT-dependent phosphorylation and nuclear export (350). 
Furthermore, Brunet et al. demonstrated that removal of GF stimulation 
resulted in FOXO dephosphorylation, nuclear accumulation and enhanced 
transcriptional activity, indicating that FOXO cellular distribution represents a 
highly dynamic process (277). AKT-phosphorylated FOXOs are exported from the 
nucleus by interactions with 14-3-3 proteins, which operate as molecular 
scaffolds via binding to RSxpS/TxP and RxxxpSxP motifs (277, 348, 350-353). 
AKT-dependent FOXO1 (T24 and S256) and FOXO3 (T32 and S253) 
phosphorylation induces 14-3-3 binding (277, 345, 354, 355). 14-3-3 proteins 
exert various mechanism to control FOXO transcriptional activity. For example, 
the association with 14-3-3 proteins expose the FOXO NES (located at the C-
terminus) and mask the availability of the NLS, thus preventing FOXO 
translocation back to the nucleus (345, 356, 357). Furthermore, 14-3-3 binding 
directly disrupts FOXO interactions with the FHRE via disturbing the FOXO DNA-
binding interface (DNA-binding domain) (Figure 1.7) (354, 358-361). FOXO 
degradation is initiated following AKT-dependent phosphorylation and nuclear 
export, in a context-dependent manner (348, 362-364). The E3 ubiquitin ligase 
S-phase kinase-associated protein 2 (SKP2) (existing in the SCFSKP2 complex) 
interacts with and polyubiquitinates AKT-phosphorylated FOXOs for targeted 
degradation via the proteasome (364).  
PI3K-AKT signalling is frequently hyperactivated in cancer, which nullifies FOXO 
activity as a result of the aforementioned mechanisms. Indeed, enhanced levels 
of AKT-dependent FOXO phosphorylation are often associated with aggressive 
disease and poor prognosis in various ‘solid’ and haematological malignancies 
(344, 347). As such, targeted inhibition of the PI3K-AKT-mTOR axis has been 






Figure 1.7 - AKT-dependent FOXO regulation (modified from (246)) 
 
1.4.2 Other mechanisms of FOXO regulation 
AKT-dependent phosphorylation of FOXOs is the most well-studied (and perhaps 
the most influential) posttranslational modification governing FOXO activity 
(345). However, it is important to note that FOXO subcellular localisation, 
transcriptional activity and degradation are influenced by multiple co-occurring 
posttranslational and posttranscriptional modifications in a highly dynamic 
process. Indeed, FOXOs are key nodes at the nexus of several signalling pathways 
(348). Alongside AKT-dependent regulation, FOXO transcriptional activity (and 
subcellular localisation) is also negatively regulated via phosphorylation by 
MAPK/ERK (366, 367), cyclin-dependent kinase 2 (CDK2) (368) and casein kinase 
1 (CK1) (369, 370) pathways. Conversely, oxidative stress-activated JNK 
phosphorylates FOXOs (and 14-3-3 proteins) to promote nuclear translocation 
and transcriptional activation (371). In response to intracellular energy 











































stability, nuclear accumulation and transcriptional activity (347, 372). Stress-
induced FOXO-mediated transcription maintains cellular homeostasis (344). 
Although beyond the scope of this thesis, other posttranslational (acetylation, 
methylation and ubiquitination) and posttranscriptional (miRNAs) modifications 
impact FOXO functionality, often with dual ‘positive’ and ‘negative’ impacts in a 
context-specific manner, reviewed in (347, 373, 374).  
1.4.3 FOXO-mediated induction of cell cycle arrest and apoptosis 
Early studies demonstrated the ability of FOXOs to induce cell cycle arrest and 
apoptosis (either by FOXO overexpression or pharmacological PI3K-AKT 
inhibition) via upregulation of cytostatic and pro-apoptotic transcripts, which 
suggested that FOXOs operate as obligate tumour suppressors downstream of 
PI3K-AKT inactivation (277, 344, 375-379). Studies have subsequently identified 
a wide array of FOXO-regulated target genes, which have highlighted their role 
as mediators of growth arrest and cell death, in a context-specific manner (348, 
380).  
Cell cycle progression is a tightly regulated process involving the timely (and 
sequential) expression of cyclin dependent kinases (CDKs), cyclins and cyclin-
dependent kinase inhibitors (CDKIs) along a succession of cell cycle phases (G0, 
G1, S, G2 and M) (365). FOXOs exert control over cell cycle progression at the 
G1/S transition via upregulation of CDKIs CDKN1A (p21CIP1) and CDKN1B (p27KIP1), 
which inhibit cyclin E-CDK2 and cyclin D-CDK4/6 complexes (376, 377, 381, 382). 
Furthermore, FOXOs have been shown to upregulate members of the INK4 family 
of CDKIs: CDKN2B (p15INK4b), CDKN2A (p16INK4a), CDKN2C (P18INK4c) and CDKN2D 
(p19INK4d), which elicit G1 cell cycle arrest via inhibition of the cyclin D-CDK4/6 
complex (344). FOXOs can also upregulate the retinoblastoma (Rb) protein 
family member p130, which induces cellular ‘quiescence’ following cell cycle 
arrest via enhanced (and chronic) formation of the inhibitory p130/E2F complex 
(preventing transcription of genes necessary for S phase) (365, 376). 
Interestingly, Schmidt et al. demonstrated that FOXOs transcriptionally repress 
CCND1 (cyclin D1) and CCND2 (cyclin D2) expression (involved in cell cycle 




FOXOs are also implicated in the regulation of transcripts involved in the 
‘intrinsic’ and ‘extrinsic’ apoptotic pathways, leading to the activation of 
caspase 3- and caspase 7-dependent programmed cell death (344). The 
‘intrinsic’ pathway is initiated in response to apoptotic stimuli, which results in 
mitochondrial outer membrane permeabilization (MOMP). MOMP is initiated by 
the activity of BAK and BAX proteins (located on the outer mitochondrial 
membrane), which are activated by binding of pro-apoptotic BH3-only (BID, BIM, 
PUMA, and NOXA) proteins. Conversely, MOMP is inhibited by anti-apoptotic 
(BCL2, BCL-xL and MCL-1) proteins, which bind to (and nullify) pro-apoptotic 
proteins (383). FOXOs contribute to the ‘intrinsic’ pathway via upregulation of 
pro-apoptotic BCL2-L11 (BIM) and BBC3 (PUMA) proteins, while FOXO-mediated 
repression of BCL2-L1 (BCL-xL) has been reported (344, 365). The ‘extrinsic’ 
pathway is triggered via engagement of ‘death receptors’ (FAS, TNFR1 and 
TRAILR1), which leads to the assembly of the ‘death-inducing signalling complex’ 
(DISC) (383). FOXOs contribute to the ‘extrinsic’ pathway via upregulation of 
‘death receptor’ cognate ligands FASL and TRAIL (344, 365).  
1.4.4 FOXO function in ‘normal’ B cells 
FOXOs fulfil distinct roles throughout B cell maturation (reviewed in (384)). At 
the earliest stages of B cell development, Welinder et al. demonstrated that 
Foxo1 expression was induced by E proteins E2A and HeLa E-box binding protein 
(HEB), which concertedly trigger differentiation of the common lymphoid 
progenitor (CLP) to the pro-B cell stage. Ablation of E2A or HEB resulted in a 
block at the CLP stage, which coincided with reduced Foxo1 expression (385). 
The transition between the pro-B cell and pre-B cell stages is governed by 
successful V(D)J recombination facilitated by RAG proteins (228). Two groups 
showed that Foxo1 directly activated Rag1 and Rag2 transcription, which was 
reduced in Foxo1-depleted early B cells (386, 387). Importantly, Dengler et al. 
demonstrated that Foxo1-ablation (and not Foxo3) impaired V(D)J recombination 
in pro-B cells, while Foxo1 loss reduced L chain rearrangements in pre-B cells. 
Furthermore, Foxo1-deletion in pro-B cells blocked commitment to the pre-B 
cell stage via diminished IL-7Rα expression. Paradoxically, loss of Foxo1 at the 
pro-B cell stage induced apoptosis, which was associated with elevated Bcl2-l11 
expression and reduced Bcl2-l1 (387). FOXO1 depletion induced apoptosis in pre-




levels) (388) and ‘negative’ (via transcriptional activation of BCL6) (389) impacts 
on pre-B cell proliferation in a temporal-specific manner (384). In mature B 
cells, FOXO1 is the most abundantly expressed FOXO family member (390), 
which is downregulated (and inactivated) following BCR ligation via PI3K-AKT 
signalling (391). In their study, Yusuf et al. showed that PI3K-AKT-mediated 
FOXO1 inactivation was necessary for optimal B cell proliferation. Here, PI3K 
inhibition or expression of a constitutively active form of FOXO1 (FOXO1-A3), 
which is insensitive to AKT-dependent phosphorylation, promoted apoptosis and 
cell cycle arrest (390). Along these lines, Srinivasan et al. demonstrated that 
FOXO1 induced apoptosis of BCR-depleted B cells, which was rescued by ectopic 
expression of constitutively active PI3K. Furthermore, BCR-ablated B cells had 
elevated levels of FOXO-targets BCL2-L11 and CDKN1B (275). Conversely, 
Dengler et al. revealed that conditional deletion of Foxo1 (CD21-Cre+) reduced 
LN-resident B cells, indicating Foxo1 is necessary for B cell maintenance. 
Interestingly, B cells lacking Foxo1 also possessed impairments in BCR signalling 
and proliferation (387). In a subset of mature B cells, antigen encounter within 
the SLOs leads to the formation of the GC, a specialised microanatomical 
structure wherein mature B cells undergo rapid clonal expansion, Ig SHM and 
class switch recombination (CSR) to generate affinity-enhanced antibodies in 
support of the adaptive immune response (392). On a functional level, the GC is 
polarised into a highly proliferative ‘dark zone’ (DZ), which is the site of SHM, 
and a ‘light zone’ (LZ), where B cells undergo activation, CSR and selection 
(393). FOXO1 is abundantly expressed in B cells within the proliferative DZ 
compartment, where it instructs a gene expression programme favouring DZ 
formation (394, 395). Indeed, FOXO1 induces the expression of CXCR4, retaining 
B cells within the DZ (394). Furthermore, FOXO1 mediates transcription of AICDA 
(encoding AID), a key component involved in SHM and CSR (387). Along these 
lines, FOXO1 knockdown in GC-B cells impeded the formation of the DZ, CSR was 
defective, whereas normal SHM was maintained (384, 387, 394, 395).  
1.4.5 The role of FOXOs in B cell malignancies 
The diverse functionality of FOXO1 throughout B cell maturation is often 
hijacked in the development, maintenance and progression of B cell 
malignancies (comprehensively reviewed in (384)). In their study, Xie et al. 




(cHL) cell lines (and virtually absent in the majority of examined cHL patient 
samples) compared to ‘normal’ human tonsillar CD19+ cells via overexpression of 
the FOXO1-targetting miR-183–miR-96–miR-182 cluster and constitutive 
activation of AKT and ERK kinases. Importantly, expression of FOXO1-A3 induced 
growth arrest and apoptosis, coinciding with enhanced levels of CDKN1B and 
BCL2-L11. The authors proposed that low FOXO1 expression contributed to cHL 
progression, suggesting that FOXO1 is a putative tumour suppressor (396). The 
roles of FOXOs in DLBCL, BL and B-cell precursor acute lymphoblastic leukaemia 
(BCP-ALL) are contradictory (384).  
Szydlowski et al. demonstrated that FOXO1 was an effector of SYK inhibition 
(R406) in GCB-DLBCL, which is dependent upon ‘tonic’ BCR signalling. FOXO1 
activation resulted in enhanced expression of BIM and p27KIP1, while FOXO1 
depletion shielded GCB-DLBCL cells from R406-induced apoptosis and cell cycle 
arrest (397). Conversely, FOXO1 mutations have been reported in ~9 % of DLBCL 
patients, nearly half of which (~46 %) possess recurrent mutations in the N-
terminal region. These mutations negated FOXO1T24 phosphorylation, diminished 
binding to 14-3-3 proteins and promoted nuclear accumulation (398). 
Importantly, FOXO1 mutations were associated with poor prognosis and worse 
response to therapy (384, 398, 399).  
In BL, FOXOs have been purported as tumour suppressors by virtue of their 
antagonistic relationship with MYC (384), the defining oncogene in BL 
pathogenesis (400). In contrast, Kabrani et al. showed that recurrent FOXO1 
mutations (preventing AKT-dependent FOXOT24 phosphorylation) restricted 
FOXO1 to the nucleus, which promoted cell proliferation and survival. Nuclear 
FOXO1 depletion (via CRISPR/Cas9 editing) compromised tumour growth, 
indicating that nuclear FOXO1 is a key oncogenic event in BL (401).  
In pre-BCR+ BCP-ALL, Köhrer et al. showed that FOXO1 was a key effector of pre-
BCR signalling inactivation. Pharmacological inhibition of SYK (PRT318) in pre-
BCR+ BCP-ALL cell lines blocked FOXO1T24 phosphorylation, enhanced FOXO1 
expression and promoted nuclear accumulation. Furthermore, ectopic FOXO1-A3 
expression reduced cell viability, indicating that maintenance of pre-BCR+ BCP-
ALL required inactivation of FOXO1 (384, 402). In contrast, Wang et al. 




G1 cell cycle arrest and enhanced caspase-dependent cell death in pre-BCR- and 
pre-BCR+ BCP-ALL cell lines (via CCND3 downregulation, reduced mTOR activity 
and increase p27KIP1), indicating that BCP-ALL cell maintenance is reliant on 
FOXO1 expression (403).  
Comparatively speaking, little evidence exists about the role of FOXOs in CLL 
disease biology. In their study, Palacios et al. demonstrated that proliferating 
CLL cells were dependent upon overexpression of miR-22, which downregulated 
PTEN activity and subsequently enhanced PI3K-AKT-FOXO1 signalling, specifically 
in ‘proliferative’ cells from U-CLL patients. Inactivated FOXO1 (cytoplasmic 
localisation) was associated with reduced levels of p27KIP1 (291). In line with 
these findings, Ticchioni et al. showed that ‘homeostatic’ chemokines (CXCL12, 
CCL21, CCL19 and CXCL13) induced CLL cell survival via PI3K-AKT-induced 
FOXO3A inactivation and correlated with reduced levels of BIM. Expression of 
‘triple mutant’ FOXO3A (constitutively active) induced cell death, while FOXO3A 
siRNA enhanced ‘basal’ CLL survival (286). Collectively, these studies point 
towards a tumour suppressive role for FOXOs in CLL. However, scant evidence 
exists about endogenous FOXO expression levels (patient-derived cells and LN 
biopsies) or FOXO regulation downstream of BCR ligation in CLL. 
1.4.6 FOXOs: tumour suppressors or promotors (or both)? 
FOXOs have been generally regarded as ‘classical’ tumour suppressors due to 
their ability to induce cell cycle arrest and apoptosis (344). Indeed, a seminal 
report by Paik et al. demonstrated that conditional (and inducible) deletion of 
Foxo1, Foxo3, and Foxo4 in adult mice (Mx-Cre+; Foxo1/3/4L/L) resulted in 
tumour phenotypes characterised by thymic lymphomas and widespread 
haemangiomas, indicating that FOXOs were ‘bona fide’ tumour suppressors. 
Importantly, this study also highlighted the potential for functional redundancy 
and/or developmental compensation of FOXOs as ‘dual’ knockouts resulted in 
only mild cancer phenotypes (404). However, numerous reports (as described in 
B cell malignancies) also indicate that FOXOs can promote tumorigenesis by 
upholding cellular resilience and facilitating drug resistance (344). Indeed, FOXO 
‘activating’ mutations have been linked with disease progression in BL (401) and 
DLBCL (398), while FOXO upregulation has been associated with poor prognosis 




that FOXOs possess ‘dual faceted’ or ‘bimodal’ roles, i.e. FOXOs can be tumour 
suppressors and promotors within the same indication in a context-dependent 
manner (344). In their study, Hornsveld et al. demonstrated that either 
inducible activation or depletion of FOXOs repressed cell growth and metastasis 
in a model of metastatic breast cancer, indicating a role for FOXOs in tumour 
maintenance and metastasis formation. Indeed, the authors proposed that FOXO 
activity is finely tuned to support cancer cell homeostasis (408). As described, 
this supposed ‘two-faced’ behaviour has also been observed in pre-BCR+ BCP-ALL 
(402, 403). Akin to ‘normal’ B cells, these studies indicate that FOXO activity is 
maintained within an optimum that promotes cellular homeostasis, as deviations 
outside this range have deleterious effects on cell growth and survival (344, 
403). Despite the depth of knowledge about FOXOs in ‘normal’ and ‘malignant’ 
scenarios, the functional importance of these transcription factors (whether 
‘positive’, ‘negative’ or both) in CLL disease biology remains poorly understood.  
1.5 Project aims 
This thesis explores mTOR kinase as a potential therapeutic target in CLL. Along 
these lines, the efficacy of the dual mTOR kinase inhibitor AZD8055 is addressed, 
alongside its potential as a partner drug for the BTK inhibitor ibrutinib. We 
further investigate a mechanism of action for AZD8055 as a monotherapy (and in 
combination with ibrutinib), which centres on AKT-dependent regulation of 
FOXO transcription factors. As such, we aim to define whether targeting 
negative regulators of FOXOs represent a promising therapeutic strategy for CLL.   
I. Ascertain the effect of AZD8055 treatment on CLL cells at a molecular and 
functional level - exploring a potential mechanism of action. 
II. Address the regulation (phosphorylation, localisation and DNA-binding 
activity) of FOXO transcription factors as functional consequence of BCR 
ligation in CLL cells. 
III. Investigate the functional importance (cell growth, proliferation and 
survival) of FOXOs as an effector of combined mTOR kinase and BTK 








Applied Biosystems   
(Thermo Fisher 
Scientific) 
Unit 3, Fountain Dr, Inchinnan, Renfrew PA4 9RF, 
UK 
Abcam plc Discovery Drive Cambridge Biomedical Campus, 
Cambridge CB2 0AX, UK 
Active Motif Office Park Nysdam, Avenue Reine Astrid 92, B-
1310 La Hulpe, BE 
Agilent Technologies 
LDA UK Ltd (DAKO) 
Cheadle Royal Business Park, Stockport, Cheshire 
SK8 3GR, UK 
AstraZeneca PLC 1 Francis Crick Avenue, Cambridge Biomedical 
Campus, Cambridge CB2 0AA, UK 
BD Biosciences Binningerstrasse 94, 4123 Allschwil, CH 
Biolegend UK Ltd 4B, Highgate Business Centre, 33 Greenwood Pl, 
Kentish Town, London NW5 1LB, UK 
Bioline Edge Business Centre, Humber Rd, London NW2 
6EW, UK 
Carl Zeiss Ltd. ZEISS House Building 1030, Cambourne Business 
Park, Cambourne, Cambridge CB23 6DW, UK 
Cell Signalling 
Technology Europe BV 
(CST) 
Dellaertweg 9b, 2316 WZ Leiden, NL 
Clarivate Analytics Friars House, Blackfriars Rd, London SE1 8EZ, UK 
Fisher Scientific    
(Thermo Fisher 
Scientific) 
Unit 3, Fountain Dr, Inchinnan, Renfrew PA4 9RF, 
UK 
GE Healthcare Amersham Pl, Little Chalfont HP7 9NA, UK 
Griener Bio-One Ltd. Unit 5 Brunel Way, Stonehouse GL10 3SX 
Hendley-Essex Ltd Oakwood Hill Industrial Estate Loughton IG10 3TZ, 
UK 
Invitrogen             
(Thermo Fisher 
Scientific) 




Siemensstraße 25, 61352 Bad Homburg vor der 
Höhe, DE 
Merck Millipore Merck KGaA, Frankfurter Strasse 250, Darmstadt, 
64293, DE 
Miltenyi Biotech Friedrich-Ebert-Straße 68, 51429 Bergisch 
Gladbach, DE 





Olympus Life Sciences 
(KeyMed Ltd) 
KeyMed House, Stock Road, Southend-on-Sea, Essex 
SS2 5QH, UK 
PeproTech EC Ltd. 29 Margravine Rd, Hammersmith, London W6 8LL, 
UK 
QIAGEN Ltd Skelton House, Lloyd Street North, Manchester M15 
6SH, UK 
Sakura Europe Flemingweg 10, 2408 AV Alphen aan den Rijn, NL 
Santa Cruz 
Biotechnology 
Bergheimer Str. 89-2, 69115 Heidelberg, DE 
Sartorius GmbH Otto-Brenner-Str. 20, 37079 Götingen, DE 
Scientific Lab Supplies 
(SLS) Ltd. 
204 Main St, Coatbridge, ML5 3RB, UK 
Sigma-Aldrich Co Ltd. Second Ave, Heatherhouse Industrial Estate, Irvine 
KA12 8NB, UK 
STEMCELL Technologies Cambridge Research Park, 8100 Beach Dr, 
Waterbeach, Cambridge CB25 9TL, UK 
Stratech Scientific Ltd. Cambridge House, St Thomas' Pl, Ely CB7 4EX, UK 
Thermo Fisher 
Scientific 
Unit 3, Fountain Dr, Inchinnan, Renfrew PA4 9RF, 
UK 
Table 2.1 - Companies/Suppliers 
 
2.1.2 Flow Cytometry 
2.1.2.1 Antibodies/dyes 
Antibodies/Dyes Cat. Supplier 
7-AAD 559925 BD Biosciences 
APC Annexin V 550475 BD Biosciences 
APC-Cy7 Mouse Anti-Human CD19 (SJ25C1) 557791 BD Biosciences 
APC-Cy7 Mouse Anti-Human CD45 (2D1) 557833 BD Biosciences 
FITC Annexin V 556419 BD Biosciences 
FITC Mouse Anti-Human CD5 (UCHT2) 555352 BD Biosciences 
Human TruStain Fc Receptor Blocking Solution 422302 Biolegend 
Pacific Blue anti-Human CD3 (UCHT1) 300431 Biolegend 
PE-Cy7 Mouse Anti-Human CD19 (SJ25C1) 557835 BD Biosciences 







Antibody Dilution Cat.  Supplier 
Fox01 (C29H4) Rabbit mAb 1:100 2880S CST 
Alexa Fluor 488 Goat anti-
Rabbit, IgG (H+L)  1:500 A11008 ThermoFisher Scientific 
Alexa Fluor 594 anti-
mouse/human CD45R/B220 (RA3-
6B2) 
1:200 103254 Biolegend 
P-Akt (S473) (D9E) XP Rabbit 
mAb 1:400 4060S CST 





Antibody Dilution Cat.  Supplier 
Fox01 (C29H4) Rabbit mAb 1:100 2880S CST 
P-Akt (S473) (D9E) XP Rabbit 
mAb 1:100 4060S CST 
Table 2.4 – IHC antibodies 
 
 
2.1.5 Western blotting 
2.1.5.1 Antibodies 
Antibody Dilution Dilutent Cat. Supplier 
14-3-3 (pan) Rabbit Ab 1:1000 5 % BSA/TBST 8312S CST 
4E-BP1 (53H11) Rabbit mAb 1:1000 5 % BSA/TBST 9644S CST 
Akt (pan) (C67E7) Rabbit mAb 1:1000 5 % BSA/TBST 4691S CST 





Anti-mouse IgG, HRP-linked Antibody  1:2000 2 % Milk/TBST 7076S CST 
Anti-rabbit IgG, HRP-linked Antibody  1:2000 2 % Milk/TBST 7074S CST 




Antibody Dilution Dilutent Cat. Supplier 
Bcl-xL Rabbit Ab 1:1000 5 % BSA/TBST 2762S CST 
beta-Tubulin Rabbit Ab 1:1000 5 % BSA/TBST 2146S CST 
BIM (C34C5) Rabbit mAb 1:1000 5 % BSA/TBST 2933S CST 
Btk (D3H5) Rabbit mAb 1:1000 5 % Milk/TBST 8547S CST 
CDK2 (78B2) Rabbit mAb 1:1000 5 % BSA/TBST 2546S CST 





Cyclin D1 (92G2) Rabbit mAb 1:1000 5 % BSA/TBST 2978S CST 
cyclin D2 (34B1-3) Rat mAb 1:1000 5 % Milk/TBST sc-452 
Santa 
Cruz 
Cyclin E1 (HE12) Mouse mAb 1:1000 5 % Milk/TBST 4129S CST 
Cyclin E2 Rabbit Ab 1:1000 5 % BSA/TBST 4132S CST 
Fox01 (C29H4) Rabbit mAb 1:1000 5 % BSA/TBST 2880S CST 
Fox03a (75D8) Rabbit mAb 1:1000 5 % BSA/TBST 2497S CST 
Fox04 Rabbit Ab  1:1000 5 % BSA/TBST 9472S CST 
GAPDH (D16H11) XP Rabbit mAb 1:2000 5 % Milk/TBST 5174S CST 
GSK-3beta (D5C5Z) XP Rabbit mAb 1:1000 5 % BSA/TBST 12456S CST 
IRDye 680RD Goat-anti Rabbit IgG 1:15000 TBST 926-68071 LI-COR 
IRDye 800CW Goat-anti Mouse IgG 1:15000 TBST 827-08364 LI-COR 
Lamin A/C Rabbit Ab 1:1000 5 % BSA/TBST 2032S CST 
Mcl-1 Rabbit Ab 1:1000 5 % BSA/TBST 4572S CST 
Monoclonal Anti-gamma-Tubulin 
antibody (Mouse) 1:1000 
2 % 
Milk/TBST T5326 Sigma 
P-4E-BP1 (T37/46) Rabbit Ab 1:1000 5 % BSA/TBST 9459S CST 
P-Akt (S473) (D9E) XP Rabbit mAb 1:1000 5 % BSA/TBST 4060S CST 
P-Akt (T308) (D25E6) XP Rabbit mAb 1:1000 5 % BSA/TBST 13038S CST 
P-Btk (Y223) (D9T6H) Rabbit mAb 1:1000 5 % Milk/TBST 87141S CST 




Antibody Dilution Dilutent Cat. Supplier 
P-Fox01 (T24)/Fox03a (T32) Rabbit 
Ab 1:1000 
5 % 
BSA/TBST 9464S CST 
P-GSK-3beta (S9) (D85E12) XP Rabbit 
mAb 1:1000 
5 % 
BSA/TBST 5558S CST 
P-p44/42 MAPK (T202/Y204) 
(D13.14.4E) XP Rabbit mAb 1:1000 
5 % 
BSA/TBST 4370S CST 
P-PRAS40 (T246) (C77D7) Rabbit mAb  1:1000 5 % BSA/TBST 2997S CST 
P-Rb (S780) Rabbit mAb 1:1000 5 % BSA/TBST 9307S CST 
P-Rb (S807/811) Rabbit mAb 1:1000 5 % BSA/TBST 9308S CST 
P-S6 Ribsomal Protein (S235/236) 
(D57.2.2E) XP Rabbit mAb 1:1000 
5 % 
BSA/TBST 4858S CST 
p21 Waf1/Cip1 (12D1) 1:1000 5 % BSA/TBST 2947S CST 
p44/42 MAPK (Erk1/2) (137F5) Rabbit 
mAb 1:1000 
5 % 
BSA/TBST 46953S CST 
PARP (46D11) Rabbit mAb 1:1000 5 % Milk/TBST 9532S CST 
PRAS40 (D23C7) XP Rabbit mAb  1:1000 5 % BSA/TBST 2691S CST 
Purified Mouse Anti-p27 [Kip1]  1:2000 5 % Milk/TBST 610241 BD 
Rb (4H1) Mouse mAb 1:2000 5 % Milk/TBST 9309S CST 
S6 Ribsomal Protein (54D2) Mouse 
mAb 1:1000 
5 % 
BSA/TBST 2317S CST 
Survivin (71G4B7) Rabbit mAb 1:1000 5 % BSA/TBST 2808S CST 





2.1.6.1 TaqMan assays 
Target Assay ID Supplier 
BBC3 Hs00248075_m1 ThermoFisher Scientific 
BCL2L1 Hs00236329_m1 ThermoFisher Scientific 
BCL2L11 Hs00197982_m1 ThermoFisher Scientific 
CCND1 Hs00765553_m1 ThermoFisher Scientific 
CCND2 Hs00153380_m1 ThermoFisher Scientific 
CCND3 Hs01017690_g1 ThermoFisher Scientific 
CCNG2 Hs00171119_m1 ThermoFisher Scientific 




Target Assay ID Supplier 
CDKN1B Hs01597588_m1 ThermoFisher Scientific 
FOXO1 Hs01054576_m1 ThermoFisher Scientific 
FOXO3 Hs00818121_m1 ThermoFisher Scientific 
FOXO4 Hs00936217_g1 ThermoFisher Scientific 
GADD45A Hs00169255_m1 ThermoFisher Scientific 
GUSB Hs00939627_m1 ThermoFisher Scientific 
IGF1R Hs00609566_m1 ThermoFisher Scientific 
MCL1 Hs01050896_m1 ThermoFisher Scientific 
SESN3 Hs00914870_m1 ThermoFisher Scientific 
SOD2 Hs00167309_m1 ThermoFisher Scientific 
Table 2.6 - TaqMan assays for RT-qPCR 
 
2.2 Methods 
This section will provide a broad description of the methods used to generate 
the data represented within this thesis. Please refer section 2.1 ‘Materials’, for 
specific information regarding suppliers, antibodies and TaqMan assays. 
2.2.1 General Tissue Culture 
2.2.1.1 Cell culture conditions 
Cell culture methods were executed using sterile technique in a laminar flow 
hood. Cell cultures were maintained in a humidified incubator at 37 °C in 5 % 
carbon dioxide (CO2). procedure 
2.2.1.2 Cell culture media 
Cell culture media containing supplements are herein referred to as ‘complete’ 
media. Unless otherwise stated, ‘complete RPMI’ consists of RPMI-1640 cell 
culture medium containing 10% FBS, 50 U/mL penicillin, 50 mg/mL streptomycin 
(1 % Pen Strep) and 2 mM L-glutamine (1 % L-glutamine) (ThermoFisher 
Scientific). ‘Complete DMEM’ consists of DMEM cell culture medium containing 
10% FBS, 50 U/mL penicillin, 50 mg/mL streptomycin (1 % Pen Strep) and 2 mM 




2.2.1.3 Primary CLL cells 
Ethical approval was granted from the West of Scotland Research Ethics 
Committee, NHS Greater Glasgow and Clyde, UK. PB samples were drawn from 
(clinically-diagnosed) CLL patients after written informed consent. Patients were 
either treatment naïve or had not received therapy in the previous 3 months, 
unless otherwise stated. Peripheral blood mononuclear cells (PBMCs) from CLL 
patients were isolated by density gradient centrifugation using Histopaque-1077 
Hybri-Max (Histopaque) (Sigma) according to the manufacturer’s instructions. 
Briefly, PB samples (EDTA blood collection tubes (BD)) from CLL patients were 
diluted 1:1 with RT CLL wash buffer (PBS, 0.5 % FBS, 2 mM EDTA). Histopaque 
was aliquoted into reaction tubes (10 mL Histopaque into a 50 mL reaction tube 
for 30 mL PB sample or 4mL Histopaque into a 15 mL reaction tube for 10 mL PB 
sample). The sample was carefully layered on top of the Histopaque layer and 
centrifuged at 300g for 30 min at RT. Importantly, the temperature of the 
centrifuge was maintained at RT prior to centrifugation as differences in 
temperature would impact the enrichment of mononuclear cells. Moreover, it is 
imperative that the brake on the centrifuge is switched off to prevent disruption 
of the liquid interface as a result of sudden breaking. The white ‘buffy’ layer of 
mononuclear cells between the plasma:histopaque interface was harvested and 
transferred into a fresh 50 mL reaction tube (Greiner Bio-One). The cell 
suspension was washed with 4 volumes of CLL wash buffer and centrifuged at 
300g for 10 min at RT. The cell pellet was resuspended with 10 mL CLL wash 
buffer and centrifuged at 300g for 10 min at RT. The pellet was then 
resuspended in a volume of CLL wash buffer (<40 mL) (418). The cells were 
counted before proceeding to flow cytometry to check the purity of CLL cells. 
PBMCs isolated from CLL patients were >90 % CD19+ CD5+ cells as determined by 
flow cytometry.  
PB samples from CLL patients with low leukocyte counts, defined as <40 x109 
leukocytes/L, were processed using the RosetteSep human B-cell enrichment 
cocktail (STEMCELL Technologies) according to the manufacturer’s instructions. 
Briefly, the PB sample was transferred to a 50 mL reaction tube and 50 µL of the 
RosetteSep cocktail was added per mL of blood and incubated for 20 min at RT. 
The sample was then diluted 1:1 with RT CLL wash buffer. The protocol was then 




enrichment, B cell purity was >90 % as determined by flow cytometry. Freshly 
isolated primary CLL cells were cultured at 1 x107 cells/mL in complete RPMI or 
cryopreserved (section 2.2.1.6).  
Information about the primary samples used within this thesis, including patient 
pseudonym and prior treatment, can be found in Table 2.7. Of note, prognostic 
biomarkers such as Binet stage, ZAP-70 status, IGVH (IGVH mut) and TP53 (TP53 
mut) mutational status and cytogenetic abnormalities (cytogenetics) are 
included. Hyphens (-) indicate prognostic information that was not assessed in 
the clinic. Moreover, whilst multiple cytogenetic alterations exist in CLL disease 
biology, not all are assessed in the clinic. For this reason, a patient with ‘no 
del(11q)/del(17p)’ indicates that del(11q) or del(17p) were not detected. 
Therefore, it is possible that undetected cytogenetic abnormalities may exist in 















CLL8 N F A neg U-CLL - del(11q) 
CLL9 Y F B neg - - - 
CLL18 Y F B pos U-CLL Y del(11q) 
CLL28 N F A pos - - del(17p) 
CLL32 N F C pos U-CLL - no 
del(11q)/del(17p) 
CLL44 N F A neg M-CLL - no 
del(11q)/del(17p) 
CLL46 N F A pos M-CLL - no 
del(11q)/del(17p) 
CLL57 N M C pos - - no 
del(11q)/del(17p) 
CLL69 Y M A pos U-CLL - no 
del(11q)/del(17p) 
CLL72 N F A pos - - no 
del(11q)/del(17p) 
CLL80 N M C neg - - del(17p) 
CLL84 Y M B neg U-CLL - del(11q) 
CLL85 Y F A - - - del(11q) 
CLL90 Y F B pos - - no 
del(11q)/del(17p) 
CLL93 Y M C pos - - del(17p) 
CLL95 Y M B - - N no 
del(11q)/del(17p) 
CLL109 N M - - - - del(17p) 


















CLL116 N M A pos - - no 
del(11q)/del(17p) 
CLL118 N M A pos - - del(11q) 
CLL119 N F B - - - del(17p) 
CLL123 N M A - - - no 
del(11q)/del(17p) 
CLL126 N M B pos - - no 
del(11q)/del(17p) 
CLL132 N F B pos - - del(17p) 
CLL138 Y F A pos - - no 
del(11q)/del(17p) 
CLL139 N F - pos - - del(11q) 
CLL142 Y F B pos - - no 
del(11q)/del(17p) 
CLL143 Y F C pos - - del(11q) 
CLL144 N M B pos - - del(17p) 
CLL147 N M C pos - - no 
del(11q)/del(17p) 
CLL148 Y M B pos - - del(11q) 
CLL149 N M A - - - del(17p) 
CLL150 N M A pos - - no 
del(11q)/del(17p) 
CLL151 N M B - - - del(11q) 
CLL155 Y M B - - - del(11q) 
CLL157 N M - - - - del(11q) 
CLL165 N M C - - - del(11q) 
CLL168 N M B - - - Tri12 del(13q) 
CLL169 N F C - - - del(11q) 
CLL170 Y F - - - - - 
CLL172 N M - - - - no 
del(11q)/del(17p) 
CLL184 N M - - - - no 
del(11q)/del(17p) 
Table 2.7 - CLL patients (including clinical staging and prognostic stratification) 
Tx = prior therapy (yes or no); Binet Stage (A, B or C); ZAP-70 status (positive or negative); IGVH 
mutational status (U- or M-CLL); TP53 somatic mutation (yes or no); cytogenetics (as explained); 
Hyphens (-) indicate prognostic information that was not assessed in the clinic 
 
2.2.1.4 Buffy coat samples 
‘Buffy coats’ provide an enriched source of leukocytes enabling isolation of large 
numbers of immune cells. Buffy coat samples from healthy individuals were 
obtained from the Scottish National Blood Transfusion Service (SNBTS) following 
volunteer blood donations. To select for B cells, we adopted the RosetteSep 




provide a method for negative or positive selection of CD19+ B cells, 
respectively.  
The protocol for the RosetteSep human B-cell enrichment cocktail was followed 
according to the manufacturer’s instructions for buffy coat samples. Of note, it 
was important that the concentration of nucleated cells did not exceed 5 x107 
cells/mL. Briefly, 50 µL of the RosetteSep cocktail was added per mL of buffy 
coat suspension and incubated for 20 min at RT. The sample was then diluted 
with two volumes of PBS and gently mixed. The sample was then layered on an 
appropriate volume of Histopaque and centrifuged for 20 min at 1200g at RT 
with the break off. The enriched cells were removed from the 
histopaque:plasma interface and washed twice with PBS, as per the protocol 
described earlier. 
The protocol for human CD19 Microbeads using MACS separation technology was 
followed according to the manufacturer’s instructions. Importantly, cells were 
kept cold throughout the procedure and solutions were pre-cooled. In brief, 
buffy coat samples underwent density gradient centrifugation with Histopaque 
according the manufacturer’s instructions. The cell suspension was counted to 
adjust the concentration of cells to meet the requirements of the protocol. 
Before commencing magnetic labelling, the cell suspension was passed through a 
30 µm cell strainer (Sartorius) to create a single-cell suspension. At this point, 5 
x105 cells were removed from the suspension as a pre-enrichment control and 
transferred to a FACS tube (BD Biosciences). The remaining cells were 
centrifuged at 300g for 10 min and resuspended at a concentration of 1 x107 
cells/80 µL PBS. 20 µL of CD19 Microbeads was added per 1 x107 cells and 
incubated for 15 min at 4 °C. Following incubation with the microbeads, the 
cells were washed with 2 mL PBS per 1 x107 cells. After a second centrifugation 
step, up to 1 x109 cells were resuspended in 3 mL PBS. The cell suspension 
subsequently underwent magnetic separation using ‘LS’ MACS columns (Miltenyi) 
placed in the magnetic field of a suitable MACS Separator (Miltenyi). The 





Following enrichment, B cell purity was >90 % as determined by flow cytometry. 
Cell pellets of enriched B cells were generated and used immediately or ‘snap 
frozen’ until further use. B cells derived from healthy donors are herein referred 
to as ‘healthy donor B cells’ or ‘healthy CD19+’. 
2.2.1.5 Cell lines 
As a general rule, the procedure for maintaining cell lines were performed in 
accordance with ATCC or DSMZ guidelines. Where ‘working’ stocks of cell lines 
existed, a new vial was thawed once the passage number had reached 20. 
Cell line Origin Culture conditions Details 
MEC-1 EBV-transformed PB-
derived CLL cells from a 
male (61 years; 1993) 
patient with evidence of 
prolymphocytoid 
transformation. MEC-1 
cells are CD5- CD19+ and 
possess del(17p) (409). 
DMEM (10% FBS; 1% 
P/S; 1% L-glutamine); 
Maintain at about 0.5-
2.0 x10^6 cells/ml; 
optimal split ratio 1:3 
every 2-3 days; Culture 
upright in T75^2 culture 
flasks (409).  
The MEC-1 
CLL cell line 







HG-3 Transformed PB-derived 
CLL cells from a male 
(70 years; 1998) patient. 
The patient was Rai 
stage II at diagnosis. HG-
3 cells are CD5+ CD19+ 
and possess del(13q) 
(410). 
RPMI (10% FBS; 1% P/S; 
1% L-glutamine); 
Maintained at 0.5-1 x 
10^6 cells/ml; optimal 
split ratio 1:3 every 2-3 
days; Culture upright in 
T75^2 culture flasks 
(410).  
The HG-3 CLL 
cell line was 






NT-L Mouse fibroblast L cells 
were derived from 
subcutaneous connective 
tissue and represent a 
suitable transfection 
host (411). 
RPMI (10% FBS; 1% P/S; 
1% L-glutamine); 
Passage cells at 70 % 
confluency; optimal 
split ratio 1:4 to 1:10 
every 2-3 days; Culture 
in T75^2 culture flasks 
(411).  
The NT-L cell 
line was a 








Cell line Origin Culture conditions Details 
CD40L Mouse fibroblast L cells 
(as above) stably 
transfected with CD154 
(CD40L).  
RPMI (10% FBS; 1% P/S; 
1% L-glutamine); 
Passage cells at 70 % 
confluency; optimal 
split ratio 1:4 to 1:10 
every 2-3 days; Culture 
in T75^2 culture flasks.  
The CD40L 
cell line was 








The HEK293T cell line is 
version of human 
embryonic kidney 293 
cells, containing the 
SV40 T-antigen (412). 
DMEM (10% FBS; 1% 
P/S; 1% L-glutamine); 
Seed out at ~1-3 x 10^6 
cells; Passage cells at 
70 % confluency; 
optimal split ratio 1:3 
to 1:8 every 2-3 days; 
Culture in T75^2 culture 
flasks (412).  
 
Table 2.8 - Cell lines (origin, culture conditions and further details) 
 
 
2.2.1.6 Cryopreservation of cells 
Freshly isolated PB CLL cells that were not directly required for experimentation 
were cryopreserved for long-term storage in our CLL cell bank. In brief, primary 
CLL cell suspensions were counted and resuspended at a concentration of 5 x107–
1 x108 cells/mL in cell freezing solution (FBS, 10 % DMSO). The cells were then 
aliquoted into cryovials (Greiner Bio-One) and quickly transferred to a Mr. 
FrostyTM freezing container (ThermoFisher Scientific), which was subsequently 
placed at -80 °C to slowly freeze the cells at a controlled rate of 1 °C/min. After 
overnight (O/N) storage at -80 °C, the cells were transferred to liquid nitrogen 
storage. Cryopreservation of cell lines was performed to create ‘master’ and 
‘working’ stocks to ensure the continual supply of back-up cells. Importantly, 
cells should only be cryopreserved at the maximum growth rate or almost at 
confluency.  
As suspension cells, MEC-1 and HG-3 cells were cryopreserved using similar 
methods to primary CLL cells. Following an initial period of expansion of one 
‘master’ stock vial, the cells were inspected for contamination, counted and 




cells/mL to create multiple new ‘working’ stocks. The cells were then slowly 
frozen in accordance with the protocol for primary CLL cells.  
As with the suspension cultures, adherent NT-L, CD40L and HEK293T cells were 
expanded to create multiple working stocks. Once the cells had reached 70–80 % 
confluency, the cells were washed twice with 10 mL PBS (adding gently to avoid 
disturbing the cell layer). The cells were then detached using 1 mL pre-warmed 
Trypsin-EDTA (0.5 %; Thermo Fisher Scientific) for <3 min, ensuring gentle 
dissociation to minimise damage to the cells. The cells were viewed under a 
microscope to observe detachment. Once >90 % of the cells were detached, 9 
mL complete medium was added to the cell suspension to establish a viable cell 
count. The cells were subsequently resuspended in cell freezing solution at a 
concentration of 4–8 x106 cells/mL and slowly frozen as per the standard 
protocol.  
2.2.1.7 Thawing cryopreserved cells 
Frozen primary CLL cells were thawed quickly (<2 min) in a 37 °C water bath and 
transferred to a 15 mL reaction tube (one vial per reaction tube) (Greiner Bio-
One). The cells were diluted slowly (dropwise) over 10 min using 10 mL pre-
warmed ‘DAMP’ solution (PBS, 10 U/mL DNase I, 1 % HSA, 2.5 mM Magnesium 
Chloride (MgCl2), 8.2 mM Tri-Sodium Citrate (Na3C6H5O7)). The cell suspension 
was centrifuged at 300g and then resuspended in 10 mL complete RPMI. After a 
final centrifugation step, the cells were resuspended in complete RPMI at a 
concentration of 1 x 107 cells/mL and cultured O/N to recover prior to beginning 
an experiment. Following recovery, a viable cell count was obtained. Of note, 
primary CLL cells were cultured upright in an appropriately sized culture flask 
(Greiner Bio-One).  
Cell lines were thawed quickly in a 37 °C water bath and transferred to a 15 mL 
reaction tube. The cells were diluted slowly (dropwise) using 10 mL pre-warmed 
complete medium. Following centrifugation at 300g, the cells were resuspended 
in 10 mL complete medium and transferred to an appropriately sized culture 
flask. The cells were observed daily to monitor cell recovery before commencing 




and had reached at least the second passage. Of note, when necessary, cell lines 
were expanded to create ‘working’ stocks from ‘master’ stocks of cell lines.  
2.2.1.8 Drug treatments 
AZD8055, AZD2014, ibrutinib, rapamycin and AS1842856 were solubilised in 
DMSO (Sigma) to make 10 mM stock solutions. AZD5363 was solubilised in DMSO 
to make a 100 mM stock solution. Stock solutions were stored in 10 µL aliquots 
for up to 2 years at -80 °C. Once thawed, aliquots were stored at 4 °C for up to a 
week. Unless otherwise stated, the standard working concentration of each drug 
used in experiments was as follows: 
Drug Stock concentration (mM) Working concentration (µM) 
AZD8055 10 0.1 
AZD2014 10 0.5 
Ibrutinib 10 1 
Rapamycin 10 0.01 
AS1842856 10 0.03 
AZD5363 100 1 




Working concentrations were made by diluting stock solutions in appropriate cell 
culture media, depending on the cells being examined. DMSO was used as a 
vehicle control (vehicle) or ‘no drug control’ (NDC) in drug treatments. Unless 
otherwise stated, cells were incubated with the appropriate working 
concentration of drug or vehicle for the entirety of the treatment period.  
Prior to F(ab’)2 stimulations (section 2.2.1.9), cells were ‘pre-treated’ with drug 
for 30 min. In NT-L and CD40L/IL-4 co-cultures (with the exception of the 
primary CLL cell proliferation assay), primary CLL cells were co-cultured O/N 
with the stromal cells before starting the drug treatment for the indicated time 
period (section 2.2.1.10).  
2.2.1.9 F(ab’)2 stimulation 
F(ab’)2 fragments (Stratech Scientific) are polyclonal IgM-specific secondary 




use of F(ab’)2 fragments represent an established method of stimulating and 
initiating antigen-dependent BCR signalling in CLL cells (213). F(ab’)2 fragments 
were solubilised in a sterile-filtered liquid at a concentration of 1.3 mg/mL and 
stored for up to a year at 4 °C. Depending on the application, 1 x107/mL primary 
CLL cells or 1 x106/mL MEC-1 cells were seeded into tissue culture plates and 
stimulated with 10 µg/mL F(ab’)2 fragments diluted directly into the culture 
medium for the indicated time period. Following the indicated stimulation 
period, the cells were harvested and processed for downstream applications.  
2.2.1.10 Short-term NT-L and CD40L/IL-4 co-culture systems 
NT-L and CD40L cells are immortalised stromal cells utilised in an established in 
vitro co-culture system designed to mimic the CLL-T cell interactions within the 
CLL-TME (186).  
Depending on the downstream application, 3 x105/mL NT-L or CD40L cells were 
seeded into cell culture plates and left for 2 h to adhere. Freshly isolated or 
thawed cryopreserved CLL cells were counted and subsequently added to the 
stromal cells at a ratio of 25:1 (CLL cell:stromal cell) in complete RPMI. For 
CD40L co-cultures, complete growth medium was supplemented with 10 ng/mL 
interleukin-4 (IL-4) diluted directly into the culture medium. This co-culture 
system is commonly known as the CD40L/IL-4 system. Recombinant human IL-4 
(PeproTech) was reconstituted in dH2O to make a 10 µg/mL stock solution and 
stored in 10 µL aliquots for up to 3 months at -80 °C. The co-cultures were 
incubated O/N prior to treating the cells with drug or vehicle control. The length 






Figure 2.1 – CLL cells co-cultured with NT-L / CD40L 
Representative micrograph images (20x) of ‘plastic’ (top panel), NT-L (middle panel) and CD40L 
(bottom panel) co-cultures after 48 h incubation. CLL patient pseudonym CLL141. Dashed boxes 
(left panel) represent a region of interest (ROI) within the field of view that have been scaled (right 
panel) to more easily identify primary CLL cells (black arrows) and NT-L / CD40L stromal cells 
(white arrows). Of note, primary CLL cells form close interactions with CD40L cells, demonstrated 
as large ‘clumps’ surrounding CD40L cells. Scale bar = 50 µm. 
 
2.2.2 Flow cytometry 
The working concentration of fluorochrome-linked antibodies and dyes used in 
flow cytometry panels were determined in accordance with the manufacturer’s 
recommendations. Data generated by flow cytometry were acquired on a 
FACSCanto II analyser (BD Biosciences) connected to FACSDiva software (BD 





2.2.2.1 CLL patient samples 
On receipt of a PB CLL sample, 30 µL whole blood was transferred to a FACS 
tube under sterile conditions and stained in the presence of Human TruStain Fc 
receptor block (Biolegend) with the ‘primary CLL cell’ panel for 30 min at 4 °C, 
protected from light. Importantly, unstained and ‘fluorescence minus one’ (FMO) 
controls were run alongside the test samples.  
Component  Volume (uL)/Test 
Human TruStain Fc Receptor Blocking Solution 1 
APC-Cy7 Mouse Anti-Human CD45 2.5 
FITC Mouse Anti-Human CD5 2.5 
PE-Cy7 Mouse Anti-Human CD19 (clone SJ25C1) 2.5 
PBS to a final volume of 100 uL 
 
Table 2.10 - Primary CLL FACS panel 
 
 
Immediately after incubation with the antibody panel, 500 µL EasyLyseTM 
erythrocyte-lysing reagent (DAKO) was added to the blood and mixed 
immediately. The sample was incubated with the lysing reagent for 10-15 min at 
RT prior to acquisition on the flow cytometer. Of note, if the samples were not 
analysed within 45 min, they were placed on ice and acquired within 2 h.   
Following density gradient centrifugation of a PB CLL sample (section 2.2.1.3), 
the lymphocyte fraction was counted and 1 x106 viable cells were transferred to 
a FACS tube. Following centrifugation at 300g for 5 min at RT, the cell pellet 
was resuspended in 100 µL PBS and stained in the presence of Human TruStain Fc 
receptor block with the ‘primary CLL cell panel’ for 30 min at 4 °C, protected 
from light. Of note, unstained were run alongside the test samples. After the 
incubation period, the cells underwent a final washing (1 mL PBS) and 
centrifugation (300g for 5 min at RT) step. The cell pellet was then resuspended 
in 400 µL PBS and subsequently acquired on the flow cytometer.  
For both methods, the percentage of CD19+ CD5+ cells in patient CLL samples 
were determined by flow cytometry. A CD45+ population composed of >90 % 





Figure 2.2 – Gating strategy for CLL patient-derived PBMCs 
After density gradient centrifugation, PBMCs from CLL patients were stained with the ‘primary CLL 
cell panel’. The following describes the gating strategy performed to identify CD19+ CD5+ CLL cells 
by flow cytometry. (A) Forward scatter (FSC) and side scatter (SSC) were used to gate all cells and 
exclude dead cells - including the lymphocyte population (left panel) - and subsequently selected 
for single cell events or ‘singlets’ (middle panel). Further analysis was performed to select for 
CD45+ cells using a univariate histogram (right panel). (B) A bivariate histogram was then used to 
identify CD19+ CD5+ cells from the CD45+ population. PBMCs derived from CLL patients were 
typically >90 % CD19+ CD5+ cells. 
 
2.2.2.2 Buffy coat samples  
Following B cell selection using the RosetteSep human B-cell enrichment cocktail 
or human CD19 Microbeads (section 2.2.1.4), the cell suspension was counted 
and 5 x105 cells were transferred to FACS tubes. The cells were then centrifuged 
at 300g for 5 min and the resultant cell pellet was washed with 1 mL PBS. After 




stained in the presence of Human TruStain Fc receptor block with an anti-CD19 
antibody for 30 min at 4 °C, protected from light (Table 2.11). Following the 
incubation period, the cells were washed with 1 mL PBS and centrifuged at 300g 
for 5 min. The cells were then resuspended in 400 µL PBS and analysed on the 
flow cytometer. B cell purity was determined by the percentage of CD19+ cells. 
A population >90 % CD19+ cells was considered acceptable. The remaining cells 
were pelleted, snap-frozen and stored at -80 °C.  
Component  Volume (uL)/Test 
Human TruStain Fc Receptor Blocking Solution 1 
APC-Cy7 Mouse Anti-Human CD19 2.5 
PBS to a final volume of 100 uL 
 




Figure 2.3 - Gating strategy for isolated 'buffy coat' samples 
CD19+ B cells were negatively or positively selected from buffy coat samples using the RosetteSep 




gating strategy performed to identify CD19+ B cells using CD19 Microbeads (MACS separation 
technology) by flow cytometry. (A) FSC and SSC were used to gate all cells - including the 
lymphocyte population (left panel) - and subsequently selected for singlets (middle panel). 
Following density gradient centrifugation, ~5 x105 cells were removed from the cell suspension to 
assess the percentage of CD19+ cells prior to CD19 enrichment (right panel). (B) After enrichment, 
the percentage of CD19+ cells were examined using the ‘negative’ (flow-through) and ‘positive’ 
(CD19+) fractions generated from MACS separation. Following CD19 enrichment, the positive 
fraction cell was typically >90 % CD19+ cells. 
 
2.2.2.3 Apoptosis assay 
Dual Annexin V/7-AAD staining enables the discrimination of viable (Annexin 
Vneg, 7-AADneg), early apoptotic (Annexin Vpos, 7-AADneg) or late apoptotic 
(Annexin Vpos, 7-AADpos) cells following treatment and/or stimulation. 
Unless otherwise stated, Annexin V/7-AAD staining was performed following drug 
treatments for a defined time period. After the treatment period had finished, 
cells were harvested and transferred to FACS tubes. The cells were then washed 
1 mL HBSS (ThermoFisher Scientific) and centrifuged at 300g for 5 min. Of note, 
HBSS must contain calcium as it is required for the binding of Annexin V to 
phosphatidylserine (PS) molecules. After another centrifugation step, the cells 
were resuspended in 100 µL HBSS and stained at a concentration of 5 x105 
cells/100 µL HBSS with Annexin V/7-AAD (Table 2.12). The cells were incubated 
for 15 min at RT, protected from light. Following incubation, 400 µL HBSS was 
added to each FACS tube prior to analysis. Of note, a further centrifugation step 
after staining was omitted as 7-AAD forms complexes in equilibrium with DNA.  
Primary CLL cells / MEC-1 / HG-3 
 
Component  Volume (uL)/Test  
FITC/APC Annexin V 2.5  
7-AAD 2.5  
HBSS to a final volume of 100 uL 
 
 
Table 2.12 - Apoptosis FACS panel (primary CLL, MEC-1 and HG-3 cells) 
 
 
Annexin V/7-AAD staining was also performed to assess cell viability following 
CLL cell co-culture with NT-L/CD40L cells. To discriminate between primary CLL 




period, cells were stained with a human anti-CD45 antibody prior to commencing 
Annexin V/7-AAD staining. In brief, cells were resuspended in 100 µL HBSS and 
stained in the presence of Human TruStain Fc receptor block with an anti-CD45 
antibody (Table 2.13) for 30 min at 4 °C, protected from light. Following the 
incubation period, the cells were washed with 1 mL HBSS and centrifuged at 
300g for 5 min. The cells were resuspended in 100 µL HBSS and subsequently 
underwent the Annexin V/7-AAD staining protocol described earlier.  
NT-L / CD40L CLL co-cultures 
 
Component  Volume (uL)/Test  
Human TruStain Fc Receptor Blocking Solution 1  
APC-Cy7 Mouse Anti-Human CD45 2.5  
HBSS to a final volume of 100 uL 
 
 
==> 30 min incubation at 4 'C, followed by washing step 
 
 
FITC Annexin V 2.5  
7-AAD 2.5  
HBSS to a final volume of 100 uL 
 
 








Figure 2.4 - Gating strategy for Annexin V/7-AAD staining 
Following drug treatment and/or stimulation, primary CLL cells or cell lines were stained with 
Annexin V/7-AAD staining to assess cell viability. The following describes the gating strategy 
performed to discriminate between viable and non-viable cells by flow cytometry. (A) FSC and SSC 
were used to gate both viable/non-viable cells (left panel) and subsequently selected for singlets 
(right panel). (B) A bivariate histogram was then used to identify intact or viable cells (Annexin V 
negative, 7-AAD negative), early apoptotic (Annexin V positive, 7-AAD negative) and late apoptotic 
cells (Annexin V positive, 7-AAD positive). The percentages of the aforementioned populations 





Figure 2.5 - Gating strategy for Annexin V/7-AAD staining (NT-L / CD40L co-cultures) 
Annexin V/7-AAD staining was performed following drug treatments and/or stimulation. Assessing 
CLL cell viability after incubation with NT-L or CD40L cells requires discrimination between primary 
CLL cells (human) and stromal cells (mouse). The following describes the gating strategy for 
Annexin V 7-AAD staining after NT-L / CD40L co-cultures by flow cytometry. (A) FSC and SSC 
were used to gate all viable cells (including CLL and stromal cells) (left panel) and subsequently 
selected for singlets (middle panel). Further analysis was performed to distinguish between CLL 
cells and mouse stromal cells using a human-specific anti-CD45 antibody. CD45+ cells were 
selected using a univariate histogram (right panel). (B) A bivariate histogram was then used to 
identify intact or viable cells (Annexin V negative, 7-AAD negative), early apoptotic (Annexin V 
positive, 7-AAD negative) and late apoptotic cells (Annexin V positive, 7-AAD positive). The 






2.2.2.4 Cell cycle analysis by propidium Iodide (PI) staining  
Cell cycle analysis by PI staining was performed to quantify the DNA content of 
cells in response to cell stimulation and/or drug treatment. Following cell 
stimulation and/or drug treatment, 1 x106 cells/mL were harvested, transferred 
to FACS tubes and washed twice in 1 mL ice-cold PBS. The cells were then fixed 
by adding 1 mL ice-cold 80 % ethanol (Sigma) dropwise (1 min) to the cell pellet 
while vortexing. Of note, vortexing ensured compete fixation of all cells and 
minimised clumping. The cells were fixed for at least 30 min or stored <5 days at 
-20 °C. At the end of fixation, cells were washed twice in 1 mL ice-cold PBS. 
Cells were centrifuged at 850g for 5 min to minimise cell loss from spinning out 
of ethanol. Importantly, as PI stains both DNA and RNA, the latter must be 
removed with ribonucleases. Following the final centrifugation step, the cells 
were resuspended with 400 µL PI/RNase staining buffer (BD Biosciences) and 
incubated for 15 min at RT, protected from light. Of note, acquisition of cells on 
the flow cytometer was performed slowly at ‘low’ to discriminate between cell 





Figure 2.6 - Cell cycle analysis by propidium iodide (PI) staining 
Cell cycle analysis by propidium iodide (PI) staining was performed to quantify the proportion of 
cells in each phase of the cell cycle (G1/0, S and G2) in response to cell stimulation and/or drug 
treatment. The following describes the gating strategy performed to assess DNA content of cells. 
(A) FSC and SSC were used to gate cells (left panel) and subsequently select for singlets (right 
panel). (B) DNA content was examined by PI staining using a univariate histogram (left panel) to 
identify each phase of the cell cycle. This data was further processed using univariate modelling 
based on the Watson Pragmatic algorithm (right panel) to quantify the percentage population in cell 
cycle phase G1 (purple), S (yellow) and G2 (green). 
 
2.2.2.5 CellTrace Violet cell proliferation assay 
CellTrace Violet (CTV) is a cell-permeable dye used to trace multiple cell 
divisions using dye dilution by flow cytometry (414). Cell proliferation was 
assessed in primary CLL cells, HG-3 and MEC-1 cells in response to stimulation 
and/or drug treatment. Despite differences in the experimental design, the 
labelling protocol for both primary cells and cells lines remains the same – albeit 




To induce primary CLL cell proliferation, an established method was used that 
adopts CD40L co-cultures (section 2.2.1.10). A key difference to the co-cultures 
described earlier is the omission of IL-4 and addition of interleukin-21 (IL-21). IL-
21 was used to promote CLL cell proliferation in vitro as a component of long-
term CD40L co-cultures. Recombinant human IL-21 (PeproTech) was solubilised 
in dH2O to make a 50 µg/mL stock solution and stored in 10 µL aliquots for up to 
3 months at -80 °C. Primary CLL cells were stimulated with 25 ng/mL IL-21 
diluted directly into the culture medium. We and others have found IL-21 to be a 
stronger proliferative signal that confers robust proliferation of CLL cells co-
cultured on CD40L (180). Importantly, CTV dye should be prepared immediately 
prior to use by adding 20 µL DMSO to one vial of CTV reagent, creating a 5 mM 
stock concentration.  
CD40L cells were seeded (depending on the experimental design and the number 
of wells required) into a 12-well culture plate at a concentration of 5 x104 
cells/mL and left for 2 h to adhere to the plate. Of note, 5 x104 NT-L cells were 
seeded for co-cultures acting as a non-proliferative control. Freshly isolated or 
thawed cryopreserved CLL cells were counted and transferred to a 15 mL 
reaction tube. The cells were centrifuged at 300g for 5 min and resuspended in 
10 mL pre-warmed PBS. Following another centrifugation step, the cells were 
resuspended in pre-warmed PBS at a concentration of 1 x107 cells/mL. An 
aliquot of cells was removed and transferred to a FACS tube for an unstained day 
0 control. To label the cells, 1 µL CTV dye was added per mL of cell suspension, 
creating a 5 µM working concentration. The cells were then incubated for 20 min 
in a 37 °C water bath, protected from light. After the incubation period, 5 times 
the original staining volume of complete growth medum was added to the cells. 
After a 5 min incubation period, the cells were centrifuged and subsequently 
resuspended in fresh pre-warmed complete RPMI at a concentration of 1.25 x106 
cells/mL. An aliquot of CTV labelled cells was removed at this step to represent 
day 0 CTV-labelled cells. 1.25 x106 labelled CLL cells (1 mL) was subsequently 
added to the co-cultures (25:1 ratio) in complete RPMI supplemented with 25 





Cell proliferation was assessed on day 0, 3, 6 and 9. For each timepoint, fresh 
NT-L and CD40L cells were seeded and left to adhere to the plates (as above).  
CTV labelled CLL cells were then harvested and resuspended in fresh complete 
RPMI (+IL-21). The cells were then added to the stromal cells and incubated for 
1 h before treatment with fresh drugs commenced.  
For each timepoint, cells were harvested and transferred to FACS tubes. Cells 
were centrifuged at 300g for 5 min and resuspended in HBSS. After another 
centrifugation, the cell pellet was resuspended in 100 µL HBSS. The cells were 
then stained in the presence of Human TruStain Fc receptor block with the cell 
proliferation panel (Table 2.14) for 30 min at 4 °C, protected from light. 
Following the incubation period, the cells were washed with HBSS and 
centrifuged at 300g. The cell pellet was then resuspended in 100 µL HBSS and 
stained with Annexin V/7-AAD for 15 min at RT, protected from light. Following 
this, 400 µL HBSS was added to the cells and subsequently acquired on the flow 
cytometer.  
Component  Volume (uL)/Test 
Human TruStain Fc Receptor Blocking Solution 1 
APC-Cy7 Mouse Anti-Human CD45 2.5 
HBSS to a final volume of 100 uL 
 
==> 30 min incubation at 4 'C, followed by washing step 
 
 
FITC Annexin V 2.5  
7-AAD 2.5  
HBSS to a final volume of 100 uL 
 
 
Table 2.14 - Cell proliferation FACS panel 
 
 
As immortalised cell lines, HG-3 and MEC-1 cells do not require external stimuli 
to undergo proliferation. As such, CD40L co-cultures or IL-21 were not required. 
The protocol for labelling HG-3 and MEC-1 cells with CTV dye was similar to 
primary CLL cells. The amendments to this protocol are outlined below. HG-3 
and MEC-1 cells were resuspended in PBS at a concentration of 2 x106 cells/mL 




resuspended in complete DMEM or complete RPMI, respectively. Proliferation 
was assessed on day 0, 1, 2, 3. The cells to be assessed were harvested and 
transferred to FACS tubes. Cells were centrifuged at 300g for 5 min and 
resuspended in HBSS. After another centrifugation step, the cell pellet was 
resuspended in 100 µL of HBSS. The cells were then stained with Annexin V/7-
AAD for 15 min at RT, protected from light. At the end of the incubation period, 






Figure 2.7 - Gating strategy for the CTV cell proliferation assay (primary CLL cells) 
Proliferation of primary CLL cells was assessed following drug treatment and/or stimulation. CLL 
cell proliferation can be induced by CD40L (+IL-21) co-cultures. Monitoring proliferation can be 
achieved by labelling CLL cells with CTV. The dye is diluted with each cell division. Each ‘peak’ 
represents a population of cells that have undergone cell division. The greater the number of 




gating strategy performed to assess proliferation of primary CLL cells. (A) FSC and SSC were used 
to gate cells (top-left panel) and subsequently select for singlets (top-right panel). Next, a univariate 
histogram was used to select for CD45+ cells (bottom-left panel). Of these CD45+ cells, Annexin 
V/7-AAD staining was performed to select for viable cells (Annexin V- 7-AAD-) (bottom-right panel). 
(B) Of the viable cells gated, a univariate histogram was used to examine fluorescent intensity of 
CTV-labelled cells (bottom-right panel) across 4 timepoints: day 0 (grey), day 3 (green), day 6 
(blue) and day 9 (red). 10,000 Q4 (Annexin V- 7-AAD-) events were recorded.  
 
Figure 2.8 - Gating strategy for the CTV cell proliferation assay (HG-3 / MEC-1 cells) 
Proliferation of CTV-labelled HG-3 and MEC-1 cells was assessed following drug treatment. The 
following describes the gating strategy performed to assess proliferation of HG-3 and MEC-1 cell 
lines. (A) FSC and SSC were used to gate cells (left panel) and subsequently select for singlets 
(middle panel). Next, Annexin V 7-AAD staining was performed to select for viable cells (Annexin V- 
7-AAD-) (right panel). (B) Of the viable cells gated, a univariate histogram was used to examine 
fluorescent intensity of CTV-labelled cells (bottom-right panel) across 4 timepoints: 0 h (grey), 24 h 





The immunofluorescence (IF) procedure described here was adapted from the 
protocol published by Abcam entitled, ‘Immunocytochemistry and 
immunofluorescence protocol’ (415).  
2.2.3.1 Tissue preparation 
IF was performed on PB-derived primary CLL cells, HG-3 and MEC-1 cell lines to 
assess localisation and intensity of FOXO1 staining following drug treatment 
and/or F(ab’)2 stimulations. To determine the spatial distribution and 
localisation of FOXO1 within the TME, frozen spleen sections from wild-type 
(WT) mice and our CLL-like PKCαKR mouse model were used.  
Primary CLL cells, HG-3 and MEC-1 cells were treated with drug or vehicle 
control in the presence or absence of F(ab’)2 stimulation (sections 2.2.1.8-
2.2.1.9). Following the stimulation period, the cells were harvested and 
transferred into 15 mL reaction tubes. The cells were centrifuged at 300g for 5 
min and resuspended in 10 mL PBS. Following another centrifugation step, the 
cells were fixed at a concentration of 5 x106 cells/mL in 4 % paraformaldehyde 
(PFA) (Santa Cruz Biotech) for 15 min at RT. After fixation, the cells were 
washed 3 times with ice-cold PBS. Cells were stored at 4 °C and used within 3 
days.  
Following the end of experimentation, spleens were harvested from WT mice 
and the CLL-like PKCαKR mouse model. Spleens carrying CLL-like disease were 
acquired from experiments carried out by Dr. Jodie Hay as left-over spleen 
tissue from in vivo experiments. The tissue was submerged in OCT freezing 
medium (Sakura), manipulated to achieve the correct orientation and carefully 
‘snap’ frozen using liquid nitrogen, ensuring the OCT medium did not ‘crack’. 
OCT-frozen spleens were stored at -80 °C until required. 
2.2.3.2 Slide preparation 
For primary CLL cells and cell lines, 10-spot multispot microscope slides (Henley-
Essex) were prepared by coating each spot with 20 µL poly-L-lysine solution 




allowed to dry at RT. Afterwards, 20 µL fixed cells (1 x105 cells/20 µL) was 
pipetted onto each ‘spot’ and left to adhere for 1–2 h.  
Sectioning of OCT-frozen mouse spleens was performed by Mr. Colin Nixon of the 
Histology Service at the Cancer Research UK (CRUK) Beatson Institute, Glasgow, 
UK. Cryo-sections were cut at 7µm and mounted onto coated histological slides. 
The sections were air-dried for 30 min at RT to prevent sections from falling off 
the slides during antibody incubations. Following this, the spleen sections were 
stored at -80 °C until required. Of note, ‘unstained’ and ‘secondary-only’ 
controls were included. 
2.2.3.3 Fixation and permeabilization  
After adhering to the slide, the cells were rinsed 3 times with 20 µL PBS. At this 
point, the cells were observed under a light microscope to observe seeding 
density. The cells were then permeabilised with ‘perm buffer’ (PBS, 0.25% 
Triton X-100) for 15 min at RT. Following incubation, the cells were washed 3 
times with 20 µL PBS, 5 min each.  
Immediately upon removal of splenic sections from -80 °C, 100 µL ice-cold 4 % 
PFA was added to the sections for 15 min at RT. After fixation, the cells were 
washed 3 times with 100 µL ice-cold PBS. At this step, a hydrophobic barrier was 
drawn around the specimen. The sections were then permeabilised with 100 µL 
perm buffer for 15 min at RT. Following incubation, the cells were washed 3 
times with 100 µL PBS, 5 min each.  
2.2.3.4 Blocking and immunostaining 
For blocking unspecific antibody binding, the cells and spleen sections were 
incubated with 20 µL or 100 µL blocking solution (PBS, 1 % BSA, 10 % Normal 
Goat Serum, 0.1 % Tween 20), respectively, for 1 h at RT. 
Following the blocking step, primary CLL cells and cell lines were stained with 
20 µL anti-FOXO1 antibody (1:100; diluted in blocking solution) (Cell Signalling 
Technology) O/N at 4 °C in a humidified staining chamber (Biolegend). Spleen 




594 anti-CD45R/B220 antibody (1:200) (Biolegend) simultaneously O/N at 4 °C in 
a humidified staining chamber.  
After O/N incubation, the cells and spleen sections were washed 3 times with 20 
µL or 100 µL wash buffer (PBS, 0.1% Tween 20), respectively, 5 min each. Next, 
the cells and spleen sections were incubated with 20 µL or 100 µL secondary 
goat-anti rabbit IgG-AlexaFluor 488 (1:500; diluted in blocking solution) 
(ThermoFisher Scientific) for 1 hr at RT, protected from light. Following a final 
washing step with wash buffer, the specimens were mounted in ProLongTM 
Diamond antifade mountant with DAPI (one drop/slide) (ThermoFisher 
Scientific), which stained the cell nuclei. The slides were left to cure for 24 h at 
RT, protected from light. The slides were stored at 4 °C until required.  
2.2.3.5 Image acquisition 
The specimens were visualised using a Zeiss Axio Imager M1 fluorescence 
microscope (Zeiss) connected to AxioVision v4.8.1 software (Zeiss). A range of 
objectives were used to visualise the specimens including 10x, 20x, 40x and 100x 
(oil) in the red, green and blue fluorescence channels. Where possible, z-stacks 
were acquired. Z-stack images, typically >25 individual images per stack, were 
used for deconvolution. The resultant images would be exported for use in image 
analysis software.  
2.2.3.6 Image analysis 
CellProfiler v2.2.0 image analysis software (CellProfiler) was used to quantify co-
localisation using object-based quantification of signal localisation for the FOXO1 
(green) and DAPI (blue) fluorescent channels. CellProfiler is free open-source 
software that enables users to create customised pipelines containing image-
processing modules. CellProfiler runs a customisable co-localisation pipeline, 
which provides various outputs for quantifying co-localisation including Pearson’s 
correlation coefficient, Manders’ overlap coefficient (MOC) and the Costes 
threshold method. Values for the Manders’ coefficient range from 0 to 1. Values 
closer to 1 correspond to greater co-localisation (284, 416). Signal thresholds 
were calculated using the Costes Auto threshold method. >360 cells were 





Figure 2.9 - Co-localisation pipeline (CellProfiler) 
CellProfiler v2.2.0 image analysis software runs a customisable co-localisation pipeline, which 
provides various outputs for quantifying co-localisation. The software requires grey scale images 
(.PNG / .TIF / .JPG) from corresponding channels such as DAPI (blue) and FOXO1 (green) 
channels. Firstly, the software aligns the two images (same image, different channels) using 
normalised cross correlation to ensure correct co-localisation. Next, the software identifies ‘primary’ 
objects, which are represented by cell nuclei (DAPI). The software then calculates ‘secondary’ 
objects or ‘cells’ by expanding the ‘primary’ object field. Finally, co-localisation analysis provides 
various outputs for quantifying co-localisation including Pearson’s correlation coefficient, Manders’ 
overlap coefficient (MOC) and the Costes threshold method.  
 
2.2.4 Immunohistochemistry 
The immunohistochemistry (IHC) procedure described here was adapted from 
the protocol published by Abcam entitled, ‘Immunohistochemistry (IHC): the 




2.2.4.1 Sample preparation 
Spleen tissue from WT mice were harvested at the end of experimentation. 
Spleens were acquired from Dr. Natasha Malik as left-over spleen tissue from in 
vivo experiments. Sample preparation, including formaldehyde fixation, 
paraffin-embedding and sectioning (microtome sections) were performed by the 
Histology Service at the CRUK Beatson Institute. 
Sample preparation, staining and image acquisition of CLL patient LN biopsies 
was performed by Dr Mark Catherwood, Department of Histopathology, Belfast 
City Hospital, Belfast, UK.  
2.2.4.2 Antigen retrieval 
Heat-induced epitope retrieval was performed with specimens immersed in 
sodium citrate buffer (10 mM Tri-sodium citrate, 0.05 % Tween 20, pH 6.0). 
Sodium citrate buffer was stored at RT for <3 months. 1 L sodium citrate antigen 
retrieval buffer was added to a pressure cooker. The pressure cooker was 
positioned on a pre-heated hot plate on full power. Of note, the lid of the 
pressure cooker should not be secured. In the meantime, the sections were de-
paraffinised and rehydrated by placing the slides into a rack and performing the 
subsequent washes sequentially in a Coplin jar (all volumes 50 mL): Xylene (3 
min), Xylene (3 min), 1:1 Xylene:100 % ethanol (3 min), 100 % ethanol (3 min), 
100 % ethanol (3 min), 95 % ethanol (3 min), 70 % ethanol (3 min), 50 % ethanol 
(3 min). Following the washes, the slides were placed in cold running tap water 
to rinse off the excess ethanol. As soon as the antigen retrieval buffer was 
boiling, the slides were placed into the pressure cooker and the lid was securely 
fixed. Once the pressure cooker had reached full pressure, the slides were left 
for 3 min. After the time had elapsed, the pressure cooker was transferred to a 
sink and de-pressurised. Afterwards, cold tap water was run into the pressure 
cooker (still containing the slides) for 10 min.   
2.2.4.3 Staining procedure 
Following antigen retrieval, the slides were washed 2 times in 50 mL ‘wash 
buffer’ (1X TBS, 0.025 % Triton X-100) with gentle agitation. At this step, a 




in 100 µL blocking solution (1X TBS, 1 % BSA, 10 % Normal Goat Serum) for 2 h at 
RT. After the incubation period, the slides were drained and then stained with 
100 µL anti-FOXO1 antibody (1:100) or anti-AKTS473 antibody (1:100) (Cell 
Signalling Technology) diluted in SignalStain antibody dilutent (Cell Signalling 
Technology). The sections were incubated in a humidified staining chamber O/N 
at 4 °C. The following morning, the slides were rinsed twice in wash buffer with 
gentle agitation. As the sections would be incubated with an HRP-conjugates 
secondary antibody, the specimens were immersed in 100 µL 0.3 % hydrogen 
peroxide (H2O2) (Sigma) in TBS for 15 min to suppress endogenous peroxide 
activity. After rinsing off the 0.3 % H2O2 with wash buffer, the sections were 
covered with 50 µL SignalStain Boost IHC Detection Reagent (HRP, Rabbit) (Cell 
Signalling Technology) and incubated in a humidified chamber for 30 min at RT. 
The sections were then rinsed 4 times in 100 µL TBS and incubated with 50 µL 
DAB Substrate Kit (Abcam) according to the manufacturer’s instructions. The 
slides were developed for up to 10 min for the desired colour to emerge. Of 
note, a ‘secondary only’ control was used to determine the incubation period 
with chromogen substrate. The slides were placed in a sink and rinsed in running 
tap water for 5 min and subsequently counterstained with haemtoxylin (Sigma) 
for 1 min. Following counterstaining, the sections were dehydrated (washing 
step for rehydration in reverse e.g. starting with 50 % ethanol) and mounted 
using a drop of HistoLab mounting medium (Pertex). The slides were then cured 
for 24 hr at RT and stored at 4 °C until required. 
2.2.4.4 Image acquisition 
Sections were visualised using EVOS XL Core Cell Imaging System. 10x and 40x 
objectives were used to acquire images. 
2.2.5 Western blotting 
Western blotting was performed to examine the expression, phosphorylation 
status and subcellular localisation of proteins in response to cell stimulation 
and/or drug treatment. This technique, alongside the expression of a loading 
control, enables conclusions to be drawn about the effect of drug treatment 




2.2.5.1 Preparation of protein lysates 
Cells Cell pellet Volume of Protein Lysis Buffer (uL) 
Primary CLL cells ~ 1 x10^7 35 
MEC-1 / HG-3 ~ 2 x10^6 55 
Table 2.15 - Cell numbers for western blotting 
 
 
Following cell stimulation and/or drug treatment, cells were harvested and 
transferred to pre-cooled 15 mL reaction tubes. Of note, all reagents required 
were placed on ice prior to harvesting the cells. The cells were washed with 1 
mL ice-cold PBS and centrifuged at 300g for 5 min at 4 °C. Following another 
centrifugation and washing step, the cells were resuspended in 500 µL PBS and 
transferred to a 1.5 mL reaction tube. The cells underwent a final centrifugation 
step at 300g to pellet the cells. The cell pellet was then resuspended in 35 
µL/50µL protein lysis buffer (1X Tris-EDTA pH 8.0, 1 % Triton X-100, 1 mM DTT) 
containing 1X c0mplete mini, EDTA-free protease inhibitor cocktail (Sigma) and 
1X PhosSTOP phosphatase inhibitor cocktail (Sigma). The lysate was vortexed for 
10 s at the highest setting and then placed on ice for 20 min. After the 
incubation period, the lysate was centrifuged at 15000g for 20 min at 4 °C to 
pellet the cellular debris. The supernatant (protein lysate) was transferred to a 
new pre-cooled 1.5 mL reaction tube and the cellular debris was discarded. For 
the purpose of protein quantitation, 5 µL protein lysate was transferred to a 0.5 
mL reaction tube. The lysates were stored at -80 °C until required.  
2.2.5.2 Cellular fractionation  
Cellular fractionation was performed to assess translocation of proteins from 
nuclear to cytoplasmic compartments, or vice versa, in response to drug 
treatment and/or stimulation using the Nuclear Extract Kit (Active Motif). Of 
note, a whole-cell lysate was generated as a ‘fractionation’ control. Unless 
otherwise stated, cells were pre-treated with drug or DMSO vehicle control for 
30 min followed by a 1 h F(ab’)2 stimulation.    
The protocol for generating nuclear, cytoplasmic and whole-cell fractions was 
followed according to the manufacturer’s instructions ‘Protocol I: Adherent or 




condition) and 2 x106 HG-3 or MEC-1 cells (per condition) were used as starting 
material. At Step 2.1 and 2.2, both primary CLL cells and cell lines were 
resuspended in 50 µL Hypotonic Buffer and subsequently lysed with 1.67 µL 
detergent (418). For the purpose of protein quantitation, 5 µL of the nuclear, 
cytoplasmic and whole-cell lysates was transferred to a 0.5 mL reaction tube. 
The lysates were stored at -80 °C until required.  
2.2.5.3 Protein quantitation 
Protein concentration of cellular lysates or subcellular fractions was quantified 
using the Bicinchoninic acid (BCA) assay (Thermo Fisher Scientific) according to 
the manufacturer’s instructions for the ‘Microplate Procedure’. All reagents 
were pre-cooled on ice prior to commencing the assay. 
To prepare the protein samples, 45 µL of ice-cold dH2O was added to the 5 µL 
aliquots removed from the original protein lysates, creating a 1:10 dilution. 
Next, 20 µL of each standard and unknown sample was added to one well of a 
96-well assay plate in duplicate. Following this, 200 µL of the working reagent, 
as determined by the number of samples to be analysed, was added to each well 
and mixed on a plate shaker for 30 s. The plate was covered and placed in a 37 
°C incubator for 30 min. After incubation, the plate was cooled to RT and 
measured at 562 nm on a SpectraMax M5 microplate reader (Molecular Devices).  
2.2.5.4 Gel electrophoresis and transfer 
Gel electrophoresis and ‘transfer’ was performed using the XCell SureLock Mini-
Cell electrophoresis system (Thermo Fisher Scientific) and XCell II Blot Module 
(Thermo Fisher Scientific), respectively, according to the manufacturer’s 
instructions.  
Following protein quantitation, 20-40 µg of protein was transferred to a 1.5 mL 
reaction tube. Of note, equal amounts of protein were added across each 
condition. If necessary, dH2O was added to the reaction tubes to create an equal 
final volume. Next, appropriate volumes of 4X LDS Sample Buffer (Thermo Fisher 
Scientific) and 10X Sample Reducing Agent (Thermo Fisher Scientific) were 




°C for 10 min. After a quick vortex, the samples were loaded into either 10-, 12- 
or 15-well NuPAGETM 4-12 % Bis-Tris Protein Gels (Thermo Fisher Scientific) 
immersed in 1X MES or MOPS Running Buffer (Thermo Fisher Scientific). Of note, 
the HyperPAGE Molecular Weight Marker (Bioline) was loaded next to the lysates 
to identify the approximate size of target proteins separated by gel 
electrophoresis. When necessary, two gels were run simultaneously containing 
equal amounts of protein lysate in duplicate, termed ‘mirror’ blots. Mirror blots 
were performed to interpret relative differences between the amount of 
phosphorylated and ‘total’ protein in response to drug treatment and/or 
stimulation.  
For protein transfer, the gels and apparatus were assembled as per the 
manufacturer’s instructions. The 1X Transfer Buffer (Thermo Fisher Scientific) 
contained either 10 % or 20 % methanol depending on whether one or two gels 
were being transferred, respectively. Separated proteins were transferred onto 
0.45 µm Polyvinylidene Fluoride (PVDF) membranes (Thermo Fisher Scientific), 
which had been activated in methanol prior to protein transfer. In contrast to 
the manufacturer’s protocol, protein transfer was run at 30V for 70 min.   
2.2.5.5 Immunoblotting 
At the end of transfer, the ‘sandwich’ was dissembled, and the membranes were 
rinsed in dH2O to remove excess transfer buffer. To check for transfer 
efficiency, the proteins were visualised by staining the membranes with 5 mL 
Ponceau solution (Sigma). If necessary, the membranes were cut at this point to 
probe for different proteins simultaneously. The membranes were then washed 3 
times with 10 mL TBST (1X TBS, 0.1 % Tween 20) to remove protein-bound 
Ponceau solution. Once all the Ponceau had been removed, the membranes were 
then blocked with 10 mL 5 % (w/v) Milk/TBST for 1 h at RT. After the blocking 
step, the membranes were transferred to 50 mL reaction tubes and washed 4 
times in 5 mL TBST, 5 min each. The membranes were then incubated with 5 mL 
primary antibody diluted in 5 % (w/v) BSA/TBST or 5 % (w/v) Milk/TBST 
according to the antibody datasheet provided by the manufacturer. The 




The following morning, the primary antibody was decanted, and the membranes 
were washed 4 times in 5 mL TBST, 5 min each. Of note, primary antibodies 
were re-used up to 4 times or stored for <2 weeks at 4 °C. Furthermore, multiple 
primary antibodies were sometimes incubated together. After the washing step, 
5 mL HRP-linked secondary anti-rabbit IgG (1:2000) or anti-mouse IgG (1:2000) 
(Cell Signalling Technology) diluted in 2 % (w/v) Milk/TBST was incubated with 
the membrane for 1 h at RT. On occasions, 5 mL fluorescently-linked IRDye 
680RD goat anti-rabbit (1:15000) or IRDye 700CW goat anti-mouse (1:15000) 
secondary antibodies (LI-COR) diluted in TBST were used for near-infrared (NIR) 
detection. After a final washing step, proteins were visualised using the Odyssey 
Fc Imaging System (LI-COR) connected to ImageStudio v5.2.5 software (LI-COR). 
Membranes probed with HRP-linked secondary antibodies were immersed in 
Immobilon Forte Western HRP Substrate (Millipore) prior to chemiluminescent 
detection. Conversely, membranes probed with fluorescently-linked secondary 
antibodies were visualised directly in the imaging system using either 700 nm or 
800 nm channels. Following acquisition, the membranes were rinsed in 10 mL 
dH2O and stored at 4 °C, submerged in 50 mL dH2O for re-probing. For long-term 
storage, membranes were dried O/N at RT and stored at – 20 °C. 
2.2.5.6 Membrane re-probing 
Membranes were re-probed without ‘stripping’, as long as subsequent antibodies 
did not target proteins of similar sizes or where non-specific background staining 
had occupied targeted regions of the membrane. 
Following acquisition of Western blot images, membranes were rinsed in dH2O to 
remove excess chemiluminescent ECL reagent, as necessary. The membranes 
were then washed 4 times in TBST for 5 min each and subsequently probed with 
the next primary antibody O/N at 4 °C. The protocol was followed therein in 
accordance with the standard immunoblotting procedure.  
2.2.5.7 Densitometry 
Densitometry (via quantitation of signal intensity) was performed using Image 
StudioTM Lite (version 5.2.5) software (LI-COR) with images acquired on the 




from the ‘Image StudioTM Lite V5.x Quick Start Guide’ and ‘Image StudioTM 
Software Background Subtraction Guide’ available on the manufacturer’s 
website. For a detailed description of the methods used, please refer to our 
recently published methods paper (418). 
2.2.6 RT-qPCR 
In ‘two-step’ reverse transcription-quantitative PCR (RT-qPCR), RNA is reverse 
transcribed to complementary DNA (cDNA). The cDNA is then used as a template 
for the qPCR reaction in an entirely different reaction (419). TaqMan gene 
expression assays (ThermoFisher Scientific) were used to assess target gene 
expression in the qPCR reaction. The methods are outlined below.  
2.2.6.1 RNA isolation 
RNA was isolated using the RNeasy Mini Plus Kit (QIAGEN) according to the 
manufacturer’s instructions.  
After drug treatment and/or stimulation, cells were harvested as per the 
protocol described (section 2.2.5.1). Cell pellets were then resuspended and 
lysed in an appropriate volume of RLT Plus buffer (Table 2.16). The lysate was 
then homogenised by vortexing for 30 s. The lysate was stored at -80 °C until 
required. The protocol was then followed in accordance with the manufacturer’s 
instructions.  
 
Cells Cell number Volume of RLT Plus Buffer (uL) 
Primary CLL cells ~5 x10^6 350 
MEC-1/HG-3 ~1 x10^6 350 
Table 2.16 - Cell numbers for RT-qPCR 
 
 
For pelleted ex vivo primary CLL cells, the pellet (~2 x107 cells) was thawed on 
ice and gently ‘flicked’ to dislodge the pellet. The cells were then lysed in an 
appropriate volume of RLT Plus buffer (Table 2.16) and homogenised by 
vortexing for 30 s. The protocol was then followed in accordance with the 




The concentration and purity of RNA was determined using the NanoDrop 
spectrophotometer (ThermoFisher Scientific), according to the manufacturer’s 
instructions. Of note, RNA concentration (ng/µL), 260/280 and 260/230 ratios 
were considered. RNA was stored at -80 °C until required. 
2.2.6.2 First-strand cDNA synthesis 
Total RNA was reverse-transcribed to cDNA with SuperScript III Reverse 
Transcriptase (ThermoFisher Scientific) according to the manufacturer’s 
instructions. Of note, equal quantities of RNA (>150 ng) were used across each 
condition for first-strand cDNA synthesis. A maximum of 500 ng RNA from each 
condition/sample was used in the reaction. cDNA was generated using the 
ProFlex PCR system (ThermoFisher Scientific), following the thermal conditions 
described in the manufacturer’s protocol. Of note, reverse transcriptase (RT) 
minus (RT-) controls were used, where possible. cDNA was diluted 1:5 with RT-
PCR grade water (ThermoFisher Scientific) and stored at -20 °C until required. 
First-Strand cDNA Synthesis 
 
Component Volume (uL)  
Oligo(dT) 12-18 Primer 1  
dNTP Mix PCR Grade 10 mM  1  
500 ng RNA x  
dH2O to a final volume of 13 uL 
 
 
==> Heat mixture to 65 'C, 5 min. Incubate on ice for >1 min.  
 
 
5X First-Strand Buffer 4  
0.1 M DTT 1  
RNaseOUT Recombinant RNase Inhibitor 1  
SuperScript III RT 1  
==> Heat mixture to 50 'C, 60 min. Inactivate reaction by heating to 70 
'C, 15 min. 
 
 






2.2.6.3 Polymerase Chain Reaction (PCR) 
The TaqMan assays used in the qPCR reaction are listed in Table 2.6. The 
reaction was followed according to the manufacturer’s instructions. 
Glucuronidase beta (GUSB) was used as a ‘housekeeping’ or internal reference 
gene in all reactions. The cDNA and qPCR reagents were loaded into MicroAmp 
Optical 384-Well Reaction Plates (ThermoFisher Scientific). The qPCR reaction 
was performed in a 7900HT Fast Real-Time PCR System (ThermoFisher Scientific) 
running SDS v2.4 software. The reaction underwent the following thermal cycling 
conditions: Stage 1: 50 °C (2 min); Stage 2: 95 °C (10 min); Stage 3: 95 °C (15 s) 
60 °C (1 min). The reaction (stage 3) underwent 40 cycles. CT values were 
generated with RQ Manager software.  
 Volume for 10 uL 
 




20X TaqMan Gene Expression Assay 0.5 1.5  
2X TaqMan Universal PCR Master 
Mix 5 15 
 
cDNA Template 2 6  
RT-PCR grade H2O 2.5 7.5  
Table 2.18 - RT-qPCR reaction 
 
 
2.2.7 FOXO1 activity assay 
The TransAM FKHR (FOXO1) Activity Kit (Active Motif) is a DNA-binding ELISA 
used to study FOXO1 transcription factor activation in cell (nuclear) extracts.  
2.2.7.1 Preparation of nuclear lysates 
The TransAM method requires the generation of highly enriched nuclear fractions 
from cellular lysates. For this purpose, we used the protocol described in section 
2.2.5.2. Although the cytoplasmic fraction is not required in the assay, both the 
cytoplasmic and nuclear fractions can be used to assess FOXO1 translocation in 
response to drug treatment and/or stimulation by Western blotting. Nuclear 




2.2.7.2 TransAMTM FKHR (FOXO1) Activity Kit 
The procedure for the TransAM FOXO1 Activity Kit was followed according to the 
manufacturer’s instructions. Equal amounts of nuclear lysate (>4 µg) were used 
as starting material. Relevant controls, including Raji nuclear extract as a 
positive control and ‘blank’ negative control wells, were used. In addition, 
‘competitive binding’ experiments were performed to monitor the specificity of 
the assay using WT and mutated consensus oligonucleotides to compete with 
activated FOXO1 in nuclear extracts.  
Of note, for ‘Step 4: Colorimetric Reaction’, the developing solution was 
incubated for <10 min in all cases. Following incubation, absorbance was read at 
450 nm (reference wavelength 655 nm) using a SpectraMax M5 microplate 
reader. Of note, absorbance must be read within 5 min. 
2.2.8 shRNA-mediated knockdown of FOXO1 
RNA interference (RNAi)-mediated knockdown of FOXO1 expression was achieved 
via lentiviral-delivery of short hairpin RNA (shRNA) molecules. The method below 
describes the procedures performed to deliver and expand shRNA constructs, 
generating stably-transduced MEC-1 cells to assess the impact of FOXO1 





Figure 2.10 - pLKO.1-puro shRNA construct (420)  
(A) Schematic of the pLKO.1-puro vector with shRNA insert. Image was modified from Addgene’s 
‘Protocol – pLKO.1–TRC Cloning Vector’, available at addgene.org.  
 
2.2.8.1 Glycerol stocks of shRNA constructs 
Multiple shRNA constructs (pLKO.1-puro TRC cloning vector containing shRNA 
target sequence) targeting FOXO1 were assessed (Table 2.19).  
Symbol Clone ID Target sequence Vector ID Clone name Region 
FOXO1A TRCN0000039582 GCCGGAGTTTAGCCAGTCCAA pLKO.1 NM_002015.2-472s1c1 CDS 
FOXO1A TRCN0000039581 CAGGACAATAAGTCGAGTTAT pLKO.1 NM_002015.2-1712s1c1 CDS 
FOXO1A TRCN0000039580 GCCACCAAACACCAGTTTGAA pLKO.1 NM_002015.2-1609s1c1 CDS 
FOXO1A TRCN0000039579 GCTTAGACTGTGACATGGAAT pLKO.1 NM_002015.2-2211s1c1 CDS 
FOXO1A TRCN0000039578 GCCTGTTATCAATCTGCTAAA pLKO.1 NM_002015.2-2941s1c1 3' UTR 







The aforementioned pre-cloned, sequence-verified shRNA constructs targeting 
FOXO1 were derived from a bacterial glycerol stock (Terrific Broth (TB), 100 
µg/mL carbenicillin, 15 % glycerol) library (MISSION shRNA; Sigma) belonging to 
Dr. Xu Huang (University of Glasgow, Glasgow, UK). Of note, the pLKO.1-puro 
clones were transformed into Escherichia coli prior to the generation of a 
glycerol stock. pLKO.1-puro includes ampicillin and puromycin antibiotic 
resistance genes for selection in bacteria or mammalian cell lines, respectively 
(Figure 2.10). 
2.2.8.2 Isolation of bacterial colonies and inoculation of liquid cultures  
As glycerol stocks will be used isolate plasmid DNA, it was important to isolate 
individual bacterial clones (single colonies), which reduced the chance of 
obtaining an assortment of different plasmids in the purified DNA. Of note, the 
following protocol was performed using aseptic technique in a sterile 
environment.  
Luria Broth (LB) agar (LB-amp) plates containing 100 µg/mL ampicillin were 
prepared (Table 2.20). Sterility was maintained by working near a flame. Using a 
sterile toothpick, a small amount of bacteria was scratched from the surface of 
a glycerol stock and gently spread over the surface of a LB-amp plate. A second 
sterile toothpick was used to drag through the previous streak into another 
section of the plate. A third sterile toothpick was used to drag the second streak 
of bacteria over the last section of the plate. The plate was incubated O/N at 37 
°C. Of note, this was repeated for each construct (glycerol stock) in a fresh LB 
agar plate. In addition, a LB-amp plate without bacteria was used as a negative 










Component - Final Concentration (ug/mL) 
 
InvivoGen Fast-Media LB Agar Base  1 pouch -  
dH20 200 mL -  
==> microwave in pulses. Allow to cool. 
 
 
Ampicillin 100 mg/mL 500 uL 100 ug/mL  
Table 2.20 – LB-Agar preparation 
  
 
Prior to picking individual colonies, TB containing 100 µg/mL ampicillin (TB-amp) 
was prepared (Table 2.21). The procedure has been adapted from the protocol 
‘Inoculating a Liquid Bacterial Culture’ (421). 
Teriffic Broth (TB)- ampicillin (TB-amp) 
 
Component - Final Concentration (ug/mL)  
TB 23.5 g -  
dH2O 500 mL -  
==> Autoclave. Allow to cool. 
 
 
Ampicillin 100 mg/mL 500 uL 100  
Table 2.21 - TB-amp preparation 
 
 
Following O/N incubation, the plates were observed for individual bacterial 
colonies. If required, the plates were placed at 37 °C to allow for further 
growth. In the meantime, 5 mL TB-amp was transferred to a sterile 13 mL 
inoculation tube (Fisher Scientific). Once single colonies were observed, a single 
colony was selected from the LB agar plate using a pipette tip (without filter) 
and dropped directly into the liquid TB-amp. The liquid culture was swirled and 
then loosely covered with the lid of the inoculation tube. The bacterial culture 
was incubated O/N, shaking (200 rpm) at 37 °C. Thereafter, the liquid cultures 
were examined for bacterial growth. Of note, a TB-amp liquid culture without 





Minipreparation or ‘miniprep’ of plasmid DNA from bacteria was performed using 
the QIAprep Spin Miniprep Kit (QIAGEN) according to the manufacturer’s 
instructions. The plasmid DNA isolated from the miniprep procedure is used to 
visualise the presence of a shRNA sequence (target sequence) within the PLKO.1-
TRC cloning vector by diagnostic digests.  
From the original 5 mL TB-amp liquid bacterial culture, 4 mL was used for the 
miniprep procedure, whilst the remaining 1 mL was used in subsequent large-
scale liquid bacterial cultures for ‘maxiprep’ procedures or to generate glycerol 
stocks. Of note, large-scale liquid bacterial cultures were only performed once 
the presence of a shRNA sequence insert was confirmed, as determined by a 
diagnostic digest. 
The concentration and purity of the plasmid DNA was determined using the 
NanoDrop spectrophotometer, according to the manufacturer’s instructions. The 
plasmid DNA was then used for diagnostic digests or stored at -20 °C until 
required.  
2.2.8.4 Maxiprep 
Following the presence of shRNA sequence inserts in plasmid DNA generated by 
the miniprep procedure, the remaining 1 mL bacterial liquid culture from each 
construct was transferred to separate sterile conical flasks containing 100 mL 
TB-amp. The liquid culture was swirled and then loosely covered with aluminium 
foil. The bacterial culture was incubated O/N, shaking at 37 °C. Liquid cultures 
were examined for bacterial growth. Of note, a TB-amp liquid culture without 
bacteria was used as a negative control for bacterial growth.  
Following incubation, a maxipreparation or ‘maxiprep’ was performed using the 
EndoFree Plasmid Maxi Kit (QIAGEN) according to the manufacturer’s 
instructions. The concentration and purity of plasmid DNA was determined using 
the NanoDrop spectrophotometer, according to the manufacturer’s instructions. 





2.2.8.5 Diagnostic digests 
Diagnostic digests were performed to confirm the presence of an shRNA 
sequence insert before commencing subsequent steps. The protocol for 
diagnostic digests were generated using NEBcloner v1.3.14 software (New 
England Biolabs) and followed according to the manufacturer’s protocol. 
Protocols generated by NEBcloner software differed depending on the specific 
restriction enzymes used. In brief, 500 ng plasmid DNA, isolated using either the 
miniprep or maxiprep protocol, was digested with Nde1 (New England Biolabs) 
and Spe1_HF (New England Biolabs) or Nde1 and BamH1_HF (New England 
Biolabs) restriction enzymes, theoretically generating ~555 base pairs (bp) or 
~812 bp insert and ~6495 bp or ~6238 bp backbone fragments, respectively. The 
reaction was performed in the presence of 1X CutSmart Buffer (New England 
Biolabs) for 1 h at 37 °C. Of note, uncut, ‘single’ cut and non-template (dH2O) 
controls were run alongside test samples. The fragments generated from the 
diagnostic digest were assessed by gel electrophoresis (Figure 2.11). 
 
Figure 2.11 - Diagnostic digest and gel electrophoresis (including pLKO.1-puro construct) 
(a) Schematic of the pLKO.1-puro plasmid indicating restriction sites Nde1 and BamH1, creating a 






2.2.8.6 DNA gel electrophoresis 
Gel electrophoresis was performed to visualise the resulting DNA fragments 
generated by the diagnostic digests. The pattern of fragments on the gel 
determined the presence (or absence) of shRNA sequence inserts within the 
pLKO.1-puro plasmids.   
To make a 1 % agarose gel, 1 g agarose (Sigma) was added to 100 mL 1X TAE 
buffer (diluted from a 50X TAE buffer stock solution (40 mM Tris, 20 mM acetate, 
1 mM EDTA, pH 8.2) in a microwaveable flask. The agarose was dissolved in the 
microwave in ‘pulses’, ensuring the mixture did not over boil. Once the agarose 
solution had cooled, 10 µL 10000X SYBR Safe DNA gel Stain concentrate (Thermo 
Fisher Scientific) was added to the solution and gently swirled to prevent bubble 
formation. The agarose was subsequently poured into a gel tray with an 
appropriate well comb in place and allowed to solidify for ~1 h.  
To prepare the samples, 1-part 6X TriTrack DNA Loading Dye (ThermoFisher 
Scientific) was added to 5-parts DNA digest. Once the agarose gel had set, it was 
placed in a suitable gel box, which was subsequently filled with 1X TAE buffer. 
First, the GeneRuler 1 kb DNA ladder (Thermo Fisher Scientific) was loaded into 
the first well, followed by the uncut, single-cut and digested DNA samples. A 
non-template (dH2O) control was loaded in the final well. 
The gel was run as 5 V/cm until the ‘dye line’ had reached ~70 % of the way 
down the gel. The DNA fragments were visualised using the Odyssey Fc Imaging 
System connected to ImageStudio v5.2.5 software. Of note, the 600 nm channel 
was used for visualising DNA gels (Figure 2.11). 
2.2.8.7 Transfection / 2nd Generation Lentiviral Plasmids 
The following procedure was adapted from the protocol ‘pLKO.1–TRC Cloning 
Vector’ (420). Transfection of HEK293T cells was performed adopting the 
calcium phosphate method to produce lentiviral particles (containing shRNA 
constructs) used to infect target cells.  
For each shRNA construct to be transfected, including ‘scrambled’ and GFP 




free DMEM media in 6 cm tissue culture plates (Greiner Bio-One). The cells were 
incubated O/N at 37 °C, 5 % CO2. 3 h prior to transfection, the HEK293T cells 
were monitored under a microscope to determine cell density. The cells should 
be between 70-80 % confluent. The cells were then replenished with fresh 
serum/antibiotic-free DMEM. For each transfection, Solution A (1.25 µg shRNA 
construct, 0.75 µg VSV.G envelope vector, 0.5 µg HIV-1 packaging vector, 50 µL 
2.5 M CaCl2, made up to 150 µL with sterile dH2O) and Solution B (150 µL 2X 
HEPES buffer saline (Sigma)) was prepared in two separate polypropylene tubes 
(Greiner Bio-One). Solution A was slowly added to Solution B, whilst vigorously 
bubbling air through Solution B. The mixture was briefly vortexed and incubated 
at RT for 20 min (enabling a precipitate to form). Following incubation, the 
mixture was added dropwise to the culture medium containing the HEK293T 
cells. The plate was gently agitated back and forth to ensure the precipitate was 
evenly distributed and incubated O/N at 37 °C, 5 % CO2. The following morning 
(<15 h), the transfection solution was removed and replaced with fresh complete 
DMEM. The cells were then incubated for 24 h at 37 °C, 5 % CO2.  
After the incubation period, the media was harvested from the cells using a 
sterile 10 mL syringe and filtered directly into a 15 mL reaction tube using a 0.45 
µm filter (Sartorius) to remove the cells. This media contains lentiviral particles 
(viral supernatant). The viral supernatant was then stored at 4 °C. Another 5 mL 
fresh complete DMEM was added to the cells and incubated for a further 24 h at 
37 °C, 5 % CO2. After incubation, the media was harvested, filtered and pooled 
with the media from the previous day. If the viral supernatant was not required 
immediately, it was aliquoted and stored at -80 °C.  
2.2.8.8 Lentiviral infection / transduction  
1 x106 target cells/mL were seeded in 6-well culture plates the evening before 
transduction and incubated O/N at 37 °C, 5 % CO2. The following day, the cells 
(MEC-1 and HG-3) were harvested, centrifuged at 300g for 5 min and 
resuspended in 1 mL fresh complete DMEM containing 10 µg/mL polybrene 




To begin lentiviral infection/transduction, 1 mL fresh or thawed viral 
supernatant (section 2.2.8.7) was added to the corresponding cell suspension. 
Importantly, the addition of the viral supernatant dilutes the concentration of 
polybrene in the cell suspension 2-fold, creating a culture with a desired 
concentration of 5 µg/mL polybrene. Of note, aliquots of frozen viral 
supernatant were thawed slowly on ice for around 2-3 h prior to transduction. 
The cells were incubated for 24 h at 37 °C, 5 % CO2 before puromycin selection 
and the generation of stable cell lines.  
2.2.8.9 Generation of stable FOXO1-knockdown MEC-1 cell lines 
Following 24 h of lentiviral infection, cells were given fresh complete DMEM 
supplemented with 2 µg/mL puromycin to select for transduced cells. Puromycin 
was only added to the culture 24 h after infection to enable expression of 
puromycin resistance gene. Non-transduced cells were cultured in parallel as a 
positive control for puromycin selection. The efficiency of transduction was 
monitored by examining the cells transduced with the GFP-expressing construct 
either qualitatively under a fluorescence microscope or quantitatively by flow 
cytometry. 
Fresh puromycin-containing complete DMEM was given to cells every 3 days. Cell 
density of puromycin-selected cells was monitored to optimise cell growth and 
increase cell number by transferring cells to appropriately sized culture 
plates/flasks. Cell viability of non-transduced/uninfected cells was examined 72 
h after the introduction of puromycin by Annexin V/7-AAD staining (section 
2.2.2.3). Once all the non-transduced cells were Annexin V+ 7-AAD+, the infected 
cells were monitored for growth.  
At 7- and 13-days post-infection, viable transduced cells were counted and 
approximately 1 x106 cells were removed from culture for RNA isolation and 
protein lysate preparation (sections 2.2.6.1 and 2.2.5.1, respectively). The 
expression levels of FOXO1 for each construct, including scrambled control, were 
subsequently determined by RT-qPCR and Western blotting. The two constructs 




expanded in the presence of 1 µg/mL puromycin to maintain a selection pressure 
for transduced cells.  
2.2.9 Resazurin assay 
Resazurin (Sigma) is a non-toxic, non-fluorescent and cell-permeable compound. 
Upon exposure to viable cells, resazurin is reduced to resorufin, a highly 
fluorescent red-coloured compound (422). As such, changes in cell viability in 
response to drug treatment can be assessed using a fluorescence-based plate 
reader.  
Resazurin solution (25 mM) 
Components - Final Concentration (M) 
Resazurin Sodium Salt              
(MW = 251.17) 313 mg  0.025 
dH₂O 50 mL  
Of note, Resazurin solution was filter-sterilised prior to use. 
 
Table 2.22 - Resazurin solution (25 mM) 
 
 
Before each timepoint, 500 µM resazurin was prepared by diluting 25 mM 
Resazurin stock solution (1:50) with pre-warmed complete growth media (Table 
2.22). Of note, suitable controls including cell-free wells with and without 
Resazurin was used to blank the experiment.  
2.2.9.1 Dose-response curves 
Dose-response curves were generated to determine the half maximal effective 
concentration (EC50), defined as the concentration of drug that gives half-
maximal response (423). 
Freshly isolated or thawed primary CLL cells were seeded into each well of a 96-
well culture plate in triplicate (3 x 105 cells/200 µL growth medium). The cells 
were then treated with increasing concentrations of drug (typically log or half-
log concentrations) for 44 h at 37 °C, 5 % CO2. Following incubation, 20 µL 500 




CO2. Fluorescence was read on a SpectraMax M5 microplate reader using a 
fluorescence excitation wavelength at 570 nm and emission wavelength at 585 
nm. Dose-response curves and resultant EC50 values were generated using Prism 
6 software (GraphPad).   
 
Figure 2.12 – Resazurin assay (dose-response curves) 
Dose-response curves can be generated using the Resazurin assay. Cells are seeded into each 
well of a 96-well plate in triplicate. Of note, complete media (without cells) is used to ‘blank’ the 
reaction. Next, the cells are treated with increasing concentration of drug. After 44 h incubation, 
resazurin was added to the wells and incubated for a further 4 h at 37’C. Fluorescence was read on 
a microplate reader using a fluorescence excitation wavelength at 570 nm and emission 
wavelength at 585 nm. Dose-response curves and resultant EC50 values were generated using 
Prism 6 software (GraphPad).  
 
2.2.9.2 Analysis of drug synergy 
Combination therapy represents a highly effective treatment modality for cancer 
patients (424). Drug synergism is defined as the interaction between two or 
more drugs that evokes an effect greater than the sum of their individual parts 
(425).  
Drug synergy between AZD8055/AZD2014 and ibrutinib was determined in vitro 
using primary CLL samples via the resazurin cell viability assay. Following O/N 
recovery, thawed CLL cells (1 x 107 cells/mL) were resuspended in RPMI 
complete medium. 3 x 105 cells/200 µL were seeded per well of a 96-well plate 
and treated with increasing concentrations of drug at a non-constant ratio. The 




(6.25, 12.5, 25, 50, 100, 200 nM); AZD2014 (0.125, 0.25, 0.5, 1, 2, 4 µM); and 
ibrutinib (0.0625, 0.125, 0.25, 0.5, 1, 2 µM). Cells were incubated for 44 h at 
37°C, 5% CO2. Thereafter, 20 µL 500 µM resazurin (1:10) was added to the cells 
and incubated for 4 h at 37°C, 5 % CO2. Following incubation, fluorescence was 
read on a SpectraMax M5 microplate reader using a fluorescence excitation 
wavelength at 570 nm and emission wavelength at 585 nm. Combination index 
(CI) values were calculated using the median-drug effect analysis method (425) 
with the CompuSyn software package (Biosoft), where a CI < 1 indicates synergy 
and CI > 1 indicates an antagonistic effect. Of note, drug concentrations were 
chosen based on clinically achievable doses calculated from dose escalation 
studies (439-441). With reference to the Chou and Talalay method (425), it is 
often necessary to calculate IC50 values for each drug to ascertain accurate CI 
values. However, IC50 values generated in vitro are not always applicable in 
vivo. Fortunately, IC50 values can be extrapolated using this method. Thus, the 
Chou and Talalay method can accommodate data points entirely above or below 
the IC50 of a given drug (425). Experimentally, this simplifies the use of 
heterogenous primary samples with variable IC50 values. 
2.2.10 Statistics 
Data were analysed using Prism 6 software (GraphPad) and are presented as 
mean values ± standard error of the mean (SEM), unless otherwise stated. All n 
values refer to the number of biological replicates. P values were determined by 
paired and unpaired, two-tailed Student’s t test for analysis of two groups. One-
way ANOVA with Tukey’s multiple comparisons test was used for ³ 3 groups. P 
values £0.05 were considered statistically significant. Unless otherwise stated, 
significant results are indicated by asterisks: P £0.05 *, P £0.01 **, P £0.001 ***, P 




3 Results I 
3.1 Introduction 
The advent of small-molecule inhibitors targeting BCR signalling components 
have revolutionized management strategies for CLL patients (45). Indeed, the 
BTK inhibitor ibrutinib (72, 131, 426) has proven tremendously effective among 
previously-treated, R/R and/or patients harbouring poor prognostic features 
(45). However, the emergence of drug resistance, treatment relapse and therapy 
discontinuation (87-89, 148) highlights the need to develop novel therapeutic 
strategies for CLL patients.  
The clinical activity of BCR kinase inhibitors emphasises the significance of BCR 
signalling in CLL pathogenesis (9), most notably within the LN microenvironment 
(45, 207). mTOR kinase, through the coordinated activities of protein complexes 
mTORC1 and mTORC2, orchestrates PI3K-mediated growth and survival signals 
emanating from BCR engagement in normal B cells (266, 269). In fact, mTOR is 
prominently placed to integrate PI3K- and MAPK/ERK-mediated signals from a 
multitude of microenvironment stimuli (270). However, little is known about the 
role of mTOR signalling in CLL pathogenesis.  
Despite encouraging preclinical data with the mTORC1-selective inhibitor 
rapamycin (313, 336, 337, 428), the rapalogue everolimus only had modest anti-
tumour activity in a CLL clinical trial (339). Clinical activity of mTORC1-selective 
inhibitors are limited due to incomplete blockade of mTORC1-induced 4E-BP1 
phosphorylation (312) and abrogation of negative feedback loops (mediated via 
S6K1) that enhance pro-survival signalling via increased mTORC2-AKT activity 
(314-317). The development of ‘second generation’ ATP-competitive mTOR 
inhibitors avoid these issues by inhibiting both mTORC1 and mTORC2 (293). As 
such, we sought to address whether inhibition of mTORC1 and mTORC2 with the 
dual mTOR kinase inhibitor AZD8055 would represent an effective therapeutic 






I. Explore mTOR activity in PB-derived CLL cells and patient LN biopsies. 
II. Investigate in vitro modulation of mTOR activity downstream of TME 
stimuli. 
III. Examine the ability of AZD8055, rapamycin and ibrutinib to inhibit mTOR 
activity in CLL cells. 
IV. Determine and compare the functional impact of inhibiting mTOR with 






3.2.1 mTOR is active in ex vivo primary CLL cells 
Mindful that studies have previously demonstrated constitutively active PI3K 
(252) and AKT (285) in freshly isolated CLL cells, it was of interest to discover 
the activation status of mTOR complexes mTORC1 and mTORC2 in ex vivo 
primary CLL cells. To determine the basal level of mTOR activity in different 
prognostic subgroups of CLL patients, the phosphorylation status of mTORC1 (4E-
BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets was assessed 
in ex vivo primary CLL cells (derived from PB) compared with B cells from 
healthy donors (Figure 3.1). These data revealed that phosphorylation of AKTS473, 
4E-BP1T37/46 and S6S235/236 was present among CLL patient samples, but at varying 
levels (Figure 3.1a). In comparison to healthy donor B cells, phosphorylation 
levels of AKTS473, 4E-BP1T37/46 and S6S235/236 were significantly lower in CLL cells 
(Figure 3b-d). Interestingly, while there was no difference in AKT expression 
(Figure 3.1f), a trend towards increased 4E-BP1 (p = 0.12; Figure 3.1g) and 
decreased S6 (p = 0.07; Figure 3.1h) expression was observed in CLL patient 
samples compared to B cells from healthy donors. Within this CLL patient 
cohort, stratification of AKTS473, 4E-BP1T37/46 and S6S235/236 phosphorylation levels 
based upon distinct cytogenetic alternations showed no significant difference 
(Figure 3.1i-k). However, a modest trend towards decreased levels of AKTS473 
and 4E-BP1T37/46 phosphorylation was observed in poor-prognostic CLL patients 
with del(17p), compared to patients with undetected abnormalities in del(11q) 





Figure 3.1 - mTOR is active in ex vivo primary CLL cells 
(a) Western blot of healthy donor B cells (Healthy CD19+; n=3) and CLL patients (n=11), 















































































































































































































































(n=3). ‘No del(11q) / del(17p)’ refers to an absence of detected del(11q) or del(17p) alterations. 
Blots were probed for AKTS473, AKT, 4E-BP1T37/46, 4E-BP1, S6S235/236, S6 and GAPDH (loading 
control; #1 and #2 referring to mirror blots). (b, c, d) Relative phosphorylation levels of (b) AKTS473, 
(c) 4E-BP1T37/46 and (d) S6S235/236 in Healthy CD19+ (n=6; purple bars) and CLL samples (CLL; n = 
31; peach bars) calculated by first normalising phosphorylation and expression levels by GAPDH, 
followed by normalised phosphorylation divided by normalised expression levels. (e) Schematic 
demonstrating mTORC1/2 activity between Healthy CD19+ and CLL, showing increased 
mTORC1/2 activity in healthy donor B cells. (f,g,h) Normalised expression levels of (f) AKT, (g) 4E-
BP1 and (h) S6 in Healthy CD19+ (n=6; dark blue bars) and CLL samples (CLL; n = 31; light blue 
bars) calculated by normalising expression levels by GAPDH. (i, j, k) Relative phosphorylation 
levels of (i) AKTS473, (j) 4E-BP1T37/46 and (k) S6S235/236 in CLL patients stratified according to 
cytogenetics ‘No del(11q) / del(17p)’ (n=13), del(11q) (n=10) and del(17p) (n=8). Individual patient 
datapoints are represented by white circles. Data expressed as the mean ± SEM. Statistics 
calculated by unpaired Student’s t-test for two groups and one-way ANOVA for three groups, 
where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
3.2.2 Regulation of mTORC1 activity in CLL patient LN biopsies 
Following the assessment of basal mTOR activity in freshly isolated CLL cells, it 
was of interest to investigate mTOR activity within the CLL lymphoid 
compartment (Figure 3.2). The CLL-TME promotes BCR, CD40 and chemokine 
receptor engagement, which transmits signals through the PI3K-AKT-mTOR axis 
to promote cell survival, growth and proliferation (9, 207). To examine mTOR 
activity within the CLL-TME, the phosphorylation status of mTORC1 (4E-BP1T37/46 
and S6S235/236) downstream targets was assessed by IHC of LN biopsies derived 
from distinct prognostic subgroups of CLL patients (Figure 3.2). The patients had 
previously been categorised into ‘indolent’ or ‘progressive’ disease, based upon 
cytogenetics, IGVH gene mutational status and CD38 expression. These 
experiments showed that 4E-BP1T37/46 phosphorylation was observed at varying 
levels in CLL patient LN biopsies (Figure 3.2a). Of the 20 CLL patients examined, 
5 (25 %) had undetected 4E-BP1T37/46 phosphorylation. Moreover, no significant 
difference was observed in 4E-BP1T37/46 phosphorylation levels between indolent 
or progressive CLL patients (Figure 3.2b). Interestingly, despite the presence of 
4E-BP1T37/46 phosphorylation, little or no S6S235/236 phosphorylation was detected 
(Figure 3.2c). Only 3 (15 %) of the 20 CLL patients assessed exhibited S6S235/236 
phosphorylation (Figure 3.2d). Phosphorylation levels were scored as an intensity 





Figure 3.2 – Regulation of mTORC1 activity in CLL patient LN biopsies 
(a, c) IHC of CLL patient LN biopsies stratified into ‘indolent’ and ‘progressive’ disease based on 
cytogenetics and IGVH gene mutational status. LN sections were stained for (a) 4E-BP1T37/46 and 
(c) S6S235/236. Prognostic information is found below each micrograph. Staining was performed by 
Dr. Mark Catherwood (Belfast City Hospital, Belfast). (b) 4E-BP1T37/46 and (d) S6S235/236 intensity 
score (IS) for CLL patient LN biopsies subdivided into indolent (n=11; salmon bars) and 
progressive (n=9; blue bars) disease. IS is scored from 0 to 5; 0 indicating undetected signal and 5 
corresponding to highest signal. All slides were scored by an experienced histopathologist. 
Individual patient datapoints are represented by white circles. Data expressed as the mean ± SEM. 
 
3.2.3 BCR stimulation enhances mTOR activity in vitro 
To explore mTOR activation downstream of BCR ligation in vitro, primary CLL 
cells derived from PB were stimulated with soluble F(ab’)2 fragments (213). 
Following short-term F(ab’)2 stimulation, the phosphorylation status of mTORC1 
(4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets was 























































signalling in CLL cells (234) and mTORC1 is a downstream effector of the 
MAPK/ERK pathway (429, 430), ERK1/2T202/Y204 phosphorylation was assessed. 
Western blotting of F(ab’)2-stimulated primary CLL samples revealed an increase 
in phosphorylation of the aforementioned mTORC1/2 targets and ERK1/2T202/Y204 
(Figure 3.3a). Importantly, these data demonstrated the heterogeneity of BCR 
signalling responses among CLL patients, where a subset of CLL samples are 
virtually unaffected by F(ab’)2 engagement (Figure 3.3a). Nevertheless, F(ab’)2 
stimulation of primary CLL samples resulted in a significant increase in relative 
phosphorylation levels of ERK1/2T202/Y204 (Figure 3.3e) and mTORC1 downstream 
target S6S235/236 (Figure 3.3d). Additionally, near-significant increases in relative 
phosphorylation of mTORC2 substrate AKTS473 (p = 0.068; Figure 3.3b) and 
mTORC1 substrate 4E-BP1T37/46 (p = 0.07; Figure 3.3c) were observed.  
mTOR activity was further characterised in CLL cell lines HG-3 and MEC-1, which 
have cytogenetic alterations associated with favourable and poor prognosis, 
respectively (431, 432). Of note, HG-3 and MEC-1 cells are immortalised, 
Epstein-Barr virus (EBV)-transformed cell lines with unlimited proliferative 
capacity (431, 432). It must be stressed that while HG-3 and MEC-1 cells are 
reflective of certain aspects of CLL disease biology (i.e. cytogenetic alterations), 
one cannot make direct comparisons between these cell lines and primary CLL 
cells. Indeed, HG-3 and MEC-1 cells are characterised by hyperactive oncogenic 
signalling (distinct from CLL cells that require external stimulation), which will 
likely influence drug sensitivity/activity. This being said, MEC-1 cells display 
constitutive BTK activation (501) and express unmutated IGHV genes (409, 410), 
highlighting possible BCR signalling involvement. Thus, it was of interest to 
address mTOR activity in these cell lines. Additionally, unrestricted proliferation 
of HG-3 and MEC-1 cells will offer insights into the cytostatic ability of mTOR 
kinase inhibitors. To determine the activity of mTOR in HG-3 and MEC-1 cells, 
the phosphorylation status of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 
(AKTS473) downstream targets was examined (Figure 3.3f-i). ERK1/2T202/Y204 
phosphorylation was also assessed (Figure 3.3f,j). These data revealed that 
phosphorylation of AKTS473, 4E-BP1T37/46 and S6S235/236 was present in HG-3 and 
MEC-1 cells (Figure 3.3f). In comparison to HG-3 cells, relative phosphorylation 
levels of mTORC2 substrate AKTS473 was significantly decreased in MEC-1 cells 

























































































































































































































































(a) Western blot of individual primary CLL samples (n=5) unstimulated (-) or stimulated (+) with 
F(ab’)2 fragments (10 ng/mL) for 1 h. Blots were probed for AKTS473, AKT, 4E-BP1T37/46, 4E-BP1, 
S6S235/236, S6, ERK1/2T202/Y204, ERK1/2 and GAPDH (loading control; #1 and #2 referring to mirror 
blots). (b, c, d, e) Relative phosphorylation levels of (b) AKTS473, (c) 4E-BP1T37/46, (d) S6S235/236 and 
(e) ERK1/2T202Y204 between unstimulated (unstim.; white circles) and F(ab’)2-stimulated (black 
circles) CLL samples (AKTS473, 4E-BP1T37/46 n=12; S6S235/236 n=10; ERK1/2T202Y204 n=5). For each 
CLL patient sample, relative phosphorylation levels for unstim. and F(ab’)2 are connected by a grey 
line. Relative phosphorylation is calculated by first normalising phosphorylation and expression 
levels by GAPDH, followed by normalised phosphorylation divided by normalised expression 
levels. (f) Representative western blot of HG-3 (n=2) and MEC-1 (n=3) protein lysates probed for 
AKTS473, AKT, 4E-BP1T37/46, 4E-BP1, S6S235/236, S6, ERK1/2T202/Y204, ERK1/2 and GAPDH. (g, h, i, j) 
Relative phosphorylation levels of (g) AKTS473, (h) 4E-BP1T37/46, (i) S6S235/236 and (j) ERK1/2T202Y204 
in HG-3 (n=3; blue bars) and MEC-1 (n=3; orange bars) cells. Individual datapoints are represented 
by white circles. Data expressed as the mean ± SEM. Statistics calculated by paired and unpaired 
Student’s t-test, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
ERK1/2T202/Y204 phosphorylation (Figure 3.3j). Despite no significant difference 
between the relative phosphorylation levels of 4E-BP1T37/46 in HG-3 and MEC-1 
cells (Figure 3.3 h), a trend towards increased levels of S6S235/236 phosphorylation 
was observed in MEC-1 cells (p =0.12; Figure 3.3i). Importantly, while there was 
no difference in AKT, S6 or ERK1/2 expression (Figure 3.3f; data not shown), a 
trend towards increased 4E-BP1 (p = 0.12; Figure 3.3f; data not shown) 
expression was observed in HG-3 cells compared to MEC-1 cells. 
 
3.2.4 AZD8055 inhibits phosphorylation of mTORC1/2 
downstream targets in F(ab’)2-stimulated CLL cells 
After demonstrating that mTOR is a downstream effector of BCR stimulation in 
CLL cells (Figure 3.4b), it was important to address whether pharmacological 
inhibition of mTOR using the dual mTOR kinase inhibitor AZD8055 possessed anti-
tumour activity. To examine AZD8055 selectivity for mTORC1 and mTORC2 in 
unstimulated and F(ab’)2-stimulated CLL cells, the phosphorylation status of 
mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets 
was assessed following short-term treatment with increasing doses of AZD8055 
(Figure 3.4). After 30 min pre-treatment with the indicated doses of AZD8055, 
CLL cells remained unstimulated or were F(ab’)2-stimulated for 1 h. This 
experiment showed that AZD8055 treatment resulted in a dose-dependent 
inhibition of F(ab’)2-dependent 4E-BP1T37/46, S6S235/236 and AKTS473 
phosphorylation (Figure 3.4a). With the exception of 4E-BP1T37/46, 
phosphorylation levels of S6S235/236 and AKTS473 were undetectable or noticeably 
reduced in unstimulated CLL cells (Figure 3.4a). In F(ab’)2-stimulated CLL cells, 




achievable dose of AZD8055, while S6S235/236 phosphorylation was reduced (Figure 
3.4a). Importantly, AZD8055 was effective in blocking a F(ab’)2-dependent 
increase in mTOR activity (Figure 3.4a,c). Unexpectedly, treatment with 
AZD8055 also resulted in a dose-dependent inhibition of F(ab’)2-induced AKTT308 
phosphorylation (Figure 3.4a).  
 
Figure 3.4 - Treatment of primary CLL cells with the dual mTOR inhibitor AZD8055 reveals a 
dose-dependent inhibition of mTORC1/2 activity 
(a) Representative western blot of a primary CLL sample (CLL80; n=3 CLL samples) unstimulated 
or F(ab’)2-stimulated for 1 h following 30 min pre-treatment with increasing concentrations of 






BP1T37/46, 4E-BP1, S6S235/236, S6 and GAPDH (loading control; #1 and #2 referring to mirror blots). 
(b, c) Schematic of (b) mTOR pathway activation following F(ab’)2 stimulation and (c) AZD8055 
drug selectivity for mTORC1/2, inhibiting phosphorylation of downstream targets AKTS473, 4E-
BP1T37/46 and S6S235/236. 
 
To further explore drug selectivity for mTORC1 and mTORC2, AZD8055 was 
compared with the mTORC1-selective inhibitor rapamycin and BTK inhibitor 
ibrutinib (Figure 3.5). As treatment of BCR-stimulated CLL cells with ibrutinib 
has been shown to abrogate MAPK/ERK signalling (126), ERK1/2T202/Y204 
phosphorylation was also assessed. Following pre-treatment with AZD8055 (100 
nM), rapamycin (10 nM) or ibrutinib (1 µM) for 30 min, CLL cells remained 
unstimulated or were F(ab’)2-stimulated for 1 h (Figure 3.5a). Consistent with 
Figure 3.4, these data showed that F(ab’)2-dependent phosphorylation of 
mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets 
were inhibited following short-term AZD8055 treatment, resulting in a near-
significant trend towards reduced AKTS473 phosphorylation (p = 0.09; Figure 
3.5b). In contrast, AZD8055 treatment did not reduce ERK1/2T202/Y204 
phosphorylation levels (Figure 3.5a). Consistent with observation that rapamycin 
differentially affects 4E-BP1 and S6K activity (312), these data showed that 4E-
BP1T37/46 phosphorylation remained largely unaffected by rapamycin (Figure 
3.5a,c), whereas S6S235/236 phosphorylation was significantly inhibited in 
unstimulated CLL cells (Figure 3.5d). Moreover, increased F(ab’)2-dependent 
S6S235/236 phosphorylation was also blocked with rapamycin to a similar extent as 
AZD8055 (Figure 3.5d). Conversely, rapamycin did not significantly affect AKTS473 
(Figure 3.5b) and ERK1/2T202/Y204 phosphorylation levels (Figure 3.5a). Short term 
treatment of F(ab’)2-stimulated CLL cells with ibrutinib resulted in a near-
significant reduction in AKTS473 phosphorylation compared to F(ab’)2-stimulated 
vehicle control (p = 0.08; Figure 3.5b). While ibrutinib treatment did not 
significantly impact phosphorylation levels of mTORC1 downstream targets 4E-
BP1T37/46 (Figure 3.5c) and S6S235/236 (Figure 3.5d) in unstimulated CLL cells, 
phosphorylation of 4E-BP1T37/46 and S6S235/236 was reduced in F(ab’)2-stimulated 
CLL cells (Figure 3.5a,c,d). However, whereas inhibition of F(ab’)2-dependent 
S6S235/236 phosphorylation was readily observable, 4E-BP1T37/46 inhibition was 
much more variable. Consistent with previous studies (126), ibrutinib treatment 
of F(ab’)2-stimulated CLL cells effectively inhibited ERK1/2T202/Y204 





Figure 3.5 - A clinically-achievable dose of AZD8055 effectively inhibits phosphorylation of 
mTORC1/2 targets following F(ab’)2 stimulation, superior to the mTORC1-selective inhibitor 
rapamycin 
(a) Representative western blot of a primary CLL sample (CLL57) unstimulated or F(ab’)2-









Ibrutinib (1 µM) or DMSO vehicle control. Blots were probed for AKTS473, AKT, 4E-BP1T37/46, 4E-
BP1, S6S235/236, S6, ERK1/2T202/Y204, ERK1/2 and GAPDH (loading control; #1 and #2 referring to 
mirror blots). (b, c, d) Relative phosphorylation levels of (b) AKTS473, (c) 4E-BP1T37/46 and (d) 
S6S235/236 in primary CLL samples (n=4) treated as described in (a). Relative phosphorylation is 
calculated by first normalising phosphorylation and expression levels by GAPDH, followed by 
normalised phosphorylation divided by normalised expression levels. Relative phosphorylation 
levels are relative to unstimulated vehicle control. Unstimulated (teal bars) and F(ab’)2-stimulated 
(dark blue bars). Individual patient datapoints are represented by white circles. Data expressed as 
the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001. 
 
3.2.5 AZD8055 treatment does not affect HG-3 and MEC-1 cell 
viability 
To examine the impact of dual mTOR inhibition upon CLL cell survival, HG-3 and 
MEC-1 cells were treated with AZD8055 (100 nM), rapamycin (10 nM) or ibrutinib 
(1 µM) for 48 h. Of note, ibrutinib treatment was included in recognition of the 
inhibitory effect upon F(ab’)2-dependent mTORC1 (S6S235/236) and mTORC2 
(AKTS473) activity (Figure 3.5). Following treatment, the cells were stained with 
Annexin V/7-AAD and analysed by flow cytometry (Figure 3.6a). These data 
showed that treatment with AZD8055, rapamycin or ibrutinib did not 
significantly affect the viability of HG-3 or MEC-1 cells (Figure 3.6a-e). Notably, 
AZD8055 treatment modestly increased the percentage of viable (Annexin Vneg 7-
AADneg) HG-3 cells (p = 0.056; Figure 3.6b). Consistent with this result, AZD8055 
treatment corresponded to a visible decrease in the percentage of apoptotic 
(Annexin Vpos 7-AADpos) HG-3 cells (p = 0.08; Figure 3.6c). However, these data 
are likely explained by biological variability and do not represent biological 
significance. With hindsight, it would have been appropriate to treat the cells 
with a known apoptosis-inducing agent (as a positive control) to consider the 
scale of the effect of each treatment and enable comparisons to be drawn. 
mTOR signalling plays a role in the regulation (activity and expression levels) of 
pro- and anti-apoptotic BCL2 family proteins, which shift the balance between 
cellular life and death (433, 434). Intrigued by the perceived lack of sensitivity 
of HG-3 and MEC-1 cells to mTOR inhibition, it was of interest to explore the 
regulation of anti-apoptotic (MCL-1, BCL-xL, BCL2 and Survivin) and pro-
apoptotic (BIM) proteins in response to AZD8055, rapamycin or ibrutinib 
treatment (Figure 3.6f). The presence of PARP fragments or ‘cleaved’ PARP was 
also assessed as a marker for caspase-dependent apoptosis (435). These data 




and MEC-1 cells, the levels were too low to resolve (Figure 3.6f). Interestingly, 
differential regulation of anti- and pro-apoptotic proteins was observed HG-3 
and MEC-1 cells following treatment. For example, while the expression of anti-
apoptotic MCL-1 was downregulated in HG-3 cells following treatment, MCL-1 
expression was increased in MEC-1 cells. AZD8055 treatment downregulated 
MCL-1 expression to a greater extent than rapamycin or ibrutinib in HG-3 cells. 
Conversely, AZD8055 treatment upregulated MCL-1 expression to a larger extent 
than rapamycin or ibrutinib in MEC-1 cells (Figure 3.6f). Basal expression of the 
anti-apoptotic protein BCL-xL was higher in MEC-1 cells compared to HG-3 cells. 
Nevertheless, BCL-xL expression was elevated in HG-3 cells after rapamycin or 
ibrutinib treatment. AZD8055 treatment only caused a modest upregulation in 
BCL-xL expression in HG-3 cells. As for MEC-1 cells, treatment with AZD8055, 
rapamycin and ibrutinib resulted in an upregulation in BCL-xL expression (Figure 
3.6f). Overexpression of the anti-apoptotic protein BCL2 is a central 
characteristic of CLL pathology (436). As such, high levels of BCL2 expression 
were observed in HG-3 and MEC-1 cells, which was maintained despite treatment 
with AZD8055, rapamycin or ibrutinib (Figure 3.6b). Basal expression of anti-
apoptotic protein Survivin was higher in MEC-1 cells compared to HG-3 cells. 
Although the expression of Survivin was downregulated in HG-3 cells following 
treatment, Survivin expression was upregulated in MEC-1 cells with AZD8055 and 
rapamycin treatment. Interestingly, treatment with ibrutinib resulted in an 
upregulation of Survivin in HG-3 cells, while the same treatment caused a 
downregulation of Survivin in MEC-1 cells (Figure 3.6f). The expression of pro-
apoptotic protein BIM (BIMEL, BIML and BIMS) was upregulated in HG-3 and MEC-1 
cells following AZD8055, rapamycin and ibrutinib treatment. AZD8055 caused a 
modest increase in BIM expression in HG-3 cells, which was comparative to 
rapamycin. Similarly, AZD8055 treatment caused a larger increase in BIM 
expression (compared with rapamycin) in MEC-1 cells. Of note, AZD8055 
upregulated the expression of BIMS in MEC-1 cells, widely considered the most 






Figure 3.6 - AZD8055 promotes a modest increase in HG-3 cell viability 
(a) Representative FACS plot of HG-3 (top panel) and MEC-1 (bottom panel) cells stained with 









Rapamycin (10 nM), Ibrutinib (1 µM) or DMSO vehicle control (Vehicle) for 48 h. Please refer to 
section 2.2.2.3 for gating strategy. (b, d) Percentage viable (b) HG-3 (n=5) and (d) MEC-1 (n=5) 
cells treated with AZD8055 (grey bar), Rapamycin (gold bar), Ibrutinib (blue bar) or DMSO vehicle 
control (green bar) for 48 h, as described in (a). Viability is defined as Annexin Vneg and 7-AADneg. 
(c, e) Percentage apoptotic (c) HG-3 (n=5) and (e) MEC-1 (n=5) cells treated as described in (a). 
Apoptotic cells are defined as Annexin Vpos and 7-AADpos. (f) Representative western blot of HG-3 
(n=3) and MEC-1 (n=3) cells treated with AZD8055, Rapamycin, Ibrutinib or DMSO vehicle control 
for 48 h. Blots were probed for PARP, MCL-1, BCL-xL, BCL2, Survivin, BIM (BIMEL, BIML, and 
BIMS) and GAPDH (loading control; #1 and #2 referring to mirror blots). Individual patient 
datapoints are represented by white circles. Data expressed as the mean ± SEM. Statistics 
calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
3.2.6 mTOR inhibition is sustained in F(ab’)2-stimulated CLL cells  
Studies have previously highlighted the dynamic adaptability of various cancers 
in response to mTOR inhibition (293, 314, 324). To address whether mTOR 
inhibition is short-lived, primary CLL cells (Figure 3.7a) and MEC-1 cells (Figure 
3.7b) were F(ab’)2-stimulated for the indicated time points in the presence of 
AZD8055. Thereafter, the phosphorylation status of mTORC1 (4E-BP1T37/46 and 
S6S235/236) and mTORC2 (AKTS473) downstream targets was examined (Figure 3.7). 
Since AZD8055 has been shown to suppress feedback inhibition of RTKs, which 
ultimately results in PI3K-induced AKTT308 rephosphorylation (324), the 
phosphorylation status of AKTT308 was also assessed. F(ab’)2 stimulation of CLL 
cells conferred a transient increase in AKTT308, AKTS473 and S6S235/236 
phosphorylation, while 4E-BP1T37/46 phosphorylation was largely unaffected 
(Figure 3.7a). As demonstrated in Figure 3.4a, AZD8055 inhibited 
phosphorylation of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) 
downstream targets in F(ab’)2-stimulated CLL cells (Figure 3.7a). Moreover, 
inhibition of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) activity 
was sustained for up to 24 h. Interestingly, AZD8055 treatment also inhibited 
AKTT308 phosphorylation, which was maintained throughout the duration of the 
timecourse (Figure 3.7a).  
As demonstrated in Figure 3.3f, mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 
(AKTS473) downstream targets were phosphorylated in MEC-1 cells. F(ab’)2 
stimulation of MEC-1 cells did not confer an increase in AKTS473, 4E-BP1T37/46 and 
S6S235/236 phosphorylation, while a modest increase in AKTT308 phosphorylation 
was observed (Figure 3.7b). Of note, relative phosphorylation levels of AKTT308, 
AKTS473, 4E-BP1T37/46 and S6S235/236 reduced towards the end of the timecourse 
(Figure 3.7b). Consistent with Figure 3.7a, AZD8055 inhibited phosphorylation of 





Figure 3.7 - mTOR inhibition is sustained in F(ab’)2-stimulated CLL cells 
(a, b) Representative western blots of a (a) primary CLL sample (CLL80; n=3 primary CLL 
samples) and (b) MEC-1 cells (n=3) stimulated with F(ab’)2 for the indicated timepoints (0, 0.5, 1, 3, 
5 and 24 h) following 30 min pre-treatment with AZD8055 (100 nM) or vehicle control. Blots were 
probed for AKTT308, AKTS473, AKT, 4E-BP1T37/46, 4E-BP1, S6S235/236, S6 and GAPDH (loading 








F(ab’)2-stimulated MEC-1 cells (Figure 3.7b). However, unlike F(ab’)2-stimulated 
CLL cells, AZD8055 treatment did not inhibit AKTT308 phosphorylation in F(ab’)2-
stimulated MEC-1 cells (Figure 3.7b). Importantly, inhibition of mTORC1 
(S6S235/236) and mTORC2 (AKTS473) activity was sustained for the duration of the 
timecourse. However, an increase in 4E-BP1T37/46 phosphorylation was observed 
at 24 h (Figure 3.7b). It is important to consider that MEC-1 cells are not ‘wired’ 
to be stimulated in the same way as primary CLL cells, owing to the fact that 
this cell line is EBV-transformed. Figure 3.7 highlights that MEC-1 cells are 
hyperactivated without external stimulation, whereas primary CLL cells require 
external stimulation (e.g. F(ab’)2 stimulation) to activate mTOR signalling. Thus, 
these factors demonstrably influence drug sensitivity/activity, inasmuch as 
AZD8055 cannot inhibit something that is almost unstimulated. 
3.2.7 Dual mTOR inhibitors synergise with ibrutinib to enhance 
CLL cell death in vitro 
To investigate the sensitivity of CLL cells to AZD8055, AZD2014 (AZD8055 clinical 
analogue) and ibrutinib, CLL cells were treated with increasing concentrations of 
drug for 48 h. The resazurin cell viability assay was subsequently used to 
quantify cell viability, from which the half-maximal effective concentration 
(EC50) was calculated. As reported by Pike et al., AZD8055 was shown to be a 
potent inhibitor of mTOR kinase (IC50=0.00013) and inhibited mTORC1/2 
downstream targets (S6S235/236 IC50=0.027 µM; AKTS472 IC50=0.024 µM). Despite 
encouraging preclinical evaluation in vitro, AZD8055 exhibited unfavourable 
bioavailability (pharmacokinetics) among murine species (mouse=81 %; rat=12 
%). Furthermore, AZD8055 was quickly metabolised in human hepatocytes 
(36.4µL/min/106). Given the potential risks associated with these factors, 
AZD8055 was further optimised to improve bioavailability, aqueous solubility and 
reduce turnover (318). A detailed explanation of the chemical modifications 
generated to synthesise AZD2014 was reviewed (318). In brief, AZD2014 was 
synthesised from AZD8055 in a stepwise process via modification of amide and 
methoxy groups to reduce turnover in human hepatocytes. AZD2014 
demonstrated reduced metabolism (<4.2 µL/min/106), improved bioavailability 
in rodents (mouse=>100 %; rat=40 %), enhanced solubility (>600 µM) maintained 
good potency against mTOR kinase (IC50=0.0028) and inhibited downstream 




highly selective against other PIKK family members (IC50 >3 µM). However, 
chemical modifications rendered AZD2014 less potent than AZD8055 (318). 
Treatment of CLL cells with increasing concentrations of AZD8055 (Figure 3.8a), 
AZD2014 (Figure 3.8b) or ibrutinib (Figure 3.8c) resulted in a dose-dependent 
reduction in cell viability. However, CLL cells were largely insensitive to 
AZD8055 (EC50 = 12.415 µM) and AZD2014 (EC50 = 10.229 µM) at clinically 
achievable doses (Figure 3.8a,b). Conflicting with earlier reports (318), AZD2014 
was slightly more potent than AZD8055 in primary CLL cells. Although CLL cells 
were more sensitive to ibrutinib (EC50 = 5.446 µM), only modest reductions in 
cell viability were observed at clinically achievable doses (Figure 3.8c).  
As demonstrated in Figure 3.5a, AZD8055 or ibrutinib treatment as single agents 
targeted distinct components of pro-survival signalling pathways in F(ab’)2-
stimulated CLL cells. For example, while ibrutinib failed to inhibit 4E-BP1T37/46 
phosphorylation, it diminished phosphorylation of ERK1/2T202/Y204. Conversely, 
while AZD8055 was unable inhibit ERK1/2T202/Y204 phosphorylation, it reduced 
phosphorylation of 4E-BP1T37/46 (Figure 3.5a). Furthermore, although AZD8055 
inhibited AKTS473 phosphorylation, AKT is unlikely to be completely inactivated 
due to the presence of PI3K-mediated AKTT308 phosphorylation (Figure 3.7b). 
Suppression of multiple oncogenic axes represents a rationale for drug 
combination studies (424). Given the inhibitory effect of ibrutinib on PI3K and 
MAPK/ERK pro-survival pathways (438), it was of interest to assess the impact of 
AZD8055 and ibrutinib combination therapy on cell viability in vitro (Figure 3.8d-
f). To determine whether dual mTOR kinase inhibitors (AZD8055 and AZD2014) 
synergise with ibrutinib to enhance CLL cell apoptosis, a median-drug effect 
analysis was performed to calculate combination index (CI) values according to 
the Chou and Talalay method (425), where a CI<1 indicates synergism and CI>1 
indicates antagonism (Figure 3.8d). Freshly isolated CLL cells were treated with 
various concentrations of AZD8055 (Figure 3.8d; left panel) or AZD2014 (Figure 
3.8d; right panel) in combination with ibrutinib at a non-constant ratio for 48 h. 
Subsequently, the resazurin cell viability assay was performed to quantify cell 
viability, from which the CI values were calculated by CompuSyn software. The 
representative heat map depicts CI values (0 – 2) for each individual drug 
combination, where the yellow colouring indicates greater synergism (Figure 





Figure 3.8 - Dual mTOR inhibitors synergise with ibrutinib to enhance CLL cell death in vitro 
(a, b, c) Dose-response/dose-effect curve of primary CLL samples (n=5) treated with increasing 
concentrations of (a) AZD8055 (3, 10, 30, 100, 300, 1000, 3000, 10000 nM), (b) AZD2014 (3, 10, 
30, 100, 300, 1000, 3000, 10000 nM), and (c) Ibrutinib (3, 10, 30, 100, 300, 1000, 3000, 10000 nM) 
as determined by the resazurin cell viability assay. EC50 values generated by nonlinear regression 
(curve fit) as an average of each primary CLL sample. (d) Representative median-effect analysis of 
a primary CLL sample (CLL158) examining drug synergy between combinations of AZD8055 and 
Ibrutinib (left panel) and AZD2014 and Ibrutinib (right panel). The following concentrations were 
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used at a non-constant ratio: AZD8055 (6.25, 12.5, 25, 50, 100, 200 nM), AZD2014 (0.0625, 0.125, 
0.25, 0.5, 1, 2 µM) and Ibrutinib (0.0625, 0.125, 0.25, 0.5, 1, 2 µM). Indicated CI values were 
calculated using the median-drug effect analysis method with the CompuSyn software package, 
where CI < 1 indicates synergy and CI > 1 indicates an antagonistic effect. (e, f) Graphs depicting 
CI values plotted against fraction affected (Fa) for select combinations of (e) AZD8055:Ibrutinib 
(0.1:1 (purple circles); 0.05:2 (green circles); 0.2:0.5 (blue circles) µM) and (f) AZD2014:Ibrutinib 
(0.5:1 (purple circles); 0.25:0.5 (green circles); 1:0.25 (blue circles) µM). Individual datapoints 
within each combination represent different CLL patient samples (n=6). (g, h) Representative 
(CLL158) median-effect plots (Chou plot) for (g) AZD8055 and ibrutinib combination and (h) 
AZD2014 and ibrutinib combination where the x-intercept (log Dm) signifies drug potency. 
AZD8055 (blue circles), ibrutinib (red squares) and COMBO (green triangles). 
 
represented by red datapoints, both AZD8055 and AZD2014 synergised with 
ibrutinib at multiple concentrations to enhance CLL cell death (Figure 3.8d and 
Table 3.1). For the combinations of AZD8055 and ibrutinib indicated (Figure 
3.8e), the obtained CI values were 0.45±0.13, 0.15±0.06 and 0.34±0.06, 
respectively. Similarly, for the combinations of AZD2014 and ibrutinib presented 
(Figure 3.8f), the CI values were 0.15±0.05, 0.15±0.05 and 0.19±0.08, 
respectively. Importantly, AZD8055 and AZD2014 synergised with ibrutinib to 
enhance CLL cell death at clinically achievable doses (439-441) (Figure 3.8e,f). 
Furthermore, median-effect plots (Chou plots) indicated drug synergy at 
multiple concentrations for AZD8055 or AZD2014 in combination with ibrutinib 
(Figure 3.8g,h). CI values for AZD2014 and ibrutinib were generally lower than 
those calculated for AZD8055 and ibrutinib, which might be explained by the 
increased potency of AZD2014 (contrary to previous reports (318)) in CLL cells. 
Nevertheless, a conclusive explanation remains elusive. 
 
3.2.8 AZD8055 and ibrutinib combination inhibits mTOR- and 
MAPK activity in HG-3 and MEC-1 cells  
Encouraged by the enhanced, synergistic effect of AZD8055 and ibrutinib 
combination treatment (herein referred to as ‘COMBO’) on CLL cell viability (via 
the resazurin assay), it was of interest to explore the impact of the treatment on 
mTOR activity in HG-3 and MEC-1 cells. The phosphorylation status of mTORC1 
(4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets was 
assessed following short-term AZD8055 (100 nM), ibrutinib (1 µM) or COMBO 
treatment. For the reasons stated previously, AKTT308 and ERK1/2T202/Y204 
phosphorylation was also examined (Figure 3.9). Consistent with Figure 3.7b, 
AZD8055 treatment inhibited phosphorylation of mTORC1 (4E-BP1T37/46 and 





Figure 3.9 - AZD8055 and ibrutinib combination inhibits mTOR- and MAPK activity in HG-3 
and MEC-1 cells 
(a) Representative western blot of HG-3 (n=3) and MEC-1 (n=3) cells treated with AZD8055 (100 












h. Blots were probed for AKTT308, AKTS473, AKT, 4E-BP1T37/46, 4E-BP1, S6S235/236, S6, 
ERK1/2T202/Y204, ERK1/2 and GAPDH (loading control; #1 and #2 referring to mirror blots). (b, c, d, 
e, f) Relative phosphorylation levels of (b) AKTT308, (c) AKTS473, (d) 4E-BP1T37/46 (e) S6S235/236 and 
(f) ERK1/2T202/Y204 in HG-3 (n=3; yellow bars) and MEC-1 (n=3; purple bars). Relative 
phosphorylation is calculated by first normalising phosphorylation and expression levels by 
GAPDH, followed by normalised phosphorylation divided by normalised expression levels. Relative 
phosphorylation levels for each condition are relative to vehicle control for HG-3 or MEC-1 cells. 
Individual datapoints are represented by white circles. Data expressed as the mean ± SEM. 
Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001. 
 
AKTT308 and ERK1/2T202/Y204 phosphorylation was largely unaffected (Figure 3.9a-
e). Similarly, AZD8055 treatment blocked phosphorylation of mTORC1 (4E-
BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets in HG-3 cells, 
while a visible trend was observed towards reduced AKTT308 and increased 
ERK1/2T202/Y204 phosphorylation (Figure 3.9a-e). Ibrutinib significantly reduced 
AKTT308 (Figure 3.9a,b), AKTS473 (Figure 3.9a,c), S6S235/236 (Figure 3.9a,e) and 
ERK1/2T202/Y204 (Figure 3.9a,f) phosphorylation in MEC-1 cells, while 4E-BP1T37/46 
(Figure 3.9a,d) was unaffected. Equally, ibrutinib treatment blocked AKTS473 
(Figure 3.9a,c) and ERK1/2T202/Y204 (Figure 3.9a,f) phosphorylation in HG-3 cells, 
while a noticeable trend towards reduced S6S235/236 (Figure 3.9a,e) and AKTT308 
(Figure 3.9a,b) phosphorylation was observed. Unlike MEC-1 cells, 4E-BP1T37/46 
phosphorylation was significantly reduced in HG-3 cells (Figure 3.9a,d). 
Importantly, the COMBO treatment significantly inhibited mTORC1 (4E-BP1T37/46 
and S6S235/236) and mTORC2 (AKTS473) downstream targets in MEC-1 cells (Figure 
3.9a,c-e). Interestingly, COMBO enhanced inhibition of S6S235/236 phosphorylation 
in MEC-1 cells, greater than the inhibitory effect of AZD8055 or ibrutinib alone 
(Figure 3.9e). Perhaps most crucially, COMBO significantly inhibited 
ERK1/2T202/Y204 (Figure 3.9a,f) phosphorylation in MEC-1 cells, while a discernible 
trend towards reduced AKTT308 (Figure 3.9a,b) phosphorylation was observed. In 
HG-3 cells, COMBO treatment also conferred a robust inhibition of AKTT308 
(Figure 3.9a,b), AKTS473 (Figure 3.9a,c), 4E-BP1T37/46 (Figure 3.9a,d), S6S235/236 
(Figure 3.9a,e) and ERK1/2T202/Y204 (Figure 3.9a,f) phosphorylation.  
 
3.2.9 HG-3 and MEC-1 cell viability is unaffected by COMBO 
treatment 
Combining AZD8055 with ibrutinib broadly inhibited AKT-mTOR and MAPK/ERK 
pro-survival pathways in HG-3 and MEC-1 cells (Figure 3.9). Given the lack of 




(Figure 3.6), it was of interest to establish whether the COMBO treatment could 
enhance cell death. HG-3 and MEC-1 cells were treated with AZD8055 (100 nM) 
or ibrutinib (1 µM) alone and in combination for 48 h. Following treatment, the 
cells were stained with Annexin V/7-AAD and analysed by flow cytometry (Figure 
3.10a). These data showed that the COMBO treatment did not affect the viability 
(Annexin Vneg 7-AADneg) of HG-3 or MEC-1 cells (Figure 3.10a,b,d). Although 
AZD8055 significantly reduced the proportion of apoptotic (Annexin Vpos 7-AADpos) 
HG-3 cells, this unlikely represents biological significance given the small 
percentages involved (Figure 3.10c). Consistently, treatment of HG-3 or MEC-1 
cells with COMBO did not impact upon the relative levels of apoptotic cells 
(Figure 3.10c,e). 
Considering these data, it was decided to explore the regulation of anti-
apoptotic (MCL-1, BCL-xL, BCL2 and Survivin) and pro-apoptotic (BIM) proteins in 
response to the COMBO treatment (Figure 3.10f). Consistent with Figure 3.6f, 
differential regulation of anti- and pro-apoptotic proteins was observed 
following AZD8055 or ibrutinib treatment in HG-3 and MEC-1 cells (Figure 3.10f). 
Interestingly, COMBO resulted in an upregulation of anti-apoptotic MCL-1 and 
BCL-xL expression in HG-3 and MEC-1 cells, while Survivin was downregulated 
compared to vehicle control (Figure 3.10f). Concurrently, the expression of pro-
apoptotic BIM (BIMEL, BIML and BIMS) was upregulated in HG-3 and MEC-1 cells in 
response to COMBO compared to vehicle control (Figure 3.10f). BCL2 expression 





Figure 3.10 - HG-3 and MEC-1 cell viability is unaffected by AZD8055 and ibrutinib 
combination treatment 
(a) Representative FACS plot of HG-3 (top panel) and MEC-1 (bottom panel) cells stained with 








(1 µM), AZD8055 and Ibrutinib combination (COMBO) or DMSO vehicle control (Vehicle) for 48 h. 
Please refer to section 2.2.2.3 for gating strategy. (b, d) Percentage viable (b) HG-3 (n=5) and (d) 
MEC-1 (n=5) cells treated with AZD8055 (grey bar), Ibrutinib (blue bar), COMBO (gold bar) or 
Vehicle (green bar) for 48 h, as described in (a). Viability is defined as Annexin Vneg and 7-AADneg. 
(c, e) Percentage apoptotic (c) HG-3 (n=5) and (e) MEC-1 (n=5) cells, treated as described in (a). 
Apoptotic cells are defined as Annexin Vpos and 7-AADpos. Percentage viable and apoptotic cells for 
each condition are relative to vehicle control for HG-3 or MEC-1 cells. (f) Representative western 
blot of HG-3 (n=3) and MEC-1 (n=3) cells treated with AZD8055, Ibrutinib, COMBO or Vehicle for 
48 h. Blots were probed for PARP, MCL-1, BCL-xL, BCL2, Survivin, BIM (BIMEL, BIML, and BIMS) 
and GAPDH (loading control; #1 and #2 referring to mirror blots). Individual patient datapoints are 
represented by white circles.  Data expressed as the mean ± SEM. Statistics calculated by one-
way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
3.2.10 MEC-1 cell size is reduced by COMBO treatment  
mTOR controls cell size, at least in part, through mTORC1-dependent 
phosphorylation of its downstream targets S6K1 and 4E-BP1 (270, 442). To 
examine the functional impact of mTOR inhibition on CLL cell size, HG-3 and 
MEC-1 cells were treated with AZD8055 (100 nM), ibrutinib (1 µM), COMBO or 
rapamycin (10 nM) for 48 h. Of note, rapamycin treatment was included to 
compare the effect of mTORC1-selective inhibition with dual mTOR inhibition. 
Following treatment, cell size was quantified as a measure of ‘forward scatter-
area (FSC-A)’ by flow cytometry (Figure 3.11a). These data revealed an 
observable trend towards reduced cell size in HG-3 cells treated with AZD8055 
or rapamycin (p = 0.12 and p = 0.11, respectively) compared to vehicle control 
(Figure 3.11b). However, there was neither a visible nor significant difference in 
HG-3 cell size between AZD8055 and rapamycin treatment (Figure 3.11b). 
Equally, ibrutinib or COMBO showed no significant difference in HG-3 cell size 
(Figure 3.11b). Conversely, treatment with AZD8055, ibrutinib, COMBO or 
rapamycin resulted in a significant reduction in MEC-1 cell size compared to 
vehicle control (Figure 3.11c). Furthermore, AZD8055 treatment caused a near-
significant greater reduction in MEC-1 cell size compared to rapamycin (p = 0.11; 
Figure 3.11c). Importantly, the COMBO treatment resulted in a significant 






Figure 3.11 - MEC-1 cell size is reduced by AZD8055 and ibrutinib combination treatment 
(a) Representative FACS histogram displaying geometric mean of forward scatter-area (FSC-A) of 
HG-3 (left panel) and MEC-1 (right panel) cells treated with AZD8055 (100 nM; dark pink 
histogram), Ibrutinib (1 µM; medium-pink histogram), AZD8055 and Ibrutinib combination (COMBO; 
light pink histogram), Rapamycin (10 nM; grey histogram) or DMSO vehicle control (Vehicle; white 
histogram) for 48 h. A black vertical line represents the peak of the Vehicle control histogram. (b, c) 
Relative cell size (geometric mean) of (b) HG-3 (n=5) and (c) MEC-1 (n=5) cells treated as 
described in (a). Geometric means for each condition are relative to vehicle control for HG-3 or 
MEC-1 cells. Individual datapoints are represented by white circles. Data expressed as the mean ± 








3.2.11 COMBO treatment promotes G1 cell cycle arrest in HG-
3 and MEC-1 cells  
mTOR plays a crucial role in mediating cell cycle progression via the activity of 
S6K1 and 4E-BP1 (443). Rapamycin (444) and everolimus (445, 446) have been 
shown to inhibit the G1/S transition by prolonging the G1 phase of the cell cycle. 
Moreover, mTOR inhibitors have been shown to cause cell cycle arrest in CLL 
cells (313, 428). More recently, AZD8055 has been shown to inhibit proliferation 
by inducing G1 cell cycle arrest in adult T-cell leukaemia (ATL) (447). To assess 
the impact of dual mTOR kinase inhibition on cell cycle progression in CLL cells, 
HG-3 and MEC-1 cells were treated with AZD8055 (100 nM), ibrutinib (1 µM), 
COMBO or rapamycin (10 nM) for 48 h. Rapamycin treatment was included to 
compare the effect of mTORC1-selective inhibition with dual mTOR inhibition. 
Following treatment, HG-3 and MEC-1 cells were stained with PI to quantify DNA 
content by flow cytometry (Figure 3.12a). Interestingly, rapamycin, ibrutinib or 
COMBO caused a significant increase in the proportion of DNA in the G1/G0 
phase of the cell cycle, while no significant difference was observed in AZD8055-
treated HG-3 cells (Figure 3.12b). Furthermore, treatment of HG-3 cells with 
COMBO instigated a near-significant reduction in the proportion of DNA in S 
phase, compared to vehicle control (p = 0.06; Figure 3.12b). Conversely, 
AZD8055, ibrutinib, COMBO or rapamycin all conferred a significant elevation in 
the proportion of DNA in the G1/G0 phase of the cell cycle in MEC-1 cells 
compared to vehicle control (Figure 3.12c). While there was no significant 
difference between AZD8055 and rapamycin, a modest trend towards a higher 
proportion of DNA in the G1/G0 phase of the cell cycle was observed in 
AZD8055-treated MEC-1 cells compared to rapamycin (Figure 3.12c). Finally, 
treatment of MEC-1 cells with AZD8055, ibrutinib, COMBO or rapamycin 
corresponded to a significant reduction in the proportion of DNA in S phase 
compared to vehicle control (Figure 3.12c). The incubation time (48 h) was 
chosen to align with prior cell viability experiments. The doubling time for HG-3 
(410) and MEC-1 cells (409) is approximately 40-50 hours. Upon reflection, the 
incubation time should have been extended to account for the intrinsic 
characteristics for each cell line. Moreover, cell synchronisation via ‘starvation’ 






Figure 3.12 - AZD8055 and ibrutinib combination promotes G1 cell cycle arrest in HG-3 and 
MEC-1 cells 
(a) Representative FACS histogram of HG-3 (left panel) and MEC-1 (right panel) cells stained with 
propidium iodide (PI) for cell cycle analysis by quantitation of DNA content following treatment with 
AZD8055 (100 nM; blue histogram), Ibrutinib (1 µM; orange histogram), AZD8055 and Ibrutinib 
combination (COMBO; light-green histogram), Rapamycin (10 nM; dark-green histogram) or DMSO 
vehicle control (Vehicle; red histogram) for 48 h. Please refer to section 2.2.2.4 for gating strategy. 
(b, c) Quantification of DNA content (%) for cycle cycle phase G1/G0 (purple bars), S (blue bars) 
and G2 (green bars) in (b) HG-3 (n=6) and (c) MEC-1 (n=5). Data from each replicate are depicted 
as ‘fraction of total’, where total values are equal to 100. Data expressed as the mean ± SEM. 
Statistics calculated by two-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001. 
 
3.2.12 COMBO treatment enhances inhibition of MEC-1 cell 
proliferation, corresponding to increased expression of 
p27KIP1 
CLL proliferation within ‘proliferation centres’ of SLOs is a key determinant for 
disease progression (9). Thus, treatments that block cell proliferation represent 






in MEC-1 cells (Figure 3.12), it was of interest to investigate the functional 
impact of mTOR inhibition on CLL cell proliferation. HG-3 and MEC-1 cells were 
treated with AZD8055 (100 nM), ibrutinib (1 µM), COMBO or rapamycin (10 nM) 
for 72 h. Prior to treatment, HG-3 and MEC-1 cells were stained with CTV to 
enable quantification of cell proliferation by flow cytometry (Figure 3.13a). 
These data revealed that AZD8055, COMBO and rapamycin resulted in a near-
significant reduction in HG-3 cell proliferation (p = 0.08, p = 0.0503 and p = 
0.13, respectively) compared to vehicle control (Figure 3.13b). Moreover, the 
COMBO treatment conferred a significant increase in CTV geometric mean, i.e. a 
greater inhibition of proliferation, compared to AZD8055 alone (Figure 3.13b). 
Interestingly, ibrutinib was unable to inhibit proliferation in HG-3 cells (Figure 
3.13b), despite inducing G1 cell cycle arrest (Figure 3.12b). AZD8055 and COMBO 
treatment significantly inhibited MEC-1 cell proliferation compared to vehicle 
control (Figure 3.13c). Additionally, COMBO resulted in a near-significant greater 
inhibition of MEC-1 cell proliferation than AZD8055 alone (p = 0.07; Figure 
3.13bc). Similarly, rapamycin conferred a near-significant inhibition of cell 
proliferation, though to a lesser extent than AZD8055 or COMBO (Figure 3.13c). 
As in Figure 3.13b, ibrutinib was unable to inhibit MEC-1 cell proliferation, 
however an observable trend towards increased inhibition was evident (Figure 
3.13c).  
Encouraged by the anti-proliferative effect of treatment on HG-3 and MEC-1 
cells, the regulation of ‘cell cycle proteins’ was investigated, particularly those 
that govern the G1/S phase transition (Figure 3.13d,e,f). To explore treatment-
induced cell cycle regulation at a molecular level, the expression of cell cycle 
proteins Cyclin E1, CDK2, Cyclin D2, CDK4, p27KIP1 and p21CIP1 were assessed by 
western blotting (Figure 3.13d). Basal expression levels of Cyclin E1, CDK4 and 
p27KIP1 were visibly higher in MEC-1 cells compared to HG-3 cells (Figure 3.13d). 
AZD8055, ibrutinib, COMBO and rapamycin treatment upregulated the expression 
of Cyclin E1 in MEC-1 cells compared to vehicle control (Figure 3.13d). Moreover, 
the expression of CDK2 was largely unaffected by treatment in HG-3 and MEC-1 
cells (Figure 3.13d). Interestingly, as demonstrated previously (Figures 3.6f and 
3.10f), differential regulation was observed in HG-3 and MEC-1 cells in response 
to treatment. For example, while AZD8055 treatment increased the expression 





Figure 3.13 - AZD8055 and ibrutinib combination enhances inhibition of MEC-1 cell 
proliferation, corresponding to increased expression of p27KIP1 
(a) Representative FACS histogram of HG-3 (left panel) and MEC-1 (right panel) cells stained with 
CellTrace Violet (CTV) to assess cell proliferation following treatment with AZD8055 (100 nM; blue 








green histogram), Rapamycin (10 nM; dark-green histogram) and DMSO vehicle control (Vehicle; 
red histogram) for 72 h. A black vertical line represents the peak of the HG-3 and MEC-1 vehicle 
control histogram. Please refer to section 2.2.2.5 for gating strategy. (b, c) Assessment of CTV 
geometric mean for (b) HG-3 (n=4) and (c) MEC-1 (n=3) cells treated as described in (a). 
Geometric means for each condition are relative to vehicle control for HG-3 or MEC-1 cells. (d) 
Representative western blot of HG-3 (n=3) and MEC-1 (n=3) cells treated with AZD8055, Ibrutinib, 
COMBO, Rapamycin and Vehicle for 48 h. Blots were probed for Cyclin E1, CDK2, Cyclin D2, 
CDK4, p27KIP1, p21CIP1 and GAPDH (loading control; #1 and #2 referring to mirror blots). (e, f) 
Densitometry of (e) p27KIP1 (dark brown bars) and (f) p21CIP1 (light brown bars) expression in MEC-
1 (n=3) cells following treatment as in (d). Normalised expression is relative to Vehicle for HG-3 or 
MEC-1 cells. Individual datapoints from each replicate are shown as white circles. Data expressed 
as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001. 
 
cells. Furthermore, whereas COMBO did not visibly effect Cyclin D2 expression in 
HG-3 cells, Cyclin D2 was upregulated in MEC-1 cells (Figure 3.13d). Although 
AZD8055 or ibrutinib treatment alone resulted in an elevation of CDK4 
expression in MEC-1 cells, COMBO did not noticeably effect CDK4 expression in 
MEC-1 cells (Figure 3.13d). Interestingly, CDK4 expression was not observed in 
HG-3 cells (Figure 3.13d). AZD8055 or ibrutinib treatment alone resulted in a 
significant upregulation of the cell cycle inhibitor p27KIP1 in MEC-1 cells(Figure 
3.13d,e). An observable trend towards enhanced p27KIP1 expression was evident 
following the COMBO treatment, greater than each treatment alone (Figure 
3.13d,e). Similarly, rapamycin treatment resulted in a trend towards increased 
p27KIP1 expression in MEC-1 cells compared to vehicle control (Figure 3.13d,e). 
Interestingly, AZD8055 treatment caused a near-significant downregulation of 
p21CIP1 expression in MEC-1 cells (p = 0.08), while ibrutinib conferred a 
demonstrable trend towards increased p21CIP1 expression (Figure 3.13d,f). p21CIP1 
expression was largely unaffected by rapamycin or COMBO treatment in MEC-1 
cells (Figure 3.13d,f).      
 
3.2.13 mTOR and MAPK activity is inhibited by COMBO in 
F(ab’)2 stimulated CLL cells 
To assess drug selectivity in F(ab’)2-stimulated primary CLL cells, the 
phosphorylation status of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 
(AKTS473) downstream targets was assessed following short-term AZD8055 (100 
nM), ibrutinib (1 µM) or COMBO treatment. After 30 min pre-treatment, CLL cells 
remained unstimulated or were F(ab’)2 stimulated for 1 h (Figure 3.14). As with 
Figure 3.3a-e, F(ab’)2 stimulation of primary CLL samples resulted in a near-




0.12; Figure 3.14e) and mTORC1 downstream target S6S235/236 (p = 0.06; Figure 
3.14d) relative to vehicle control. Additionally, phosphorylation of AKTS473 and 
AKTT308 was increased (Figure 3.14b), whereas 4E-BP1T37/46 phosphorylation was 
largely unaffected (Figure 3.14c). Consistent with Figure 3.5, AZD8055 
treatment inhibited phosphorylation of AKTS473 (Figure 3.14b) and 4E-BP1T37/46 
(Figure 3.14c) in unstimulated and F(ab’)2-stimulated CLL cells. Moreover, while 
AZD8055 treatment resulted in a near-significant decrease in S6S235/236 
phosphorylation (p = 0.08; Figure 3.14d), ERK1/2T202/Y204 phosphorylation was 
only moderately reduced in the presence of BCR stimulation (p = 0.15; Figure 
3.14e). As noted in Figure 3.7a, AZD8055 also eliminated AKTT308 phosphorylation 
in F(ab’)2 stimulated CLL cells (Figure 3.14a). Furthermore, short term 
treatment with ibrutinib resulted in decreased AKTS473 and AKTT308 
phosphorylation (Figure 3.14a,b) in F(ab’)2 stimulated CLL cells (consistent with 
Figures 3.5a and 3.9a, respectively). Similarly, a near-significant decrease in 
S6S235/236 (p = 0.07; Figure 3.14d) and ERK1/2T202/Y204 (p = 0.13; Figure 3.14e) 
phosphorylation was observed. In contrast, 4E-BP1T37/46 phosphorylation was 
largely unaffected by ibrutinib treatment in unstimulated and F(ab’)2 stimulated 
CLL cells (Figure 3.14c). Consistent with Figure 3.9, the COMBO treatment 
inhibited mTORC1 (4E-BP1T37/46 (p = 0.09) and S6S235/236) and mTORC2 (AKTS473) 
downstream targets in unstimulated and F(ab’)2-stimulated CLL cells (Figure 
3.14a-d). COMBO enhanced inhibition of S6S235/236 phosphorylation compared to 
ibrutinib alone (p = 0.053; Figure 3.14d). Furthermore, COMBO elicited a near-
significant inhibition of ERK1/2T202/Y204 phosphorylation (p = 0.059; Figure 3.14e) 
and visibly reduced AKTT308 phosphorylation (Figure 3.14a) in the presence of 





Figure 3.14 - mTOR and MAPK activity is inhibited by AZD8055 and ibrutinib combination in 
F(ab’)2-stimulated CLL cells 
(a) Representative western blot of a primary CLL sample (CLL157) unstimulated or F(ab’)2 









AZD8055 and Ibrutinib combination (COMBO) or DMSO vehicle control (Vehicle). Blots were 
probed for AKTT308, AKTS473, AKT, 4E-BP1T37/46, 4E-BP1, S6S235/236, S6, ERK1/2T202/Y204, ERK1/2 
and GAPDH (loading control; #1 and #2 referring to mirror blots). (b, c, d, e) Relative 
phosphorylation levels of (b) AKTS473 (n=8), (c) 4E-BP1T37/46 (n=7), (d) S6S235/236 (n=9) and (e) 
ERK1/2T202/Y204 (n=6) in primary CLL samples treated as described in (a). Unstimulated (light-green 
bars) and F(ab’)2 stimulated (dark-green bars). Relative phosphorylation is calculated by first 
normalising phosphorylation and expression levels by GAPDH, followed by normalised 
phosphorylation divided by normalised expression levels. Relative phosphorylation levels are 
relative to unstimulated vehicle control. Individual datapoints are represented by white circles. Data 
expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
3.2.14 AZD8055 and ibrutinib combination overcomes BCR-
mediated survival signals  
Given the lack of sensitivity of HG-3 and MEC-1 cells to AZD8055, ibrutinib or 
COMBO treatment (Figure 3.10), it was of interest to establish whether COMBO 
could overcome BCR-mediated survival signals to enhance cell death (Figure 
3.15). Primary CLL cells were pre-treated with AZD8055 (100 nM), ibrutinib (1 
µM) or COMBO for 30 min. Thereafter, CLL cells remained unstimulated or 
F(ab’)2-stimulated for 48 h. Following treatment, the cells were stained with 
Annexin V/7-AAD and analysed by flow cytometry (Figure 3.15). These data 
showed a modest trend towards increased CLL cell viability as a consequence of 
F(ab’)2 stimulation (Figure 3.15a,b). Nevertheless, AZD8055 treatment resulted 
in a near-significant reduction in cell viability in unstimulated (p = 0.12) CLL 
cells, while a trend towards decreased viability was observed in F(ab’)2 
stimulated CLL cells (Figure 3.15a,b). Furthermore, ibrutinib significantly 
reduced cell viability in unstimulated and, perhaps unsurprisingly, F(ab’)2 
stimulated CLL cells (Figure 3.15a,b). Importantly, COMBO treatment caused a 
near-significant decrease in the viability of unstimulated (p = 0.054) and F(ab’)2-
stimulated (p = 0.068) CLL cells (Figure 3.15a,b). A trend towards reduced cell 
viability existed between AZD8055 and COMBO in F(ab’)2 stimulated CLL cells (p 





Figure 3.15 - Combination of AZD8055 and Ibrutinib reduces primary CLL cell survival and 
overcomes F(ab’)2-mediated survival signals 
(a) Representative FACS plot of a primary CLL sample stained with Annexin V and 7-AAD 
following pre-treatment with AZD8055 (100 nM), Ibrutinib (1 µM), AZD8055 and Ibrutinib 
combination (COMBO) or DMSO vehicle control (Vehicle) and subsequent long-term F(ab’)2 
stimulation for 48 h. (b) Relative viability (Annexin Vneg and 7-AADneg cells) of unstimulated (blue 
bars) or F(ab’)2 stimulated (red bars) primary CLL samples (n=7) treated as described in (a). 
Percentage viability for each condition is relative to unstimulated vehicle control. Individual 
datapoints are represented by white circles. Data expressed as the mean ± SEM. Statistics 
calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
 
Encouraged by these data, the regulation of anti- and pro-apoptotic proteins in 
response to treatment in unstimulated and F(ab’)2 stimulated CLL cells was 
explored (Figure 3.16). Initially the expression of anti-apoptotic MCL-1 and 






MCL-1 expression varied in response to F(ab’)2 stimulation. Nevertheless, 
AZD8055 treatment resulted in a trend towards decreased MCL-1 expression in 
unstimulated and F(ab’)2 stimulated CLL cells (Figure 3.16a). Ibrutinib treatment 
resulted in a significant downregulation of MCL-1 in unstimulated CLL cells, 
while a near-significant downregulation of MCL-1 was observed in F(ab’)2 
stimulated CLL cells (p = 0.052) (Figure 3.16a). Interestingly, COMBO caused a 
significant reduction in MCL-1 expression in unstimulated and F(ab’)2 stimulated 
CLL cells, significantly greater than AZD8055 treatment alone (Figure 3.16a). A 
trend towards increased BCL2-L1 expression was evident as a consequence of 
F(ab’)2 stimulation (Figure 3.16b). Nevertheless, AZD8055 treatment resulted in 
a near-significant downregulation of BCL2-L1 in unstimulated (p = 0.12) CLL 
cells, while a significant decrease in BCL2-L1 expression was observed in F(ab’)2 
stimulated CLL cells (Figure 3.16b). Moreover, ibrutinib treatment resulted in a 
significant downregulation of BCL2-L1 in unstimulated and F(ab’)2-stimulated 
CLL cells (Figure 3.16b). Equally, while a visible trend towards decreased BCL2-
L1 expression was evident in unstimulated CLL cells, COMBO resulted in a 
significant downregulation of BCL2-L1 in F(ab’)2-stimulated CLL cells (Figure 
3.16b).  
The regulation of anti-apoptotic (MCL-1 and BCL2) and pro-apoptotic (BIM) 
proteins were then assessed by western blotting (Figure 3.16c). These data 
showed a visible trend towards reduced levels of cleaved PARP in the presence 
of BCR stimulation (Figure 3.16c,d). Importantly, AZD8055, ibrutinib or COMBO 
treatment resulted in an increase in the presence of cleaved PARP in 
unstimulated and F(ab’)2 stimulated CLL cells (Figure 3.16c,d). COMBO conferred 
a trend towards elevated levels of cleaved PARP, greater than each single agent, 
in unstimulated and F(ab’)2 stimulated CLL cells (Figure 3.16c,d). Consistent 
with Figure 3.16a, regulation of anti-apoptotic MCL-1 protein expression varied 
in response to F(ab’)2 stimulation (Figure 3.16e). Nevertheless, AZD8055 
treatment resulted in a significant downregulation of MCL-1 expression in 
unstimulated CLL cells, while a visible trend toward decreased MCL-1 was 
observed in F(ab’)2 stimulated CLL cells (Figure 3.16c,e). Ibrutinib treatment 
resulted in a trend towards decreased levels of MCL-1 in unstimulated and 
F(ab’)2 stimulated CLL cells (Figure 3.16c,e). Similarly, while COMBO caused a 





Figure 3.16 - Combination of AZD8055 and Ibrutinib reduces expression levels of anti-
apoptotic BCL2-L1 and MCL1 in primary CLL cells 
(a, b) RT-qPCR to assess expression of (a) MCL-1 (n=9) and (b) BCL2-L1 (n=10) in unstimulated 
(pink bars) or F(ab’)2 stimulated (purple bars) primary CLL samples (24 h stimulation) pre-treated 
with AZD8055 (100 nM), Ibrutinib (1 µM) and AZD8055 and Ibrutinib combination (COMBO). The 








internal reference gene GUSB and then made relative to unstimulated vehicle control. (c) 
Representative western blot of a primary CLL sample (CLL151; n=4 primary CLL samples) 
unstimulated or F(ab’)2 stimulated for 48 h following pre-treatment with AZD8055, Ibrutinib and 
COMBO. Blots were probed for PARP (cleaved PARP), MCL-1, BCL2, BIM (BIMEL, BIML, and 
BIMS) and GAPDH (loading control; #1 and #2 referring to mirror blots). (d, e, f) Densitometry of (d) 
cleaved PARP, (e) MCL-1 and (f) BIMS in unstimulated (pink bars) or F(ab’)2 stimulated (purple 
bars) primary CLL samples (n=4) treated as described in (c). Normalised expression is relative to 
unstimulated vehicle control. Individual datapoints are represented by white circles. Data 
expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
reduction in MCL-1 expression was observed in F(ab’)2 stimulated CLL cells (p = 
0.1) (Figure 3.16c,e). Interestingly, a concurrent decrease in the expression of 
pro-apoptotic BIM isoform BIMS was observed following treatment in F(ab’)2 
stimulated CLL cells (Figure 3.16c, f). These data contrast with the observed 
results in HG-3 and MEC-1 cells (Figure 3.10f). Despite treatment, BCL2 
expression remained constant (Figure 3.16c).  
3.2.15 AZD8055 and COMBO inhibits mTOR activity in CLL 
cells co-cultured on NT-L and CD40L (+IL-4) 
Within the CLL-TME, CLL cells co-localise with activated CD4+ T cells expressing 
CD40L (via analysis of patient LN-biopsies) (182), which promotes proliferation 
and survival (183, 184). These findings, among others, facilitated the 
development of in vitro co-culture systems replicating the signals that promote 
CLL cell growth and survival in the CLL-TME (210). The established NT-L/CD40L 
(+IL-4) co-culture system is one such model mimicking T cell interactions in the 
CLL microenvironment (186, 217, 448). Given its inhibitory effect on mTOR 
activity downstream of BCR ligation, it was of interest to elucidate the impact of 
the COMBO treatment on mTOR activity downstream of CD40 engagement in CLL 
cells in vitro. Following overnight co-culture on NT-L and CD40L cells (+IL-4), 
CLL cells were treated with AZD8055 (100 nM), ibrutinib (1 µM) or COMBO for 1 
h. Thereafter, the phosphorylation status of mTORC1 (4E-BP1T37/46 and S6S235/236) 
and mTORC2 (AKTS473) downstream targets was assessed by western blotting 
(Figure 3.17). AZD8055 treatment resulted in a visible trend towards reduced 
AKTS473 phosphorylation in CLL cells co-cultured on NT-L and CD40L (Figure 
3.17a,b). Moreover, ibrutinib caused a modest inhibition of AKTS473 
phosphorylation in CLL cells co-cultured on NT-L and CD40L (+IL-4) (Figure 
3.17a,b). Notably, COMBO mimicked the effect of AZD8055 treatment alone, 





Figure 3.17 - AZD8055 treatment alone, and in combination with ibrutinib, inhibits mTOR 
activity in CLL cells co-cultured on NT-L and CD40L (+IL-4) 
(a) Representative western blot of a primary CLL sample (CLL148; n=4 primary CLL samples) co-









(1 µM), AZD8055 and Ibrutinib combination (COMBO) and DMSO vehicle control (Vehicle) for 1 h. 
Blots were probed for AKTS473, AKT, 4E-BP1T37/46, 4E-BP1, S6S235/236, S6 and GAPDH (loading 
control; #1 and #2 referring to mirror blots). (b, c, d) Relative phosphorylation levels of (b) AKTS473, 
(c) 4E-BP1T37/46 and (d) S6S235/236 in primary CLL samples (n=4) co-cultured on NT-L (grey bars) 
and CD40L (+IL-4) (pink bars) treated as described in (a). Relative phosphorylation levels are 
relative to NT-L vehicle control. Individual datapoints are represented by white circles. Data 
expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
inhibition of AKTS473 phosphorylation in CLL cells co-cultured on NT-L and CD40L 
(+IL-4) (Figure 3.17a,b). AZD8055 treatment resulted in a significant inhibition of 
mTORC1 downstream targets 4E-BP1T37/46 (Figure 3.17a,c) and S6S235/236 (Figure 
3.17a,d) in CLL cells co-cultured on NT-L cells, while a observable trend towards 
reduced 4E-BP1T37/46 (Figure 3.17a,c) and S6S235/236 (Figure 3.17a,d) 
phosphorylation was present in CLL cells co-cultured on CD40L cells (+IL-4). 
Interestingly, ibrutinib was largely ineffective in reducing phosphorylation of 4E-
BP1T37/46 (Figure 3.17a,c) and S6S235/236 (Figure 3.17a,d) in CLL cells co-cultured 
on NT-L or CD40L (+IL-4). Furthermore, COMBO treatment resulted in a 
significant inhibition of 4E-BP1T37/46 (Figure 3.17a,c) and S6S235/236 (Figure 
3.17a,d) phosphorylation in CLL cells co-cultured on NT-L cells. Finally, the 
COMBO treatment visibly reduced phosphorylation of 4E-BP1T37/46 (Figure 
3.17a,c) and S6S235/236 (Figure 3.17a,d) in CLL cells co-cultured on CD40L (+IL-4), 
resulting in a near-significant inhibition of 4E-BP1T37/46 (p = 0.054) and S6S235/236 
(p = 0.11) compared to ibrutinib treatment alone (Figure 3.17a,c,d).  
3.2.16 COMBO treatment overcomes stromal-mediated 
survival signals to enhance CLL cell death   
Given the inhibitory effect of the COMBO treatment on mTOR activity 
downstream of stromal- and CD40L-mediated signals, it was of interest to 
establish whether the combination could overcome the enhanced survival 
advantages conferred by the NTL/CD40L (+IL-4) co-culture systems (Figure 3.18). 
Following overnight co-culture on NT-L and CD40L cells (+IL-4), CLL cells were 
treated with AZD8055 (100 nM), ibrutinib (1 µM) or COMBO for 48 h. 
Subsequently, the cells were stained with Annexin V/7-AAD and analysed by flow 
cytometry (Figure 3.18a-c). These data revealed that although CLL cells co-
cultured on CD40L cells (+IL-4) were largely insensitive to AZD8055, ibrutinib or 





Figure 3.18 - AZD8055 and ibrutinib combination overcomes stromal-mediated survival 
signals to enhance CLL cell death 
(a) Representative FACS plot of a primary CLL sample stained with Annexin V/7-AAD following 







treatment with AZD8055 (100 nM), Ibrutinib (1 µM), AZD8055 and Ibrutinib combination (COMBO) 
or DMSO vehicle control (Vehicle) for 48 h. (b, c) Relative viability (Annexin Vneg and 7-AADneg 
cells) of primary CLL samples (n=14) co-cultured on (b) NT-L (blue bars) or (c) CD40L (+IL-4) (red 
bars) treated as described in (a). Percentage viability for each condition is relative to vehicle 
control. Individual datapoints are represented by white circles. (d) Representative western blot of a 
primary CLL sample (CLL149; n=4 primary CLL samples) co-cultured on NT-L or CD40L (+IL-4) 
overnight and treated with AZD8055, Ibrutinib, COMBO or Vehicle for 48 h. Blots were probed for 
PARP (cleaved PARP), MCL-1, BCL-xL, BCL2, BIM (BIMEL, BIML, and BIMS) and GAPDH (loading 
control; #1 and #2 referring to mirror blots). Individual datapoints are represented by white circles. 
Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
AZD8055 treatment (Figure 3.18a,c), akin to HG-3 and MEC-1 cells (Figure 3.10). 
Furthermore, a slight trend towards reduced cell viability was visible in response 
to the COMBO treatment (Figure 3.18a,c). Despite the lack of sensitivity in CLL 
cells co-cultured on CD40L cells (+IL-4), AZD8055 treatment resulted in a near-
significant reduction in cell viability in CLL cells co-cultured on NT-L cells (p = 
0.15; Figure 3.18a,b). Moreover, ibrutinib and COMBO treatment induced a 
significant decrease in cell viability (Figure 3.18a,b). Importantly, the COMBO 
treatment significantly enhanced cell death, greater than AZD8055 or ibrutinib 
treatment alone (Figure 3.18a,b).  
The regulation of anti-apoptotic (MCL-1, BCL-xL and BCL2) and pro-apoptotic 
(BIM) proteins were assessed by western blotting (Figure 3.18d). AZD8055 and 
COMBO treatment resulted in a decrease in the presence of cleaved PARP in CLL 
cells co-cultured in NTL and CD40L (+IL-4) (Figure 3.18d), which conflicted with 
the viability data presented in Figure 3.18a-c. Nevertheless, anti-apoptotic MCL-
1 was downregulated following COMBO treatment in CLL cells co-cultured on NT-
L compared to vehicle control (Figure 3.18d). In contrast, MCL-1 expression was 
unaffected by COMBO treatment in CLL cells co-cultured on CD40L (+IL-4) 
(Figure 3.18d). As expected, the expression of anti-apoptotic BCL-xL was 
upregulated in CLL cells co-cultured on CD40L (+IL-4), which was downregulated 
following treatment with AZD8055, ibrutinib or COMBO (Figure 3.18d). A 
decrease in the expression of pro-apoptotic BIM isoform BIMS was observed 
following COMBO treatment in CLL cells co-cultured on NT-L (Figure 3.18d), 
whereas BIMS was unaffected by treatment in CLL cells co-cultured on CD40L 
(+IL-4) (Figure 3.18d). Despite treatment, BCL2 expression remained constant 




3.2.17 AZD8055 and COMBO treatment inhibits CD40L (+IL-4)-
induced increased CLL cell size 
As demonstrated in Figure 3.11, AZD8055 and ibrutinib treatment alone 
significantly reduced MEC-1 cell size, which was further enhanced in 
combination. Co-culture on CD40L (+IL-4) activates mTORC1 signalling (Figure 
3.17a), priming cellular growth and expansion (293). With this in mind, the 
functional impact of mTOR inhibition on CLL cell size downstream of CD40-
ligation was explored (Figure 3.19). Following overnight co-culture on CD40L 
cells (+IL-4), CLL cells were treated with AZD8055 (100 nM), ibrutinib (1 µM) or 
COMBO treatment for 48 h. Thereafter, cell size was quantified as a measure of 
FSC-A by flow cytometry (Figure 3.19a,b). AZD8055 treatment resulted in a 
significant inhibition of CD40L (+IL-4)-induced CLL cell growth (Figure 3.19c). 
Moreover, a significant reduction was also observed in CLL cells treated with 
ibrutinib (Figure 3.19c). Despite this, the scale of inhibition was comparatively 
much larger in AZD8055-treated CLL cells (Figure 3.19c). Importantly, the 
COMBO treatment significantly blocked CLL cell growth facilitated by CD40L 
(+IL-4) co-culture (Figure 3.19c). Consistent with Figure 3.11, the COMBO 
treatment resulted in a significantly greater decrease in CLL cell size compared 
to ibrutinib treatment alone (Figure 3.19c), while a near-significant reduction 





Figure 3.19 - AZD8055 treatment alone, and in combination with ibrutinib, inhibits CD40L 
(+IL-4)-mediated CLL cell growth 
(a) Representative FACS plot (forward scatter-area (FSC-A) against sideward scatter-A (SSC-A)) 
assessing cell size of a primary CLL sample following overnight co-culture on CD40L (+IL-4) and 
subsequent treatment with AZD8055 (100 nM), Ibrutinb (1 µM), AZD8055 and Ibrutinib combination 
(COMBO) or DMSO vehicle control (Vehicle) for 48 h. (b) Representative FACS histogram 
displaying geometric mean of FSC-A of a primary CLL sample co-cultured on CD40L (+IL-4) and 
treated with AZD8055 (light-pink histogram), Ibrutinib (medium-pink histogram), COMBO (dark-pink 
histogram) or Vehicle (grey histogram) for 48 h. (c) (b, c) Relative cell size (geometric mean) of 
primary CLL samples (n=14) treated as described in (a). Geometric means for each condition are 
relative to Vehicle. Individual datapoints are represented by white circles. Data expressed as the 
mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001. 
 
3.2.18 CD40-induced CLL cell proliferation is inhibited by 
AZD8055 and COMBO treatment 
The CD40L co-culture system (supplemented with IL-4 or IL-21) has been 
implemented previously to induce proliferation of CLL cells in vitro (145, 180, 
279). As demonstrated in Figure 3.17, mTOR signalling is active in CLL cells co-






treatment. Given the inhibitory effect of the COMBO treatment on cell 
proliferation in HG-3 and MEC-1 cells (Figure 3.13), the impact of treatment on 
CLL cell proliferation downstream of CD40-ligation was investigated (Figure 
3.20). Following co-culture on NT-L (non-proliferative control) and CD40L (+IL-
21) cells, CLL cells were treated with AZD8055 (100 nM), ibrutinib (1 µM), 
COMBO or rapamycin (10 nM) for 9 days. Prior to treatment, CLL cells were 
stained with CTV to qualitatively and quantitatively assess cell proliferation by 
flow cytometry (Figure 3.20a). Rapamycin treatment was included to compare 
the effect of mTORC1-selective inhibition with dual mTOR inhibition. These data 
revealed a significant increase in CD40L (+IL-21)-induced CLL cell proliferation 
compared to CLL cells co-cultured on NT-L, as represented by a smaller CTV 
geometric mean (Figure 3.20a,b). AZD8055 treatment resulted in a near-
significant inhibition of cell proliferation compared to vehicle control (p = 0.11; 
Figure 3.20a,b). Moreover, the anti-proliferative effect of AZD8055 treatment 
was comparable with CLL cells co-cultured on NT-L (Figure 3.20b). Consistent 
with Figure 3.13, CLL cells co-cultured on CD40L (+IL-21) were largely 
unaffected by ibrutinib treatment, demonstrating enhanced cell proliferation 
akin to vehicle control (Figure 3.20b). Furthermore, this corresponded to a 
significant increase in cell proliferation compared to CLL cells co-cultured on 
NT-L (Figure 3.20b). COMBO treatment resulted in a trend towards reduced 
proliferation (Figure 3.20b). Equally, while rapamycin treatment showed a 
visible trend towards decreased proliferation, the inhibition conferred by 
AZD8055 was demonstrably greater than rapamycin (Figure 3.20b).  
Subsequently, the regulation of ‘cell cycle proteins’ in response to treatment 
was assessed by western blotting (Figure 3.20c). Cyclin E1 expression was 
upregulated in CLL cells co-cultured on CD40L (+IL-21) compared to NT-L (Figure 
3.20c,d). Consistent with Figure 3.13d, Cyclin E1 expression was upregulated 
following AZD8055 or ibrutinib treatment compared to vehicle treated cells, 
while the COMBO treatment downregulated Cyclin E1 (Figure 3.20c). Moreover, 
Cyclin E1 was upregulated by rapamycin treatment, noticeably greater than 
AZD8055 treatment alone (Figure 3.20c). CDK2 expression was marginally higher 
in CLL cells co-cultured on CD40L (+IL-21) compared to NT-L. Nevertheless, the 
expression of CDK2 in CD40L (+IL-21)-stimulated CLL cells was largely unaffected 




presence of AZD8055, while the COMBO treatment caused a modest upregulation 
in Cyclin D2 (Figure 3.20c). The expression of CDK4 was reduced in CLL cells 
 
Figure 3.20 - CD40-induced CLL cell proliferation is inhibited by AZD8055 treatment alone 
and in combination with ibrutinib 
(a) Representative FACS histogram of a primary CLL sample (CLL132) stained with CellTrace 
Violet (CTV) following long-term co-culture on CD40L (+IL-21) treated with AZD8055 (100 nM; 
orange histogram), Ibrutinib (1 µM; light-green histogram), AZD8055 and Ibrutinib combination 
(COMBO; dark-green histogram), Rapamycin (10 nM; pink histogram) or DMSO vehicle control 
(Vehicle; blue histogram) for 9 days. Primary CLL cells were co-cultured on NT-L as a non-
proliferative control. Please refer to section 2.2.2.5 for gating strategy. (b) Assessment of CTV 
geometric mean for primary CLL samples (n=5) treated as described in (a). Geometric means for 
each condition are relative to NT-L non-proliferative control. Individual datapoints from each 
replicate are shown as white circles. (c) Representative western blot of primary CLL sample 
CLL151 (n=5 primary CLL samples) co-cultured on CD40L (+IL-21) and treated with AZD8055, 
Ibrutinib, COMBO, Rapamycin and Vehicle for 6 days. Primary CLL cells were co-cultured on NT-L 
as a non-proliferative control. Blots were probed for RbS807/811, Rb, Cyclin E1, CDK2, Cyclin D2, 






expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
co-cultured on CD40L (+IL-21) compared to NT-L. Notably, AZD8055 and the 
COMBO treatment upregulated CDK4 expression to levels similar to NT-L. In 
contrast, CDK4 expression was unaffected by ibrutinib or rapamycin treatment 
compared to vehicle control (Figure 3.20c). Interestingly, the expression of the 
CDKI p27KIP1 was downregulated in CLL cells co-cultured on CD40L (+IL-21) 
compared to NT-L. Moreover, while each treatment caused an elevation in 
p27KIP1 expression compared to vehicle control, the largest increase in p27KIP1 
expression occurred in the presence of AZD8055 and the COMBO treatment 
(Figure 3.20c). Perhaps most intriguingly, the expression of cell cycle inhibitor 
p21CIP1 was upregulated in CLL cells co-cultured on CD40L (+IL-21) compared to 
NT-L. COMBO treatment downregulated p21CIP1 expression, while ibrutinib and 
rapamycin elicited a noticeable upregulation in p21CIP1 (Figure 3.20c). Of note, it 
would have been interesting to assess p21CIP1 subcellular localisation following 
stimulation and/or treatment to ascertain p21CIP1 activity in this context. 
Finally, these data revealed that phosphorylation of RbS807/811 increased in CLL 
cells co-cultured on CD40L (+IL-21) compared to NT-L, indicative of Rb 
inactivation and subsequent G1/S cell cycle progression (449) (Figure 3.20c).  
3.2.19 AKT-dependent FOXO1T24 phosphorylation is inhibited 
by COMBO treatment in F(ab’)2 stimulated CLL cells  
BCR stimulation elevated phosphorylation levels of AKTT308 and AKTS473 in CLL 
cells, which were inhibited following pre-treatment with AZD8055, ibrutinib or 
COMBO (Figure 3.21a). As FOXO transcription factors are AKT substrates, which 
mediate cell cycle arrest and apoptosis (384), it was of interest to explore AKT-
dependent regulation of FOXOs downstream of BCR ligation and mTOR inhibition 
(Figure 3.21). Previous studies have highlighted a prominent role for FOXO1 
throughout B cell development (384, 387, 395). For these reasons, FOXO1 
regulation was explored by assessing AKT-dependent FOXO1T24 phosphorylation in 
unstimulated and F(ab’)2 stimulated CLL cells. As expected, F(ab’)2 stimulation 
of CLL cells elicited a significant increase in AKT-dependent FOXO1T24 
phosphorylation (Figure 3.21a,b). However, preincubation with AZD8055, 





Figure 3.21 - AKT-dependent FOXO1T24 phosphorylation is inhibited by AZD8055 and 
ibrutinib combination in F(ab’)2 stimulated CLL cells 
(a) Representative western blot of a primary CLL sample (#CLL151) unstimulated or F(ab’)2 
stimulated for 1 h following 30 min pre-treatment with AZD8055 (100 nM), Ibrutinib (1 µM), 









probed for AKTT308, AKTS473, AKT, FOXO1T24, FOXO1 and GAPDH (loading control; #1 and #2 
referring to mirror blots). (b) Relative phosphorylation levels of FOXO1T24 in primary CLL samples 
(n=8) treated as described in (a). Unstimulated (light-green bars) or F(ab’)2 stimulated (dark-green 
bars). (c) Representative western blot of a primary CLL sample (#CLL143) co-cultured on NT-L or 
CD40L (+IL-4) overnight, followed by treatment with AZD8055 (100 nM), Ibrutinib (1 µM), AZD8055 
and Ibrutinib combination (COMBO) or DMSO vehicle control (Vehicle). Blots were probed for 
AKTS473, AKT, FOXO1T24, FOXO1 and GAPDH. (d) Relative phosphorylation levels of FOXO1T24 in 
primary CLL samples (n=4) co-cultured on NT-L (grey bars) or CD40L (+IL-4) (pink bars) and 
treated as described in (c). Individual patient datapoints are shown as white circles. (e) Schematic 
depicting AKT-mediated FOXO1T24 phosphorylation as a consequence of F(ab’)2 stimulation. (f) 
Pre-treatment of primary CLL cells with AZD8055 and Ibrutinib combination inhibits F(ab’)2-
dependent FOXO1T24 phosphorylation. Data expressed as the mean ± SEM. Statistics calculated 
by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
phosphorylation (Figure 3.21a,b). In line with these findings, AZD8055, ibrutinib 
or COMBO treatment diminished basal levels of FOXO1T24 in unstimulated CLL 
cells (Figure 3.21a,b). Importantly, the COMBO treatment caused a near-
significant reduction in FOXO1T24 phosphorylation in unstimulated (p = 0.1) and 
F(ab’)2 stimulated (p = 0.14) CLL cells, greater than AZD8055 treatment alone 
(Figure 3.21a,b). To address AKT-dependent regulation of FOXO1 downstream of 
CD40-ligation, phosphorylation levels of FOXO1T24 were assessed in CLL cells co-
cultured on NT-L and CD40L (+IL-4) (Figure 3.21c,d). FOXO1T24 phosphorylation 
was observed in CLL cells co-cultured on NT-L and CD40L (+IL-4), corresponding 
to increased levels of AKTS473 (Figure 3.21c,d). AZD8055 and COMBO treatment 
reduced FOXO1T24 phosphorylation in CLL cells co-cultured on NT-L and CD40L 
(+IL-4), concordant with treatment-induced AKTS473 inhibition (Figure 3.21c,d). 
Consistent with Figure 3.17, ibrutinib treatment was unable to inhibit AKTS473 
phosphorylation in CLL cells co-cultured on NT-L and CD40L (Figure 3.21c). 
Interestingly, however, a trend towards reduced FOXO1T24 phosphorylation was 
observed (Figure 3.21c,d). Therefore, BCR crosslinking induces FOXO1T24 
phosphorylation (Figure 3.21e), which can be inhibited by AZD8055, ibrutinib or 





Here, we provide insights into mTOR activity in CLL cells derived from the 
periphery and in response to microenvironment stimuli in vitro and ex vivo. 
These findings have presented a rationale for targeted inhibition of mTOR kinase 
using AZD8055, which blocks the activity of both mTORC1 and mTORC2. 
However, AZD8055 anti-tumour activity appears to be limited as a monotherapy. 
We have shown that a synergistic combination of AZD8055 and the clinically 
approved BTK inhibitor ibrutinib has deleterious effects on CLL cell growth and 
survival - and the regulation of signalling pathways therein - which will be 
discussed in more detail here.  
3.3.1 Basal mTOR activity in primary CLL cells is heterogeneous 
The data presented here demonstrates the existence of basal mTOR activity, or 
heterogeneity thereof, among PB-derived CLL samples, as determined by 
phosphorylation of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) 
downstream targets. These findings support previous studies reporting the 
presence of constitutively active PI3K (208, 252) and AKT (284-286) in primary 
CLL cells. These data suggest that PI3K-AKT-mTOR signalling might play an 
important role in CLL disease maintenance in the periphery.  
Activation of the PI3K-AKT-mTOR axis in the PB compartment, constitutive or 
otherwise, might represent a ‘functional snapshot’ (247). Indeed, Packham et al. 
postulated that circulating CLL cells carry transient imprints of recent 
stimulation within lymphoid tissues, inasmuch as recent emigrants will possess 
an ‘activated’ phenotype that diminishes over time (256). For example, mTOR 
can be transiently activated in CLL cells through binding of chemokine 
receptors, such as CXCR4 and CXCR5, which regulate CLL cell migration from PB 
to the SLOs (333, 341, 450). These factors may explain a degree of heterogeneity 
in mTOR activity among peripheral CLL samples, distinct from constitutive 
activation. Nevertheless, one cannot assume that activation of signalling 
pathways is due to prior stimulation in vivo (256). In any case, there is evidence 
to suggest that PI3K-AKT-mTOR signalling is constitutively active in CLL cells. As 
mentioned previously, studies have demonstrated that PTEN is functionally 




wherein aberrant PTEN function could potentially lead to constitutive activation 
of PI3K-AKT-mTOR signalling in CLL. Intriguingly, activation of the PI3K-AKT-
mTOR axis in unstimulated CLL cells could also be indicative of antigen-
independent autonomous or ‘tonic’ BCR signalling (247, 254, 255), supported by 
studies demonstrating constitutive activation of proximal BCR kinases LYN (250), 
SYK (251) and downstream component PI3K (252). Furthermore, one cannot 
exclude the influence of distinct pathways (e.g. MAPK/ERK) that converge upon 
mTOR (293). Finally, given the heterogeneity in responses to BCR stimulation 
among U-CLL and M-CLL patients (45), these data also raise an important point 
whether additional interpatient variability in disease biology impacts the 
regulation of mTOR. With hindsight, it would have been interesting to assess 
activation status of signalling components upstream of mTOR (proximal to the 
BCR), particularly in samples stratified according to IGVH mutational status.  
Of note, despite reports on the contrary (284, 341, 343), mTOR activity was 
unexpectedly reduced in CLL cells compared with B cells from healthy donors. A 
likely explanation is the disparity between the methods of B cell isolation. While 
CD19+ CLL cells were negatively selected, B cells derived from healthy donors 
were positively selected using anti-CD19 microbeads. Thus, without prior release 
of CD19 microbeads (252), CD19-mediated activation of PI3K signalling may have 
translated into increased mTOR activity.  
3.3.2 Stratification of mTORC1/2 activity suggests dual mTOR 
inhibition might be efficacious across CLL prognostic 
subtypes 
Stratification of mTOR activity among CLL samples revealed that phosphorylation 
of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream 
targets were irrespective of favourable- and poor-prognostic cytogenetic 
alterations. This suggests that pharmacological interventions targeting mTORC1 
and mTORC2 might be efficacious across prognostic subtypes. However, these 
data contrast with a recent study that reported differential activation of mTOR 
substrates in CLL patient samples from different prognostic subsets. Here, 
Cosimo et al. found that stratification of basal phosphorylation levels of mTORC1 
downstream targets in freshly isolated CLL samples were differentially 




phosphorylation in poorer prognostic del(17p) CLL samples (284). An explanation 
for the conflicting data could be due to the different approach taken to 
quantitatively assess relative phosphorylation levels of the aforementioned 
mTORC1 and mTORC2 downstream targets. For the data presented here, 
phosphorylation levels are relative to the expression of the ‘total’ protein, i.e. 
S6S235/236 phosphorylation is relative to S6 expression. Cosimo et al. normalised 
the phosphorylation levels to the loading control, i.e. S6S235/236 phosphorylation 
normalised to GAPDH expression (284). Despite being perfectly valid, the 
approach taken by the authors does not account for the differences in ‘total’ 
protein expression.  
While it would have been interesting to stratify mTOR activity according to IGVH 
mutational status within our CLL cohort, the presence of favourable- or poor-
prognostic cytogenetic alterations raises interesting questions regarding the 
regulation of mTOR activity. However, large patient cohorts are often required 
to tease out meaningful trends, owing to interpatient heterogeneity and the 
prevalence of certain cytogenetic abnormalities. This may explain, assuming 
there are differences, the absence of notable trends in mTOR activity among our 
stratified CLL cohort. To circumvent this experimental drawback, a crude 
method for distinguishing differences in mTOR activity according to cytogenetics 
is to use established cell lines with defined cytogenetic alterations. We used CLL 
cell lines HG-3 and MEC-1, which harbour cytogenetic abnormalities associated 
with favourable (del(13q)) and poor prognosis (del(17p)), respectively (431, 
432). Interestingly, MEC-1 cells possessed elevated levels of 4E-BP1T37/46, 
S6S235/236 and ERK1/2T202/Y204 phosphorylation, while HG-3 cells had increased 
levels of AKTS473 phosphorylation. Although mTOR is active in both cell lines, 
these data suggest that mTORC2 activity is greater in HG-3 cells, whereas 
mTORC1 activity is enhanced MEC-1 cells. Whether MEC-1 and HG-3 cells are 
more reliant on mTORC1 and mTORC2 activity, respectively, remains to be 
established. Clearly, the identification of cytogenetic abnormalities represents a 
powerful prognostic biomarker that ultimately governs treatment options for CLL 
patients (2). With reference to CLL patients harbouring del(17p) (loss of TP53) 
(451), studies have previously demonstrated communication between p53 and 
mTORC1 pathways to promote cell growth and proliferation (452). For example, 




negative regulators (294, 453, 454). Additionally, p53 blocks mTORC1 activity 
through diminishing S6K activation or inhibiting eIF4E-mediated translation via 
4E-BP1 dephosphorylation (294, 455). Considering the loss of TP53 in MEC-1 
cells, these findings may explain the increased levels of 4E-BP1T37/46 and 
S6S235/236 phosphorylation. Furthermore, MAPK/ERK activity positively regulates 
mTORC1 (293), providing another potential explanation for enhanced mTORC1 
activity in MEC-1 cells. Equally, the deletion 13q14 (del(13q)) leads to 
overexpression of anti-apoptotic BCL2, owing to impairments of BCL2 negative 
regulators miR-15a and miR-16 (54). Interestingly, miR-16 has been shown to 
target MTOR and RICTOR mRNAs, albeit in CD4+ T cells (456). Thus, loss of miR-
16 in HG-3 cells may explain the enhanced levels of AKTS473 phosphorylation. 
Taken together, these findings indicate that CLL cytogenetic alterations may 
impact upon the activity of mTORC1 and mTORC2 in HG-3 and MEC-1 cells, which 
poses implications for treatment strategies targeting mTOR. In addition, this 
underscores the need for a sound understanding of the molecular networks 
affected by cytogenetic abnormalities to develop novel treatments for CLL. 
However, it is important to consider that a number of other alterations likely 
exist in HG-3 and MEC-1 cells, distinct from cytogenetics. Thus, comparisons 
drawn purely on the presence of different cytogenetic abnormalities are unlikely 
to yield meaningful conclusions. To assess the importance of cytogenetic 
alterations on mTOR activity, one might utilise isogenic mutants (e.g. TP53 WT 
and null cell lines), which would lead to more accurate comparisons.  
3.3.3 Differential regulation of mTORC1 downstream targets in 
patient LN biopsies suggests CLL growth and proliferation 
is driven, in part, by the activity of 4E-BP1  
The ‘supportive’ LN microenvironment is a central compartment in CLL 
pathology (9), wherein BCR signalling and interactions with non-malignant 
accessory cells promote CLL cell survival, growth and proliferation (207, 457). 
Given its position downstream of many distinct signalling pathways, mTOR is 
prominently placed to integrate signals from a multitude of microenvironment 
stimuli (294). Interestingly, we observed differential regulation of mTORC1 
downstream targets in CLL patient LN biopsies, which were independent of 
‘indolent’ or ‘progressive’ clinical status. While 4E-BP1T37/46 phosphorylation was 




observed. This suggests the outcome of mTORC1 signalling in CLL cells is biased 
towards 4E-BP1 at the expense of S6K, albeit within the LN, which has 
implications for disease biology and treatment. Interestingly, studies have shown 
that the processes instigated by mTORC1-dependent 4E-BP1 phosphorylation are 
probably the most influential in terms of cancer initiation and progression (293, 
315, 458-460). Indeed, Hsieh et al. demonstrated that mTORC1-dependent S6 
phosphorylation was expendable for AKT-driven tumorigenesis, whereas 
activation of the 4E-BP1/eIF4E axis prompted translation (i.e. protein synthesis) 
of various transcripts (e.g. MCL-1) that promote lymphomagenesis in a mouse 
model of T cell lymphoma (458). Therefore, increased 4E-BP1T37/46 
phosphorylation in CLL patient LN biopsies may enhance eIF4E-mediated 
translation of proteins implicated in CLL pathogenesis (207, 284, 462). 
Decreased levels of S6S235/236 phosphorylation in CLL patient LN biopsies suggests 
the activity of S6K1 is reduced. Alongside phosphorylation of S6S235/236, S6K 
mediates a negative feedback loop between mTORC1 and mTORC2 (270, 284). 
Taken together, these findings indicate that the 4E-BP1/eIF4E axis may play a 
prominent role in CLL pathogenesis within the LN microenvironment. Equally, 
these data imply that AKT is active, owing to increased 4E-BP1T37/46 
phosphorylation and reduced S6K-dependent negative feedback on mTORC2/AKT 
signalling (299). However, in the absence of AKTS473 stained CLL patient LN 
sections, for example, these conclusions are difficult to convincingly resolve.  
From a clinical standpoint, these results offer an alternative explanation as to 
why everolimus had only modest antitumor activity against CLL in clinical trial 
(339). Rapalogues (derivatives of rapamycin) do not entirely inhibit 4E-BP1 
phosphorylation (312) and are unable to nullify negative feedback loops 
(mediated via S6K1) that enhance pro-survival signalling via increased mTORC2-
AKT activity (270, 314, 315). Mindful of mTORC1 activity within the CLL LN, 
these findings point to a pathophysiological state whereby selective mTORC1 
inhibitors have only limited efficacy in CLL. This suggests, therefore, that dual 
mTORC1/2 inhibition may elicit a more potent inhibitory response in CLL cells by 





3.3.4 Increased mTORC1/2 activity in F(ab’)2 stimulated CLL cells 
suggests mTOR is a key effector downstream of BCR 
ligation 
The CLL-TME appears to be the primary site of BCR activation for CLL cells (122, 
207). As a key signalling node coordinating the activities of PI3K-AKT (269), 
mTOR integrates growth and survival signals emanating downstream of the BCR 
(266). Using anti-IgM F(ab’)2 fragments to ligate the BCR, we observed elevated 
phosphorylation levels of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 
(AKTS473) downstream targets in CLL cells. These data indicate that mTOR is a 
downstream effector of BCR stimulation. Furthermore, this supports previous 
studies demonstrating the PI3K-AKT-mTOR axis is intact in BCR-stimulated CLL 
cells (284, 341, 343). Interestingly, mTOR activation was heterogenous among 
CLL samples, which is likely a reflection of the marked differences in 
responsiveness to BCR stimulation (45) pertaining to IGVH mutational status (4, 
5) and ZAP-70 expression (258). However, without prior clinical assessment, i.e. 
classification of IGVH mutational status, the observed heterogeneity among CLL 
samples cannot be conclusively attributed to U-CLL or M-CLL. Nevertheless, 
these data indicate that dual mTOR inhibition may overcome PI3K-AKT-mediated 
survival signals downstream of the BCR. Therefore, among the current arsenal of 
BCR signalling inhibitors, targeted inhibition of mTORC1 and mTORC2 could 
represent a promising and innovative therapeutic approach for CLL.  
3.3.5 AZD8055 targets both mTORC1 and mTORC2, which is 
necessary to inhibit subsequent rephosphorylation of 
AKTS473 
The rapalogue everolimus was less efficacious in CLL clinical trial than previously 
predicted from preclinical studies of rapamycin (270, 293, 313, 339, 463). With 
reference to the shortcomings associated with selective mTORC1 inhibitors (312, 
314-317), ‘second generation’ ATP-competitive mTOR inhibitors, such as 
AZD8055 (318), were developed to avoid these issues by inhibiting the activity of 
mTORC1 and mTORC2 (293). Here, to initially assess AZD8055 specificity for 
mTORC1/2, unstimulated and F(ab’)2 stimulated CLL cells underwent short-term 
treatment with increasing concentrations of AZD8055. This revealed that 
AZD8055 overcame BCR stimulation to inhibit phosphorylation of mTORC1 (4E-




dependent manner, suggesting that AZD8055 is capable of inhibiting mTOR-
coordinated growth and survival signals emanating from the BCR. Importantly, 
this was achieved at clinically achievable doses (441). These findings support 
previous studies that have demonstrated the selectivity and potency of AZD8055 
for mTORC1 and mTORC2 in vitro (284, 319-322, 464). Interestingly, AZD8055 
inhibited AKTT308 phosphorylation in a dose dependant manner, which has also 
been shown in earlier studies (319, 324). Interestingly, it has been proposed that 
AKTS473 stabilises AKTT308 phosphorylation (306, 465, 466), indicating that 
sustained inhibition of mTORC2 by AZD8055 destabilises AKTT308. Furthermore, 
the mTOR kinase inhibitor PP242 also inhibited AKTT308 phosphorylation, 
indicating this is a not an AZD8055-specific ‘off-target’ effect but a typical 
feature of these inhibitors (324, 467). However, the rapid and transient nature 
of AZD8055-induced AKTT308 inhibition likely initiates PI3K-mediated feedback 
mechanisms, which may have implications for long-term AZD8055 treatment 
(324).  
We next compared the ability of AZD8055, rapamycin and the BTK inhibitor 
ibrutinib to block mTOR substrate phosphorylation in unstimulated and F(ab’)2 
stimulated CLL cells. A clinically achievable dose of AZD8055 inhibited 
phosphorylation of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) 
downstream targets in the presence or absence of BCR stimulation. This 
suggested that mTORC2-AKT feedback activation was fully suppressed in 
AZD8055-treated CLL cells. Unsurprisingly, short-term rapamycin treatment was 
unable to fully inhibit phosphorylation of 4E-BP1T37/46 and AKTS473, while S6S235/236 
phosphorylation was reduced to levels comparable with AZD8055 in unstimulated 
and F(ab’)2 stimulated CLL cells. These findings further support studies 
demonstrating in the inability of rapamycin to completely inhibit 4E-BP1 
phosphorylation (312, 468) and that ATP-competitive catalytic mTOR inhibitors 
can overcome the drawbacks associated with mTORC1 inhibitors (468). 
Furthermore, rapamycin was unable to inhibit the mTORC2 substrate AKTS473. As 
explained earlier, inhibition of mTORC1 abolishes negative feedback loops 
mediated by S6K, resulting in enhanced mTORC2-dependent 
AKTS473 phosphorylation (and AKT reactivation) (316, 317, 341). Despite this, 
elevated AKTS473 phosphorylation was not observed in rapamycin-treated CLL 




transient effects of F(ab’)2 stimulation. Collectively, these data suggest that 
AZD8055 treatment may enhance CLL cell death by inhibiting pro-survival 
mTORC2/AKT signalling and enabling inhibitory 4E-BP1/eIF4E complex 
formation. Nevertheless, the functional response to long-term AZD8055 
treatment remains to be elucidated. As BTK is required for BCR-mediated 
activation of AKT (469), we assessed the ability of ibrutinib to inhibit 
phosphorylation of mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) 
downstream targets in CLL. Equally, as ibrutinib has been shown to inhibit BCR-
mediated MAPK/ERK signalling (126), ERK1/2T202/Y204 phosphorylation was also 
evaluated. Ibrutinib treatment inhibited AKTS473 phosphorylation in F(ab’)2 
stimulated CLL cells. This suggests PI3K-dependent phosphorylation of AKTT308 is 
inhibited, which is required for a SIN1-mediated positive feedback loop between 
mTORC2 and AKT (276). Moreover, ibrutinib reduced phosphorylation of S6S235/236 
in F(ab’)2 stimulated CLL cells. These findings correspond to recently published 
data showing the ability of ibrutinib to downregulate mTOR signalling in ABC-
DLBCL (470). Interestingly, the impact of ibrutinib on S6S235/236 phosphorylation 
was arguably greater than AZD8055 treatment alone. Mindful that short-term 
ibrutinib treatment inhibited BCR crosslinking-induced ERK1/2T202/Y204 
phosphorylation, this indicates that ibrutinib unleashes an additive effect via 
inhibition of distinct pathways, such as PI3K/AKT and MAPK/ERK signalling, that 
ultimately converge to regulate mTORC1 activity (293). However, this effect was 
not observed for 4E-BP1T37/46, suggesting that ibrutinib may also perturb 
mTORC1-independent mechanisms regulating S6S235/236 phosphorylation in CLL 
cells.  
3.3.6 AZD8055 cytotoxicity is limited in HG-3 and MEC-1 cells, 
likely due to sustained AKTT308 phosphorylation  
After assessing the ability of AZD8055, rapamycin and ibrutinib to block mTOR 
substrate phosphorylation in unstimulated and F(ab’)2 stimulated CLL cells, we 
next compared the impact of each drug on HG-3 and MEC-1 cell viability. As a 
monotherapy, rapamycin has limited toxicity, but elicits robust anti-proliferative 
effects in CLL cells (313, 428). Moreover, in early preclinical studies of ibrutinib, 
Herman et al. demonstrated only modest CLL cell apoptosis in vitro (126). 
Importantly, AZD8055 has been shown to induce caspase-dependent apoptosis, 




signalling activation in primary AML cells (320). In contrast, HG-3 and MEC-1 cells 
were largely insensitive to AZD8055, rapamycin or ibrutinib treatment. These 
data highlight the immense adaptive capability of mTOR signalling (270), which 
poses implications for long term AZD8055 treatment. Indeed, Rodrik-
Outmezguine et al. recently demonstrated that AZD8055 suppressed feedback 
inhibition of RTKs, which ultimately reactivated PI3K-AKT pro-survival signalling 
(324). Incidentally, AZD8055 has also been shown to induce autophagy (320), 
which can help maintain cancer cell survival (293). This being said, HG-3 and 
MEC-1 cells appear to be driven by overactive PI3K signalling, owing to the 
presence of constitutive AKTS473 phosphorylation, which may enhance or 
overwhelm the effect of AZD8055-induced PI3K activation. Indeed, Cosimo et al. 
recently compared the response of unstimulated CLL patient samples to 
AZD8055, rapamycin and ibrutinib treatment. Here, the authors reported a 
comparable, but modest, reduction in cell viability upon AZD8055 or ibrutinib 
treatment, whereas rapamycin did not affect CLL cell survival (284). This 
suggests, in the absence of sustained PI3K activation, AZD8055 is capable of 
inducing apoptosis in CLL cells, greater than the effect of rapamycin treatment.  
While PI3K-mediated AKTT308 phosphorylation was not assessed alongside survival 
data, potential reactivation of AKT is an interesting and probable explanation for 
AZD8055 insensitivity in HG-3 and MEC-1 cells. There is growing evidence that 
AKT-mediated upregulation of the anti-apoptotic protein MCL-1 is crucial for CLL 
cell survival (278), particularly downstream of sustained BCR stimulation (471). 
Indeed, through its association with poor-prognostic markers, MCL-1 expression 
has clinical significance in CLL (462). As such, BCR signalling inhibitors have been 
shown to disrupt the delicate balance between pro- and anti-apoptotic proteins 
by decreasing MCL-1 expression (434, 472). Interestingly, AZD8055 has been 
shown to reduce MCL-1 expression in rhabdomyosarcoma (473), triple-negative 
breast cancer (474) and ovarian cancer (475). In contrast, we showed that 
AZD8055-treated MEC-1 cells upregulated MCL-1, BCL-xL and Survivin expression. 
This might be indicative of treatment-induced AKT reactivation (278). However, 
an exception to the rule was the upregulation of pro-apoptotic BIM isoforms 
(BIMEL, BIML and BIMS) in AZD8055-treated MEC-1 cells. Studies have shown that 
AKT-dependent BIMS87 phosphorylation induces its proteasomal degradation (434, 




and pro-apoptotic proteins in HG-3 and MEC-1 cells might be specific to these 
cell lines, which is not replicated in primary CLL cells. Indeed, Cosimo et al. 
recently showed that treatment of F(ab’)2-stimulated CLL cells with AZD8055 
and rapamycin inhibited BCR-mediated survival and reduced MCL-1 expression 
(284). This indicates that BCR-ligated CLL cells respond differently to dual mTOR 
inhibition than HG-3 and MEC-1 cells.  
To assess whether extended AZD8055 treatment induced reactivation of AKT, we 
compared the response of F(ab’)2 stimulated CLL cells and MEC-1 cells to 
AZD8055 treatment at various timepoints up to 24 h. For primary CLL cells, the 
response to F(ab’)2 stimulation was transient (< 3h), as determined by 
phosphorylation of AKTT308 and AKTS473. Importantly, the inhibition of mTORC1 
(4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets was 
sustained for up to 24 h after AZD8055 treatment had commenced, 
corresponding to previous reports (324). Unlike AKTS473, inhibition of AKTT308 
phosphorylation was not immediate. This suggests elimination of AKTT308 
phosphorylation is a secondary event to AKTS473 inhibition, supporting the notion 
that AKTS473 phosphorylation stabilises AKTT308 (306, 465, 466). This being said, 
rephosphorylation of AKTT308 was not observed in AZD8055-treated F(ab’)2 
stimulated CLL cells up to 24 h. Although these findings conflict with the data 
posed by Rodrik-Outmezguine et al., the authors based their findings on cell 
lines (324), which are unlikely to have the same response as primary cells. In 
some cases, however, AKTT308 rephosphorylation appeared 48 h after treatment 
(324), so it might be possible that reactivation of PI3K-AKT signalling occurs 
later, but this seems unlikely in primary CLL cells devoid of sustained 
stimulation. Nevertheless, prolonged inhibition of AKTT308 and AKTS473 
phosphorylation in F(ab’)2 stimulated CLL cells suggests AKT kinase activity is 
eliminated, which may explain reduced MCL-1 expression in F(ab’)2 stimulated 
CLL cells following AZD8055 treatment (284). In the case of MEC-1 cells, the 
response to prolonged AZD8055 treatment was somewhat different. As with in 
F(ab’)2 stimulated CLL cells, inhibition of AKTS473 and S6S235/236 phosphorylation 
was observed in MEC-1 cells throughout the treatment period. However, despite 
a gradual reduction in AKTT308 phosphorylation in vehicle control MEC-1 cells, 
AKTT308 phosphorylation was present for up to 24 h in AZD8055-treated MEC-1 




AKT is partially active and capable of eliciting kinase activity. Additionally, the 
presence of AKTT308 phosphorylation in AZD8055-treated MEC-1 cells at 24 h 
(compared to vehicle control) might indicate treatment-induced PI3K 
reactivation. Interestingly, despite initial suppression, 4E-BP1T37/46 
phosphorylation rebounded to near-basal levels between 5 and 24 h after 
incubation with AZD8055. This has also been observed previously (324), and was 
shown to be specific to AKT reactivation and not simply a drop in drug 
concentration (324). Therefore, rephosphorylation of 4E-BP1T37/46 may promote 
eIF4E-dependent translation of mRNAs associated with CLL progression, 
establishing a new ‘setpoint’ that facilitates resistance to AZD8055 (324). Taken 
together, these findings may explain why MEC-1 cells were insensitive to long-
term AZD8055 treatment, owing to enhanced MCL-1, BCL-xL and Survivin 
expression likely induced by partial reactivation of AKT-mTORC1-(4E-BP1) axis. 
This casts doubt over the efficacy of AZD8055 as a monotherapy, which 
subsequently invokes strategies for novel drug combinations that target both 
mTOR and PI3K/AKT signalling to confer a more robust inhibitory response in 
CLL.  
3.3.7 Dual mTOR inhibitors synergise with ibrutinib to enhance 
CLL cell apoptosis, likely due to targeted inhibition of 
multiple survival pathways 
The clinical effectiveness of combination therapies is underscored by the ability 
to perturb regulatory processes entwined within complex biological networks, 
which can often adapt to monotherapies via multiple feedback mechanisms to 
promote cellular resilience (477). Therefore, pharmacological inhibition of 
multiple oncogenes residing within distinct signalling pathways represents a 
rationale for drug combination studies (424). In MEC-1 cells, sustained AKTT308 
phosphorylation amidst AZD8055 treatment likely induces downstream survival 
(and growth) processes sufficient to overcome monotherapy. Until now, we have 
assumed short-term ibrutinib treatment inhibits AKTT308 in MEC-1 cells, owing to 
the importance of BTK for AKT activation (469, 470) and the absence of AKTS473 
in ibrutinib-treated MEC-1 cells, which implies the reciprocal feedback loop 
between mTORC2 and AKT is defunct (276). For these reasons, we hypothesised 
that combining AZD8055 with ibrutinib would block AKT-mediated survival 




because ibrutinib also inhibits MAPK/ERK and NF-κB survival pathways (126), we 
envisage this might augment anti-cancer activity in CLL. Interestingly, a study 
performing a large-scale combinatorial screen to identify drugs that partner with 
ibrutinib to enhance apoptosis in ABC-DLBCL cells showed that inhibitors of PI3K-
AKT-mTOR signalling were chief among the candidates that interacted 
favourably with ibrutinib to promote cell death (478). Following this, a study 
reported a synergistic interaction between ibrutinib and AZD2014 that 
potentiated apoptosis in ABC-DLBCL cells (470). As monotherapies, the ability of 
AZD8055, AZD2014 and ibrutinib to induce CLL cell apoptosis was negligible, 
especially at clinically achievable concentrations (439-441). To determine 
whether dual mTOR inhibitors, AZD8055 and AZD2014, synergise with ibrutinib to 
enhance CLL cell death, a median-drug effect analysis was performed to 
calculate CI values according to the Chou and Talalay method (425). This 
revealed that AZD8055 and AZD2014 synergised with ibrutinib at multiple 
clinically-achievable doses (439-441) to enhance apoptosis of primary CLL cells. 
These results were encouraging, not least because they supported the rationale 
that targeting multiple survival pathways would render CLL cells vulnerable to 
apoptosis. However, to confirm the ability of the combination to inhibit mTOR 
and MAPK/ERK activity, we needed to assess the phosphorylation status of 
mTORC1/2 downstream targets and ERK1/2T202/Y204.  
Initially, we determined the selectivity of the combination for mTOR and 
MAPK/ERK activity in HG-3 and MEC-1 cells. Along with the data presented in 
Figure 3.3f-j, this further suggested that MEC-1 cells might be more reliant on 
AKT/mTORC1 signalling than HG-3 cells, which may impact upon mTORC1-driven 
responses. While AZD8055 was unable to inhibit AKTT308 and ERK1/2T202/Y204 
phosphorylation in HG-3 and MEC-1 cells, the addition of ibrutinib successfully 
blocked activation of these targets. Similarly, while ibrutinib was unable to 
inhibit 4E-BP1T37/46 in MEC-1 cells, AZD8055 effectively abrogated 4E-BP1T37/46 
phosphorylation. This suggests that synergy between AZD8055 and ibrutinib is 
due to 1) targeted inhibition of distinct signalling pathways, and 2) a more 
complete blockade of the same pathway (284). Combining AZD8055 and ibrutinib 
caused a stronger inhibition of S6S235/236 than each agent alone, particularly in 
MEC-1 cells, indicating that ibrutinib targets distinct pathways that regulate S6K 




AKT stimulation in DLBCL cell lines insensitive to AKT inhibition via increased 
expression of PIM2 (479). Interestingly, other kinases have been shown to 
modulate S6S235/236 phosphorylation including RSK1-4 (480), PKC (481) and Protein 
Kinase A (PKA) (482), suggesting that ibrutinib may influence S6K1-S6 activity 
independently of mTOR (470).  
We next sought to confirm the ability of the combination to inhibit mTOR and 
MAPK/ERK survival pathways in unstimulated and F(ab’)2 stimulated CLL cells. 
Consistent with the response in HG-3 and MEC-1 cells, AZD8055 and ibrutinib 
combination acted cooperatively to inhibit the activity of AKT/mTOR and 
MAPK/ERK in unmanipulated and BCR-stimulated primary CLL cells. These data 
indicate that following short-term treatment, BCR-mediated CLL survival can be 
overcome by a favourable interaction between AZD8055 and ibrutinib. 
Interestingly, we again observed an additive inhibitory effect of the combination 
treatment on S6S235/236 phosphorylation in F(ab’)2-stimulated CLL cells, which 
further highlights the potential impact of ibrutinib on S6S235/236 phosphorylation 
via a mechanism unrelated to mTORC1 (470), perhaps through established off-
target activity (125). How this is resolved in the context of the CLL TME, where 
patient LN biopsies have revealed minimal S6S235/236 phosphorylation, remains to 
be elucidated. 
To assess the inhibitory effect of the combination treatment downstream of 
CD40 ligation, we used the well-established CD40L/IL-4 system (186, 217, 448). 
mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473) downstream targets 
were activated in CLL cells co-cultured on NT-L or CD40L (+IL-4), indicating that 
mTORC1 and mTORC2 regulate stromal- and CD40L-induced CLL survival, which 
can be targeted by combining AZD8055 with ibrutinib. AZD8055 treatment 
successfully inhibited mTORC1 and mTORC2 activity. However, unlike in F(ab’)2 
stimulated CLL cells, ibrutinib monotherapy only marginally reduced AKTS473 
phosphorylation, while mTORC1 (4E-BP1T37/46 and S6S235/236) downstream targets 
were largely unaffected in CLL cells co-cultured on NT-L or CD40L (+IL-4). Partial 
inhibition of CD40L-induced AKTS473 phosphorylation by ibrutinib has been shown 
previously with soluble CD40L (126). Nevertheless, combining AZD8055 and 
ibrutinib blocks phosphorylation of mTORC1 (4E-BP1T37/46 and S6S235/236) and 




treatment. However, without assessment of AKTT308 and ERK1/2T202/Y204 
phosphorylation, it is difficult to conclude the relative contributions of AZD8055 
and ibrutinib in this context. Therefore, it remains to be seen whether this 
combination could reduce AKT-mediated survival signals emanating from 
CD40/IL-4R ligation. Nevertheless, ibrutinib is known to block interactions 
between CLL cells with non-malignant accessory cells of the CLL-TME (126, 127). 
Furthermore, ibrutinib treatment causes a downregulation of chemokine 
receptor CXCR4, which subsequently leads to CLL cell redistribution (or 
‘dropping out’) into the periphery (124, 129, 483). Interestingly, unpublished 
data has also revealed that ibrutinib causes impaired IL-4R-signalling and blocks 
IL-4R-mediated survival in CLL cells (484).  
3.3.8 AZD8055 and ibrutinib combination overcomes BCR-
mediated survival, likely caused by inhibition of AKT-
mediated MCL-1 expression 
Ezell et al. demonstrated that combining ibrutinib with AZD2014 strongly 
induced apoptosis in ABC-DLBCL cell lines and OCI-LY10-derived xenograft 
models. In their case, the combination’s mechanism of action converged on the 
regulation of 4E-BP1 and JAK/STAT3 signalling (470). Here, we proposed that the 
combination of AZD8055 and ibrutinib would act through concerted inhibition of 
multiple survival pathways, with emphasis on ‘full’ AKT inactivation through 
abrogation of AKTT308 rephosphorylation, to promote CLL cell apoptosis. 
Encouragingly, Cosimo et al. recently showed that treating a CLL-like mouse 
model (485) with a combination of AZD2014 and ibrutinib reduced the 
percentage of CLL-like cells in PB and decreased tumour burden in the BM and 
spleen (284). However, the underlying inhibitory mechanisms in vivo were not 
determined.  
The initial approach was to assess the impact of the combination on HG-3 and 
MEC-1 cell viability. We previously demonstrated the relative insensitivity of HG-
3 and MEC-1 cells to AZD8055 treatment as a monotherapy, citing sustained 
phosphorylation of AKTT308 following long-term AZD8055 treatment in MEC-1 
cells. We subsequently determined that combining AZD8055 with ibrutinib 
inhibited both AKTS473 and AKTT308 phosphorylation, suggesting AKT kinase 




we demonstrated that the COMBO treatment had minimal impact on cell 
viability or apoptosis compared to the single agents. While visible trends towards 
reduced cell viability and enhanced apoptosis were observed, these effects are 
unlikely to have biological significance. Therefore, this may suggest that AKT 
inactivation is transient and/or HG-3 and MEC-1 cells are capable of overcoming 
AKT, MAPK and NF-κB inhibition by distinct mechanisms. AZD8055 or ibrutinib 
monotherapy increased MCL-1 expression, which was surprisingly augmented 
when the drugs were combined. As such, considering the assumption that AKT is 
fully inactivated by COMBO treatment, these findings conflict with the notion 
that AKT mediates MCL-1 upregulation (278). AKT controls the expression of 
BCL2 family proteins through regulation of transcription factors (434). Indeed, 
AKT regulates NF-κB activation, which promotes anti-apoptotic BCL-xL 
upregulation (434, 486, 487). Conversely, AKT negatively regulates FOXO 
transcription factors, which supress expression of pro-apoptotic proteins (e.g. 
BIM) (375, 434). Confoundingly, we observed enhanced expression of both BCL-xL 
and BIM following COMBO treatment. Therefore, how these findings reconcile 
with the observation that AKT is fully inactivated after short-term treatment, 
remains to be elucidated. Nevertheless, concurrent upregulation of pro- (BIM) 
and anti-apoptotic (MCL-1 and BCL-xL) proteins perhaps suggests HG-3 cells and 
MEC-1 cells are capable of readdressing the balance of pro- and anti-apoptotic 
factors in response to treatment (434). Equally, constitutive expression of BCL2 
could offer resistance to HG-3 and MEC-1 cells by sequestering BIM, which has 
been shown previously in CLL cells (488). Nevertheless, the response of HG-3 and 
MEC-1 cells in the face of agents altering this delicate balance warrants further 
investigation.  
The impact of COMBO treatment on HG-3 and MEC-1 cell viability may be skewed 
due to their overactivated (PI3K-driven) phenotype, which is unlikely to mimic 
the effects of treatment in primary CLL cells. Indeed, Cosimo et al. already 
demonstrated that AZD8055 and ibrutinib as monotherapies are capable of 
inducing cell death in PB-derived CLL cells (284). Therefore, we next assessed 
the ability of AZD8055 and ibrutinib combination treatment to reduce cell 
viability in unstimulated and F(ab’)2-stimulated CLL cells. Stimulation of primary 
CLL cells with F(ab’)2 fragments modestly enhanced CLL survival and 




demonstrated previously (278). Encouragingly, the COMBO treatment reduced 
cell viability in unstimulated and F(ab’)2 stimulated CLL cells, which also 
corresponded to decreased MCL1 and BCL2-L1 transcript abundance and 
enhanced PARP cleavage. Moreover, while BCL2 levels remained consistent, 
MCL-1 protein expression was reduced following combination treatment in 
unstimulated and F(ab’)2 stimulated CLL cells. These data suggest that AZD8055 
and ibrutinib act concertedly to inhibit multiple BCR-induced survival pathways 
to induce CLL cell apoptosis. Indeed, decreased MCL-1 expression is likely 
indicative of reduced AKT activation (278), while reduced BCL2-L1 expression 
suggests abrogation of NF-κB transcriptional activity (486, 487).  
Evaluating the ability of the COMBO treatment to overcome stromal- and 
CD40L/IL-4-mediated survival signals, we found that combining AZD8055 with 
ibrutinib reduced cell viability of CLL cells co-cultured on NT-L stromal cells to a 
greater extent than each drug alone. This corresponded to a decrease in MCL-1 
expression, which implies a reduction in AKT activity (278) and perhaps 
highlights the importance of MCL-1 in CLL survival (462). Moreover, these 
findings aligned with an early preclinical study of ibrutinib that demonstrated 
enhanced cell death in ibrutinib-treated CLL cells co-cultured on Hs5 stromal 
cells (126). Thus, it was reassuring to observe an improved response through 
positive cooperation between AZD8055 and ibrutinib. However, AZD8055 and 
ibrutinib as monotherapies or in combination had minimal impact on the viability 
of CLL cells co-cultured on CD40L (+IL-4), despite overcoming CD40L/IL-4-
induced upregulation of BCL-xL. Nevertheless, MCL-1 expression remained 
constant in CLL cells co-cultured on CD40L, which supports the notion that MCL-
1 possesses a greater influence on CLL survival than BCL-xL (278, 462). This 
result was somewhat surprising, especially considering that studies have 
demonstrated the ability of ibrutinib to block survival signals emanating from 
CD40L-engagement (126) and IL-4R-ligation (484). This being said, it is possible 
that prolonged CD40-engagement in our co-culture system, as opposed to soluble 
factors (126), overwhelms the potential effect of the treatment. Indeed, 
sustained signalling downstream of CD40-ligation likely upregulates additional 
BCL2 family members (perhaps akin to overactivation of HG-3 and MEC-1 cells), 
which offers a degree of protection to CLL cells and confers resistance to the 




CD40L (+IL-4) stimulation, it cannot fully recapitulate the complex modes of 
stimulation (i.e. crosstalk) likely occurring within the CLL-TME in vivo. 
Nonetheless, given the profound effects of ibrutinib in vivo, including inhibition 
of cell proliferation, downregulation of chemokine receptors and subsequent 
redistribution into the periphery (124, 129, 483), this raises the possibility that 
the strengths of the COMBO treatment may lie elsewhere.  
3.3.9 Combining AZD8055 with ibrutinib enhances inhibition of 
CLL cell proliferation, suggesting COMBO treatment could 
suppress clonal expansion in the LN microenvironment 
The proliferative pool of CLL cells within ‘proliferation centres’ of the CLL-TME 
promotes rapid expansion of the malignant clone, facilitates clonal evolution 
and drives cancer progression (74, 76, 88, 489). Therefore, inhibiting the signals 
that orchestrate cell growth/proliferation are key to disrupting disease 
progression. Decker et al. demonstrated the ability of rapamycin to inhibit 
proliferation (i.e. cell cycle arrest) of CpG stimulated-CLL cells (313, 428). 
Although this underscores the importance of mTORC1 signalling for regulating 
cell growth, we were interested to assess whether dual mTOR kinase inhibition 
would augment cell growth arrest via abrogation of mTORC2-AKT signalling. 
AZD8055 has been shown to block proliferation of AML (320) and renal cell 
carcinoma (321) cell lines, with the latter demonstrating that AZD8055 conferred 
a greater inhibitory effect than rapamycin. Given the inhibitory effect of 
ibrutinib on CLL proliferation in vivo (127), we sought to explore whether 
combining AZD8055 with ibrutinib would augment cell growth arrest.  
A prerequisite that permits cellular proliferative expansion is the accumulation 
of biomass (i.e. cells need to increase in size) (293). Fingar et al. showed that 
the reduction in cell size caused by rapamycin could be rescued by expression of 
a rapamycin-resistant mutants (mTOR or S6K1) or overexpression of eIF4E, 
demonstrating the importance of mTORC1 for this process (442). Interestingly, 
however, PI3K/mTOR-mediated coordination of cell growth and cell cycle 
progression also impinges upon mTORC2 (270). Therefore, we compared the 
ability of rapamycin and AZD8055 to regulate HG-3 and MEC-1 cell size. These 
data showed that AZD8055 and rapamycin significantly reduced MEC-1 cell size. 




greater than rapamycin, suggesting the involvement of mTORC2-mediated 
signalling. Indeed, a recent study demonstrated that genetic depletion of the 
mTORC2 component SIN1 decreased cell size and diminished proliferation in 
normal B cells. Interestingly, Li et al. showed that SIN1 controlled mTORC1 
activity, in part, through AKT-dependent inactivation of TSC1/2 (490). This 
indicates that mTORC2/AKT activity augments mTORC1-mediated cell growth 
expansion to prime cells for proliferation, which may explain the enhanced 
inhibitory effect of AZD8055 over rapamycin. Mindful of the impact of the 
COMBO treatment on AKT/mTOR activity, the effects of COMBO treatment on 
cell growth were assessed. Ibrutinib treatment reduced MEC-1 cell size, possibly 
due to collective inhibition of ERK1/2T202/Y204, mTORC1 (S6S235/236) and mTORC2 
(AKTS473) activity. Interestingly, the COMBO treatment further decreased MEC-1 
cell size to an extent greater than each single agent. This additive effect is 
likely explained by a more complete inhibition of AKTT308, MAPK (ERK1/2T202/Y204), 
mTORC1 (4E-BP1T37/46 and S6S235/236) and mTORC2 (AKTS473). These findings 
suggest that AZD8055 and ibrutinib work cooperatively to enhance cell growth 
arrest, which might have implications for CLL cell cycle progression and 
proliferation. HG-3 cells were largely insensitive to treatment, despite near-
significant reductions in cell size with AZD8055 and rapamycin. Although this 
requires further experimentation, these observations could be due to reduced 
basal mTORC1 activity in HG-3 cells compared to MEC-1 cells.  
Rapamycin-induced G1 cell cycle arrest in CLL cells was shown to be a 
manifestation of reduced translation of mRNAs encoding proteins essential for 
G1 cell cycle progression (313, 428). Although mTORC1 substrates 4E-BP1 and 
S6K are key players in cell cycle progression (443), mTORC2 controls 
proliferation via ‘full’ activation of AKT (293, 465). Indeed, the decrease in cell 
size caused by rapamycin is seldom associated with an outright suppression of 
proliferation (491). Therefore, we initially sought to compare the effect of 
AZD8055 and rapamycin on cell cycle progression and proliferation in 
unsynchronised HG-3 and MEC-1 cells. We demonstrated that AZD8055 and 
rapamycin induced G1 cell cycle arrest in MEC-1 cells. Although marginal, a 
larger proportion of AZD8055-treated MEC-1 cells were arrested in G1, which 
aligns with previous studies demonstrating enhanced inhibitory effect of dual 




rapalogues) (320, 321, 447, 492). As before, this suggests the involvement of 
mTORC2/AKT-mediated signals in cell cycle progression (490). Encouragingly, 
these findings translated into reduced proliferation following AZD8055 or 
rapamycin treatment in MEC-1 cells, with AZD8055 arguably conferring a larger 
inhibitory effect, albeit modest, compared to rapamycin. This indicates that 
dual mTOR inhibition is better placed to inhibit proliferative signals that are 
coordinated by both mTOR complexes. AZD8055 and rapamycin induced 
upregulation of the cell cycle inhibitor p27KIP1, contrasting with a previous study 
(313). Whereas PB-derived CLL cells express high levels of p27KIP1 (493), low 
expression levels of p27KIP1 have been observed within ‘proliferation centres’ of 
the CLL LN microenvironment (494). This suggests that p27KIP1 is an active 
participant in cell cycle regulation that is modulated in cycling CLL cells (463). 
The ability of AZD8055 to upregulate p27KIP1 has been shown previously (495) and 
likely explains the inhibitory effect on G1 cell cycle progression in MEC-1 cells.  
Subsequently, the effects of the COMBO treatment on cell cycle progression and 
proliferation were assessed. Ibrutinib treatment induced G1 cell cycle arrest in 
HG-3 and MEC-1 cells, which was likely a result of concurrent upregulation of 
cell cycle inhibitors p21CIP1 and p27KIP1. However, ibrutinib was unable to block 
HG-3 and MEC-1 cell proliferation to the same extent as AZD8055 or rapamycin. 
This contrasts with the prevailing view that ibrutinib is a potent inhibitor of CLL 
proliferation in vivo (127). However, ibrutinib likely affects CLL cell 
proliferation, in part, by promoting redistribution of CLL cells out of the 
‘proliferative niche’ (124, 129, 483). Although the COMBO treatment induced G1 
cell cycle arrest in MEC-1 cells, COMBO did not confer an additive effect upon 
cell cycle progression compared to each agent alone. Despite this, COMBO 
treatment surprisingly enhanced inhibition of HG-3 and MEC-1 proliferation. This 
suggests that COMBO treatment-induced AKT inactivation blocks proliferative 
signals downstream of PI3K/AKT. Indeed, enhanced upregulation of p27KIP1 is 
indicative of relieved AKT-mediated negative regulation of FOXO transcription 
factors, which contribute towards cell cycle control (382). These findings suggest 
that COMBO treatment elicits its anti-proliferative effects, in part, through ‘full’ 




To confirm these results, we tested the ability of the COMBO treatment to 
inhibit cell growth and proliferation in primary CLL cells.  However, despite the 
importance of BCR signalling within the proliferative LN microenvironment in 
vivo (207), current ex vivo BCR stimulation protocols are unable to promote 
proliferation of CLL cells (496). Thus, we used the established CD40L/IL-4 (144) 
and CD40L/IL-21 co-culture systems (180). Consistent with MEC-1 cells, AZD8055 
and ibrutinib as monotherapies blocked increased cell size induced by co-culture 
on CD40L (+IL-4), with AZD8055 conferring a greater inhibitory effect. This is 
likely due to complete inhibition of mTORC1/2 activity, whereas ibrutinib only 
poorly inhibits 4E-BP1T37/46 phosphorylation. The inhibitory effect of COMBO on 
cell growth was larger than each agent alone, likely due to ‘full’ inhibition of 
AKT kinase activity alongside inhibition of signalling pathways and/or adaptive 
mechanisms that converge on mTORC1. Ibrutinib was unable to confer an anti-
proliferative effect in CLL cells co-cultured on CD40L (+IL-21), which conflicted 
with reports on the contrary (127). Interestingly, however, studies have shown 
that CD40L (+IL-4)-stimulated ‘normal’ B cells retain the ability to proliferate 
following treatment with PI3K inhibitors (266, 497). Nevertheless, AZD8055 alone 
and COMBO inhibited CD40L (+IL-21)-induced CLL proliferation, highlighting the 
importance of mTOR signalling in coordinating proliferative signals downstream 
of CD40/IL-21R ligation. These data indicate that the COMBO treatment could 
represent an effective strategy to prevent clonal expansion within the CLL-TME.  
3.3.10 Inactivation of AKT by COMBO treatment may 
reactivate FOXO1 activity to promote apoptosis and cell 
cycle arrest 
A consequence of combining AZD8055 with ibrutinib involves the reduction of 
AKT kinase activity, through inhibition of AKTT308 and AKTS473 phosphorylation. 
This coincided with elevated p27KIP1 expression levels, which may contribute to 
the observed inhibition of cell cycle progression in MEC-1 cells. Interestingly, 
p27KIP1 is a target gene of FOXO transcription factors (382), which control diverse 
cellular processes such as survival and cell cycle progression (384). Since FOXOs 
are AKT substrates (246), we hypothesised that the combination’s mechanism of 
action involved relieving AKT-mediated negative regulation of FOXOs to promote 
transactivation of FOXO target genes (348). To answer this question, we assessed 




phosphorylation site (345), downstream of BCR-ligation and NT-L/CD40L (+IL-4) 
co-cultures. Here, we found that BCR stimulation increased AKTT308, AKTS473 and 
FOXO1T24 phosphorylation in F(ab’)2 stimulated CLL cells, indicating that FOXO1 
is a target of BCR crosslinking-induced AKT kinase activity. Because AKT 
negatively regulates FOXO1, this demonstrates that BCR simulation (albeit short-
term) inhibits FOXO1 activity in CLL cells. Indeed, studies have shown that BCR 
crosslinking-induced activation of PI3K-AKT signalling inactivates FOXO1 in 
mature B cells, which decreases expression of FOXO1 target genes BIM and 
p27KIP1 (275). Encouragingly, treatment with AZD8055, ibrutinib or COMBO 
inhibited BCR ligation-induced FOXO1T24 phosphorylation. Interestingly, COMBO-
induced AKT inactivation corresponded to a visibly enhanced inhibition of 
FOXO1T24 phosphorylation. This suggests that COMBO treatment-induced 
inhibition of AKT kinase activity enables reactivation of FOXO1. This being said, 
residual FOXO1T24 implies that AKT is active to an extent, which might be enough 
to promote CLL cell survival and proliferation. Interestingly, treatment reduced 
basal FOXO1T24 phosphorylation in unstimulated CLL cells, indicating that AKT is 
also active in circulating CLL cells. In the absence of external stimulation, this 
may support the observation that PI3K (252) and AKT (285) are constitutively 
active in unmanipulated CLL cells, and may highlight the involvement of ‘tonic’ 
BCR signalling (247, 254, 255). Importantly, similar effects on FOXO1T24 
phosphorylation were observed in CLL cells co-cultured on NT-L and CD40L (+IL-
4), indicating that AKT inactivation by the COMBO treatment is capable of 
reactivating FOXO1 activity to promote apoptosis and cell cycle arrest. However, 
whether FOXO1 is responsible for the observed inhibition in cell cycle 
progression remains to be elucidated. 
3.3.11 Summary and future directions 
Taken together, these findings demonstrate that mTOR is a key effector 
downstream of BCR stimulation in CLL cells. Enhanced mTORC1 and mTORC2 
activity can be targeted by the dual mTOR kinase inhibitor AZD8055, which 
overcomes BCR-mediated cell survival. Importantly, AZD8055 does not induce 
enhanced mTORC2/AKT pro-survival signalling associated with selective-mTORC1 
inhibitors. Nevertheless, AZD8055 anti-tumour activity is limited as a 
monotherapy. Interestingly, AZD8055 synergises with ibrutinib to enhance CLL 




Furthermore, combining AZD8055 with ibrutinib blocks CD40L/IL-4-induced cell 
growth and CD40L/IL-21-induced proliferation. Collectively, this indicates that 
concurrent targeting of mTOR and BTK may promote anti-tumour activity in CLL. 
We propose that the combination treatment confers a ‘complete’ inhibition of 
AKT kinase activity, which relieves negative regulation of the FOXO1 
transcription factor. Because active FOXO1 can promote cell death and cell cycle 
control, treatment-induced reactivation of FOXO1 may promote anti-cancer 
activity. In the following chapters, we will explore the regulation and function of 








CLL158         
 0 6.25 12.5 25 50 100 200 AZD8055 (nM) 
0 1.000 0.980 0.981 0.951 0.930 0.901 0.807  
62.5 0.841 0.848 0.849 0.831 0.821 0.793 0.752  
125 0.832 0.827 0.845 0.844 0.817 0.797 0.748  
250 0.839 0.840 0.832 0.841 0.786 0.799 0.724  
500 0.821 0.818 0.849 0.835 0.846 0.766 0.719  
1000 0.826 0.798 0.827 0.813 0.799 0.765 0.687  
2000 0.723 0.741 0.732 0.720 0.700 0.679 0.597  
Ibrutinib (nM)         
         
 0 125 250 500 1000 2000 4000 AZD2014 (nM) 
0 1.000 0.867 0.884 0.861 0.798 0.765 0.583  
62.5 0.859 0.804 0.800 0.784 0.749 0.753 0.666  
125 0.855 0.804 0.778 0.767 0.725 0.785 0.659  
250 0.855 0.795 0.756 0.708 0.738 0.749 0.666  
500 0.832 0.766 0.756 0.715 0.712 0.708 0.654  
1000 0.814 0.782 0.750 0.732 0.728 0.689 0.639  
2000 0.717 0.696 0.667 0.666 0.660 0.635 0.560  
Ibrutinib (nM)         
Table 3.1 – Drug combination studies: CLL158 cell viability 
Cell viability of a representative CLL patient sample (CLL158) treated with AZD8055 and ibrutinib 
(top) or AZD2014 and ibrutinib (bottom) at non-constant ratios for 48 h (as indicated in Figure 3.8). 
Concentrations of each drug are indicated. Cell viability was assessed using the resazurin assay. 
The values depicted represent the ‘fraction affected’ (Fa) following treatment (relative to vehicle 
control). Fa values were used to generate CI values (depicted in Figure 3.8) according to the Chou 
and Talalay method (via Compusyn software).  
 
AKT (T308) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.704 0.820 0.297  ns ns **** ns ns 
2 1 0.745 0.320 0.252        
3 1 0.565 0.356 0.256        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.796 0.375 0.187  ns * ns ns ns 
2 1 1.247 0.414 0.695        
3 1 0.861 0.316 0.252             
           
AKT (S473) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 













2 1 0.007 0.102 0.002        
3 1 0.020 0.092 0.007        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.060 0.071 0.003  **** **** **** ns ns 
2 1 0.052 0.048 0.003        
3 1 0.041 0.036 0.020             
           
4E-BP1 (T37/46) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.075 0.400 0.036  **** * **** ns ns 
2 1 0.049 0.406 0.033        
3 1 0.039 0.229 0.017        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.059 1.408 0.118  **** ns ** ns ns 
2 1 0.030 0.718 0.031        
3 1 0.058 0.712 0.035             
           
S6 (S235/236) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.217 0.695 0.060  ** ns **** ns ns 
2 1 0.155 0.835 0.056        
3 1 0.131 0.584 0.104        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.288 0.585 0.061  ** * *** * ** 
2 1 0.249 0.627 0.057        
3 1 0.341 0.680 0.118             
           
ERK1/2 (T202/Y204) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.844 0.118 0.082  ns ** **** ns ns 
2 1 1.592 0.043 0.057        
3 1 1.681 0.154 0.082        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 













2 1 1.167 0.071 0.121        
3 1 0.745 0.006 0.052             
           
FOXO1 (T24) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.335 0.168 0.127  ns * ns ns ns 
2 1 0.361 0.388 0.187        
3 1 0.581 0.302 0.415        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 









1 1 0.713 0.293 0.224  ns **** * ns ns 
2 1 0.333 0.250 0.095        
3 1 0.652 0.286 0.130             
Table 3.2 – Western blot densitometry: 1 h treatment (HG-3 and MEC-1 cells) 
AKTT308, AKTS473, 4E-BP1T37/46, S6S235/236, ERK1/2T202/Y204 and FOXO1T24 phosphorylation levels in 
HG-3 (n=3) and MEC-1 (n=3) cells following short-term (1 h) treatment with AZD8055, ibrutinib or 
COMBO (as described in Figure 3.9). Densitometry was calculated using Image Studio Lite 
software (relative to vehicle control). Statistical analysis was performed using a one-way ANOVA 
with Tukey’s multiple comparisons test. p > 0.05 ‘ns’ = not significant; p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 
0.001 ***;  p ≤ 0.0001 ****.   
 
Viability (Annexin V negative / 7-AAD negative) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 
Sample Vehicle AZD8055 Ibrutinib COMBO  Vehicle/AZD8055 Vehicle/Ibrutinib Vehicle/COMBO AZD8055/COMBO Ibrutinib/COMBO 
1 1 1.016 0.974 1.009  ns ns ns ns ns 
2 1 1.113 1.085 1.106        
3 1 1.031 0.974 1.006        
4 1 1.062 1.016 1.029        
5 1 1.035 0.981 1.022        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 
Sample Vehicle AZD8055 Ibrutinib COMBO  Vehicle/AZD8055 Vehicle/Ibrutinib Vehicle/COMBO AZD8055/COMBO Ibrutinib/COMBO 
1 1 0.993 0.960 1.003  ns ns ns ns ns 
2 1 1.024 0.989 1.032        
3 1 0.985 0.969 1.011        
4 1 1.034 0.978 1.012        
5 1 1.073 1.031 1.037             
           
Apoptosis (Annexin V positive / 7-AAD positive) 
HG-3  Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 
Sample Vehicle AZD8055 Ibrutinib COMBO  Vehicle/AZD8055 Vehicle/Ibrutinib Vehicle/COMBO AZD8055/COMBO Ibrutinib/COMBO 
1 1 0.752 1.283 0.898  * ns ns ** * 
2 1 0.389 0.619 0.491        




4 1 0.374 0.996 0.635        
5 1 0.598 1.652 0.730        
MEC-1   Statisitic (one-way ANOVA; Tukey's multiple comparisons test) 
Sample Vehicle AZD8055 Ibrutinib COMBO  Vehicle/AZD8055 Vehicle/Ibrutinib Vehicle/COMBO AZD8055/COMBO Ibrutinib/COMBO 
1 1 1.105 1.400 0.927  ns ns ns ns ns 
2 1 0.919 1.210 0.724        
3 1 1.224 1.274 0.620        
4 1 0.725 1.051 0.744        
5 1 0.495 0.625 0.581             
Table 3.3 - Cell viability analysis: 48 h treatment (HG-3 and MEC-1 cells) 
HG-3 (n=5) and MEC-1 (n=5) cell viability (Annexin V/7-AAD staining) following long-term (48 h) 
treatment with AZD8055, ibrutinib or COMBO (as described in Figure 3.10). Values indicate the 
proportion of viable (top) and apoptotic (bottom) cells (relative to vehicle control). Statistical 
analysis was performed using a one-way ANOVA with Tukey’s multiple comparisons test. p > 0.05 







Sample Vehicle AZD8055 Ibrutinib COMBO Vehicle AZD8055 Ibrutinib COMBO   
CLL151 1 0.065 0.762 0.867 372.267 0.951 0.998 0.329   
CLL157 1 0.642 0.294 1.566 983.808 4.717 0.315 8.488   
CLL80 1 0.003 0.003 0.064 52.177 0.228 3.496 0.130   
CLL138 1 0.234 0.596 0.333 2.678 0.474 0.544 0.193   
CLL113  1 0.015 0.051 0.005 16.199 0.003 0.471 0.009   
CLL148 1 0.300 1.400 0.600 20.500 1.200 3.600 0.800   
CLL90 1 0.045 1.792 8.194 152.349 2.102 4.951 5.658   
CLL69 1 0.041 0.032 0.002 26.532 0.027 0.384 0.048   
           




















*** ns ns ns ns ns ns ns ns ns ns 






Sample Vehicle AZD8055 Ibrutinib COMBO Vehicle AZD8055 Ibrutinib COMBO   
CLL151 1 0.162 1.379 0.165 1.166 0.244 0.962 0.139   
CLL157 1 0.060 0.582 0.048 1.160 0.092 1.509 0.216   
CLL119 1 0.122 1.182 0.156 1.385 0.087 0.761 0.066   
CLL80 1 0.073 0.492 0.016 0.530 0.027 0.393 0.137   
CLL113 1 0.164 0.783 0.104 1.233 0.122 0.845 0.127   
CLL90 1 0.007 0.089 0.005 0.394 0.010 0.075 0.030   
CLL69 1 0.305 2.121 0.131 2.834 0.526 1.971 0.095   
























**** ns **** ns ns * ns ns ns ns ns 






Sample Vehicle AZD8055 Ibrutinib COMBO Vehicle AZD8055 Ibrutinib COMBO   
CLL151 1 0.455 1.377 0.410 10.371 4.260 2.012 0.831   
CLL157 1 0.218 1.650 0.199 14.252 4.014 4.799 0.302   
CLL119 1 0.039 0.838 0.040 1.192 0.072 1.000 0.042   
CLL80 1 0.085 0.650 0.076 11.661 6.110 4.518 0.699   
CLL138 1 0.385 0.769 0.137 1.005 0.258 0.313 0.324   
CLL113 1 0.067 0.570 0.066 7.577 0.307 1.601 0.035   
CLL148 1 0.167 0.417 0.357 14.732 4.274 2.536 0.333   
CLL90 1 0.343 1.268 0.273 9.393 0.819 1.035 0.331   
CLL69 1 0.195 0.277 0.083 26.424 1.534 2.418 0.152   
           




















**** ns **** ns ns ns ns * ns ns ns 






Sample Vehicle AZD8055 Ibrutinib COMBO Vehicle AZD8055 Ibrutinib COMBO   
CLL151 1 0.079 1.507 1.222 38.752 30.020 2.823 16.313   
CLL157 1 2.311 2.195 2.868 24.225 23.283 2.823 3.132   
CLL80 1 1.915 1.084 1.519 27.248 21.756 6.435 3.443   
CLL113 1 1.055 0.330 0.396 2.413 2.015 0.644 0.479   
CLL90 1 1.074 0.434 0.388 12.629 7.151 1.675 0.700   
CLL69 1 1.632 0.529 0.448 13.650 5.821 2.116 2.195   
            




















ns ns ns ns ns ns ns ns ns ns ns 









Sample Vehicle AZD8055 Ibrutinib COMBO Vehicle AZD8055 Ibrutinib COMBO   
CLL151 1 0.668 0.567 0.363 2.436 1.311 1.101 0.464   
CLL119 1 0.705 0.506 0.563 1.416 0.662 0.456 0.251   
CLL80 1 0.399 0.195 0.067 1.429 0.572 1.146 0.297   
CLL138 1 0.303 0.273 0.212 1.515 0.515 0.424 0.242   
CLL113  1 0.389 0.207 0.037 1.199 0.938 0.295 0.545   
CLL148 1 0.308 0.231 0.154 1.769 1.385 1.000 0.385   
CLL90 1 0.089 0.198 0.205 1.654 0.018 0.075 0.282   
CLL69 1 0.558 0.322 0.250 2.276 1.068 0.850 0.461   
           




















** **** **** ns ns ** ** *** ns ns * 
Table 3.4 – Western blot densitometry: 1 h treatment (primary CLL cells) 
AKTS473, 4E-BP1T37/46, S6S235/236, ERK1/2T202/Y204 and FOXO1T24 phosphorylation levels in primary 
CLL samples (pseudonym indicated) following short-term (1 h) treatment with AZD8055, ibrutinib or 
COMBO with or without F(ab’)2 stimulation (as described in Figure 3.14). Densitometry was 
calculated using Image Studio Lite software (relative to vehicle control). Statistical analysis was 
performed using a one-way ANOVA with Tukey’s multiple comparisons test. p > 0.05 ‘ns’ = not 
significant; p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.001 ***; p ≤ 0.0001 ****.     
 





Sample Vehicle AZD8055 Ibrutinib COMBO Vehicle AZD8055 Ibrutinib COMBO   
CLL151 1 0.797 0.815 0.781 1.075 1 0.885 0.86   
CLL69 1 1.007 0.935 0.96 0.996 1.018 0.965 0.956   
CLL157 1 0.896 0.787 0.793 1.056 1.013 0.907 0.875   
CLL90 1 0.852 0.677 0.574 0.959 0.932 0.816 0.645   
CLL80 1 0.9354 0.8436 0.8188 0.962 0.913 0.895 0.8908   
CLL113 1 0.9782 0.9269 0.9128 1.014 0.998 0.955 0.952   
CLL119 1 0.8719 0.7964 0.7799 1.018 0.885 0.799 0.755   
           




















ns * ns ns ns ns * ns ns ns ns 
           





Sample Vehicle AZD8055 Ibrutinib COMBO Vehicle AZD8055 Ibrutinib COMBO   
CLL151 1 1.604 1.483 1.599 0.744 1 1.353 1.429   




CLL157 1 1.889 2.83 2.83 0.521 0.961 1.769 1.979   
CLL90 1 1.14 1.27 1.282 0.988 1.091 1.221 1.303   
CLL80 1 1.078 1.026 1.184 0.936 1.047 1.034 1.005   
CLL113 1 1.168 1.415 1.415 0.99 1.118 1.257 1.247   
CLL119 1 1.258 1.4 1.445 1.008 1.275 1.42 1.45   
           




















ns ns ns ns ns ns ns ns ns ns ns 
Table 3.5 - Cell viability analysis: 48 h treatment (primary CLL cells) 
Cell viability (Annexin V/7-AAD staining) of primary CLL samples (n=7) following long-term (48 h) 
treatment with AZD8055, ibrutinib or COMBO with or without F(ab’)2 stimulation (as described in 
Figure 3.15). Values indicate the proportion/percentage of viable (top) and apoptotic (bottom) CLL 
cells (relative to vehicle control). Statistical analysis was performed using a one-way ANOVA with 
Tukey’s multiple comparisons test. p > 0.05 ‘ns’ = not significant; p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.001 







4 Results II 
4.1 Introduction 
Widely considered ‘bona fide’ tumour suppressors, FOXO transcription factors 
regulate transcription of an array of genes involved in cell cycle arrest, 
apoptosis, metabolism and stress resistance (348). Subcellular localisation 
largely dictates FOXO transcriptional activity, which is influenced by multiple 
posttranslational modifications (345). Perhaps most prominently, AKT-dependent 
phosphorylation (T24, S256 and S319 in FOXO1) (344) promotes sequestration of 
FOXOs in the cytoplasm (277), which ultimately prevents transcription of FOXO 
target genes (365).  
Although FOXOs has been extensively studied in normal and malignant B cells 
(384), little is known about the regulation of FOXO activity and subcellular 
localisation in CLL. Earlier, we demonstrated that BCR crosslinking elicited AKT-
dependent FOXO1T24 phosphorylation in CLL cells, suggesting that FOXO1 
inactivation is a functionally relevant consequence of CLL-BCR signalling. In 
‘activated’ mature B cells, AKT-dependent FOXO1 nuclear export was essential 
for cell cycle progression and survival (390). Assuming CLL cells conform to the 
paradigm observed in normal B cells, re-activation of FOXOs might represent a 
promising anti-proliferative and apoptotic treatment strategy, as demonstrated 
in vitro in DLBCL (397) and classical Hodgkin lymphoma (cHL) (396). 
Encouragingly, we previously demonstrated that BCR crosslinking-induced 
FOXO1T24 phosphorylation was largely inhibited by AZD8055 and ibrutinib 
treatment as monotherapies or in combination, suggesting that FOXO1 might be 
an effector of BCR signalling inhibition.  
In this chapter, we address FOXO1 subcellular localisation and DNA-binding 
activity following in vitro BCR ligation in CLL cells. We further explore whether 
AKT (AZD5363), mTOR kinase (AZD8055) and BTK (ibrutinib) inhibition has the 
ability to re-engage FOXO1 activity, potentially mediating the functional 





I. Determine the expression and activity of FOXO family members in ex vivo 
primary CLL samples and healthy donor B cells. 
II. Address the effect of BCR ligation on FOXO1 activity and subcellular 
localisation in CLL cells. 
III. Investigate whether AKT, mTOR kinase and BTK inhibition impacts BCR 
crosslinking-induced FOXO1 activity and subcellular localisation. 
IV. Visualise FOXO1 expression and distribution in CLL patient LN biopsies and 






4.2.1 FOXO1 is the most highly expressed FOXO family member 
in ex vivo CLL cells 
We first addressed the expression levels of each FOXO family member in PB-
derived CLL cells (CLL) and B cells from healthy donors (Healthy CD19+). The 
transcript abundance of FOXO1, FOXO3 and FOXO4 was measured by RT-qPCR, 
from which relative expression levels were calculated using the ΔCT method 
(Figure 4.1a). These data showed that FOXO1 was the most highly expressed 
 
Figure 4.1 - FOXO1 is the most highly expressed FOXO family member in CLL cells. 
(a) RT-qPCR to assess expression of FOXO1, FOXO3 and FOXO4 in healthy donor B cells 
(Healthy CD19+; grey bars; n = 6) and CLL patient samples (CLL; FOXO1 = yellow bars; FOXO3 = 
turquoise bars; FOXO4 = blue bars; n = 23). The ΔCT method was used to calculate expression 
levels, where samples were normalised to the internal reference gene GUSB. (b, c, d) RT-qPCR to 
assess expression of (b) FOXO1 (yellow bars), (c) FOXO3 (turquoise bars) and (d) FOXO4 (blue 




del(11q) (n = 7) or del(17p) (n = 4). The ΔCT method was used to calculate expression levels, 
where samples were normalised to the internal reference gene GUSB. Individual datapoints are 
represented by white circles. Data expressed as the mean ± SEM. Statistics calculated by one-way 
ANOVA, where *** p ≤ 0.001, **** p ≤ 0.0001. 
 
FOXO family member among CLL patient samples and, perhaps expectedly, B 
cells from healthy donors (Figure 4.1a). Although mRNA expression levels of 
FOXO1, FOXO3 and FOXO4 did not significantly differ between CLL cells and 
healthy donor B cells, FOXO3 expression was visibly reduced in CLL cells (Figure 
4.1a). Within this CLL patient cohort, stratification of FOXO1 (Figure 4.1b), 
FOXO3 (Figure 4.1c) and FOXO4 (Figure 4.1d) expression based upon distinct 
cytogenetic alternations showed no significant difference. However, a modest 
but demonstrable trend towards decreased levels of FOXO3 was observed in poor 
prognostic CLL patients with del(17p), compared to patients with undetected 
abnormalities in del(11q) or del(17p) (‘no del(11q)/del(17p)) (p = 0.15; Figure 
4.1c).  
Through the assessment of basal mTOR activity, we observed varying levels of 
AKTS473 phosphorylation among CLL patient samples (Figure 3.1). Since AKT 
negatively regulates FOXO1 transcriptional activity via phosphorylation at 
conserved RxRxxS/T residues (FOXO1T24, FOXO1S256 and FOXO1S319) (384), we 
assessed FOXO1 activity in ex vivo primary CLL cells compared with B cells from 
healthy donors (Figure 4.2). These data revealed that basal FOXO1T24 
phosphorylation levels were heterogenous among CLL patient samples; some 
patients exhibited high levels of FOXO1T24 phosphorylation, while others 
demonstrated virtually undetectable levels (Figure 4.2a,b). Analysis of FOXO1 
expression levels in CLL patient samples mirrored these findings; FOXO1 was 
elevated in some patients, while largely absent in others (Figure 4.2a,c). 
Subsequent stratification of FOXO1T24 phosphorylation (Figure 4.2d) and FOXO1 
expression levels (Figure 4.2e) according to cytogenetic factors showed no 
significant difference between favourable (no del(11q)/del(17p)) or poor 
prognostic (del(11q) or del(17p)) CLL patients. Nevertheless, relative FOXO1T24 
phosphorylation levels were noticeably higher in CLL patient samples compared 
to healthy donor B cells, albeit not significantly (Figure 4.2b). Conversely, 
FOXO1 expression was significantly reduced in CLL patient samples compared to 





Figure 4.2 - FOXO1 expression is reduced in PB-derived primary CLL cells compared to 
healthy donor B cells.  
(a) Western blot of healthy donor B cells (Healthy CD19+; n=3) and CLL patients (n=11), 
subdivided into cytogenetic alterations ‘No del(11q) / del(17p)’ (n=5), del(11q) (n=3) and del(17p) 
(n=3). Blots were probed for FOXO1T24, FOXO1 and GAPDH (loading control; #1 and #2 referring 
to mirror blots). (b) Relative phosphorylation levels FOXO1T24 and (c) relative expression levels of 
FOXO1 in Healthy CD19+ (n=6; purple bar) and CLL samples (CLL; n = 31; peach bar). (d) Relative 
FOXO1T24 phosphorylation and (c) FOXO1 expression levels in CLL patients stratified according to 
cytogenetics ‘No del(11q) / del(17p)’ (dark orange bars; n=12), del(11q) (light orange bar; n=9) and 
del(17p) (yellow bar; n=6). Individual patient datapoints are represented by white circles. Data 
expressed as the mean ± SEM. Statistics calculated by unpaired Student’s t-test for two groups 




4.2.2 F(ab’)2 stimulation transiently enhances AKT-dependent 
FOXO1T24 phosphorylation in CLL cells 
We earlier demonstrated that BCR crosslinking transduced signals to FOXO1 via 
activation of AKT in CLL cells (Figure 3.21). However, F(ab’)2-induced AKTT308 
and AKTS473 phosphorylation was only transient (Figure 3.7). We therefore asked 
whether AKT-dependent FOXO1T24 phosphorylation (and subsequent inactivation) 
is only short-lived following F(ab’)2 stimulation. To answer this question, CLL 
cells (Figure 4.3a) and MEC-1 cells (Figure 4.3b) underwent F(ab’)2 stimulation 
for the indicated time points. Thereafter, FOXO1T24 phosphorylation status and 
FOXO1 expression levels were examined (Figure 4.3a,b). Consistent with Figure 
3.7, F(ab’)2 stimulation conferred a transient increase in AKT-dependent 
FOXO1T24 phosphorylation in CLL cells, whereas MEC-1 cells were unaffected 
(Figure 4.3a,b). Interestingly, F(ab’)2 stimulation also resulted in a transient 
increase in FOXO1 expression in CLL cells, followed by a brief downregulation 
before returning to basal levels within 24 h (Figure 4.3a). Notably, modulation of 
FOXO1 expression levels following F(ab’)2 stimulation appeared to be restricted 
to primary cells (Figure 4.3a,b). To build upon the observations in Figure 3.21, 
we analysed AKT-dependent FOXO1T24 phosphorylation following BCR crosslinking 
in CLL cells (Figure 4.3c). As expected, short-term F(ab’)2 stimulation elevated 
FOXO1T24 phosphorylation in CLL cells, which corresponded to increased AKTT308 
and AKTS473 phosphorylation levels (Figure 4.3c,d). Consistent with earlier 
observations (Figure 4.3a), FOXO1 expression was significantly enhanced in CLL 
cells following short-term F(ab’)2 stimulation (Figure 4.3c,e). Because the 
intensity of FOXO1 expression varied among F(ab’)2-stimulated CLL patient 
samples, we wondered whether this heterogeneity corresponded to CLL patient 
prognosis (Figure 4.3f). Stratification of FOXO1 expression levels in F(ab’)2 
stimulated CLL samples (relative to unstimulated) according to favourable (no 
del(11q)/del(17p)) or poor ((del(11q) or del(17p)) prognostic factors revealed no 





Figure 4.3 - Short-term F(ab’)2 stimulation increases FOXO1 expression and relative 
phosphorylation levels in primary CLL cells. 
(a, b) Representative western blots of (a) primary CLL cells (#CLL80; n=3 primary CLL samples) 
and (b) MEC-1 cells (n=3) unstimulated (US) or F(ab’)2 stimulated for the indicated timepoints (0, 
0.5, 1, 3, 5 and 24 h). Blots were probed for FOXO1T24, FOXO1 and GAPDH (loading control; #1 
and #2 referring to mirror blots). (c) Western blot of primary CLL samples (n=5; CLL# patient 




FOXO1T24, FOXO1, AKTT308, AKTS473, AKT and GAPDH (loading control; #1 and #2 referring to 
mirror blots). (d) Relative FOXO1T24 phosphorylation and (e) FOXO1 expression levels in 
unstimulated (unstim.; white circles) and F(ab’)2 stimulated (F(ab’)2; black circles) CLL samples 
(n=7). For each CLL sample, relative phosphorylation/expression levels for unstim. and F(ab’)2 are 
connected by a grey line. (f) Relative FOXO1 expression levels in ‘favourable-’ (n=5; blue bars) and 
‘poor-prognostic’ (n=6; orange bars) CLL patient samples following F(ab’)2 stimulation for 1 h. 
FOXO1 expression is normalised to GAPDH and relative to unstimulated. Individual datapoints are 
represented by white circles. Data expressed as the mean ± SEM. Statistics calculated by paired 
and unpaired Student’s t-test, where ** p ≤ 0.01. 
 
4.2.3 Short-term F(ab’)2 stimulation promotes FOXO1 nuclear 
export and subsequent decrease in FOXO1 activity 
AKT phosphorylates nuclear FOXO1 to induce its association with 14-3-3 proteins, 
which ultimately shuttles FOXO1 out of the nucleus (350, 352, 361). Because 
short-term F(ab’)2 stimulation promotes AKT-dependent FOXO1T24 
phosphorylation in CLL cells, we assessed localisation of FOXO1 following BCR 
crosslinking by IF (Figure 4.4a,b) and subcellular fractionation (Figure 4.4d-f). 
Both methods showed that FOXO1 was localised within the nucleus and 
cytoplasm of unstimulated CLL cells (Figure 4.4a,d). As expected, a greater 
proportion of FOXO1 was localised in the nuclear fraction compared to the 
cytoplasmic fraction in unstimulated CLL cells (Figure 4.4d). F(ab’)2 stimulation 
resulted in a large proportion of FOXO1 shuttling from the nucleus to the 
cytoplasm (Figure 4.4a), which was quantified by assessing the degree of co-
localisation between FOXO1 and the nucleus (DAPI channel) using the Manders’ 
colocalisation coefficient (Figure 4.4b). This was confirmed by subcellular 
fractionation (Figure 4.4d), which showed that FOXO1 expression significantly 
increased in the cytoplasmic fraction (Figure 4.4e) and concurrently decreased 
in the nuclear fraction (Figure 4.4f) following F(ab’)2 stimulation. These data 
demonstrated that short-term BCR crosslinking favoured cytoplasmic 
accumulation of FOXO1 in CLL cells (Figure 4.4c). Finally, we asked whether 
F(ab’)2-dependent FOXO1 nuclear export resulted in decreased FOXO1 
transcriptional activity. Using the TransAM transcription factor activation assay 
we showed that FOXO1 DNA binding activity was significantly reduced in F(ab’)2 





Figure 4.4 - Short-term F(ab’)2 stimulation promotes FOXO1 cytoplasmic translocation and 
reduces DNA-binding activity in primary CLL cells. 
(a) IF micrographs (100x) of unstimulated (left panel) and F(ab’)2 stimulated (+ F(ab’)2; right panel) 
CLL patient samples (n=3; CLL# patient pseudonym) probed for FOXO1 (green) and counter 
stained with DAPI (DNA; blue). Scale bar = 5 µm. (b) Analyses of FOXO1 and DAPI co-localisation 




samples (n=5) using the Manders’ (Costes) Co-localisation Coefficient (CellProfiler). >360 cells 
were quantified/condition from each sample. (c) Schematic depicting FOXO1 cytoplasmic 
translocation following F(ab’)2-mediated BCR ligation. (d) Subcellular fractionation of an 
unstimulated (-) and F(ab’)2 stimulated (+) CLL sample (#CLL113). Cytoplasmic, nuclear and whole 
cell lysate (WCL) fractions were generated. Blots were probed for FOXO1, Lamin A/C and β-
Tubulin. β-Tubulin and Lamin A/C represent markers for cytoplasmic and nuclear fractions, 
respectively. Densitometry for cytoplasmic (FOXO1/β-Tubulin) and nuclear (FOXO1/Lamin A/C) 
FOXO1 expression are shown (relative to unstimulated). (e, f) Densitometry of FOXO1 expression 
in (e) cytoplasmic and (f) nuclear fractions from unstimulated (unstim.; grey bar) and F(ab’)2 
stimulated (F(ab’)2; green bar) CLL samples (n=8), as calculated in (d). (g) FOXO1 DNA-binding 
activity (OD450) of unstimulated (unstim.; yellow bar) and F(ab’)2 stimulated (F(ab’)2; blue bar) CLL 
patient samples (n=11), as determined by the TransAM FOXO1 activity assay (ActiveMotif). 
Individual datapoints are represented by white circles. Data expressed as the mean ± SEM. 
Statistics calculated by paired Student’s t-test, where * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001. 
 
4.2.4 AKT inhibition blocks F(ab’)2-induced FOXO1 cytoplasmic 
translocation 
After demonstrating that FOXO1 activity was diminished via BCR-induced FOXO1 
nuclear export (Figure 4.4), we argued that FOXO1 may have a tumour 
suppressor role in the context of BCR activation in CLL cells. Therefore, 
pharmacological inhibition of BCR ligation-induced FOXO1 inactivation may 
favour nuclear retention and/or re-engage FOXO1 activity, as shown previously 
(277, 376, 377, 498). Because AKT plays a prominent role in the regulation of 
FOXO1 activity (277, 387) (Figure 4.5a), we examined FOXO1 phosphorylation 
(Figure 4.5b), localisation (Figure 4.5c-g) and DNA binding activity (Figure 4.5h) 
in unstimulated and F(ab’)2 stimulated CLL cells following short-term treatment 
with the AKT inhibitor AZD5363 (499). The ability of AZD5363 to inhibit AKT-
dependent FOXO1 phosphorylation was assessed in CLL cells with or without BCR 
crosslinking by Western blotting (Figure 4.5b). AZD5363 treatment effectively 
inhibited F(ab’)2-induced FOXO1T24 and FOXO1S256 phosphorylation in a dose-
dependent manner, whereas AKTT308 and AKTS473 phosphorylation was 
progressively enhanced in unstimulated and F(ab’)2 stimulated CLL cells (Figure 
4.5b). Because AZD5363 inhibited BCR ligation-induced FOXO1 phosphorylation, 
we next addressed the ability of AZD5363 to block F(ab’)2-induced FOXO1 
cytoplasmic translocation by IF and subcellular fractionation (Figure 4.5c-g). 
Although F(ab’)2 stimulation visibly promoted FOXO1 nuclear exclusion by IF 
(Figure 4.5c), subsequent analysis via the Manders’ colocalisation coefficient did 
not support this observation (Figure 4.5d). Nevertheless, subcellular 
fractionation confirmed that short-term F(ab’)2 stimulation facilitated FOXO1 
cytoplasmic translocation (Figure 4.6b). Consistent with Figure 4.4d-f, 





Figure 4.5 - The AKT inhibitor AZD5363 inhibits BCR ligation-induced FOXO1T24/ FOXO1S256 
phosphorylation and prevents F(ab’)2-mediated FOXO1 nuclear export. 
(a) Schematic depicting AKT-dependent regulation of FOXO1 activity. Active AKT (blue) inactivates 




western blot a primary CLL sample (#CLL80; n=3 CLL samples) unstimulated or F(ab’)2 stimulated 
(+F(ab’)2) for 1 h following 30 min pre-treatment with increasing concentrations of AZD5363 
(Vehicle, 10, 100, 1000, 10000 nM). Blots were probed for FOXO1T24, FOXO1S256, FOXO1, 
AKTS473, AKTT308, AKT and GAPDH (loading control; #1 and #2 referring to mirror blots). (c) 
Representative IF micrographs (100x) of a CLL patient sample (#CLL80; n=5 CLL samples) 
unstimulated (top panel) or F(ab’)2 stimulated (+ F(ab’)2; bottom panel) for 1 h following 30 min pre-
treatment with AZD5363 (1 µM). Cells were probed for FOXO1 (green) and counter stained with 
DAPI (DNA; blue). Scale bar = 5 µm. (d) Analyses of FOXO1 and DAPI co-localisation 
(Manders’ (Costes) Co-localisation Coefficient) in unstimulated (unstim.; grey bars) and F(ab’)2 
stimulated (+ F(ab’)2; red bars) CLL patient samples (n=5) treated with AZD5363 (+) or vehicle 
control (-). >360 cells were quantified/condition from each sample. (e) Subcellular fractionation of a 
CLL patient sample (#CLL151; n=4 CLL samples) unstimulated (unstim.) or F(ab’)2 stimulated (+ 
F(ab’)2) for 1 h following 30 min pre-treatment with 1 µM AZD5363 (+) or vehicle control (-). 
Cytoplasmic, nuclear and whole cell lysate (WCL) fractions were generated. Blots were probed for 
FOXO1, Lamin A/C and β-Tubulin. Densitometry for cytoplasmic (FOXO1/β-Tubulin) and nuclear 
(FOXO1/Lamin A/C) FOXO1 expression are shown (relative to unstimulated vehicle control). (f, g) 
Densitometry of FOXO1 expression in (f) cytoplasmic and (g) nuclear fractions from unstimulated 
(unstim.; grey bar) and F(ab’)2 stimulated (F(ab’)2; purple bar) CLL samples (n=4) treated with 
AZD5363 (+) or vehicle control (-), as calculated in (e). (h) FOXO1 DNA-binding activity (OD450) of 
CLL patient samples (n=4) unstimulated (unstim.; grey bar) and F(ab’)2 stimulated (+ F(ab’)2; green 
bar) with (+) or without (-) AZD5363 treatment. Individual datapoints are represented by white or 
black circles. Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where 
* p ≤ 0.05. 
 
(Figure 4.5e,f), while nuclear FOXO1 expression was concomitantly decreased in 
F(ab’)2 stimulated CLL cells (Figure 4.5e,g). AZD5363 treatment enhanced 
retention of nuclear FOXO1 in F(ab’)2 stimulated CLL cells (Figure 4.5c), which 
was supported by the Manders’ colocalisation coefficient (Figure 4.5d). In line 
with these findings, subcellular fractionation demonstrated that F(ab’)2-induced 
FOXO1 cytoplasmic translocation was inhibited by AZD5363 treatment (Figure 
4.5e-g). AZD5363 treatment significantly reduced cytoplasmic FOXO1 expression 
in F(ab’)2 stimulated CLL cells (Figure 4.5a,b), which corresponded to a 
significant increase in nuclear FOXO1 expression compared to F(ab’)2 stimulated 
vehicle control (Figure 4.5a,c). Since AZD5363 inhibited F(ab’)2-induced FOXO1 
cytoplasmic translocation, it was of interest to determine whether FOXO1 
nuclear retention conferred an increase in FOXO1 DNA binding activity (Figure 
4.5h). Consistent with Figure 4.4g, FOXO1 DNA-binding activity was reduced in 
response to F(ab’)2 stimulation (p = 0.09; Figure 4.5h). Furthermore, AZD5363 
preincubation produced a notable trend, albeit modest, towards enhanced 
FOXO1 transcriptional activity in F(ab’)2 stimulated CLL cells (Figure 4.5h).  
4.2.5 AZD8055 inhibits BCR crosslinking-induced FOXO1 nuclear 
export 
Earlier experiments demonstrated that BCR-induced AKTS473 and FOXO1T24 




demonstrating that mTOR kinase activity regulates AKT-dependent FOXO1T24 
phosphorylation (Figure 3.21). To further examine the ability of AZD8055 to 
prevent AKT-mediated FOXO1 inactivation, the phosphorylation status of 
FOXO1T24, AKTT308 and AKTS473 was assessed following treatment with increasing 
concentrations of AZD8055 with or without BCR crosslinking (Figure 4.6a). 
AZD8055 treatment resulted in a dose-dependent inhibition of AKT kinase 
activity (AKTT308 and AKTS473 phosphorylation) and AKT-dependent FOXO1T24 
phosphorylation in F(ab’)2 stimulated CLL cells (Figure 4.6a). Importantly, 
inhibition of FOXO1T24 phosphorylation was achieved at clinically achievable 
concentrations (Figure 4.6a). Interestingly, while AKT expression levels were 
largely unaffected by AZD8055, FOXO1 expression was progressively reduced in 
response to increasing concentrations of AZD8055 (Figure 4.6a). Because 
AZD8055 inhibited AKT-dependent FOXO1T24 phosphorylation, we next assessed 
FOXO1 localisation in unstimulated and F(ab’)2 stimulated CLL cells with or 
without AZD8055 by IF (Figure 4.6b,c) and subcellular fractionation (4.7a-c). 
Consistent with Figure 4.4, IF analysis demonstrated that short-term F(ab’)2 
stimulation promoted FOXO1 cytoplasmic translocation (Figure 4.6b), 
represented by a near-significant decrease in Manders’ co-localisation 
coefficient compared to unstimulated vehicle control (p = 0.056; Figure 4.6c). 
Encouragingly, AZD8055 treatment inhibited BCR crosslinking-induced FOXO1 
nuclear export in F(ab’)2 stimulated CLL cells (Figure 4.6b,c), resulting in a 
significant increase in Manders’ co-localisation coefficient compared to F(ab’)2 
stimulated vehicle control (Figure 4.6c). Finally, AZD8055 treatment visibly 





Figure 4.6 - AZD8055 inhibits BCR crosslinking-induced FOXO1 cytoplasmic translocation 
in primary CLL cells (1/2). 
(a) Representative western blot a primary CLL sample (#CLL80; n=3 CLL samples) unstimulated or 
F(ab’)2 stimulated (+F(ab’)2) for 1 h following 30 min pre-treatment with increasing concentrations 




AKTS473, AKTT308, AKT and GAPDH (loading control; #1 and #2 referring to mirror blots). (b) 
Representative IF micrographs (100x) of a CLL patient sample (#CLL80; n=5 CLL samples) 
unstimulated or F(ab’)2 stimulated (+ F(ab’)2) for 1 h following 30 min pre-treatment with AZD8055 
(100 nM) or vehicle control. Cells were probed for FOXO1 (green) and counter stained with DAPI 
(DNA; blue). Individual channel and merged images shown. Scaled image (far-right panel) of 
representative cell (white border; merged channel). Scale bar = 5 µm. (c) Analyses of FOXO1 and 
DAPI co-localisation (Manders’ (Costes) Co-localisation Coefficient) in CLL patient samples (n=5) 
unstimulated (unstim.; grey bars) and F(ab’)2 stimulated (+ F(ab’)2; blue bars) for 1 h following 30 
min pre-treatment with AZD8055 (+) or vehicle control (-). >360 cells were quantified/condition from 
each sample. Individual datapoints are represented by white or black circles. Data expressed as 
the mean ± SEM. Statistics calculated by one-way ANOVA, where ** p ≤ 0.01. 
 
Subcellular fractionation confirmed that F(ab’)2-induced FOXO1 cytoplasmic 
translocation was blocked by AZD8055 treatment (Figure 4.7a-c). Consistent with 
Figure 4.4d, cytoplasmic FOXO1 expression was enhanced following BCR 
crosslinking (Figure 4.7a,b), while nuclear FOXO1 expression was concurrently 
decreased in F(ab’)2 stimulated CLL cells (Figure 4.7a). AZD8055 treatment 
reduced cytoplasmic FOXO1 expression in unstimulated CLL cells (p = 0.07; 
Figure 4.7a,b), which corresponded to a concomitant increase in nuclear FOXO1 
expression (Figure 4.7a,c). Moreover, F(ab’)2-induced cytoplasmic FOXO1 
expression was reduced by AZD8055 (Figure 4.7a,b), which was paralleled by a 
concurrent increase in nuclear FOXO1 expression (p = 0.08; Figure 4.7a,c). As 
mentioned earlier, AKT-dependent FOXO1T24 phosphorylation induces its nuclear 
export via association with 14-3-3 proteins (398). We therefore examined the 
localisation of AKT and 14-3-3 following BCR crosslinking with or without 
AZD8055 treatment by subcellular fractionation (Figure 4.7a). These data 
showed that AKT and 14-3-3 remained largely cytoplasmic irrespective of F(ab’)2 
stimulation and/or treatment (Figure 4.7a). Previous experiments detected AKT 
kinase activity (Figure 3.3f,g and 3.7b) and AKT-dependent FOXO1T24 (Figure 
4.3b) phosphorylation in MEC-1 cells. We were therefore curious to assess FOXO1 
localisation in MEC-1 cells following BCR crosslinking with or without AZD8055 
treatment (Figure 4.7d,e). Interestingly, abundant nuclear and cytoplasmic 
FOXO1 expression was observed in unstimulated MEC-1 cells (Figure 4.7d). 
Furthermore, short-term F(ab’)2 stimulation induced FOXO1 cytoplasmic 
translocation, demonstrated by a visible reduction in Manders’ co-localisation 
coefficient (Figure 4.7e). Consistent with earlier findings (Figure 4.6b,c), 
AZD8055 treatment enhanced FOXO1 nuclear accumulation in unstimulated and 
F(ab’)2 stimulated MEC-1 cells, as shown by a significant increase in Manders’ co-





Figure 4.7 - AZD8055 inhibits BCR crosslinking-induced FOXO1 cytoplasmic translocation 
in primary CLL cells and MEC-1 cells (2/2). 
(a) Subcellular fractionation of a CLL patient sample (#CLL151; n=4 CLL samples) unstimulated 
(unstim.) or F(ab’)2 stimulated (+ F(ab’)2) for 1 h following 30 min pre-treatment with 100 nM 
AZD8055 (+) or vehicle control (-). Cytoplasmic, nuclear and whole cell lysate (WCL) fractions were 
generated. Blots were probed for FOXO1, AKT, 14-3-3 (pan), Lamin A/C and β-Tubulin. 
Densitometry for cytoplasmic (FOXO1/β-Tubulin) and nuclear (FOXO1/Lamin A/C) FOXO1 
expression are shown (relative to unstimulated vehicle control). (b, c) Densitometry of FOXO1 
expression in (b) cytoplasmic and (c) nuclear fractions from unstimulated (unstim.; grey bar) and 
F(ab’)2 stimulated (F(ab’)2; purple bar) CLL samples (n=4) treated with AZD8055 (+) or vehicle 




unstimulated (top panel) or F(ab’)2 stimulated (+ F(ab’)2; bottom panel) for 1 h following 30 min pre-
treatment with AZD8055 (100 nM). Cells were probed for FOXO1 (green) and counter stained with 
DAPI (DNA; blue). Scale bar = 5 µm. (e) Analyses of FOXO1 and DAPI co-localisation 
(Manders’ (Costes) Co-localisation Coefficient) in unstimulated (unstim.; grey bars) and F(ab’)2 
stimulated (+ F(ab’)2; blue bars) MEC-1 cells (n=5 IF images/condition) treated with AZD8055 (+) or 
vehicle control (-). Individual datapoints are represented by white circles. Data expressed as the 
mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, *** p ≤ 0.001. 
 
4.2.6 Rapamycin is unable to inhibit AKT-mediated FOXO1T24 
phosphorylation and subsequent nuclear export  
We earlier showed that AZD8055 (Figure 3.21 and 4.6a) or ibrutinib (Figure 3.21) 
treatment inhibited F(ab’)2 stimulation-induced AKTS473 and FOXO1T24 
phosphorylation in CLL cells. These findings demonstrated the ability of these 
agents to inhibit ‘full’ mTORC2-dependent AKT activation, which is ordinarily 
required for FOXO inactivation (500). In contrast, mTORC1-selective rapamycin 
was unable to inhibit AKTS473 phosphorylation following BCR ligation (Figure 3.5). 
We therefore examined the effect of short-term rapamycin treatment on 
FOXO1T24 phosphorylation, alongside AZD8055 and ibrutinib, in unstimulated and 
F(ab’)2 stimulated CLL cells (Figure 4.8). Consistent with previous experiments, 
AZD8055 and ibrutinib successfully inhibited AKTS473 phosphorylation in F(ab’)2 
stimulated CLL cells, whereas rapamycin was unable to block F(ab’)2-induced 
AKTS473 phosphorylation (Figure 4.8a). In support of Figure 3.21, AZD8055 
treatment inhibited AKT-dependent FOXO1T24 phosphorylation in unstimulated 
CLL cells to a greater extent than rapamycin (p = 0.07; Figure 4.8a,b). 
Reproducibly, AZD8055 and ibrutinib (p = 0.09) treatment blocked BCR ligation-
induced FOXO1T24 phosphorylation (Figure 4.8a,b). Perhaps expectedly, 
rapamycin was unable to inhibit AKT-dependent FOXO1T24 phosphorylation in 
F(ab’)2 stimulated CLL cells (Figure 4.8a,b). Consistent with Figure 4.3e, short-
term BCR ligation resulted in a near-significant increase in FOXO1 expression (p 
= 0.059; Figure 4.8a,c). Interestingly, while AZD8055 and ibrutinib visibly 
reduced FOXO1 expression in unstimulated and F(ab’)2 stimulated CLL cells 
(Figure 4.8a,c), FOXO1 expression was largely unaffected by rapamycin 





Figure 4.8 - Rapamycin does inhibit BCR ligation-induced AKT-mediated FOXO1T24 
phosphorylation in primary CLL cells. 
(a) Representative western blot of a primary CLL sample (#CLL149) unstimulated or F(ab’)2 
stimulated for 1 h following 30 min pre-treatment with AZD8055 (100 nM), Rapamycin (10 nM), 
Ibrutinib (1 µM) or vehicle control. Blots were probed for FOXO1T24, FOXO1, AKTS473, AKT and 
GAPDH (loading control; #1 and #2 referring to mirror blots). (b) Relative FOXO1T24 
phosphorylation and (c) FOXO1 expression levels in primary CLL samples (n=4), treated as 
described in (a). Unstimulated (teal bars) and F(ab’)2 stimulated (dark blue bars). Individual patient 
datapoints are represented by white circles. Data expressed as the mean ± SEM. Statistics 
calculated by one-way ANOVA, where * p ≤ 0.05. 
 
We next assessed FOXO1 localisation in unstimulated and F(ab’)2 stimulated CLL 
cells following AZD8055 or rapamycin treatment by IF (Figure 4.9a) and 
subcellular fractionation (Figure 4.9b-d). IF showed that rapamycin was unable 
to inhibit FOXO1 cytoplasmic translocation in F(ab’)2 stimulated CLL cells (Figure 





Figure 4.9 - Rapamycin does not prevent F(ab’)2-induced FOXO1 cytoplasmic translocation 
in primary CLL cells. 
(a) Representative IF micrographs (40x) of a CLL patient sample (#CLL142; n=5 CLL samples) 




treatment with AZD8055 (100 nM) or rapamycin (10 nM). Cells were probed for FOXO1 (green) 
and counter stained with DAPI (DNA; blue). Scale bar = 5 µm. (b) Subcellular fractionation of a CLL 
patient sample (#CLL113; n=3 CLL samples) unstimulated (unstim.) or F(ab’)2 stimulated (+ 
F(ab’)2), treated as in (a). Cytoplasmic, nuclear and whole cell lysate (WCL) fractions were 
generated. Blots were probed for FOXO1, Lamin A/C and β-Tubulin. Densitometry for cytoplasmic 
(FOXO1/β-Tubulin) and nuclear (FOXO1/Lamin A/C) FOXO1 expression are shown (relative to 
unstimulated vehicle control). (c, d) Densitometry of FOXO1 expression in (c) cytoplasmic and (d) 
nuclear fractions from unstimulated (unstim.; peach bars) and F(ab’)2 stimulated (F(ab’)2; blue bars) 
CLL samples (n=3), treated as in (a). (e) FOXO1 DNA-binding activity (OD450) of unstimulated 
(unstim.; grey bar) or F(ab’)2 stimulated (+ F(ab’)2; green bar) CLL patient samples (n=3), treated 
as in (a). Individual datapoints are represented by white or black circles. Data expressed as the 
mean ± SEM. Statistics calculated by one-way ANOVA. 
 
FOXO1 nuclear exclusion (Figure 4.9a). In line with these findings, subcellular 
fractionation confirmed that F(ab’)2-induced FOXO1 nuclear-to-cytoplasmic 
translocation was unaffected by rapamycin treatment (Figure 4.9b-d). In 
contrast, F(ab’)2-induced cytoplasmic FOXO1 expression was reduced by 
AZD8055 treatment (p = 0.06; Figure 4.9b,c), which corresponded to a 
concomitant increase in nuclear FOXO1 expression (Figure 4.9b,d). To examine 
FOXO1 transcriptional activity in unstimulated and F(ab’)2 stimulated CLL cells 
following AZD8055 or rapamycin treatment, we determined the DNA binding 
activity of FOXO1. This experiment revealed that AZD8055 blocked F(ab’)2-
induced FOXO1 inactivation to near-basal (unstimulated) levels (Figure 4.9d). 
Conversely, rapamycin was largely unable to prevent F(ab’)2-induced FOXO1 
inactivation (Figure 4.9d). Of note, FOXO1 DNA-binding activity was unaffected 
by treatment in unstimulated CLL cells (Figure 4.9d).  
4.2.7 AZD8055-induced inhibition of FOXO1T24 phosphorylation is 
sustained in CLL cells 
We previously demonstrated that AZD8055 treatment sustained inhibition of AKT 
kinase activity in F(ab’)2 stimulated CLL cells for up to 24 hours (Figure 3.7a). 
We therefore asked whether inhibition of AKT-dependent FOXO1T24 
phosphorylation was also endured. To answer this question, CLL cells underwent 
F(ab’)2 stimulation for the indicated time points in the presence of AZD8055. 
Thereafter, the phosphorylation status of FOXO1T24, AKTT308 and AKTS473 was 
examined (Figure 4.10a,b). As expected, FOXO1T24 phosphorylation was 
influenced by the extent and duration of F(ab’)2-induced AKTS473 and AKTT308 
phosphorylation (Figure 4.10a,b). Interestingly, F(ab’)2-induced modulation of 
FOXO1 expression appeared to correspond to the degree of AKT kinase activity 




crosslinking-induced AKTS473 and AKTT308 phosphorylation for at least 24 h (Figure 
4.10a,b). Encouragingly, AZD8055-induced inhibition of FOXO1T24 
phosphorylation was also sustained for the duration of the timecourse compared 
to F(ab’)2-stimulated vehicle control (Figure 4.10a,b).  
 
Figure 4.10 - AZD8055-induced inhibition of FOXO1T24 phosphorylation is sustained in CLL 
cells. 
(a, b) Representative western blots of primary CLL samples (a) #CLL113 and (b) #CLL170 (n=3 
primary CLL samples) stimulated with F(ab’)2 for the indicated timepoints (0, 0.5, 1, 3, 5 and 24 h) 
following 30 min pre-treatment with 100 nM AZD8055 (+) or vehicle control (-). Blots were probed 
for FOXO1T24, FOXO1, AKTT308, AKTS473, AKT and GAPDH (loading control; #1 and #2 referring to 




4.2.8 Ibrutinib inhibits F(ab’)2-induced FOXO1 nuclear exclusion 
Earlier experiments showed that F(ab’)2-induced AKTS473 and FOXO1T24 
phosphorylation was inhibited by treatment with ibrutinib (Figure 3.21). 
Furthermore, ibrutinib also reduced FOXO1T24 phosphorylation in unstimulated 
CLL cells (Figure 3.21), perhaps demonstrating that ‘cell autonomous’ (ligand-
independent) BCR signalling induces AKT-dependent FOXO1 phosphorylation 
(397). To further examine the ability of ibrutinib to prevent AKT-mediated 
FOXO1 inactivation, the phosphorylation status of FOXO1T24, AKTT308 and AKTS473 
was assessed following treatment with increasing concentrations of ibrutinib 
with or without F(ab’)2 stimulation (Figure 4.11a). Ibrutinib treatment resulted 
in a dose-dependent inhibition of AKT kinase activity and AKT-dependent 
FOXO1T24 phosphorylation in F(ab’)2 stimulated CLL cells at clinically achievable 
levels (Figure 4.10a). Interestingly, as demonstrated with AZD8055 (Figure 4.6a), 
FOXO1 expression was progressively reduced in response to increasing 
concentrations of ibrutinib (Figure 4.11a). Because ibrutinib inhibited AKT-
dependent FOXO1T24 phosphorylation, we next examined FOXO1 localisation in 
unstimulated and F(ab’)2 stimulated CLL cells with or without ibrutinib 
treatment by IF (Figure 4.11b,c) and subcellular fractionation (4.11d). 
Consistent with previous experiments (Figure 4.4a,b and 4.6b,c), short-term 
F(ab’)2 stimulation promoted FOXO1 nuclear exclusion (Figure 4.11b), resulting 
in a significant decrease in Manders’ co-localisation coefficient compared to 
unstimulated vehicle control (Figure 4.11c). Ibrutinib inhibited F(ab’)2-induced 
FOXO1 cytoplasmic translocation (Figure 4.10b,c), represented by a significant 
increase in Manders’ co-localisation coefficient compared to F(ab’)2 stimulated 
vehicle control (Figure 4.11b,c). Furthermore, ibrutinib treatment resulted in a 
notable trend towards enhanced FOXO1 nuclear localisation in unstimulated CLL 
cells (p = 0.12; Figure 4.11c). In support of these data, subcellular fractionation 
confirmed that F(ab’)2-induced FOXO1 nuclear-to-cytoplasmic translocation was 
blocked by ibrutinib treatment (Figure 4.11d). Cytoplasmic FOXO1 was enhanced 
following BCR ligation (Figure 4.11d), while nuclear FOXO1 was simultaneously 
decreased in F(ab’)2 stimulated CLL cells (Figure 4.11d). Furthermore, F(ab’)2-
induced cytoplasmic FOXO1 expression was visibly reduced by ibrutinib 
treatment, which corresponded to a concurrent increase in nuclear FOXO1 




3 localisation remained predominantly cytoplasmic irrespective of F(ab’)2 
stimulation and/or treatment (Figure 4.11d).  
 
Figure 4.11 - Ibrutinib inhibits F(ab’)2-induced nuclear-to-cytoplasmic FOXO1 translocation 




(a) Representative western blot a primary CLL sample (#CLL46; n=3 CLL samples) unstimulated or 
F(ab’)2 stimulated (+F(ab’)2) for 1 h following 30 min pre-treatment with increasing concentrations 
of ibrutinib (Vehicle, 10, 100, 1000, 10000 nM). Blots were probed for FOXO1T24, FOXO1, AKTS473, 
AKTT308, AKT and GAPDH (loading control; #1 and #2 referring to mirror blots). (b) Representative 
IF micrographs (100x) of a CLL patient sample (#CLL80; n=6 CLL samples) unstimulated or F(ab’)2 
stimulated (+ F(ab’)2) for 1 h following 30 min pre-treatment with ibrutinib (1 µM) or vehicle control. 
Cells were probed for FOXO1 (green) and counter stained with DAPI (DNA; blue). Individual 
channel and merged images shown. Scaled image (far-right panel) of representative cell (white 
square; merged channel). Scale bar = 5 µm. (c) Analyses of FOXO1 and DAPI co-localisation 
(Manders’ (Costes) Co-localisation Coefficient) in unstimulated (unstim.; grey bars) and F(ab’)2 
stimulated (+ F(ab’)2; purple bars) CLL patient samples (n=5) treated with ibrutinib (+) or vehicle 
control (-). >360 cells were quantified/condition from each sample. (d) Subcellular fractionation of a 
CLL patient sample (#CLL151; n=4 CLL samples) unstimulated (unstim.) or F(ab’)2 stimulated (+ 
F(ab’)2) for 1 h following 30 min pre-treatment with 1 µM ibrutinib (+) or vehicle control (-). 
Cytoplasmic, nuclear and whole cell lysate (WCL) fractions were generated. Blots were probed for 
FOXO1, AKT, 14-3-3 (pan), Lamin A/C and β-Tubulin. Densitometry for cytoplasmic (FOXO1/β-
Tubulin) and nuclear (FOXO1/Lamin A/C) FOXO1 expression are shown (relative to unstimulated 
vehicle control). Individual datapoints are represented by white circles. Data expressed as the 
mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05. 
 
4.2.9 F(ab’)2 stimulation promotes FOXO1T24 phosphorylation in 
CLL patient samples with prior ibrutinib treatment 
Studies have previously shown that FOXOs induce apoptosis in response to BTK 
(ibrutinib) (501) or PI3K/AKT (502) inhibitors in B cell malignancies and 
pancreatic cancer, respectively. On the other hand, FOXOs have been reported 
to mediate drug resistance in NHL (503), chronic myeloid leukaemia (CML) 
(K562) cells (504) and breast cancer (MCF-7/ADR) cells (505). Because ibrutinib 
treatment blocks short-term F(ab’)2-induced AKT kinase activity and AKT-
dependent FOXO1T24 phosphorylation in CLL cells (Figure 3.21), thereby enabling 
FOXO1 nuclear exportation (Figure 4.11), we argued that FOXO1 behaves as a 
tumour suppressor in this context. To further examine the effect of ibrutinib on 
FOXO1 activity, we acquired serial samples from CLL patients before (pre) and 
after (post) ibrutinib treatment (Figure 4.12a). Pre- and post-ibrutinib treated 
CLL cells subsequently underwent short-term F(ab’)2 stimulation ex vivo to 
assess the phosphorylation status of FOXO1T24, AKTT308, AKTS473, ERK1/2T202/Y204 
and BTKY223 (an autophosphorylation site of activated BTK) (Figure 4.12b-d). As 
expected, ex vivo F(ab’)2 stimulation of CLL cells from patients before ibrutinib 
treatment enhanced FOXO1T24, AKTT308, AKTS473, ERK1/2T202/Y204 and BTKY223 
phosphorylation compared to unstimulated control (Figure 4.12b-d). Of note, 
basal activity of FOXO1T24 and BTKY223 was observed in CLL patients CLL157 
(Figure 4.12b) and CLL184 (Figure 4.12b) prior to ibrutinib treatment. 
Reassuringly, basal and F(ab’)2-induced BTKY223 phosphorylation was inhibited in 




however, F(ab’)2 stimulation nevertheless elevated AKTT308, AKTS473, AKT-
dependent FOXO1T24 and ERK1/2T202/Y204 phosphorylation despite prior ibrutinib 
treatment (Figure 4.12b-d). 
 
Figure 4.12 - F(ab’)2 stimulation promotes FOXO1T24 phosphorylation in CLL patient samples 
with prior ibrutinib treatment. 
(a) Schematic depicting experimental design. Primary CLL cells were derived from CLL patients at 




pre-IBR and post-IBR treated CLL patients (b) CLL157, (c) CLL9 and (d) CLL184 unstimulated (-) 
or F(ab’)2 stimulated (+) for 1 hour. Unless otherwise stated (‘D’ = days), pre-IBR represents 1 
month (1M) prior to ibrutinib treatment and post-IBR signifies 1 month (1M) after ibrutinib treatment. 
Blots were probed for FOXO1T24, FOXO1, BTKY223, BTK, AKTT308, AKTS473, AKT, ERK1,2T202/Y204, 
ERK1,2 and GAPDH (loading control; #1 and #2 referring to mirror blots). 
 
4.2.10 Combining AZD8055 with ibrutinib blocks F(ab’)2-
dependent FOXO1 nuclear export in CLL cells 
As shown previously, combining AZD8055 with ibrutinib visibly enhanced 
inhibition of AKT-dependent FOXO1T24 phosphorylation to a greater extent than 
AZD8055 alone in unstimulated and F(ab’)2 stimulated CLL cells (Figure 3.21). 
Building upon the experiments that demonstrated the ability of AZD8055 (Figure 
4.6 and 4.7) or ibrutinib (Figure 4.11) to inhibit F(ab’)2-induced FOXO1 
cytoplasmic translocation, we examined FOXO1 localisation following COMBO 
treatment in F(ab’)2-stimulated CLL cells by IF (Figure 4.13) and subcellular 
fractionation (Figure 4.14). Consistent with earlier experiments, F(ab’)2 
stimulation promoted FOXO1 cytoplasmic translocation (Figure 4.13a), 
demonstrated by a significant reduction in Manders’ co-localisation coefficient 
(Figure 4.13b). AZD8055 treatment resulted in a near-significant (p = 0.09) 
increase in Manders’ co-localisation coefficient compared to F(ab’)2 stimulated 
CLL cells, while ibrutinib significantly blocked F(ab’)2-induced FOXO1 nuclear 
exclusion (Figure 4.13a,b). The COMBO treatment visibly enhanced FOXO1 
nuclear retention (Figure 4.13a), resulting in a near-significant increase in 
Manders’ co-localisation coefficient compared to F(ab’)2 stimulated CLL cells (p 
= 0.07; Figure 4.13b). Interestingly, the degree to which FOXO1 co-localised with 
the nucleus following the COMBO treatment was notably less than ibrutinib 
treatment alone (Figure 4.13b).  
To further support these data, subcellular fractionation showed that F(ab’)2-
induced FOXO1 cytoplasmic localisation was largely blocked by the COMBO 
treatment (Figure 4.14a-c). Cytoplasmic FOXO1 was visibly enhanced following 
BCR crosslinking (Figure 4.14a,b), while nuclear FOXO1 was concurrently 
decreased in F(ab’)2 stimulated CLL cells (Figure 4.14a,c). Treatment with 
AZD8055 or ibrutinib reduced cytoplasmic FOXO1 (Figure 4.13a,b), which 
corresponded to an increase in nuclear FOXO1 compared to F(ab’)2 stimulated 
vehicle control (Figure 4.14a,c). Finally, the COMBO treatment similarly reduced 





Figure 4.13 - AZD8055 and Ibrutinib combination inhibits BCR crosslinking-induced FOXO1 
cytoplasmic sequestration in primary CLL cells (1). 
(a) Representative IF micrographs (100x) of a CLL patient sample (#CLL80; n=4 CLL samples) 
unstimulated or F(ab’)2 stimulated (+ F(ab’)2) for 1 h following 30 min pre-treatment with AZD8055 
(100 nM), ibrutinib (1 µM), AZD8055 and ibrutinib combination (COMBO) or vehicle control. Cells 
were probed for FOXO1 (green) and counter stained with DAPI (DNA; blue). Individual channel and 
merged images shown. Scaled image (far-right panel) of representative cell (region designated by 




localisation (Manders’ (Costes) Co-localisation Coefficient) in unstimulated (US; grey bar) and 
F(ab’)2 stimulated (+ F(ab’)2; purple bars) CLL patient samples (n=4), treated as described in (a). 
>360 cells were quantified/condition from each sample. Individual datapoints are represented by 
white circles. Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where 
* p ≤ 0.05, ** p ≤ 0.01. 
 
nuclear FOXO1 expression (Figure 4.14a,c). These data demonstrate that BCR 
crosslinking-induced FOXO1T24 phosphorylation favours FOXO1 cytoplasmic 
translocation (Figure 4.14d), which can be inhibited by AZD8055 and ibrutinib as 
monotherapies or in combination via treatment-induced inhibition of AKT kinase 
activity (Figure 4.14e).  
 
Figure 4.14 - AZD8055 and Ibrutinib combination inhibits BCR crosslinking-induced FOXO1 




(a) Subcellular fractionation of a CLL patient sample (#CLL80; n=4 CLL samples) unstimulated 
(US) or F(ab’)2 stimulated (+ F(ab’)2) for 1 h following 30 min pre-treatment with AZD8055 (100 
nM), ibrutinib (1 µM), COMBO or vehicle control. Cytoplasmic, nuclear and whole cell lysate (WCL) 
fractions were generated. Blots were probed for FOXO1, Lamin A/C and β-Tubulin. Densitometry 
for cytoplasmic (FOXO1/β-Tubulin) and nuclear (FOXO1/Lamin A/C) FOXO1 expression are shown 
(relative to unstimulated vehicle control). (b, c) Densitometry of FOXO1 expression in (b) 
cytoplasmic and (c) nuclear fractions from unstimulated (US; grey bar) and F(ab’)2 stimulated (+ 
F(ab’)2; peach bars) CLL samples (n=4), treated as described in (a). Densitometry calculated as in 
(a). (d, e) Schematic of (d) F(ab’)2-induced AKT-dependent FOXO1 inactivation/cytoplasmic 
translocation and (e) COMBO-mediated inhibition of BCR crosslinking-induced FOXO1 nuclear 
export. Individual datapoints are represented by white circles. Data expressed as the mean ± SEM.  
 
4.2.11 AZD8055 and ibrutinib combination enhances FOXO1 
transcriptional activity in CLL cells  
Since the COMBO treatment inhibited BCR crosslinking-induced FOXO1 nuclear 
export (Figure 4.13 and 4.14), it was of interest to determine whether 
treatment-induced FOXO1 nuclear localisation conferred an increase in FOXO1 
transcriptional activity. Following treatment with AZD8055, ibrutinib or COMBO, 
CLL cells remained unstimulated or underwent short-term F(ab’)2 stimulation. 
Thereafter, FOXO1 DNA-binding activity was determined (Figure 4.15a). As 
expected, FOXO1 DNA-binding activity was reduced in response to short-term 
F(ab’)2 stimulation (p = 0.053; Figure 4.15a). AZD8055 or ibrutinib alone 
significantly enhanced FOXO1 transcriptional activity to near-basal levels in 
F(ab’)2 stimulated CLL cells (Figure 4.15a). The COMBO treatment evoked a 
near-significant increase in FOXO1 transcriptional activity in F(ab’)2 stimulated 
CLL cells (p = 0.06), which was notably greater than each monotherapy (Figure 
4.15a). Statistically speaking, modulation of FOXO1 transcriptional activity in 
unstimulated CLL cells was largely unaffected by treatment (Figure 4.15a). 
However, the response was heterogenous; for example, some patient samples 
considerably enhanced FOXO1 activation in response to AZD8055 treatment, 
while others simultaneously downregulated FOXO1 DNA-binding activity (Figure 
4.15a).   
FOXOs regulate gene expression of targets involved in growth factor signalling, 
cell cycle arrest and apoptosis (344, 380, 506). We therefore measured the 
transcript abundance of a group of FOXO target genes, including FOXO1, FOXO3, 
FOXO4, CCND1 (Cyclin D1), CCND2 (Cyclin D2), CDKN1A (p21CIP1), CDKN1B 
(p27KIP1), BCL2-L11 (BIM) and GADD45A, in unstimulated and F(ab’)2 stimulated 
CLL cells following treatment with AZD8055, ibrutinib or COMBO (Figure 4.15b-





Figure 4.15 - COMBO treatment inhibits F(ab’)2-induced FOXO1 inactivation in primary CLL 
cells. 
(a) FOXO1 DNA-binding activity (OD450) of CLL patient samples (n=5) unstimulated (grey bars) or 
F(ab’)2 stimulated (+ F(ab’)2; green bars) for 1 h following 30 min pre-treatment with AZD8055 (100 
nM), ibrutinib (1 µM), COMBO or vehicle control. (b – j) RT-qPCR to assess transcript abundance 
of (b) FOXO1 (n=12), (c) FOXO3 (n=9), (d) FOXO4 (n=10), (e) CCND1 (Cyclin D1) (n=12), (f) 
CCND2 (Cyclin D2) (n=10), (g) CDKN1A (p21CIP1) (n=10), (h) CDKN1B (p27KIP1) (n=11), (i) BCL2-
L11 (BIM) (n=12) and (j) GADD45A (n=6) in unstimulated (pink bars) or F(ab’)2 stimulated (+ 
F(ab’)2; purple bars) primary CLL samples (24 h stimulation) pre-treated as described in (a). The 
ΔΔCT method was used to calculate expression levels, where samples were first normalised to the 




datapoints are represented by white or black circles. Data expressed as the mean ± SEM. 
Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001. 
 
expression (Figure 4.15e,f,g), these data showed that transcript abundance of 
the selected FOXO target genes were largely unaffected by F(ab’)2-induced BCR 
crosslinking (Figure 4.15b-j). AZD8055 treatment significantly enhanced FOXO1 
expression in unstimulated CLL cells, while transcript levels of CCND2 and 
CDKN1A were significantly decreased (Figure 4.15b,f,g). Moreover, AZD8055 
treatment conferred visible trends towards increased FOXO3, FOXO4, CDKN1B, 
BCL2-L11 and GADD45A expression in unstimulated CLL cells (Figure 4.15c,d,h,j). 
In F(ab’)2 stimulated CLL cells, FOXO1 and FOXO3 transcript levels were 
significantly enhanced following AZD8055 treatment, while CDKN1A was 
significantly reduced (Figure 4.15b,c,g). AZD8055 treatment also increased 
FOXO4 expression in F(ab’)2 stimulated CLL cells, whereas CCND1, CCND2, 
CDKN1B, BCL2-L11 trended towards decreased expression (Figure 4.15d-f,h,i). 
Ibrutinib treatment significantly decreased CCND2 and CDKN1A transcript 
abundance in unstimulated CLL cells, while trends towards enhanced FOXO1 
CDKN1B, BCL2-L11 and GADD45A expression and decreased CCND1 were 
observed (Figure 4.15b,e-j). In F(ab’)2 stimulated CLL cells, CDKN1A expression 
was significantly decreased following ibrutinib treatment, whereas notable 
trends towards increased transcript levels of FOXO1, CDKN1B and GADD45A and 
reduced FOXO3, CCND1 and CCND2 were detected (Figure 4.15b,c,e-h,j). The 
COMBO treatment significantly downregulated CCDN2 and CDKN1A expression in 
unstimulated CLL cells, while trends towards increased FOXO1, FOXO3, CDKN1B, 
BCL2-L11 and GADD45A were observed (Figure 4.15b,c,f-j). FOXO1 transcript 
levels was significantly upregulated following COMBO treatment in F(ab’)2 
stimulated CLL cells, whereas CDKN1A was significantly reduced (Figure 
4.15b,g). Finally, the COMBO treatment increased transcript abundance of 
FOXO3 and GADD45A in F(ab’)2 stimulated CLL cells, while trends towards 
reduced CCND1 and CCND2 were observed (Figure 4.15c,e,f,j). With the 
exception of CDKN1A expression in unstimulated CLL cells (Figure 4.15g), FOXO 
target transcript levels were not augmented by the COMBO treatment compared 




4.2.12 FOXO1 is expressed in B220/CD45R+ cells in ex vivo 
spleen sections derived from WT and PKC⍺KR CLL-like 
mice 
In murine models, reports have established a key role for FOXO1 in the 
maintenance of the GC, where it regulates gene transcription favouring 
formation of the proliferative GC DZ (394, 395). In line with these findings, we 
sought to confirm the expression and localisation of FOXO1 in spleen sections 
from WT mice by IHC (Figure 4.16a,b) and IF (Figure 4.16a,c). As expected, 
FOXO1 expression was enhanced in structures resembling B cell follicles (Figure 
4.16b). ‘Dual’ staining with the mouse B cell marker B220/CD45R revealed 
FOXO1 was almost exclusively expressed in B220/CD45R+ cells (Figure 4.16c). 
Among B220/CD45R+ cells, FOXO1 expression was elevated within a ‘central 
core’, surrounded by a band of B220/CD45R+ cells with lower FOXO1 expression 
(Figure 4.16c). As observed previously (394, 395), B220/CD45R+ cells showed 
almost exclusive nuclear expression of FOXO1 (Figure 4.16c). We subsequently 
examined AKTS473 phosphorylation (marker of PI3K-AKT activity (394, 395)) in WT 
spleen sections by IHC (Figure 4.16b). Interestingly, strong punctate AKTS473 
staining was observed within an outer margin of B cell follicles, which was 
virtually absent towards the centre of the structure (Figure 4.16b). We next 
assessed FOXO1 expression and localisation in spleen sections from a poor 
prognostic CLL-like mouse model, generated as described in (485, 507) (Figure 
4.17a). In brief, hematopoietic progenitor cells were retrovirally transduced 
with a dominant negative ‘kinase-dead’ PKCα (K368R) construct and adoptively 
transferred into RAG1-/- or, latterly, NSG mice. Splenocytes derived from these 
mice typically exhibit features of ‘poor-prognostic’ CLL patients including ZAP-
70 expression, U-CLL and aberrant activation of signalling pathways (ERK and 
mTOR) (485, 507). Furthermore, these mice display upregulated BCR signalling 
(Michie 2020; personal communication). As such, it was of interest to assess 
FOXO1 expression and/or localisation within this model in the context of the 
TME. Spleens carrying CLL-like disease were acquired after completion of in vivo 
experiments as ‘left-over’ spleen tissue from vehicle control mice (Figure 
4.17a). Dual staining with B220/CD45R revealed that FOXO1 was predominantly 
expressed in CLL-like B220/CD45R+ cells (Figure 4.17b). Moreover, FOXO1 




(Figure 4.17b). Interestingly, and somewhat confoundingly, AKTS473 was also 
largely detected in B220/CD45R+ cells (Figure 4.17c).  
 
Figure 4.16 - FOXO1 expression in WT mouse spleen sections is upregulated in structures 




(a) Schematic depicting experimental design. Spleens were harvested from WT mice and 
underwent either fixation/paraffin embedding (IHC) or OCT-embedding (IF). (b) IHC staining (10x 
and 40x) of a mouse WT spleen section (n=3) probed for FOXO1 and AKTS473. White arrows 
indicate AKTS473 staining. Enlarged image (40x) representative of region designated within white 
rectangle (10x). (c) IF micrographs (10x, 20x and 40x) of a WT mouse spleen section. Sections 
were probed for FOXO1 (turquoise), B220 (yellow) and counter stained with DAPI (DNA; purple). 
FOXO1 and B220 staining (left panel) and merged image (right panel) are shown. Scale bar = 200 
µm (10x), 100 µm (20x) and 50 µm (40x).  
 
 
Figure 4.17 - FOXO1 is expressed in B220/CD45R+ cells in spleen sections derived from 




(a) Schematic depicting experimental design. Spleens were harvested from PKC⍺KR CLL-like mice 
following 2 weeks of daily treatment with Kleptose (vehicle control). Spleen tissue underwent OCT-
embedding (IF). (b) IF micrographs (20x and 40x) of a PKC⍺KR CLL-like mouse spleen section. 
Sections were probed for FOXO1 (turquoise), B220 (yellow) and counter stained with DAPI (DNA; 
purple). Individual channel and merged images are shown. Scale bar = 40 µm (20x) and 20 µm 
(40x). (c) IF micrographs (40x) of a PKC⍺KR CLL-like mouse spleen section probed for AKTS473 
(turquoise), B220 (yellow) and counter stained with DAPI (DNA; purple). Individual channel and 
merged images are shown. Scale bar = 20 µm. 
 
 
4.2.13 FOXO1 is upregulated in CLL patient LN biopsies of 
poor-prognostic patients, which correlates with increased 
Ki-67+ staining 
Nuclear FOXO1 expression has been observed in proliferating (Ki-67+) GC B cells 
residing in the DZ (384, 394, 396). CLL cell proliferation within ‘proliferation 
centres’ of the LN microenvironment is inextricably linked to disease 
pathogenesis (9), therefore it was of interest to investigate FOXO1 expression 
within the CLL lymphoid compartment (Figure 4.18a-c). FOXO1 expression was 
assessed by IHC of LN biopsies derived from distinct prognostic subgroups of CLL 
patients (Figure 4.18a). As described in Figure 3.2, the patients had previously 
been categorised into ‘indolent’ or ‘progressive’ disease, based upon 
cytogenetics, IGVH gene mutational status and CD38 expression. Consistent with 
an earlier report (396), this experiment showed that FOXO1 expression was 
observed in CLL patient LN biopsies (Figure 4.18a,b). Of the 20 patients 
assessed, 19 (95%) possessed detectable levels of FOXO1 (Figure 4.18a,b). 
Interestingly, FOXO1 expression was significantly higher in patients harbouring 
poor-prognostic progressive disease markers compared to those with indolent 
disease (Figure 4.18a,b). Of the 9 progressive patients examined, 8 (89 %) 
demonstrated strong FOXO1 staining (intensity score ≥3) (Figure 4.18b). In 
contrast, only 3 (28%) of the 11 indolent patients exhibited strong FOXO1 
staining (Figure 4.18b). Consistent with earlier findings (Figure 4.16 and 4.17), 
FOXO1 distribution appeared to be almost exclusively nuclear (Figure 4.18a). Ki-
67 staining was subsequently aligned with FOXO1 in continuous sections among 
the CLL patient LN biopsies [data not shown]. Interestingly, the FOXO1 intensity 
score was positively correlated with % Ki-67 staining (R2 = 0.49; p = 0.0006; n = 





Figure 4.18 - FOXO1 is upregulated in CLL patient LN biopsies of poor-prognostic patients, 
which correlates with increased Ki-67+ staining. 
(a) IHC of CLL patient LN biopsies stratified into ‘indolent’ and ‘progressive’ disease based on 
cytogenetics and IgVH gene mutational status. LN sections were stained for FOXO1. Prognostic 
information is found below each micrograph. (b) FOXO1 intensity score (IS) for CLL patient LN 
biopsies subdivided into indolent (n=11; salmon bars) and progressive (n=9; blue bars) disease. IS 
is scored from 0 to 5; 0 indicating undetected signal and 5 corresponding to highest signal. Staining 
performed by Dr. Mark Catherwood (Belfast City Hospital, Belfast). All slides were evaluated by a 
histopathologist. Individual patient datapoints are represented by white circles. Data expressed as 
the mean ± SEM. Statistics calculated by unpaired Student’s t-test for two groups, where *** p ≤ 
0.001. (c) Correlation between FOXO1 intensity score (IS) and % Ki-67+ staining, as calculated by 
linear regression analysis (r2). 
 
4.2.14 ‘Proliferative’ CLL cells possess diminished levels of 
FOXO1T24 phosphorylation and abundant nuclear FOXO1 
expression 
Previous reports have demonstrated that PI3K-induced inactivation of FOXO1 is 
required for B cell proliferation (275, 390). In contrast, a recent study 




was impaired (508). Because of these contradictory findings, it was of interest to 
explore FOXO1 phosphorylation and localisation in proliferating CLL cells in vitro 
 
Figure 4.19 - ‘Proliferative’ CLL cells possess diminished levels of FOXO1T24 
phosphorylation and abundant nuclear FOXO1 expression. 
(a, b) Representative western blots of primary CLL samples (a) #CLL151 and (b) CLL93 (n=5 
primary CLL samples) co-cultured on CD40L (+IL-21) and treated with AZD8055, Ibrutinib, 
COMBO, Rapamycin or vehicle control for 6 days. Primary CLL cells were co-cultured on NT-L as 
a non-proliferative control. Blots were probed for FOXO1T24, FOXO1, AKTT308, AKTS473, AKT and 
GAPDH (loading control; #1 and #2 referring to mirror blots). (c) Relative FOXO1T24 
phosphorylation levels (densitometry) in primary CLL samples (n=5) co-cultured on NT-L (grey bar) 
and CD40L (+IL-21) (purple bars), treated as described in (a). Relative phosphorylation levels are 




Representative IF micrographs (100x) of a CLL patient sample (#CLL157) co-cultured on NT-L (top 
image) or CD40L (+IL-21) (bottom image) for 72 h. Cells were probed for FOXO1 (green) and 
counter stained with DAPI (DNA; blue). Solid white arrows: CLL cells; empty arrows: stromal cells. 
Scale bar = 5 µm. Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, 
where ** p ≤ 0.01.  
 
(Figure 4.19). As described earlier (Figure 3.20), ex vivo CLL cell proliferation 
was induced using the CD40L (+IL-21) co-culture system. Thereafter, the 
phosphorylation status of FOXO1T24, AKTS473 and AKTT308 was assessed by Western 
blotting (Figure 4.19a-c), and the localisation of FOXO1 was examined by IF 
(Figure 4.19d). These data showed that the level of FOXO1T24 phosphorylation 
was significantly lower in proliferative CLL cells co-cultured on CD40L (+IL-21) 
compared to non-proliferative CLL cells co-cultured on NT-L cells (Figure 4.19a-
c). Reduced FOXO1T24 phosphorylation coincided with decreased levels of AKTS473 
and AKTT308 phosphorylation in CLL cells co-cultured on CD40L (+IL-21) compared 
to NT-L cells (Figure 4.19a,b). Furthermore, FOXO1T24 phosphorylation was 
visibly lower in proliferative vehicle control CLL cells compared to CLL cells 
treated with AZD8055, ibrutinib, COMBO or rapamycin (Figure 4.19a-c). IF 
showed that FOXO1 expression was mainly localised in the nucleus of CLL cells 
co-cultured on NT-L (Figure 4.19d). Interestingly, however, proliferative CLL 
cells co-cultured on CD40L (+IL-21) also possessed nuclear FOXO1 expression 






Here, we provide insights into FOXO1 activity and subcellular localisation 
downstream of BCR crosslinking in CLL cells. BCR ligation-induced inactivation of 
FOXO1, the most abundantly expressed FOXO in CLL cells, demonstrates that the 
PI3K-AKT-FOXO1 axis likely plays an important role in CLL cell disease biology 
downstream of the BCR ligation. Additionally, re-engagement of FOXO1 DNA-
binding activity by targeted elimination of BCR signalling, via AKT (AZD5363), 
mTOR kinase (AZD8055) or BTK (ibrutinib) inhibition, suggests that FOXO1 may 
mediate the functional response to treatment. However, given the expression of 
nuclear FOXO1 in poor prognostic CLL patient LN biopsies, it becomes tempting 
to speculate that FOXO1 might contribute towards CLL pathogenesis and 
progression in a context-specific manner.  
4.3.1 BCR-dependent inactivation of FOXO1 suggests that the 
PI3K-AKT-FOXO1 axis contributes to CLL pathophysiology 
downstream of BCR ligation  
The activity of FOXO transcription factors is primarily controlled by nucleo-
cytoplasmic shuttling, governed largely by PI3K-AKT signalling (348). The results 
reported here demonstrate that BCR crosslinking enhances AKT-dependent 
FOXO1 phosphorylation, indicating that BCR signalling inactivates FOXO1 in CLL 
cells. In mature B cells, BCR ligation promotes PI3K-dependent phosphorylation 
and cytoplasmic translocation of FOXO1 (390). In line with these findings, we 
have shown that BCR ligation favours FOXO1 cytoplasmic accumulation and 
diminishes DNA-binding activity in CLL cells, suggesting that FOXO1 regulation in 
CLL cells observes the paradigm conveyed in normal B cells (390). Importantly, 
BCR crosslinking-induced FOXO1 phosphorylation was only temporary, potentially 
indicating that PI3K signalling must be diminished to enable FOXO1 re-activation 
(387). Consistent with its purported tumour suppressor role, Yusuf et al. further 
showed that expression of constitutively active FOXO1 (FOXO1-A3) induced 
apoptosis and cell cycle arrest in activated B cells (390). This demonstrated that 
inactivation of FOXO1 activity was an important functional outcome of BCR-
mediated PI3K signalling in mature B cells (390). Given the significance of BCR 
signalling in driving CLL pathogenesis and progression (45), repression of pro-




dependent FOXO1 inactivation may fulfil an integral function in CLL 
pathophysiology. Indeed, our data demonstrates that mRNA expression of D-type 
cyclins CCND1 and CCND2 is elevated following BCR ligation, which are 
reportedly transcriptionally repressed by active FOXOs in mouse embryonic 
fibroblast cells (378). Therefore, these findings indicate that FOXO1 might be an 
effector of PI3K-AKT inhibition downstream of BCR ligation to promote cell cycle 
arrest and apoptosis in CLL cells, as demonstrated in pre-BCR+ BCP-ALL (402) and 
DLBCL (397).  
Like mature B cells (222), studies have shown that CLL cell survival and 
expansion is dependent on both ‘tonic’ and antigen-triggered BCR signalling 
(122). As highlighted by Ushmorov et al., the role of FOXO1 in the survival 
programme of B cells reliant on ‘tonic’ BCR signalling is somewhat contentious  
(384). For example, Dengler et al. showed that FOXO1 ablation using a 
conditional knockout (Foxo1L/LCd21Cre) diminished survival (and proliferation) of 
mature B cells following F(ab’)2-induced BCR ligation, owing to reduced surface 
Ig expression and BCR signalling defects (384, 387). Accordingly, SYK, BLNK and 
PI3KCA were shown to be transcriptional targets of FOXOs, which are central 
components of BCR signalling, perhaps indicating that FOXO transcriptional 
activity is required to sustain ‘tonic’ signals (and survival, by extension) (384, 
509, 510). On the other hand, Srinivasan et al. demonstrated that FOXO1 
promoted apoptosis in BCR-negative (IgMneg) B cells via upregulation of pro-
apoptotic (BCL2-L11) and cytostatic (CDKN1B) transcripts, which was negated 
following FOXO1 deletion, PTEN-knockout or expression of a constitutively active 
form of PI3K (P110α) (275, 384). As summarised by Ushmorov et al., these 
findings likely indicate that FOXO1 activity (and the functional outcome) is finely 
balanced according to the strength and duration of BCR signalling, inasmuch as 
FOXO1 maintains B cell survival in response to optimal ‘tonic’ signalling, whereas 
FOXO1 mediates apoptosis in B cells with perturbed BCR signalling (384). 
Although Dengler et al. reported that FOXO1 was not necessary for B cell 
maintenance (387), others have shown that strict regulation of FOXO activity 
within an optimum contributes towards B cell homeostasis (403, 506, 511). 
Interestingly, Hornsveld et al. recently postulated that FOXOs are unlikely to 
distinguish between normal and malignant cells in accomplishing homeostatic 




responses in the maintenance of pre-BCR+ BCP-ALL. For example, 
pharmacological inactivation of pre-BCR signalling or FOXO1-A3 overexpression 
resulted in FOXO1-induced cell death (402), whereas FOXO1 repression was 
shown to induce cell cycle arrest and apoptosis via CCND3 downregulation (403). 
How these findings are resolved in the context of CLL is yet to be determined. 
Still, it is intriguing to contemplate that FOXO1 may inadvertently promote CLL 
maintenance.  
Similar to pre-BCR+ BCP-ALL (512) and GCB-DLBCL (253), studies have 
demonstrated constitutive activation of PI3K (252) and AKT (284, 285) in 
circulating CLL cells, perhaps underscored by constitutive clustering of the BCR 
(247, 248), akin to normal B cells upon antigen stimulation (225, 513, 514). 
Despite AKT-dependent FOXO1T24 phosphorylation, we have shown that a 
proportion of FOXO1 is localised in nuclei of unstimulated CLL cells, similar to 
circulating B cells devoid of growth factor stimulation (390). In quiescent B cells, 
nuclear FOXO1 instructs transcription of genes favouring cell cycle arrest and 
redistribution between the blood and SLOs (266). In line with these findings, 
‘arrested’ PB-derived CLL cells express elevated levels of cell cycle inhibitor 
p27KIP1 (493) and chemokine receptor CXCR4 (169), which are direct 
transcriptional targets of FOXO1 in B cells (275, 394). Importantly, BCR ablation 
enhances p27KIP1 expression in mature B cells (275), while IgM stimulation 
downregulates CXCR4 (515). Therefore, one might assume that optimal FOXO1 
activity contributes to CLL cell homeostasis within the periphery, and that BCR 
ligation in the SLOs elicit commensurate changes in FOXO1 transcriptional 
activity to promote CLL cell expansion in a context-dependent manner. Although 
under the influence of PI3K-AKT signalling (401), it is likely that FOXO1 
subcellular localisation exists in equilibrium (344), influenced largely by the 
extent of BCR signalling. Of note, we cannot exclude the effect BCR crosslinking 
on additional pathways, such as MAPK/ERK (366), NF-κB (516) or JNK (371), 
which also impact upon FOXO subcellular localisation (401, 517). Therefore, the 
influence of other posttranslational FOXO1 modifications (phosphorylation, 
acetylation, methylation and ubiquitination) downstream of BCR ligation 




With reference to the outcome of BCR activation among CLL patients (i.e 
‘positive’ signalling or anergy), this hypothesis could be tested by assessing 
FOXO1 localisation/expression in patient samples stratified according to IgM 
expression levels and/or IGHV mutational status. 
4.3.2 Hindering F(ab’)2-mediated BCR signal transduction re-
engages FOXO1 activity, suggesting FOXO1 is an effector of 
BCR signalling inhibition in CLL 
Notwithstanding the potential homeostatic role of FOXO1 in CLL maintenance, 
the data presented here demonstrate that in vitro BCR ligation promotes FOXO1 
inactivation in CLL cells, as evidenced by enhanced AKT-dependent FOXO1T24 
phosphorylation, nuclear export and reduced DNA-binding activity. Because 
FOXOs are purported tumour suppressors (347), re-engagement of FOXO activity 
via PI3K-AKT inhibition has been mooted as an attractive therapeutic strategy 
(365). Indeed, the PI3K inhibitor LY294002 was shown to inhibit BCR crosslinking-
induced FOXO1 cytoplasmic translocation in mature B cells, while ectopic 
expression of FOXO1-A3 resulted in cell cycle arrest and enhanced cell death 
(390). In GCB-DLBCL, a DLBCL subset characterised by increased activity of the 
PI3K-AKT pathway (253), elimination of BCR signalling via SYK inhibition 
increased FOXO1 activity and expression of direct FOXO targets including pro-
apoptotic BCL2-L11 and the cell cycle inhibitor p27KIP1 (397). As such, we 
conjecture that FOXO1 operates as an effector of PI3K-AKT inhibition 
downstream of BCR engagement to promote cell cycle arrest and apoptosis in 
CLL cells.  
Perhaps unsurprisingly (277, 350-353), the AKT inhibitor AZD5363 blocked AKT-
dependent FOXO1T24 phosphorylation in F(ab’)2-stimulated CLL cells, which 
consequently diminished BCR crosslinking-induced FOXO1 nuclear export. 
Although the analysis of DNA-binding activity was inconclusive among the CLL 
samples tested, these data confirm that BCR engagement signals via AKT to 
promote cytoplasmic translocation (and inactivation) of FOXO1. Mechanistically, 
AKT-dependent FOXO1 phosphorylation (FOXO1T24 and FOXO1S256) mediates 
interaction with 14-3-3 proteins (354, 355), which subsequently facilitate 
nuclear export via masking of the nuclear localisation sequence (277, 354) and 




activity largely retains FOXO1 in the nucleus of CLL cells, which may instruct 
transcription of targets involved in cell cycle repression and apoptosis (365). 
Indeed, Szydlowski et al. showed that the AKT inhibitor MK2206 reduced 
proliferation of BCR-dependent DLBCL cell lines DHL4 and Ly7 in a FOXO1-
dependent manner, inasmuch as FOXO1-depleted cells were resistant to the 
cytostatic effect of AKT inhibition (397). Furthermore, ‘preprint’ data has also 
revealed that FOXO is an effector of MK2206-induced cell cycle exit and cell 
death in multiple myeloma (MM) cells (518). Interestingly, Chapman et al. 
demonstrated that CD40L (+IL-4)-induced CLL cell proliferation was sensitive to 
AKT inhibition (AZD5363), which corresponded to enhanced p27KIP1 levels (279). 
Although FOXOs were not assessed, it is interesting to speculate that FOXO1 
might be an effector of AKT inhibition to suppress CLL cell proliferation. 
Notably, other AKT substrates, including GSK3α/β and TSC2 (246) are activated 
upon AKT inhibition in CLL cells (285, 519). Therefore, in the absence of a 
mechanistic approach targeting FOXO1, the influence of these substrates on cell 
growth, survival and proliferation must be considered. 
Earlier, we demonstrated that inhibition of mTOR kinase inhibited BCR ligation-
induced AKT (AKTS473 and AKTT308) and FOXO1T24 phosphorylation in CLL cells, 
indicating that AKT-dependent inactivation of FOXO1 is coordinated, in part, by 
mTOR signalling. In the present chapter, we show that AZD8055 treatment 
blocks BCR crosslinking-induced FOXO1 nuclear to cytoplasmic translocation, 
corresponding to enhanced DNA-binding activity and modulation of FOXO 
transcriptional targets FOXO1, FOXO3, CCND2 and CDKN1A (p21CIP1). Alongside 
our recent report (284), evidence supporting the role of mTOR kinase in the 
regulation of FOXO activity appears to be limited. However, the dual PI3K/mTOR 
inhibitors PI-103 and NVP-BEZ235 have been shown to enhance FOXO activity in 
neuroblastoma (520) and NHL (521), respectively. We further showed that the 
mTORC1-selective inhibitor rapamycin was unable to inhibit BCR crosslinking-
induced AKTS473 and FOXO1T24 phosphorylation in CLL cells, which resulted in 
FOXO1 cytoplasmic accumulation and diminished DNA-binding activity. 
Interestingly, a study showed that rapamycin treatment promoted FOXO1 
inactivation via enhanced AKTS473 phosphorylation in colon cancer cell lines, 
limiting its anti-tumour efficacy (522). These data highlight the importance of 




subsequent inactivation of FOXOs. Indeed, ablation of mTORC2 has been shown 
to compromise AKT-dependent FOXO3 phosphorylation in mice embryo 
fibroblasts (MEFs), whereas phosphorylation of AKT substrates GSK3β and TSC2 
were unaffected (500). Interestingly, this finding indicates that PI3K-dependent 
AKTT308 phosphorylation is unable to ‘fully’ inactivate FOXOs (albeit FOXO3) 
without mTORC2-dependent AKTS473 phosphorylation (384). Nevertheless, our 
data demonstrates that AZD8055 inhibits AKTS473 and AKTT308 phosphorylation, 
indicating AZD8055 indirectly controls FOXO1 activity via ‘full’ AKT inactivation. 
Therefore, the relative importance of mTORC2-dependent AKTS473 
phosphorylation over PI3K-dependent AKTT308 is difficult to decipher in this 
context.  
Treatment with the BTK inhibitor ibrutinib blocked BCR ligation-induced AKT 
(AKTS473 and AKTT308) and FOXO1T24 phosphorylation, suggesting the BTK 
imbibition influences FOXO1 activity in CLL cells. In support of these data, 
Kapoor et al. recently demonstrated that ibrutinib (10 µM) inhibited FOXO3aS253 
phosphorylation in MEC-1 cells, leading to FOXO3a-dependent BIM expression 
(501). In pre-BCR+ BCP-ALL, ibrutinib was shown to inhibit baseline AKT-
dependent FOXO1T24, FOXO3aT32 and FOXO4T28 phosphorylation, which 
corresponded to a concomitant increase in p27KIP1 (523). Here, we demonstrated 
that ibrutinib blocked BCR crosslinking-induced FOXO1 nuclear export in CLL 
cells, resulting in FOXO1 nuclear accumulation and enhanced DNA-binding 
activity. In line with these findings, ibrutinib treatment modulated transcript 
abundance of FOXO target genes CCND2 and CDKN1A (p21CIP1). Collectively, 
these data indicate that FOXO1 is an effector of BTK inhibition in CLL cells, 
which might contribute to the anti-proliferative and apoptotic properties of 
ibrutinib observed in vitro and in vivo (126, 127, 129). From a clinical point of 
view, FOXO1 might also represent a biomarker of clinical activity and/or 
resistance to BTK inhibitors. Indeed, Landau et al. recently generated an RNA 
sequencing (RNA-seq) dataset of serial CLL patient samples pre- and post-
ibrutinib treatment (88). Using the gene expression profiling (GEP) data 
produced by the expression of FOXO1-A3 in Hodgkin lymphoma cell lines (524), it 
would be interesting to glean insights into FOXO1 transcriptional activity in CLL 




In a recent study, however, BCR ligation (via stimulation with anti-IgM) of CLL 
cells undergoing ibrutinib treatment was shown to induce signal transduction 
along the PI3K-AKT axis, despite inhibition of BTK and PLCɣ2 activity (146). 
Consistent with these findings, we have shown that AKT (AKTS473 and AKTT308), 
FOXO1T24 and ERK1/2T202/Y204 phosphorylation was still inducible upon F(ab’)2 
stimulation of CLL samples undergoing ibrutinib treatment, despite inhibition of 
BTKY223 phosphorylation. These data suggest that a proportion of CLL cells 
enduring long-term ibrutinib therapy adapt to treatment, in part, by preserving 
BCR signal transduction through PI3K-AKT-FOXO1 and MAPK/ERK (146), which 
may represent a precursor to treatment resistance (13). Indeed, Kapoor et al. 
recently showed that ibrutinib-resistant CLL (MEC-1) and ABC-DLBCL (RIVA) cell 
lines possess enhanced AKTS473 phosphorylation and aberrant cytoplasmic 
localisation of FOXO3a. Interestingly, inhibition of PI3Kδ (idelalisib) or AKT 
(MK2206) signalling, or restoration of nuclear FOXO3a, enhanced ibrutinib-
induced apoptosis in ibrutinib-resistant cells, demonstrating that re-engagement 
of FOXO activity nullifies acquired ibrutinib resistance (501). Collectively, 
therefore, FOXO re-activation can be exploited by drug combinations targeting 
BCR-mediated PI3K-AKT signalling at multiple levels to promote apoptosis and 
inhibit compensatory pathways that promote therapy resistance (397, 501). 
Encouragingly, our findings demonstrate that combining AZD8055 with ibrutinib 
inhibits BCR crosslinking-induced AKT-dependent FOXO1T24 phosphorylation, 
leading to FOXO1 nuclear retention and enhanced DNA-binding activity, as 
evidenced by modulation of FOXO targets FOXO1, CCND2 and CDKN1A (p21CIP1). 
These data suggest that FOXO1 may underscore the anti-proliferative and 
apoptotic response to mTOR kinase and BTK inhibition downstream of the BCR. 
Indeed, Szydlowski et al. showed that FOXO1-depleted BCR-dependent DLBCL 
cells were resistant to combined inhibition of SYK (R406) and AKT (MK2206), 
indicating that FOXO1 mediated the cytotoxic effect of this combination (397).  
Considerable evidence demonstrates that FOXOs are heavily implicated in the 
cytostatic and apoptotic response to PI3K-AKT inhibitors (344). Importantly, 
however, FOXOs have also been shown to facilitate therapy resistance, as 
demonstrated in doxorubicin-resistant breast cancer (MCF-7) (505) and CML 
(K562) (504) cell lines (344). In CLL-like mouse models, resistance to the PI3Kδ 




growth factor 1 receptor (IGFR1), mediated by functional activation of FOXO1 
(147). Furthermore, FOXO1 activating mutations in NHL have been implicated in 
the resistance to rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisone (R-CHOP). Here, Pyrzynska et al. showed that CD20 expression was 
negatively regulated by FOXO1 in NHL cell lines, which resulted in reduced 
efficacy of the clinically-approved CD20 monoclonal antibody rituximab (503). 
Intriguingly, a phase II clinical trial (#NCT02007044) comparing ibrutinib with or 
without rituximab in patients with R/R CLL or untreated del(17p) patients 
revealed no improvement in PFS or OS (median follow-up of 36 months) by 
combining the two agents (525). One might speculate, therefore, that ibrutinib-
induced FOXO1 activation may repress CD20 expression, reducing the efficacy of 
rituximab in CLL. Taken together, treatments that re-activate FOXOs are 
potentially problematic, as FOXOs clearly partake in feedback mechanisms to 
support cellular resilience (344). Therefore, a detailed understanding of FOXO1 
transcriptional output in a CLL- and context-specific manner is required.  
4.3.3 BCR ligation transiently enhances FOXO1 expression in 
CLL cells, suggesting FOXO1 is protected from proteasomal 
degradation  
In a study by Hinman et al., BCR engagement downregulated FOXO1 mRNA 
expression in normal B cells via a mechanism facilitated by PI3K and BTK 
signalling (391), which largely corresponds to the well-established paradigm of 
AKT-mediated FOXO1 nuclear export (348) and proteasomal degradation (362-
364). Reproducibly, we have shown that FOXO1 expression was diminished within 
3 h following BCR ligation in CLL cells, before returning to ‘basal’ expression 
levels within 24 h. Interestingly, however, FOXO1 expression was significantly 
upregulated in the initial stages of BCR stimulation in CLL cells, which was not 
reported in mature B cells (390). Importantly, inhibition of BTK (ibrutinib), AKT 
(AZD5363) or mTOR kinase (AZD8055) decreased BCR crosslinking-induced FOXO1 
upregulation, suggesting that FOXO1 is transiently stabilised in the cytoplasm of 
CLL cells following BCR engagement (529). The E3 ubiquitin ligase SKP2 interacts 
with and polyubiquitinates AKT-phosphorylated FOXO1S256 for targeted 
degradation via the proteasome, inhibiting FOXO1’s tumour suppressor function 
(364). Interestingly, a study showed that SKP2 expression was low in CLL cells 




impaired. Furthermore, FOXO3 has been shown to repress SKP2 transcription, 
representing a feedforward mechanism promoting stabilisation of FOXOs (528). 
Nevertheless, we have demonstrated the FOXO1 downregulation (and likely 
proteasomal degradation) eventually occurred following BCR engagement, akin 
to mature B cells (391), so it seems unlikely that ubiquitin-proteasome 
machinery is fundamentally compromised. In normal B cells, 14-3-3σ protein has 
been shown to stabilise FOXO1 at levels required for optimal BCR signalling 
(529). Here, we have shown that 14-3-3 (pan) expression was almost exclusively 
cytoplasmic in response to BCR ligation. Interestingly, Dobson et al. 
demonstrated that 14-3-3ζ binding increased steady-state FOXO3 levels and 
protected cytoplasmic FOXO3 from dephosphorylation (and ultimately 
degradation), suggesting that 14-3-3 abundance may control and/or stabilise 
FOXO protein levels (345, 530). Ordinarily the abundance of 14-3-3 proteins is 
tightly regulated in a context-dependent manner (345). Indeed, aberrant 
overexpression of 14-3-3 proteins have been linked to poor prognosis (531) in 
breast cancer (532), lung cancer (533), glioblastoma (534) and MM (535). 
Although expression levels of 14-3-3 proteins have not yet been established in 
CLL, a study has shown that 14-3-3ζ facilitated Wnt5a/ROR1 signalling-
dependent CLL migration and proliferation (536). Taken together, enhanced BCR 
crosslinking-induced cytoplasmic FOXO1 expression might be linked to an 
aberrant abundance of 14-3-3 proteins in CLL cells, which directs FOXO1 activity 
in a context-dependent manner (345, 530). Therefore, an assessment of ‘steady-
state’ 14-3-3 protein expression and modulation downstream of BCR ligation 
warrants further investigation.  
4.3.4 Abundant nuclear FOXO1 expression in CLL patient LN 
biopsies is indicative of transcriptional activation, 
suggesting that FOXO1 may contribute to the oncogenic 
programme of CLL  
The GC is a specialised (and transient) microanatomical structure within SLOs 
wherein activated B cells undergo rapid clonal expansion and Ig SHM to generate 
affinity-enhanced antibodies in support of the adaptive immune response (392-
394). On a functional level, the GC is polarised into a highly proliferative DZ 
(where B cells undergo clonal expansion and SHM) and a LZ (where B cell 




cells) (392-394). FOXO1 is highly expressed in the nucleus of GC B cells within 
the proliferative DZ, where it directs a gene expression programme favouring DZ 
formation (394, 395). Although established markers delineating the DZ (AID), LZ 
(FDC-M2 or CD23) or follicular B cell compartment (IgD) were omitted (394, 395), 
our results confirmed that FOXO1 was mainly localised in the nucleus of 
B220/CD45R+ cells within structures resembling B cell follicles in WT mice. 
Contradicting its well-established role as tumour suppressor (396, 397, 404, 
537), Xie et al. showed that nuclear FOXO1 expression in the DZ co-localised 
with Ki-67+ staining in human tonsillar tissue (396). Correspondingly, FOXO1 
ablation towards a later stage of the GC reaction impaired GC B cell 
proliferation (508). Collectively, these findings demonstrate that FOXO1, 
perhaps in concert with other transcriptional regulators (394), mediates and/or 
promotes proliferation in the GC DZ (394, 395, 508). Relevantly, this highlights 
the ability of FOXOs to promote oncogenesis in a context-dependent manner, as 
demonstrated previously (401, 408, 538, 539). 
Several B cell malignancies, such as Burkitt lymphoma (BL) and GCB-DLBCL, 
originate from GC B cells (393). In contrast, CLL subsets have distinct cellular 
origins, with U-CLL possessing features of mature pre-GC CD5+ B cells and M-CLL 
deriving from a post-GC CD5+CD27+ subset (43). Unlike typical GCs, however, CLL 
cells form ‘proliferation centres’ or ‘pseudofollicles’ within SLOs (2). In an 
earlier report, CLL and BL patient lymphoid tissue biopsies demonstrated the 
highest levels of FOXO1 expression among B cell NHLs (396). Here, we 
demonstrated ubiquitous nuclear FOXO1 expression in CLL patient LN biopsies 
irrespective of prognosis, which positively correlated with Ki-67+ staining. Along 
these lines, FOXO1 expression was localised in the nucleus of ‘proliferative’ 
CD40L (+IL-21)-stimulated CLL cells in vitro. In our PKCαKR CLL-like mouse 
model, which forms irregular splenic follicular structures (485), FOXO1 was 
similarly, albeit not exclusively, expressed in the nucleus of ‘expansive’ 
B220/CD45R+ PKCαKR cells. Although the direct transcriptional targets are 
unknown, these findings suggest that ‘active’ nuclear FOXO1 may instruct a gene 
expression programme that facilitates CLL proliferation, akin to DZ GC B cells 




Interestingly, AKTS473 phosphorylation was also detected in B220/CD45R+ PKCαKR 
cells. Consistent with the observations made by Kabrani et al., these data 
indicate that nuclear FOXO1 expression paradoxically coincides with PI3K-AKT 
activity in CLL-like PKCαKR cells (401). In B cell malignancies, recurrent FOXO 
mutations frequently perturb AKT recognition motifs, leading to aberrant FOXO1 
nuclear retention (384, 401). Although FOXO1 mutations are rare in CLL (Michie 
and Hay, personal communication), studies have shown that significant 
proportions of BL (541) and DLBCL (398) patients possess recurrent FOXO1 
mutations, which render the transcription factor insensitive to AKT-dependent 
inactivation (394). From a clinical standpoint, these mutations are often 
associated with unfavourable response rates (398), demonstrating the 
pathogenic role of nuclear FOXO1 among B cell malignancies. Indeed, Kabrani et 
al. recently showed that aberrant FOXO1 nuclear localisation (via disruption of 
the FOXO1T24 phosphorylation site) enhanced survival and proliferation in BL 
cells (inducing a gene expression programme reminiscent of proliferative DZ GC 
B cells), demonstrating that FOXO1 nuclear localisation represents an initiating 
event in BL pathogenesis (401). Although the mechanisms that permit nuclear 
localisation of ‘genetically intact’ FOXO1 amidst active PI3K-AKT signalling 
remain unclear (401), it is intriguing to contemplate that nuclear FOXO1 may 
promote favourable conditions that facilitate CLL progression. 
4.3.5 Summary and future directions 
Taken together, these findings demonstrate that BCR crosslinking negatively 
regulates FOXO1 DNA-binding activity via AKT-dependent FOXO1 phosphorylation 
and nuclear export. Inactivation of FOXO1, the most abundantly expressed FOXO 
in CLL cells, likely represents a functionally important consequence of BCR 
engagement. Given its widely-considered role as a tumour suppressor, one might 
consider that FOXO1 inactivation might facilitate and/or enable favourable 
conditions for CLL cell survival and proliferation, akin to normal B cells (387, 
390) and DLBCL (397). For this reason, subverting BCR signalling-induced FOXO1 
inactivation might unleash its pro-apoptotic and anti-proliferative properties. 
Indeed, we have shown that elimination of BCR signal transduction, via AKT 
(AZD5363), mTOR kinase (AZD8055) or BTK (ibrutinib) inhibition, re-engaged 
FOXO1 DNA-binding activity by preventing FOXO1 nuclear export, suggesting that 




response. This being said, nuclear FOXO1 expression in ‘proliferative’ CLL cells 
and CLL patient LN biopsies is at odds with its ‘bona fide’ tumour suppressor role 
(347). Increasing evidence attests to the ability of FOXOs to elicit homeostatic 
functions that support cellular resilience (344, 506). Therefore, strict regulation 
of FOXO1 activity may facilitate CLL disease maintenance in a context-
dependent manner. In the next chapter, we will investigate whether FOXO1 is an 
effector of treatment response using genetic (shRNA knockdown) and 
pharmacological inhibition. At the same time, these methods will enable us to 






5 Results III 
5.1 Introduction 
Alongside their well-established role as tumour suppressors (396, 404), 
considerable evidence supports the notion that FOXOs are mediators of cellular 
resilience (506). In the same vein, FOXOs have been shown to facilitate tumour 
development/progression in certain cellular contexts (344). Notwithstanding the 
context-dependent ‘dual-faceted’ properties of FOXO transcription factors in 
normal and malignant B cells (384), little is known about functionality of FOXOs 
in CLL disease biology.  
Earlier, we demonstrated that elimination of BCR signal transduction inhibited 
AKT-dependent FOXO1T24 phosphorylation, upheld FOXO1 nuclear retention and 
enhanced FOXO1 DNA-binding activity in CLL cells. On a functional level, this 
corresponded to changes in FOXO target gene/protein expression, particularly 
those involved in signal transduction, cell cycle arrest and apoptosis. These 
findings suggest that FOXO1 operates as an effector of truncated BCR signalling. 
On the other hand, our data revealed that FOXO1 is localised in the nucleus of 
CLL patient LN biopsies and ‘proliferative’ CD40L (+IL-21)-stimulated CLL cells, 
indicating that FOXO1 might be implicated in CLL maintenance. One might 
speculate, therefore, that strict regulation of FOXO1 activity within an optimal 
range promotes CLL cell homeostasis, and drastic changes in FOXO1 activity 
away from this established ‘setpoint’ tilts the scales towards tumour 
suppression, as demonstrated in DLBCL (397) and pre-BCR+ BCP-ALL (402, 403). 
However, without assessing the importance of FOXO1 (either through genetic or 
pharmacological inhibition), these observations cannot be conclusively resolved.  
In this chapter, we investigate the functional consequence of shRNA-mediated 
FOXO1 knockdown on both CLL maintenance and the response to COMBO 
treatment. Furthermore, we examine the sensitivity of CLL cells to the FOXO1 
inhibitor AS1842856 and ask whether pharmacological FOXO1 inhibition protects 





I. Explore the expression, subcellular localisation and activity of FOXO1 in 
HG-3 and MEC-1 cells. 
II. Generate FOXO1-targeting shRNA molecules to investigate the functional 
impact of FOXO1 knockdown on CLL maintenance and the response to the 
COMBO treatment. 
III. Examine whether FOXO1 activity, via pharmacological FOXO1 inhibition 
(AS1842856), is required to elicit the functional response to the COMBO 
treatment.  
IV. Analyse the transcriptional response (established FOXO target genes) to 






5.2.1 HG-3 and MEC-1 cells express nuclear FOXO1 amidst 
activated PI3K-AKT signalling 
Previously, we demonstrated that FOXO1 expression was significantly higher in 
LN biopsies of patients harbouring poor-prognostic progressive disease markers 
compared to those with indolent disease (Figure 4.19a,b). We therefore  
 




(a) Western blot of FOXO1T24, FOXO1, AKTT308, AKTS473, AKT and GAPDH (#1 and #2 
representing mirror blots; loading control) expression in HG-3 (n=3) and MEC-1 (n=3) cells. (b) 
Relative FOXO1 expression and (c) FOXO1T24 phosphorylation levels in HG-3 (n=3; grey bars) and 
MEC-1 (n=3; red bars), as determined by densitometry. (d) Representative IF micrograph (100x) of 
HG-3 (n=2; top panel) and MEC-1 cells (n=2; bottom panel) stained with FOXO1 (green; left panel) 
and counter stained with DAPI (blue; middle panel). Individual channel and merged (merge; right 
panel) images are shown. Scale bar = 5 µm. (e) Representative western blot (n=2) depicting 
cellular fractionation of HG-3 and MEC-1 cells. Blots have been stained for FOXO1, Lamin A/C 
(nuclear marker; loading control) and β-Tubulin (cytoplasmic marker; loading control). Cyt = 
cytoplasmic fraction; Nuc = nuclear fraction; WCL = whole cell lysate. Relative FOXO1 expression 
within each compartment calculated by FOXO1 relative to β-Tubulin (cytoplasmic fraction) or Lamin 
A/C (nuclear fraction). Statistics calculated by unpaired Student’s t-test, where *** p ≤ 0.001. 
 
assessed FOXO1 expression, activity and subcellular localisation in CLL cell lines 
HG-3 and MEC-1, which possess prognostic features associated with favourable 
and poor prognosis, respectively (Figure 5.1a,b). These data showed that FOXO1 
expression was significantly higher in MEC-1 cells compared to HG-3 cells (Figure 
5.1a,b). Despite marked differences in FOXO1 expression, relative AKT-
dependent FOXO1T24 phosphorylation levels were comparable in HG-3 and MEC-1 
cells, irrespective of prognostic factors (Figure 5.1a,c). We next assessed 
localisation of FOXO1 in HG-3 and MEC-1 cells by IF (Figure 5.1d) and subcellular 
fractionation (Figure 5.1e). Notably, despite AKT kinase activity (Figure 5.1a) 
and AKT-dependent FOXO1T24 phosphorylation (Figure 5.1a,c), both approaches 
confirmed that HG-3 and MEC-1 cells express nuclear FOXO1 (Figure 5.1d,e).  
5.2.2 COMBO treatment promotes FOXO1 nuclear localisation 
and enhances activity in MEC-1 cells  
Earlier experiments revealed that AZD8055 treatment inhibited AKTS473 
phosphorylation in HG-3 and MEC-1 cells, whereas AKTT308 phosphorylation was 
largely unaffected (Figure 3.9). In contrast, single-agent ibrutinib or COMBO 
successfully diminished both AKTS473 and AKTT308 phosphorylation in HG-3 and 
MEC-1 cells (Figure 3.9). Because treatment reduced AKT kinase activity, it was 
of interest to discover whether this had a commensurate impact on AKT-
dependent FOXO1T24 phosphorylation. HG-3 and MEC-1 cells were subjected to 
short-term treatment with AZD8055, ibrutinib or COMBO. Thereafter, the 
phosphorylation status of FOXO1T24 was assessed (Figure 5.2a,b). Ibrutinib 
significantly reduced AKT-dependent FOXO1T24 phosphorylation in HG-3 cells, 
while AZD8055 (p = 0.07) and the combination treatment (p = 0.056) resulted in 
a near-significant reduction in FOXO1T24 phosphorylation (Figure 5.2a,b). 





Figure 5.2 - COMBO treatment inhibits AKT-mediated FOXO1T24 phosphorylation, promotes 
FOXO1 cytoplasmic translocation and increases FOXO1 DNA-binding activity in MEC-1 
cells. 
(a) Representative western blot of HG-3 (n=3) and MEC-1 (n=3) cells treated with AZD8055 (100 
nM), Ibrutinib (1 µM), COMBO or DMSO vehicle control for 1 h. Blots were probed for FOXO1T24, 
FOXO1, AKTT308, AKTS473, AKT and GAPDH (loading control; #1 and #2 referring to mirror blots). 
(b) Relative FOXO1T24 phosphorylation levels in HG-3 (n=3; yellow bars) and MEC-1 cells (n=3; 
purple bars). (c) Subcellular fractionation of MEC-1 cells (n=3) treated with AZD8055 (100 nM), 




generated. Blots were probed for FOXO1, Lamin A/C and β-Tubulin. Densitometry for cytoplasmic 
(FOXO1/β-Tubulin) and nuclear (FOXO1/Lamin A/C) FOXO1 expression are shown (relative to 
unstimulated vehicle control). (d, e) Densitometry of FOXO1 expression in (d) cytoplasmic and (e) 
nuclear fractions from MEC-1 cells (n=4), treated as described in (a). Densitometry calculated as in 
(c). (f) FOXO1 DNA-binding activity (OD450) of MEC-1 cells (n=3), treated as described in (a). 
Individual datapoints are represented by white circles. Data expressed as the mean ± SEM. 
Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001. 
 
FOXO1T24 phosphorylation in MEC-1 cells, whereas AZD8055 visibly reduced 
FOXO1T24 phosphorylation (Figure 5.2a,b). We next examined treatment-induced 
FOXO1 localisation in MEC-1 cells by subcellular fractionation (Figure 5.2c-e). 
These data showed that nuclear FOXO1 localisation was enhanced in response to 
AZD8055, ibrutinib and COMBO treatment (Figure 5.2c-e). AZD8055 and ibrutinib 
individually reduced cytoplasmic FOXO1 expression, which was concurrently 
elevated in the nuclear fraction (Figure 5.2c-e). Moreover, COMBO treatment 
significantly decreased FOXO1 expression in the cytoplasmic fraction, while 
nuclear FOXO1 was simultaneously enhanced (Figure 5.2c-e). Encouragingly, 
nuclear FOXO1 expression largely mirrored relative FOXO1T24 phosphorylation 
levels (Figure 5.2a-e). Finally, we asked whether treatment-induced FOXO1 
nuclear accumulation conferred an increase in FOXO1 activity in MEC-1 cells 
(Figure 5.2f). These data revealed that ibrutinib significantly elevated FOXO1 
DNA-binding activity in MEC-1 cells, while AZD8055 treatment only modestly 
enhanced FOXO1 activity (Figure 5.2f). Interestingly, FOXO1 activity was near-
significantly greater in ibrutinib-treated MEC-1 cells compared to AZD8055 
treatment (p = 0.07; Figure 5.2f). The COMBO treatment significantly increased 
FOXO1 transcriptional activity comparable to ibrutinib-treated MEC-1 cells 
(Figure 5.2f). 
5.2.3 Generation of FOXO1 targeting shRNAs using the pLKO.1 
lentiviral vector  
Nuclear FOXO1 expression in HG-3 and MEC-1 cells indicates that FOXO1 is (to an 
extent) transcriptionally active (Figure 5.1). Therefore, one might speculate that 
FOXO1 facilitates CLL progression by maintaining cellular homeostasis. Equally, 
COMBO treatment-induced FOXO1 nuclear translocation (Figure 5.2c-e) and 
enhanced DNA-binding activity (Figure 5.2f) suggests FOXO1 may play a role in 
mediating the response to treatment. We therefore assessed the importance of 
FOXO1 by transducing MEC-1 cells with shRNA lentiviral vectors (Figure 5.3a). 




evaluated (Table 2.19; referred to as #1, #2, #3, #4 and #5), alongside 
scrambled (Scr) shRNA control. FOXO1 depletion was verified by assessing 
transcript abundance and protein levels by RT-qPCR (Figure 5.3b) and Western 
blotting (Figure 5.3e), respectively, at 7- and 13-days post-transduction (relative 
to Scr control). FOXO1 expression was repressed by constructs #2 (0.68), #4 
(0.85) and #5 (0.41) at 13-days post-transduction, whereas constructs #1 (1.04) 
and #3 (1.23) enhanced FOXO1 expression (Figure 5.3b). Of note, FOXO1 
transcript levels were efficiently depleted by construct #5 (0.5) at 7-days post-
transduction, whereas constructs #2 (0.99) and #4 (0.92) were largely ineffective 
(Figure 5.3b). Western blotting revealed that constructs #4 (0.86) and #5 (0.34) 
repressed FOXO1 protein levels compared to Scr control 13-days post-
transduction (Figure 5.3e). Although construct #2 reduced FOXO1 transcript 
abundance (0.68), FOXO1 protein levels (1.01) were unaffected (Figure 5.3e). 
Interestingly, while construct #1 was ineffective at reducing FOXO1 mRNA 
expression (1.04), FOXO1 protein levels (0.71) were repressed (Figure 5.3e). 
Notably, FOXO1 protein levels were also efficiently depleted by construct #1 
(0.89), #4 (0.74) and #5 (0.4) at 7-days post-transduction (Figure 5.3e). As FOXOs 
exhibit functional redundancy in the context of tumour suppression (404), we 
assessed the transcript abundance of FOXO3 (Figure 5.3c) and FOXO4 (Figure 
5.3d) in FOXO1-depleted MEC-1 cells. FOXO3 transcript levels were enhanced in 
constructs #1 (1.22), #2 (1.29), #3 (1.33), #4 (1.35) and #5 (1.21) compared to 
Scr control 13-days post-transduction (Figure 5.3c). Conversely, FOXO4 
expression was decreased by constructs #1 (0.75), #2 (0.86), #4 (0.74) and #5 
(0.88), whereas construct #3 (1.16) marginally elevated FOXO4 expression 
(Figure 5.3d). Based on these data, we chose two shRNA constructs that reduced 
FOXO1 expression: #1 (Clone ID: TRCN0000039582) targeting the FOXO1 coding 
region (CDS) and #5 (Clone ID TRCN0000039578) targeting the FOXO1 3’ 
untranslated region (3’ UTR). Repressing FOXO1 expression via shRNA-mediated 
knockdown reduces the proportion of transcriptionally active FOXO1 (Figure 
5.3f). As such, this methodology will provide insights into the importance of 
FOXO1 in facilitating MEC-1 cellular homeostasis and mediating the response to 
treatment. Although FOXO1 knockdown by construct #1 was marginal, it was 
important to choose at least two constructs to validate the functional effect of 
FOXO1 knockdown. Equally, the data generated via construct #1 may provide 




appears to upregulate FOXO1 mRNA expression, the construct may act post-
translationally.  
 
Figure 5.3 - Generation of FOXO1-targeting shRNA-expressing lentiviral constructs. 
(a) Schematic depicting experimental design (modified from (420)) . HEK293T cells were 
transfected and shRNA-containing lentiviral particles subsequently harvested. Lentiviral-transduced 
MEC-1 cells were puromycin selected and expanded. (b– d) RT-qPCR to assess expression of (b) 
FOXO1 (yellow bars), (c) FOXO3 (turquoise bars) and (d) FOXO4 (dark blue bars) in puromycin-
selected (7 and 13 days) MEC-1 cells transduced with FOXO1-targeting shRNA constructs #1, #2, 
#3, #4, #5 and Scr control. The ΔΔCT method was used to calculate expression levels, where 
samples were first normalised to the internal reference gene GUSB and then made relative to Src 




transduced with FOXO1-targeting shRNA constructs #1, #2, #3, #4, #5 Scr control. Blots were 
probed for FOXO1 and GAPDH (loading control). Densitometry (FOXO1/GAPDH) for each 
construct is shown. (f) Schematic depicting FOXO1 expression and activity in CLL cells transduced 
with Scr control (left panel) and FOXO1-targeting shRNA (right panel). Reduced FOXO1 
expression via shRNA-mediated knockdown reduces the proportion of transcriptionally active 
FOXO1. 
 
5.2.4 FOXO1 expression is enhanced in FOXO1-depleted MEC-1 
cells treated with COMBO 
We first assessed the effect of shRNA-mediated FOXO1 knockdown by 
interrogating the AKT-FOXO1 axis. Interestingly, studies have demonstrated that 
FOXO1 enhances mTORC2 activity and resultant AKTS473 phosphorylation via 
upregulation of the mTORC2 component RICTOR (542, 543). Therefore, we 
examined FOXO1 (FOXO1T24) and AKT (AKTT308 and AKTS473) activity in FOXO1-
depleted MEC-1 cells with or without long-term (48 h) COMBO treatment. 
Western blotting showed that FOXO1 expression was diminished by constructs #1 
and #5 compared to Scr control (Figure 5.4a). Notably, however, FOXO1 
expression (relative to untreated) was elevated in COMBO-treated MEC-1 cells 
transduced with constructs #1 (p = 0.13) and #5, whereas FOXO1 levels were 
unaffected by COMBO treatment in Scr control cells (Figure 5.4a,b). 
Furthermore, FOXO1 expression appeared greater in COMBO-treated MEC-1 cells 
transduced with construct #5 compared to Scr control (p = 0.07; Figure 5.4a,b). 
FOXO1T24 phosphorylation was moderately enhanced by construct #1 compared 
to Scr control, whereas FOXO1T24 phosphorylation levels were near-significantly 
(p = 0.051) decreased by construct #5 (Figure 5.4a,c). Interestingly, FOXO1T24 
phosphorylation was largely unaffected by long-term COMBO treatment in MEC-1 
cells transduced with constructs #1, #5 or Scr control (relative to untreated) 
(Figure 5.4c). However, relative FOXO1T24 phosphorylation was significantly 
decreased in COMBO-treated MEC-1 cells transduced with construct #5 compared 
to construct #1 (Figure 5.4c). Additionally, a trend towards reduced FOXO1T24 
phosphorylation was observed in COMBO-treated MEC-1 cells transduced with 
construct #5 compared to Scr control cells (p = 0.11; Figure 5.4c). AKTT308 
phosphorylation was largely unaffected by FOXO1 knockdown (constructs #1 and 
#5) compared to Scr control (Figure 5.4a,d). However, although long-term 
COMBO treatment had no effect on AKTT308 phosphorylation in Scr control cells, 
AKTT308 phosphorylation was significantly inhibited by COMBO treatment in 





Figure 5.4 - FOXO1 knockdown reduces AKT-mediated FOXO1T24 phosphorylation and 
increases FOXO1 expression following COMBO treatment. 
(a) Representative western blot of puromycin-selected MEC-1 cells (n=3) transduced with FOXO1-
targeting shRNA constructs #1, #5 or Scr control and treated with COMBO or vehicle control for 48 
h. Blots were probed for FOXO1, FOXO1T24, AKTT308, AKTS473, AKT and GAPDH (loading control; 
#1 and #2 referring to mirror blots). (b) Relative FOXO1 expression and (c - e) phosphorylation 
levels of (c) FOXO1T24, (d) AKTT308 and (e) AKTS473 in MEC-1 cells (n=3) transduced with FOXO1-
targeting shRNA constructs #1, #5 or Scr control and treated with (+; peach bars) or without (-; blue 




for each construct. Individual datapoints are represented by white or black circles. Data expressed 
as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05. 
 
untreated) (Figure 5.4d). Furthermore, COMBO-induced AKTT308 phosphorylation 
levels were visibly less in FOXO1-depleted MEC-1 cells (constructs #1 and #5) 
compared with Scr control cells (Figure 5.4d). Interestingly, AKTS473 
phosphorylation was modestly enhanced by FOXO1 repression via constructs #1 
(p = 0.11) and #5 compared to Scr control (Figure 5.4e). In support of earlier 
findings (Figure 3.7b), COMBO treatment near-significantly inhibited AKTS473 
phosphorylation in MEC-1 cells with all constructs (Figure 5.4a,e).  
5.2.5 FOXO1 knockdown reduces COMBO-induced BIM 
upregulation in MEC-1 cells 
Yusuf et al. showed that treatment of mature B cells with PI3K inhibitors or 
ectopic expression of FOXO1-A3 mediated cell death in a FOXO1-dependent 
manner (390). Although MEC-1 cell viability was largely insensitive to COMBO 
treatment (Figure 3.10a,d), previous experiments demonstrated that pro-
apoptotic FOXO1-target BIM (387) was upregulated in response to COMBO 
treatment (Figure 3.10f). To determine the effect of FOXO1 depletion on cell 
viability, MEC-1 cells stably transduced with constructs #1, #5 or Scr control 
(Figure 5.5a) were incubated with or without COMBO for 48 h. Thereafter, the 
cells were stained with Annexin V/7-AAD and analysed by flow cytometry (Figure 
5.5b-d). Although MEC-1 cell viability was largely unaffected by shRNA-mediated 
FOXO1 knockdown, a slight increase in cell viability was observed in MEC-1 cells 
transduced with construct #5 (Figure 5.5b,c). Consistent with these findings, 
apoptosis was modestly decreased in FOXO1-depleted MEC-1 cells (construct #5) 
compared to Scr control (Figure 5.5a,d). In contrast with earlier experiments 
(Figure 3.10a,d), COMBO treatment significantly reduced viability of Scr control 
cells (Figure 5.5b,c), corresponding to a significant increase in apoptosis (Figure 
5.5b,d). Equally, however, cell viability of FOXO1-depleted MEC-1 cells was also 
significantly diminished by COMBO treatment (Figure 5.5b,c), reflected by a 
concomitant increase in apoptosis (Figure 5.5b,d). Thus, FOXO1 knockdown was 
unable to protect MEC-1 cells from COMBO-induced cell death (Figure 5.5b-d). 
Nevertheless, given that COMBO treatment upregulated BIM expression in MEC-1 
cells (Figure 3.10f), it was of interest to determine whether COMBO-induced BIM 





Figure 5.5 - shRNA-mediated knockdown of FOXO1 does not impact cell survival in MEC-1 
cells. 
(a) Representative western blot of FOXO1 expression in MEC-1 cells transduced with FOXO1-
targeting shRNA constructs #1, #5 or Scr control. Blots were probed for FOXO1 and GAPDH 
(loading control). Densitometry (FOXO1/GAPDH) for each construct is shown. (b) Representative 
FACS plot of transduced (#1, #5 or Scr control) MEC-1 cells stained with Annexin V/7-AAD to 
assess cell viability following treatment with COMBO or vehicle control for 48 h. (c) Percentage 
viable and (d) apoptotic MEC-1 (n=3) cells transduced with FOXO1-targeting shRNA constructs #1, 
#5 or Scr control and treated with COMBO (pink bars) or vehicle control (blue bars) for 48 h, as 
described in (b). Viability is defined as Annexin Vneg and 7-AADneg; apoptotic cells are defined as 
Annexin Vpos and 7-AADpos. (e) Representative western blot of transduced (#1, #5 or Scr control) 
MEC-1 cells (n=3) treated with COMBO or vehicle control for 48 h. Blots were probed for BIM 
(BIMEL, BIML, and BIMS) and GAPDH (loading control). (f - h) Densitometry of (f) BIMEL, (g) BIML 
and (h) BIMS expression in transduced (#1, #5 or Scr control) MEC-1 cells (n=3) treated with 




is relative to GAPDH. Individual datapoints are represented by white or black circles. Data 
expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 
0.01. 
 
(BIMEL, BIML, and BIMS) protein expression in FOXO1-depleted MEC-1 cells 
following COMBO treatment (Figure 5.5e-h). Western blotting showed that BIMEL 
(Figure 5.5e,f), BIML (Figure 5.5e,g), and BIMS (Figure 5.5e,h) expression were 
largely unaffected by FOXO1 knockdown via constructs #1 or #5 (Figure 5.5e-h). 
As expected, COMBO treatment upregulated BIMEL (p = 0.07; Figure 5.5e,f), BIML 
(p = 0.08; Figure 5.5e,g) and BIMS (p = 0.06; Figure 5.5e,h) expression in Scr 
control cells. Although BIMEL, BIML, and BIMS expression was also notably 
elevated by COMBO treatment in FOXO1-depleted MEC-1 cells (Figure 5.5e-h), 
COMBO-induced upregulation of BIMEL (p = 0.0508; Figure 5.5e,f), BIML (p = 0.06; 
Figure 5.5e,g), and BIMS (Figure 5.5e,h) was visibly reduced in MEC-1 cells 
transduced with construct #5 compared with Scr control.  
5.2.6 MEC-1 cell size is unaffected by shRNA-mediated FOXO1 
repression 
As explained earlier, mTORC1 regulates cell size via the coordinated activities of 
4E-BP1 and S6K1 (442). FOXOs have been shown to downregulate mTORC1 
activity through upregulation of sestrin 3 (SESN3), which activates mTORC1-
negative regulators TSC1/2 (384, 542). Indeed, overexpression of FOXO1 has 
been reported to reduce cardiomyocyte cell size, which was blocked by 
expression of a dominant-negative FOXO1 construct (544). We therefore assessed 
the impact of FOXO1 knockdown on MEC-1 cell size by flow cytometry (Figure 
5.6). These data showed that MEC-1 cell size was largely unaffected by shRNA-
mediated FOXO1 knockdown (Figure 5.6a-c). However, we noted that cell size 
was modestly enhanced in FOXO1-depleted MEC-1 cells via construct #5 (Figure 
5.6c). Because earlier experiments demonstrated that COMBO treatment 
reduced MEC-1 cell size (Figure 3.11), we determined whether FOXO1 
knockdown could prevent MEC-1 cell size reduction upon COMBO treatment 
(Figure 5.6). As expected, COMBO treatment significantly decreased cell size in 
Scr control cells (Figure 5.6a-c). However, COMBO treatment also significantly 
decreased cell size in MEC-1 cells transduced with constructs #1 and #5 (Figure 
5.6a-c). Thus, FOXO1 depletion had no effect on COMBO-induced MEC-1 cell size 





Figure 5.6 - FOXO1 knockdown does not affect MEC-1 cell size or COMBO-induced cell 
contraction. 
(a) Representative FACS histogram displaying geometric mean of forward scatter-area (FSC-A) of 
transduced (FOXO1 #1, FOXO1 #5 or Scrambled control) MEC-1 cells treated with COMBO (green 
histograms) or DMSO vehicle control (Vehicle; purple histograms) for 48 h. (b) Representative 
FACS plot (forward scatter-area (FSC-A) against sideward scatter-A (SSC-A)) assessing cell size 
of transduced (FOXO1 #1, FOXO1 #5 or Scrambled control) MEC-1 cells, treated as described in 
(a). (c) Relative cell size (geometric mean) of transduced (#1, #5 or Scr control) MEC-1 (n=3) cells 
treated with (+; green bars) or without (-; purple bars), as described in (a). Geometric means for 
each condition are relative to Scrambled (Scr) vehicle control. Individual datapoints are 
represented by white or black circles. Data expressed as the mean ± SEM. Statistics calculated by 





5.2.7 Cytostatic impact of COMBO treatment is unaffected by 
FOXO1 depletion, despite reduced p27KIP1 expression 
Overexpression of constitutively active FOXO1 (FOXO1-A3) in mature B cells 
(390), cHL cell lines (396) or DLBCL cell line DHL4 (397) has been shown to 
induce G1 cell cycle arrest. Equally, we earlier showed that COMBO treatment, 
which enhances FOXO1 activity (Figure 5.2f), inhibits G1/S cell cycle progression 
in MEC-1 cells (Figure 3.12). We therefore investigated the impact of FOXO1 
depletion on cell cycle progression with and without COMBO treatment by flow 
cytometry (Figure 5.7). Analysis of DNA content revealed that FOXO1 knockdown 
had little effect on cell cycle progression in unsynchronized MEC-1 cells 
transduced with constructs #1 or #5 compared to Scr control (Figure 5.7a,b). As 
expected, COMBO treatment induced G1 cell cycle arrest in Scr control cells 
(Figure 5.7a,b). However, COMBO treatment also inhibited cell cycle progression 
in FOXO1-depleted MEC-1 cells (Figure 5.7a,b). As such, FOXO1 knockdown was 
unable to rescue MEC-1 cells from COMBO treatment-induced cell cycle arrest. 
Earlier experiments demonstrated that MEC-1 cell proliferation was effectively 
inhibited by the COMBO treatment (Figure 3.13a-c), corresponding to an 
upregulation of the CDKI p27KIP1 (Figure 3.13d,e), a putative FOXO-target (377, 
382). We therefore addressed whether the anti-proliferative effect of COMBO 
treatment depended on FOXO1 expression (Figure 5.8). Of note, a recent study 
showed that FOXO1-repressed DLBCL cell lines were effectively resistant to SYK 
or AKT inhibitor-induced cell growth inhibition (397). CTV-stained FOXO1-
depleted MEC-1 cells were treated with or without COMBO for 72 h. Thereafter, 
cell proliferation was analysed by flow cytometry (Figure 5.8a,b). These data 
showed that FOXO1 knockdown via constructs #1 and #5 had no effect on cell 
proliferation (Figure 5.8a,b). Expectedly, COMBO treatment significantly 
inhibited cell proliferation in Scr control cells (Figure 5.8a,b). However, COMBO 
treatment also significantly inhibited cell proliferation in FOXO1-depleted MEC-1 
cells (Figure 5.8a,b). Thus, FOXO1 knockdown was unable to protect MEC-1 cells 
from the cytostatic effect of the COMBO treatment. Nevertheless, studies have 
shown that FOXO1 knockdown reduces CDKN1B (p27KIP1) expression in DLBCL cell 
lines DHL4 and Ly7 (397), while overexpression of FOXO1 elevates CDKN1B 
(p27KIP1) expression in cHL cell lines (396). We therefore examined modulation of 




depleted MEC-1 cells with and without COMBO treatment by Western blotting. 
Compared to Scr control, these data showed that p27KIP1 expression was largely 
unaffected by FOXO1 knockdown in MEC-1 cells (Figure 5.8c,d). However, we 
noted that FOXO1 depletion via construct #5 resulted in a modest  
 
Figure 5.7 - shRNA-mediated FOXO1 knockdown does not influence cell cycle progression 
in MEC-1 cells. 
(a) Representative FACS histograms of transduced (FOXO1 #1, FOXO1 #5 or Scrambled control) 
MEC-1 cells stained with PI for cell cycle analysis by quantitation of DNA content following 
treatment with COMBO (orange histograms; bottom panel) or DMSO vehicle control (Vehicle; 
purple histograms; top panel) for 48 h. (b) Quantification of DNA content (%) for cycle cycle phase 




1 cells (n=3) treated with (+) or without (-) COMBO. Data from each replicate are depicted as 
‘fraction of total’, where total values are equal to 100. Data expressed as the mean ± SEM. 





Figure 5.8 - FOXO1 knockdown does not affect cell proliferation, but p27KIP1 and p21CIP1 
expression levels are modulated in FOXO1-depleted MEC-1 cells following COMBO 
treatment. 
(a) Representative FACS histogram of transduced (FOXO1 #1, FOXO1 #5 or Scrambled control) 
MEC-1 cells stained with CTV to assess cell proliferation following treatment with COMBO (orange 
histograms) or DMSO vehicle control (Vehicle; blue histograms) for 72 h. A black vertical line 
represents the peak of the Scrambled vehicle control histogram. A black ‘dashed’ vertical line 




are shown. (b) Assessment of CTV geometric mean for transduced (#1, #5 or Scr control) MEC-1 
cells (n=3), treated as described in (a). (c) Representative western blot of transduced (#1, #5 or Scr 
control) MEC-1 cells (n=3) treated with (+) or without (-) COMBO for 48 h. Blots were probed for 
p27KIP1, p21CIP1 and GAPDH (loading control). (d, e) Densitometry of (d) p27KIP1 and (e) p21CIP1 
expression in transduced (#1, #5 or Scr control) MEC-1 cells (n=3) following treatment with (+; 
purple bars) or without (-; pink bars) COMBO. Individual datapoints from each replicate are shown 
as white or black circles. Data expressed as the mean ± SEM. Statistics calculated by one-way 
ANOVA, where * p ≤ 0.05, ** p ≤ 0.01. 
 
downregulation of p27KIP1 expression (Figure 5.8c,d). Consistent with previous 
experiments (Figure 3.13d,e), COMBO treatment elicited a near-significant 
upregulation in p27KIP1 expression in Scr control cells (p = 0.07; Figure 5.8c,d). 
Although COMBO treatment also visibly enhanced p27KIP1 expression in FOXO1-
depleted MEC-1 cells (compared to untreated), COMBO-induced upregulation of 
p27KIP1 was significantly decreased in MEC-1 cells transduced with construct #1, 
and near-significantly reduced by construct #5 (p = 0.09) compared to COMBO-
treated Scr control cells (Figure 5.8c,d). While p21CIP1 expression was not 
affected by FOXO1 knockdown via construct #1, it was visibly reduced in MEC-1 
cells transduced with construct #5 (Figure 5.8c,e). In contrast with Figure 3.13f, 
p21CIP1 expression was significantly reduced by COMBO treatment in Scr control 
cells (Figure 5.8c,e). Interestingly, p21CIP1 expression was also significantly 
reduced by COMBO treatment in FOXO1-depleted MEC-1 cells via construct #5 
(compared to untreated), with a similar trend seen in COMBO treated MEC-1 
cells transduced with construct #1 (Figure 5.8c,e).  
5.2.8 Modulation of FOXO target transcript abundance 
demonstrates that FOXO1 regulates genes in a highly 
context-specific manner 
Although FOXO1 knockdown had little effect on MEC-1 cell functionality or the 
physiological response to COMBO treatment, we were encouraged by the 
modulation of FOXO targets at the protein level (Figures 5.5e-h and 5.8c-e). We 
therefore assessed transcript abundance of known FOXO target genes: FOXO1, 
IGF1R, SESN3, BCL2-L11 (BIM), BBC3, GADD45A, CDKN1A, CDKN1B, CCNG2 and 
CCND2 in FOXO1-depleted MEC-1 cells with or without COMBO treatment by RT-
qPCR (Figure 5.9). As expected, FOXO1 expression was significantly reduced in 
MEC-1 cells transduced with construct #5 (Figure 5.9a), corresponding to relative 
mRNA (Figure 5.3b) and protein (Figure 5.3e) levels demonstrated earlier. 
However, FOXO1 expression was largely unaffected by construct #1 (Figure 




COMBO treatment in Scr control cells (p = 0.13; Figure 5.9a). Furthermore, 
FOXO1 expression was similarly elevated in FOXO1-depleted MEC-1 cells 
(constructs #1 and #5) following COMBO treatment (Figure 5.9a). We also noted 
that COMBO-induced FOXO1 upregulation in FOXO1-depleted or Scr control cells 
was discernibly proportionate to untreated FOXO1 expression levels (Figure 
5.9a). Irrespectively, COMBO-induced FOXO1 upregulation was visibly less in 
MEC-1 cells transduced with construct #5 than in Scr control cells (p = 0.1; 
Figure 5.9a). ‘Basal’ IGF1R transcript levels were unaffected by FOXO1 
knockdown (Figure 5.9b). However, IGF1R expression was notably enhanced 
following COMBO treatment in Scr control cells (Figure 5.9b). Interestingly, 
whereas COMBO treatment similarly induced IGF1R expression in MEC-1 cells 
transduced with construct #1 (p = 0.09; Figure 5.9b), COMBO treatment had no 
effect on IGF1R expression in FOXO1-depleted MEC-1 cells by construct #5 
(Figure 5.9b). In support of this observation, IGF1R expression in COMBO-treated 
FOXO1-depleted MEC-1 cells (construct #5) was significantly less than COMBO-
treated Scr control cells (Figure 5.9b). COMBO treatment visibly increased SESN3 
transcript abundance in Scr control cells, and to a lesser extent in MEC-1 cells 
transduced with construct #1 (Figure 5.9c). Interestingly, SESN3 expression was 
significantly downregulated in FOXO1-depleted MEC-1 cells via construct #5 
following COMBO treatment (Figure 5.9c). Unexpectedly, BCL2-L11 expression 
was not affected by FOXO1 knockdown (Figure 5.9d). However, consistent with 
earlier observations (Figure 5.5e-h), COMBO treatment upregulated BCL2-L11 
expression in Scr control cells and those transduced with construct #1, while 
BCL2-L11 expression was seemingly unaffected by COMBO treatment in FOXO1-
depleted MEC-1 cells via construct #5 (Figure 5.9d). Furthermore, BCL2-L11 
transcript levels were significantly lower in COMBO-treated MEC-1 cells 
transduced with construct #5 compared to construct #1 (Figure 5.9d). Consistent 
with Figure 5.9d, expression of pro-apoptotic BBC3 was largely unaffected by 
FOXO1 knockdown (Figure 5.9e). However, COMBO treatment produced a visible 
trend towards increased BBC3 levels in Scr control cells and MEC-1 cells 
transduced with construct #1 (Figure 5.9e). Surprisingly, COMBO treatment 
further enhanced BBC3 expression in FOXO1-depleted MEC-1 cells via construct 
#5, visibly greater than COMBO-induced BBC3 expression in Scr control cells and 
MEC-1 cells transduced with construct #1 (Figure 5.9e). GADD45A expression 





Figure 5.9 - shRNA-mediated knockdown of FOXO1 modulates expression (mRNA) levels of 
FOXO1 transcriptional targets. 
(a - j) RT-qPCR to assess transcript abundance of (a) FOXO1, (b) IGF1R, (c) SESN3, (d) BCL2-
L11 (BIM), (e) BBC3, (f) GADD45A, (g) CDKN1A (p21CIP1), (h) CDKN1B (p27KIP1), (i) CCNG2 and 
(j) CCND2 in transduced (#1, #5 or Scr control) MEC-1 cells (n=3) treated with (+; blue bars) or 
without (-; yellow bars) COMBO for 48 h. The ΔΔCT method was used to calculate expression 
levels, where samples were first normalised to the internal reference gene GUSB and then made 
relative to vehicle control. Individual datapoints are represented by white circles. Data expressed 




to Scr control, with the GADD45A transcript abundance being distinctly lower in 
MEC-1 cells transduced with construct #5 than construct #1 (p = 0.09; Figure 
5.9f). COMBO treatment near-significantly downregulated GADD45A expression 
in Scr control cells (p = 0.07; Figure 5.9f). Similarly, GADD45A expression was 
also reduced in FOXO1-depleted MEC-1 cells (constructs #1 and #5) following 
COMBO treatment (Figure 5,9f). As before (Figure 5.9a), we noted that COMBO-
induced GADD45A downregulation was largely proportionate to GADD45A 
expression levels in untreated cells (Figure 5.9f). Although CDKN1A transcript 
abundance was unaffected by FOXO1 knockdown via construct #1, CDKN1A 
expression was significantly, albeit counterintuitively, reduced in FOXO1-
depleted MEC-1 cells transduced with construct #5 (Figure 5.9g). Moreover, 
CDKN1A expression was near-significantly decreased by construct #5 compared 
to construct #1 (p = 0.06; Figure 5.9g). Nevertheless, consistent with Figure 
5.8e, COMBO treatment significantly downregulated CDKN1A expression in Scr 
control cells (Figure 5.9g). Equally, CDKN1A expression was also significantly 
reduced in COMBO-treated MEC-1 cells transduced with construct #1, and near-
significantly reduced via construct #5 (p = 0.059; Figure 5.9g). Conflicting with 
Figure 5.8d, CDKN1B expression was significantly upregulated in FOXO1-depleted 
MEC-1 cells by construct #1, and comparably so by construct #5 (Figure 5.9h). 
Furthermore, COMBO treatment elicited a modest downregulation in CDKN1B 
expression in Scr control cells (Figure 5.9h). Intriguingly, however, CDKN1B 
transcript abundance was also observably reduced by COMBO treatment in 
FOXO1-depleted MEC-1 cells (construct #1 and #5) (Figure 5.9h). FOXO1 
repression by construct #5 reduced CCNG2 expression, compared with Scr and 
construct #1 cells (p = 0.0505; Figure 5.9i), while COMBO treatment visibly 
reduced CCNG2 transcript abundance in Scr control cells (Figure 5.9i). 
Furthermore, CCNG2 expression was significantly reduced by COMBO treatment 
in MEC-1 cells transduced with construct #1 (Figure 5.9i). While CCNG2 
expression was reduced in COMBO-treated MEC-1 cells transduced with construct 
#5, a notable trend towards reduced CCNG2 expression existed between COMBO-
treated Scr control cells and COMBO-treated FOXO1-depleted MEC-1 cells via 
construct #5 (p = 0.09; Figure 5.9i). FOXO1 knockdown- and COMBO treatment-
induced CCND2 modulation largely mirrored that of CCNG2 (Figure 5.9j). CCND2 
expression was marginally, but near-significantly, enhanced in MEC-1 cells 




However, consistent with Figure 5.9i, CCND2 expression was visibly 
downregulated in FOXO1-depleted MEC-1 cells via construct #5 (p = 0.1; Figure 
5.9j), near-significantly less than construct #1 (p = 0.09; Figure 5.9j). COMBO 
treatment observably reduced CCND2 transcript abundance in Scr control cells 
(Figure 5.9j). Equally, trends towards reduced CCND2 expression were observed 
in MEC-1 cells transduced with construct #1 (Figure 5.9j) and construct #5 (p = 
0.1; Figure 5.9j) following COMBO treatment. Of note, CCND2 expression was 
significantly less in COMBO-treated MEC-1 cells transduced with construct #5 
compared to COMBO-treated Scr control cells (Figure 5.9j).  
5.2.9 HG-3 and MEC-1 cells are largely insensitive to FOXO1 
inhibition with AS1842856 
Since shRNA-mediated FOXO1 knockdown was only partial, we argued that 
residual FOXO1 was capable of eliciting a proportionate response to COMBO 
treatment via induction/repression of target gene transcription. We therefore 
adopted the FOXO1-specific inhibitor AS1842856, which inhibits FOXO1 DNA-
binding activity (545). Nagashima et al. identified AS1842856 [5-amino-7-
(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid] 
via high-throughput affinity selection-mass spectrometry screening of small-
molecule compounds that bound to active (dephosphorylated) FOXO1. Using an 
insulin responsive element (IRE) promotor-driven reporter assay (luciferase), 
AS1842856 was shown to diminish FOXO1 DNA binding activity in HepG2 cells in a 
dose-dependent manner (IC50 = 0.033 µM). In contrast, FOXO3 and FOXO4 
inhibition was considerably less potent (IC50 > 1 µM). The authors further showed 
that AS1842856 (100 nM) repressed FOXO1 DNA-binding activity by 70 %, while 
FOXO3 and FOXO4 DNA-binding activity was diminished by 3 % and 20 %, 
respectively. As such, AS1842856 is described as a ‘selective’ FOXO1 inhibitor. 
Furthermore, AS1842856 had no effect on FOXO1 phosphorylation status, insulin-
induced FOXO1S256 phosphorylation nor FOXO1 mRNA expression levels. 
Importantly, the authors confirmed that AS1842856 did not bind to inactive 
(phosphorylated) FOXO1 (FOXO1S256), demonstrating that the compound 
specifically targets active (dephosphorylated) FOXO1. Although ‘full’ 
characterisation is lacking, Nagashima et al. proposed that AS1842856 interferes 
with FOXO1 binding to coactivators, such as cAMP-response-element-binding 





Figure 5.10 - The selective FOXO1 inhibitor AS1842856 confers a modest dose-dependent 
reduction in CLL cell survival. 
(a) Representative FACS plot of HG-3 (top panel) and MEC-1 (bottom panel) cells stained with 




AS1842856 (vehicle, 10, 30, 100, 300, 1000 nM) for 48 h. (b, c) Dose-response / dose-effect curve 
of (b) HG-3 (n=3) and (c) MEC-1 cells (n=3) treated as described in (a). EC50 values generated by 
nonlinear regression (curve fit) as an average of each biological replicate. (d) Graphical 
comparison of EC50 values from (b, c) for HG-3 (yellow bar) and MEC-1 cells (pink bars) treated 
with AS1842856. (e) Representative FACS plot of a primary CLL sample (#CLL113) stained with 
Annexin V/7-AAD to assess cell viability following treatment with increasing concentrations of 
AS1842856 (vehicle, 3, 10, 30, 100, 300, 1000, 3000 nM) for 48 h. (f, g) Dose-response / dose-
effect curve of primary CLL samples (n=4) treated as described in (e). (f) EC50 values generated by 
nonlinear regression (curve fit) as an average of each biological replicate. (g) Data represented as 
a bar chart. Individual datapoints (unless otherwise represented) are represented by white circles. 
Data expressed as the mean ± SEM. Statistics calculated by unpaired Student’s t-test or one-way 
ANOVA. n.s. = not significant. EC50 values generated by extrapolation by GraphPad Prism.  
 
study, Yu et al. demonstrated that AS1842856 promoted cytoplasmic 
sequestration of FOXO1 in human embryonic stem cells (hESCs) (547). In any 
case, AS1842856 inhibits FOXO1 DNA-binding activity, distinct from shRNA-
mediated knockdown of FOXO1 expression. To assess the impact of AS1842856 
treatment on cell viability, HG-3 and MEC-1 cells were incubated with increasing 
concentrations of drug for 48 h. Thereafter, cells were stained with Annexin 
V/7-AAD and analysed by flow cytometry (from which the EC50 was calculated) 
(Figure 5.10a-d). Treatment of HG-3 (Figure 5.10a,b) and MEC-1 cells (Figure 
5.10a,c) with AS1842856 resulted in a dose-dependent reduction in cell viability. 
However, HG-3 (EC50 = 4.46 µM) and MEC-1 (EC50 = 3.94 µM) cells were largely 
insensitive to AS1842856 up to 1 µM (Figure 5.10d). In primary CLL cells treated 
with AS1842856, cell viability was maintained at concentrations up to 30 nM and 
then reduced in a dose-dependent manner (Figure 5.10e-g). Moreover, although 
primary CLL cells were more sensitive to AS1842856 (EC50 = 1.225 µM) than CLL 
cell lines, only modest reductions in cell viability were observed at doses 
achievable in vivo (403, 545) with minimal off-target effects (Figure 5.10e-g). 
Because AS1842856 selectively inhibited FOXO1 DNA-binding activity (IC50 = 33 
nM) to a considerably larger extent than FOXO3 or FOXO4 (545), we proceeded 
with AS1842856 at 30 nM and 100 nM for in vitro experiments. Of note, EC50 
values were generated by extrapolation using GraphPad Prism software. 
 
5.2.10 AS1842856 does not prevent COMBO-induced FOXO1 
nuclear translocation 
AS1842856 has been shown to selectively inhibit ‘active’ FOXO1 (545, 546) and 
promote FOXO1 cytoplasmic retention in hESCs (547). To assess whether 
AS1842856 can block COMBO-induced FOXO1 nuclear translocation in MEC-1 





Figure 5.11 - Short-term AS1842856 treatment, simultaneously treated with or without 





(a) Schematic depicting AS1842856 mechanism of action. AS1842856 inhibits ‘active’ FOXO1, but 
not the ‘inactive’ phosphorylated form. (b) Subcellular fractionation of MEC-1 cells (n=3) treated 
with COMBO in the presence of absence of AS1842856 for 1 h. Cytoplasmic, nuclear and whole 
cell lysate (WCL) fractions were generated. Blots were probed for FOXO1, Lamin A/C and β-
Tubulin. Densitometry for cytoplasmic (FOXO1/β-Tubulin) and nuclear (FOXO1/Lamin A/C) FOXO1 
expression are shown (relative to unstimulated vehicle control). (c, d) Densitometry of FOXO1 
expression in (c) cytoplasmic and (d) nuclear fractions from MEC-1 cells (n=4), treated as 
described in (b). Densitometry calculated as in (b). (e) FOXO1 DNA-binding activity (OD450) of 
MEC-1 cells (n=3), treated as described in (b). Individual datapoints are represented by white 
circles. Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 
0.05, ** p ≤ 0.01. 
 
following short-term COMBO treatment with or without AS1842856 (Figure 5.11b-
d). Consistent with Figure 5.2c-e, COMBO treatment induced FOXO1 nuclear 
accumulation (Figure 5.11b-d), demonstrated by a significant reduction in 
cytoplasmic FOXO1 (Figure 5.11b,c) and concomitant increase in nuclear FOXO1 
(Figure 5.11b,d). Interestingly, treatment with AS1842856 alone had no effect on 
FOXO1 cellular distribution (Figure 5.11b-d). Furthermore, COMBO-induced 
FOXO1 nuclear translocation was unaffected by simultaneous incubation with 
AS1842856 (Figure 5.11b-d). Cytoplasmic FOXO1 was reduced in COMBO-treated 
MEC-1 cells incubated with AS1842856 (p = 0.06; Figure 5.11b,c), which 
corresponded to a significant increase in nuclear FOXO1 to levels comparable 
with COMBO treatment alone (Figure 5.11b,d). As COMBO-induced FOXO1 
nuclear accumulation was associated with enhanced DNA-binding activity (Figure 
5.2f), we next addressed whether AS1842856 could block FOXO1 activity in 
COMBO-treated MEC-1 cells (Figure 5.11e). Consistent with earlier observations 
(Figure 5.2f), COMBO treatment significantly enhanced FOXO1 DNA-binding 
activity in MEC-1 cells. (Figure 5.11e). Unexpectedly, AS1842856 treatment 
alone had no effect on FOXO1 DNA-binding activity (Figure 5.11e). Surprisingly, 
simultaneously combining AS1842856 with the COMBO treatment visibly 
enhanced FOXO1 activity to levels greater than COMBO treatment alone (Figure 
5.11e).  
 
5.2.11 FOXO1 expression is unaffected by AS1842856 
treatment in CLL cell lines, whereas AKTS473 
phosphorylation is visibly reduced  
Studies have shown that FOXO1 expression is unaffected by AS1842856 treatment 
in Fao cells (545), adipocytes (548) or hESCs (547). Furthermore, Nagashima et 




or insulin-induced AKTS407 phosphorylation in Fao cells (545). In contrast, earlier 
experiments showed that FOXO1-depleted MEC-1 cells had reduced FOXO1T24 
(Figure 5.4a,c) and increased AKTS473 phosphorylation levels (Figure 5.4a,e). In 
line with these findings, we addressed the long-term effect (48 h) of AS1842856 
treatment on FOXO1/FOXO1T24 and AKT/AKTS473 expression/phosphorylation in 
CLL cell lines with or without COMBO (Figure 5.12). Consistent with the 
aforementioned studies, FOXO1 expression was largely unaffected by AS1842856 
treatment in HG-3 and MEC-1 cells (Figure 5.12a,b). While FOXO1 expression was 
visibly enhanced by COMBO treatment in HG-3 cells, FOXO1 expression was not 
affected to the same extent in MEC-1 cells (Figure 5.12a,b). Furthermore, 
AS1842856 did not significantly impact FOXO1 expression levels in COMBO-
treated HG-3 or MEC-1 cells (Figure 5.12a,b). Although the effect of AS1842856 
treatment on FOXO1T24 phosphorylation varied markedly in HG-3 cells, FOXO1T24 
phosphorylation was modestly reduced in MEC-1 cells (Figure 5.12a,c). Moreover, 
FOXO1T24 phosphorylation was unaffected by COMBO treatment in HG-3 cells, 
whereas FOXO1T24 phosphorylation was noticeably reduced in COMBO-treated 
MEC-1 cells (Figure 5.12a,c). Interestingly, simultaneous incubation with 
AS1842856 appeared to further diminish FOXO1T24 phosphorylation in COMBO-
treated HG-3 and MEC-1 cells (Figure 5.12a,c). AS1842856 treatment discernibly 
reduced AKT expression in HG-3 cells (p = 0.1), while AKT expression in MEC-1 
cells was largely unchanged (Figure 5.12a,d). Furthermore, AKT expression was 
visibly enhanced by COMBO treatment in HG-3 cells, whereas AKT expression in 
COMBO-treated MEC-1 cells was comparable with untreated control (Figure 
5.12a,d). Interestingly, simultaneous incubation with AS1842856 further reduced 
AKT expression in COMBO-treated HG-3 (p = 0.1) and MEC-1 (p = 0.06) cells 
(Figure 5.12a,d). Furthermore, AKTS473 phosphorylation was significantly 
diminished by AS1842856 treatment in HG-3 cells (Figure 5.12a,e). Likewise, 
pharmacological inhibition of FOXO1 decreased AKTS473 phosphorylation in MEC-1 
cells (Figure 5.12a,e). Encouragingly, COMBO treatment inhibited AKTS473 
phosphorylation in HG-3 cells and MEC-1 cells (Figure 5.12a,e), while 
concurrently incubating COMBO-treated CLL cell lines with AS1842856 also 






Figure 5.12 - Long-term AS1842856 treatment, in the presence or absence of COMBO, 
modulates FOXO1T24/AKTS473 phosphorylation and FOXO1/AKT expression levels. 
(a) Representative western blot of HG-3 (n=3) and MEC-1 cells (n=3) treated with COMBO in the 
presence of absence of AS1842856 (30 nM) for 48 h. Blots were probed for FOXO1T24, FOXO1, 
AKTS473, AKT and GAPDH (loading control; #1 and #2 referring to mirror blots). (b, d) Relative 
expression levels of (b) FOXO1 and (d) AKT in HG-3 (n=3) and MEC-1 cells (n=3), treated as 
described in (a). (c, e) Relative phosphorylation levels of (c) FOXO1T24 and (e) AKTS473 in HG-3 
(n=3) and MEC-1 cells (n=3), treated as described in (a). Expression and phosphorylation levels 
are relative to vehicle control. Individual datapoints are represented by white circles. Data 
expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, *** p ≤ 





5.2.12 FOXO1 activity mediates COMBO-induced cytotoxicity 
in MEC-1 cells 
We earlier demonstrated that shRNA-mediated FOXO1 knockdown was unable to 
rescue MEC-1 cells from the cytotoxic effect of the COMBO treatment, yet 
COMBO-induced pro-apoptotic BIM upregulation was diminished in FOXO1-
depleted MEC-1 cells (Figure 5.5). Therefore, we wondered whether inhibition of 
FOXO1 activity might render the COMBO treatment unable to induce cell death 
in CLL cell lines. To achieve this, we treated HG-3 and MEC-1 cells with 
AS1842856 and assessed the sensitivity of FOXO1-inhibited cells to the COMBO 
treatment by Annexin V/7-AAD staining (Figure 5.13a-c). These data revealed 
that COMBO treatment alone visibly decreased HG-3 and MEC-1 cell viability 
(Figure 5.13a-c), which corresponded to enhanced apoptosis (Figure 5.13a). 
AS1842856 treatment protected MEC-1 cells from COMBO-induced cytotoxicity 
(Figure 5.13a,c). As expected, treatment of HG-3 and MEC-1 cells with 
AS1842856 modestly reduced cell viability in a dose-dependent manner (Figure 
5.13a-c). Although HG-3 cells appeared to be protected from COMBO-induced 
apoptosis by concomitant incubation with 30 nM AS1842856, cell viability 
rebounded to levels comparable with COMBO treatment alone when combined 
with 100 nM AS1842856 (Figure 5.13a,b). In MEC-1 cells, COMBO-induced 
cytotoxicity was discernibly reduced following simultaneous incubation with 30 
nM (p = 0.13) or 100 nM AS1842856 (Figure 5.13a,c), which was associated with a 
concurrent decrease in apoptosis (Figure 5.13a). As explained earlier, BIM 
expression was reduced in FOXO1-depleted MEC-1 cells following COMBO 
treatment (Figure 5.5e-h). Because BIM is an important mediator of FOXO1-
dependent cell death (384), we addressed the effect of AS1842856 treatment on 
COMBO-induced BIM (BIMEL, BIML, and BIMS) upregulation by Western blotting 
(Figure 5.13d-g). Consistent with Figure 5.5e-h, basal levels of BIMEL (Figure 
5.13d,e), BIML (Figure 5.13d,f) or BIMS (Figure 5.13d,g) were unaffected by 
AS1842856 treatment in HG-3 and MEC-1 cells. As expected, COMBO treatment 
alone noticeably enhanced expression of BIM in HG-3 and MEC-1 cells (Figure 
5.13d-g). Equally, BIM expression was visibly upregulated in COMBO-treated HG-3 
and MEC-1 cells simultaneously treated with AS1842856 (Figure 5.13d-g). 
However, in support of earlier findings (Figure 5.5e-h), COMBO-induced BIMEL 
(Figure 5.13d,e), BIML (p = 0.08; Figure 5.13d,f) and BIMS (Figure 5.13d,g) 




upregulation of BIML (Figure 5.13d,f) and BIMS (Figure 5.13d,g) in COMBO-treated 
HG-3 cells was moderately reduced in the presence of AS1842856.   
 
Figure 5.13 - AS1842856 treatment rescues the reduction in cell viability caused by COMBO 




(a) Representative FACS plot of HG-3 (top panel) and MEC-1 (bottom panel) cells stained with 
Annexin V/7-AAD to assess cell viability following treatment with COMBO in the presence or 
absence of AS1842856 (30 nM and 100 nM) for 48 h. (b, c) Relative viability (Annexin Vneg and 7-
AADneg cells) of (b) HG-3 (n=3) and (c) MEC-1 cells (n=3) treated as described in (a). Percentage 
viability is relative to vehicle control. (d) Representative western blot of HG-3 (n=3) and MEC-1 
cells (n=3) treated with COMBO in the presence or absence of AS1842856 (30 nM) for 48 h. Blots 
were probed for BIM (BIMEL, BIML, and BIMS) and GAPDH (loading control). (e - g) Densitometry of 
(e) BIMEL, (f) BIML and (g) BIMS expression in HG-3 (n=3) and MEC-1 cells (n=3) treated as 
described in (d). Expression is relative to GAPDH. Individual datapoints are represented by white 
circles. Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA. 
 
5.2.13 FOXO1 activity is required to regulate MEC-1 cell size 
and plays an active role mediating the effects of the COMBO 
treatment  
Although FOXO1 knockdown had minimal impact on MEC-1 cell size or the 
physiological response to COMBO treatment (Figure 5.6), we sought to determine 
whether a functional effect, if any, was dependent on transcriptional activity as 
opposed to relative expression levels. We therefore assessed the impact of 
FOXO1 inhibition via AS1842856 on HG-3 and MEC-1 cell size (Figure 5.14). 
AS1842856 (100 nM) treatment modestly enhanced HG-3 cell size (p = 0.059; 
Figure 5.14a,b). Equally, in contrast with earlier observations (Figure 5.6), MEC-
1 cell size was significantly increased as a consequence of FOXO1 inhibition by 
AS1842856 (100 nM) (Figure 5.14a,c). We also noted moderate trends towards 
enlarged HG-3 (Figure 5.14a,b) and MEC-1 (Figure 5.14a,c) cell size in response 
to AS1842856 (30 nM) treatment. Unexpectedly, HG-3 cell size was minimally 
enhanced by the COMBO treatment alone (Figure 5.14b), which conflicted with 
previous experiments (Figure 3.11a,b). Additionally, HG-3 cell size was 
unaffected by COMBO treatment in the presence of AS1842856 (30 nM or 100 nM) 
(Figure 5.14a,b). Consistent with Figure 3.11c, COMBO treatment significantly 
reduced MEC-1 cell size (Figure 5.14a,c). Furthermore, MEC-1 cell size also 
significantly contracted following COMBO treatment in the presence of 
AS1842856 (30 nM or 100 nM) (Figure 5.14a,c). Interestingly, FOXO1 appeared to 
play an active role mediating the effects of the COMBO treatment on MEC-1 cell 
size (Figure 5.14d). The relative reduction in cell size was significantly greater in 
COMBO-treated MEC-1 cells than in COMBO-treated MEC-1 cells simultaneously 
incubated with AS1842856, indicating that inhibition of FOXO1 activity partially 






Figure 5.14 - AS1842856 treatment increases the size of MEC-1 cells, while rescuing the 
reduction in cell size associated with COMBO treatment. 
(a) Representative FACS histogram displaying geometric mean of forward scatter-area (FSC-A) of 
HG-3 and MEC-1 cells treated with COMBO (green histograms) or DMSO vehicle control (Vehicle; 




Relative cell size (geometric mean) of HG-3 (n=3) and MEC-1 cells (n=3) treated as described in 
(a). Geometric means are relative to vehicle control. (d) Relative cell size (geometric mean) of 
MEC-1 cells (n=3) treated as described in (a). Data relative to vehicle control and AS1842856 (100 
nM) alone. Individual datapoints are represented by white or black circles. Data expressed as the 
mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001. 
 
5.2.14 Inhibition of FOXO1 activity rescues HG-3 and MEC-1 
cells from COMBO-induced G1 cell cycle arrest, 
corresponding to reduced expression of p27KIP1 
Encouraged by the ability of AS1842856 to shield MEC-1 cells from COMBO-
induced apoptosis (Figure 5.13) and cell size contraction (Figure 5.14), we next 
addressed the effect of FOXO1 inhibition on COMBO-induced cell cycle arrest 
(Figure 5.15). ShRNA-mediated FOXO1 knockdown did not influence the ability of 
the COMBO treatment to induce G1 cell cycle arrest in MEC-1 cells (Figure 5.7). 
Therefore, to assess whether FOXO1 activity is necessary to elicit the cytostatic 
effects of COMBO treatment, HG-3 and MEC-1 cells underwent long-term (48 h) 
COMBO treatment with or without AS1842856 (30 nM and 100 nM). Thereafter, 
cellular DNA content was analysed by flow cytometry via PI staining (Figure 
5.15). These data showed that FOXO1 inhibition by AS1842856 alone did not 
affect cell cycle DNA content distribution in HG-3 or MEC-1 cells (Figure 5.15a-
c). As expected, COMBO treatment inhibited cell cycle progression at G1 phase 
in HG-3 and MEC-1 cells, corresponding to a significant increase in G1/G0 and 
concomitant decrease in S phase DNA content (Figure 5.15a-c). In contrast to 
earlier observations (Figure 5.7), AS1842856 protected HG-3 and MEC-1 cells 
from COMBO-induced G1 cell cycle arrest (Figure 5.15a-c). In the presence of 30 
nM or 100 nM AS1842856, G1/G0 DNA content was significantly lower in COMBO-
treated HG-3 and MEC-1 cells compared to COMBO treatment alone, comparable 
to that of vehicle control (Figure 5.15a-c). Likewise, S phase DNA content was 
significantly greater in COMBO-treated HG-3 and MEC-1 cells simultaneously 
incubated with 30 nM or 100 nM AS1842856 (comparable to vehicle control) 






Figure 5.15 - AS1842856 treatment rescues the increased proportion of cells in G1 caused 
by COMBO treatment in HG-3 and MEC-1 cells. 
(a) Representative FACS histograms of HG-3 (top panel) and MEC-1 cells (bottom panel) stained 




(orange histograms; bottom panel) or DMSO vehicle control (Vehicle; purple histograms; top panel) 
in the presence or absence of AS1842856 (30 nM and 100 nM) for 48 h. (b, c) Quantification of 
DNA content (%) for cycle phase G1/G0 (purple bars), S (blue bars) and G2 (green bars) in (b) HG-
3 (n=3) and (c) MEC-1 cells (n=3) treated as described in (a). Data expressed as the mean ± SEM. 
Statistics calculated by two-way ANOVA, where ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
Our earlier observations concluded that FOXO1 knockdown visibly depleted 
COMBO-induced p27KIP1 expression levels in MEC-1 cells (Figure 5.8d), whereas 
p21CIP1 was largely unaffected (Figure 5.8e). As AS1842856 treatment shielded 
HG-3 and MEC-1 cells from COMBO-induced cell cycle arrest, we assessed 
whether inhibition of FOXO1 activity had a commensurate impact on COMBO-
induced modulation of p27KIP1 and p21CIP1 expression levels (Figure 5.16). While 
FOXO1 inhibition by AS1842856 resulted in a trend towards reduced p27KIP1 
expression in HG-3 cells, p27KIP1 expression was significantly depleted in MEC-1 
cells (Figure 5.16a,b). Expectedly, COMBO treatment alone visibly enhanced 
p27KIP1 in HG-3 cells, and significantly upregulated p27KIP1 expression in MEC-1 
cells (Figure 5.16a,b). Notably, induction of p27KIP1 expression by COMBO 
treatment was visibly less in the presence of AS1842856 than COMBO treatment 
alone in HG-3 and MEC-1 cells (Figure 5.16a,b). AS1842856 treatment alone 
increased p21CIP1 expression in HG-3 cells, whereas p21CIP1 expression was largely 
unaffected by FOXO1 inhibition in MEC-1 cells (Figure 5.16a,c). Interestingly, 
COMBO-induced modulation of p21CIP1 expression contrasted markedly between 
HG-3 and MEC-1 cells (Figure 5.16a,c). While COMBO treatment modestly 
enhanced p21CIP1 expression in HG-3 cells, p21CIP1 expression was reduced in 
COMBO-treated MEC-1 cells (Figure 5.16a,c). Nevertheless, p21CIP1 expression 
was further enhanced in COMBO-treated HG-3 cells in the presence of AS1842856 
(Figure 5.16a,c). Furthermore, unlike COMBO treatment alone, p21CIP1 expression 
appeared unaffected in COMBO-treated MEC-1 cells simultaneously incubated 






Figure 5.16 - AS1842856 decreases the expression of p27KIP1 in MEC-1 cells. 
(a) Representative western blot of HG-3 (n=3) and MEC-1 cells (n=3) treated with COMBO in the 
presence or absence of AS1842856 (30 nM) for 48 h. Blots were probed for p27KIP1, p21CIP1 and 
GAPDH (loading control). (b, c) Densitometry of (b) p27KIP1 and (c) p21CIP1 expression in HG-3 
(n=3) and MEC-1 cells (n=3) treated as described in (a). Expression relative to vehicle control. 
Individual datapoints from each replicate are shown as white circles. Data expressed as the mean 





5.2.15 FOXO1 mediates the cytostatic effect of the COMBO 
treatment in CLL cell lines and primary CLL cells co-
cultured on CD40L (+IL-21)  
FOXO1 activity plays a prominent role mediating COMBO-induced cell cycle 
arrest (Figure 5.15) and p27KIP1 expression (Figure 5.16a,b) in CLL cell lines. We 
therefore focussed on the importance of FOXO1 activity for CLL cell proliferation 
(Figures 5.17 and 5.18). CTV-stained HG-3 and MEC-1 cells were treated with 
AZD8055, ibrutinib, COMBO or rapamycin for 72 h in the presence or absence of 
AS1842856. Thereafter, cell proliferation was analysed by flow cytometry (Figure 
5.17). HG-3 and MEC-1 cell proliferation was unaffected by AS1842856 treatment 
alone (Figure 5.17a-c). Consistent with prior experiments (Figure 3.13a-c), 
AZD8055 and COMBO treatment inhibited HG-3 and MEC-1 cell proliferation, 
whereas ibrutinib was unable to confer a cytostatic effect (Figure 5.17a-c). 
Interestingly, simultaneous incubation with AS1842856 rescued AZD8055- (p = 
0.08) and COMBO-induced (p = 0.08) inhibition of HG-3 cell proliferation (Figure 
5.17a,b). Furthermore, the cytostatic effect of AZD8055 or COMBO treatment on 
MEC-1 cells was also significantly reduced by concurrent FOXO1 inhibition (Figure 
5.17a,c). We also noted that rapamycin-induced inhibition of MEC-1 cell 
proliferation was also significantly alleviated in the presence of AS1842856 
(Figure 5.17a,c). 
Given that pharmacological FOXO1 inhibition rescued CLL cell lines from the 
anti-proliferative effect of the COMBO treatment (Figure 5.17), it was of interest 
to examine the impact of AS1842856 on the proliferative capacity of primary CLL 
cells. Following co-culture on NT-L (non-proliferative control) and CD40L (+IL-21) 
cells, CLL cells were treated with COMBO in the presence or absence of 
AS1842856 for 9 days. Prior to treatment, CLL cells were stained with CTV to 
qualitatively and quantitatively assess cell proliferation by flow cytometry 
(Figure 5.18a-c). Interestingly, FOXO1 inhibition resulted in a trend towards 
enhanced CLL cell proliferation compared to CD40L (+IL-21) vehicle control 
(relative to NT-L) (p = 0.13; Figure 5.18a,b). However, relative to CD40L (+IL-21) 
vehicle control, AS1842856 treatment alone significantly increased CLL cell 
proliferation (Figure 5.18a,c). Consistent with previous experiments (Figure 






Figure 5.17 - AS1842856 treatment rescues the reduction in cell proliferation caused by 
COMBO treatment in HG-3 and MEC-1 cells. 
(a) Representative FACS histogram of HG-3 and MEC-1 cells stained with CTV to assess cell 
proliferation following treatment with AZD8055 (100 nM), ibrutinib (1 µM), COMBO, rapamycin (10 
nM) or DMSO vehicle control (Vehicle) in the presence (green histograms) or absence (blue 
histograms) of AS1842856 for 72 h. A grey vertical line represents the peak of the vehicle control 
histogram for HG-3 and MEC-1 cells. (b) Assessment of CTV geometric mean for HG-3(n=3) and 
MEC-1 cells (n=3), treated as described in (a). Individual datapoints from each replicate are shown 
as white circles. Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, 






Figure 5.18 - AS1842856 enhances CD40L (+IL-21)-induced primary CLL cell proliferation 
and rescues CLL cells from the cytostatic effect of COMBO treatment. 
(a) Representative FACS histogram of a primary CLL sample stained with CTV following long-term 
co-culture on CD40L (+IL-21) treated with COMBO or DMSO vehicle control (Vehicle) in the 
presence of absence of AS1842856 (30 nM) for 9 days. Primary CLL cells were co-cultured on NT-




(n=3) treated as described in (a). Geometric means for each condition are relative to NT-L non-
proliferative control. (c) Assessment of CTV geometric mean for primary CLL samples (n=3) 
treated as described in (a). Geometric means for each condition are relative to vehicle control. 
Individual datapoints from each replicate are shown as white circles. (d) Quantified cell counts of 
CLL cells co-cultured on CD40L (+IL-21) treated as described in (a). CLL cells were incubated with 
‘CountBright’ counting beads prior to data acquisition. The 1st, 2nd and 3rd generations are shown. 
Data expressed as the mean ± SEM. Statistics calculated by one-way ANOVA, where * p ≤ 0.05, ** 
p ≤ 0.01. 
 
note, simultaneous incubation with AS1842856 protected CLL cells from COMBO-
induced proliferative arrest to levels comparable with CD40L (+IL-21) vehicle 
control (Figure 5.18a-c). Incubating CLL cells with ‘CountBright Absolute 
Counting Beads’ prior to analysis by flow cytometry enabled us to quantify cell 
numbers in discrete generations (divisions) by comparing the ratio of bead 
events to cell events (Figure 5.18d). For CLL cells that had undergone 3 divisions 
(3rd division), the number of AS1842856-treated CLL cells was significantly 
greater than vehicle control CLL cells (Figure 5.18d), corresponding to enhanced 
proliferative capacity (Figure 5.18a,c). Consistent with the cytostatic effect of 
COMBO treatment (Figure 5.18a-c), very few COMBO-treated CLL cells had 
undergone 3 divisions compared with vehicle control CLL cells (p = 0.13; Figure 
5.18d). Interestingly, the number of COMBO-treated CLL cells simultaneously 
incubated with AS1842856 was significantly higher than the number of CLL cells 
treated with COMBO alone (Figure 5.18d).  
5.2.16 COMBO-induced transcription of FOXO gene targets 
IGFR1, SESN3, BCL2-L11 (BIM) and CDKN1A are repressed 
by AS1842856 in MEC-1 cells 
Analysis of FOXO transcriptomic data (from various lineages) revealed that FOXO 
transcription factors regulate their targets in a highly context- and cell type-
specific manner (344, 380, 387, 404, 549). We therefore compared basal 
transcript levels of FOXO target genes FOXO1, IGF1R, SESN3, BCL2-L11 (BIM), 
BBC3, GADD45A, CDKN1A, CDKN1B, CCNG2 and CCND2 in HG-3 and MEC-1 cells 
(Figure 5.19). These data showed that transcript abundance of SESN3 (Figure 
5.19c), GADD45A (Figure 5.19f), CDKN1A (Figure 5.19g) and CCND2 (Figure 5.19j) 
was significantly higher in HG-3 cells, whereas FOXO1 (Figure 5.19a), IGF1R 
(Figure 5.19b) and CCNG2 (Figure 5.19i) expression was significantly greater in 
MEC-1 cells. Expression levels of BCL2-L11 (BIM) (Figure 5.19d), BBC3 (Figure 






Figure 5.19 - RT-qPCR analysis reveals differential regulation of FOXO1 transcriptional 
targets between HG-3 and MEC-1 cells. 
(a - j) RT-qPCR to assess transcript abundance of (a) FOXO1, (b) IGF1R, (c) SESN3, (d) BCL2-
L11 (BIM), (e) BBC3, (f) GADD45A, (g) CDKN1A (p21CIP1), (h) CDKN1B (p27KIP1), (i) CCNG2 and 
(j) CCND2 in HG-3 (grey bar; n=3) and MEC-1 cells (green bar; n=3). The ΔCT method was used to 
calculate expression levels. Samples were normalised to the internal reference gene GUSB. 
Individual datapoints are represented by white circles. Data expressed as the mean ± SEM. 
Statistics calculated by one-way ANOVA, where ** p ≤ 0.01, *** p ≤ 0.001. 
 
We next assessed expression of the aforementioned FOXO target genes in 
COMBO-treated HG-3 and MEC-1 cells with or without AS1842856 treatment by 
RT-qPCR (Figures 5.20). FOXO1 expression was marginally enhanced by 




unaffected by FOXO1 inhibition in MEC-1 cells (Figure 5.20a). Expectedly, 
COMBO treatment alone elevated FOXO1 expression in HG-3 and MEC-1 cells 
(Figure 5.20a). Notably, however, FOXO1 transcript abundance was significantly 
augmented in COMBO-treated HG-3 cells simultaneously incubated with 
AS1842856, whereas inhibition of FOXO1 activity in MEC-1 cells appeared to 
block COMBO-induced FOXO1 upregulation (Figure 5.20a). AS1842856 treatment 
resulted in a trend towards reduced IGF1R expression in HG-3 cells (p = 0.11), 
while FOXO1 inhibition significantly downregulated basal IGF1R transcript levels 
in MEC-1 cells (Figure 5.20b). Furthermore, IGF1R expression was upregulated by 
COMBO treatment alone in HG-3 (p = 0.06) and MEC-1 cells (Figure 5.20b). In 
support of these observations, COMBO-induced IGF1R upregulation was reduced 
by concurrent AS1842856 treatment in HG-3 (p = 0.059) and MEC-1 cells (p = 0.1; 
Figure 5.20b). Interestingly, while FOXO1 inhibition significantly enhanced SESN3 
expression in HG-3 cells, SESN3 transcript abundance was significantly 
downregulated in MEC-1 cells (Figure 5.20c). Furthermore, COMBO treatment 
alone did not notably affect SESN3 expression in HG-3 cells, whereas SESN3 
levels were visibly enhanced by COMBO treatment in MEC-1 cells (Figure 5.20c). 
Intriguingly, FOXO1 inhibition further enhanced SESN3 expression in COMBO-
treated HG-3 cells, near significantly than AS1842856 treatment alone (p = 
0.057; Figure 5.20c). Conversely, AS1842856 treatment notably blocked COMBO-
induced SESN3 upregulation in MEC-1 cells (Figure 5.20c). A trend towards 
elevated levels of BCL2-L11 was observed in HG-3 cells treated with AS1842856 
alone (p = 0.11), whereas BCL2-L11 expression was unaffected by FOXO1 
inhibition in MEC-1 cells (Figure 5.20d). As expected, COMBO treatment 
modestly enhanced BCL2-L11 transcript levels in HG-3 and MEC-1 cells (Figure 
5.20d). Notably, while AS1842856 treatment significantly increased BCL2-L11 
expression in COMBO-treated HG-3 cells compared to COMBO treatment alone, 
BCL2-L11 expression was visibly downregulated in COMBO-treated MEC-1 cells 
simultaneously incubated with AS1842856 (Figure 5.20d). Counterintuitively, 
expression of pro-apoptotic BBC3 was significantly downregulated by FOXO1 
inhibition in HG-3 cells, and observably reduced in MEC-1 cells (Figure 5.20e). 
Furthermore, COMBO treatment alone modestly downregulated BBC3 expression 
in HG-3 and MEC-1 cells (Figure 5.20e). FOXO1 inhibition downregulated BBC3 
transcript abundance in COMBO-treated HG-3 cells to levels comparable with 





Figure 5.20 - Aberrant regulation of FOXO1 transcriptional targets following AS1842856 
treatment in HG-3 and MEC-1 cells. 
(a - j) RT-qPCR to assess transcript abundance of (a) FOXO1, (b) IGF1R, (c) SESN3, (d) BCL2-




(j) CCND2 in HG-3 (grey bars; n=3) and MEC-1 cells (green bars; n=3) treated with COMBO or 
vehicle control in the presence or absence of AS1842856 for 48 h. The ΔΔCT method was used to 
calculate expression levels, where samples were first normalised to the internal reference gene 
GUSB and then made relative to vehicle control for each cell line. Individual datapoints are 
represented by white circles. Data expressed as the mean ± SEM. Statistics calculated by one-way 
ANOVA, where * p ≤ 0.05, ** p ≤ 0.01. 
 
reduced in COMBO-treated MEC-1 cells concurrently treated with AS1842856, 
significantly downregulated compared to COMBO treatment alone (Figure 5.20e). 
GADD45A expression was significantly upregulated by AS1842856 treatment in 
HG-3 cells, whereas GADD45A transcript levels were unaffected by FOXO1 
inhibition in MEC-1 cells (Figure 5.20f). Moreover, COMBO treatment visibly 
downregulated GADD45A expression in HG-3 and MEC-1 (p = 0.056) cells (Figure 
5.20f). Concomitant incubation of COMBO-treated HG-3 cells with AS1842856 
decreased GADD45A expression to levels comparable with COMBO treatment 
alone, and significantly less than AS1842856 treatment alone (Figure 5.20f). 
Similarly, GADD45A expression was downregulated in COMBO-treated MEC-1 cells 
in the presence of AS1842856 (Figure 5.20f). Inhibition of FOXO1 activity near-
significantly enhanced CDKN1A expression in HG-3 cells (p = 0.08), while 
AS1842856 treatment significantly upregulated CDKN1A transcript abundance in 
MEC-1 cells (Figure 5.20g). Although inconclusive, CDKN1A expression appeared 
reduced by COMBO treatment in HG-3 and MEC-1 cells (Figure 5.20g). 
Nevertheless, FOXO1 inhibition in COMBO-treated HG-3 cells modestly increased 
CDKN1A transcript levels compared to COMBO treatment alone (p = 0.08; Figure 
5.20g). Furthermore, AS1842856-induced CDKN1A upregulation was near-
significantly reduced by concurrent incubation with the COMBO treatment in HG-
3 cells (p = 0.09; Figure 5.20g). Compared to COMBO treatment alone, COMBO 
treatment in the presence of AS1842856 enhanced CDKN1A expression in MEC-1 
cells to levels similar to AS1842856 treatment alone (Figure 5.20g). Although 
CDKN1B expression was unaffected by FOXO1 inhibition in HG-3 cells, CDKN1B 
was visibly downregulated by AS1842856 treatment in MEC-1 cells (Figure 5.20h). 
Expectedly, COMBO treatment resulted in a trend towards reduced CDKN1B 
transcript levels in HG-3 and MEC-1 cells (Figure 5.20h). Compared to AS1842856 
treatment alone, CDKN1B expression was discernibly reduced in COMBO-treated 
HG-3 cells in the presence of AS1842856 (p = 0.11; Figure 5.20h). Intriguingly, 
inhibition of FOXO1 in COMBO-treated MEC-1 cells further decreased CDKN1B 
expression, significantly greater than COMBO treatment alone (Figure 5.20h). 




AS1842856 treatment in HG-3 cells, CCNG2 expression was significantly 
decreased in AS1842856-treated MEC-1 cells (Figure 5.20i). Furthermore, while 
CCNG2 expression was unaffected by COMBO treatment in HG-3 cells, a near-
significant reduction in CCNG2 transcript levels was observed in MEC-1 cells (p = 
0.09; Figure 5.20i). Inhibition of FOXO1 activity in COMBO-treated HG-3 cells 
further downregulated CCNG2 expression, greater than each drug alone (Figure 
5.20i). Equally, COMBO treatment in the presence of AS1842856 augmented 
CCNG2 downregulation in MEC-1 cells, near-significantly greater than AS1842856 
treatment alone (p = 0.08) and significantly less than COMBO treatment alone 
(Figure 5.20i). Inhibition of FOXO1 activity noticeably increased CCND2 
expression in HG-3 and MEC-1 cells (Figure 5,20j). Similarly, COMBO treatment 
modestly upregulated CCND2 in HG-3 and MEC-1 (p = 0.06) cells to levels 
comparable with AS1842856 treatment alone (Figure 5.20j). While CCND2 
expression was unchanged in COMBO-treated HG-3 cells in the presence of 
AS1842856 (compared to each drug alone), CCND2 was notably downregulated in 







Here, we provide insights into the functional consequence of genetic and 
pharmacological FOXO1 inhibition on CLL maintenance and the response to 
COMBO treatment. Despite modulation of direct FOXO targets, shRNA-mediated 
FOXO1 knockdown did not affect cellular pathophysiology, indicating that MEC-1 
cells are largely resilient to changes in FOXO1 expression levels. Furthermore, 
FOXO1-depleted MEC-1 cells remained sensitive to the COMBO treatment, 
perhaps suggesting that residual FOXO1 is capable of mediating treatment 
response. In contrast, the FOXO1 inhibitor AS1842856 largely shielded CLL cells 
from the pro-apoptotic and anti-proliferative effects of the COMBO treatment. 
Indeed, pharmacological FOXO1 inhibition potentiated CD40L (+IL-21)-induced 
CLL proliferation, demonstrating that treatment-induced FOXO1 activity likely 
evokes a context-dependent gene expression programme favouring tumour 
suppression.  
5.3.1 FOXO1 nuclear localisation in HG-3 and MEC-1 cells 
suggest PI3K-AKT signalling and ‘active’ FOXO1 
paradoxically coincide in the same cells 
In the preceding chapter, we demonstrated that FOXO1 expression was elevated 
among poor prognostic CLL patient LN biopsies compared to those with indolent 
disease. Notably, FOXO1 intensity score (i.e. FOXO1 expression) positively 
correlated with Ki-67+ staining. Here, largely mimicking the findings observed in 
lymphoid tissue, FOXO1 expression was significantly greater in MEC-1 cells 
(del(17p); poor prognostic) compared with HG-3 cells (del(13q); favourable 
prognostic). While it is intriguing to speculate about the biological importance of 
enhanced FOXO1 expression in poor-prognostic tissues, these data would need to 
be validated further to unearth a potential pathogenic role. Nevertheless, 
FOXO1 downregulation in patients with indolent disease might indicate an 
important (and perhaps perturbed) biological function for FOXOs in CLL 
progression. As summarised by Szydlowski et al., evidence from other B cell 
malignancies highlight various mechanisms that modulate FOXO1 activity and/or 
expression levels (397), which could explain the differences observed between 
indolent and progressive disease. For instance, FOXO1 depletion is caused by 




Although FOXO1 loss has not been associated with ‘indolent’ 13q14 aberrations 
in CLL (and, by extension, HG-3 cells) (550, 551), analysis of primary Hodgkin 
and Reed/Sternberg (HRS) cells revealed only a fraction (~11 %) of cases with 
13q14 deletions included FOXO1 involvement (396). Thus, it would be interesting 
to re-evaluate genomic (552, 553), transcriptomic (88) and copy-number (554) 
data for potential FOXO1 involvement in this CLL patient subset. Indeed, analysis 
of established FOXO gene targets via RNA-seq or ChIP-seq would further 
illuminate FOXO involvement. Additionally, aberrant expression of FOXO1-
specific miRNAs, such as miR-96, miR-182 and miR-183 in cHL (396) and miR-21 
in DLBCL (555), have been shown to repress FOXO1 expression and activity (397). 
In CLL, miR-29 is upregulated specifically in patients with indolent disease (556, 
557). Interestingly, Guérit et al. demonstrated that FOXO3 was a direct target of 
miR-29 in mesenchymal stem cells (MSCs) (558), suggesting that miR-29 might 
downregulate FOXO expression in indolent CLL patients. Therefore, analysis of 
the FOXO-targeting miRNA landscape among CLL prognostic subtypes (559), 
particularly downstream of BCR ligation (560), warrants further assessment.  
Earlier, our results demonstrated that FOXO1 was localised in the nucleus of 
‘proliferative’ CD40L (+IL-21)-stimulated CLL cells, murine CLL-like PKCαKR cells 
and CLL patient LN biopsies (irrespective of prognosis). As discussed, these 
findings suggested that ‘active’ nuclear FOXO1 (particularly for LN-resident CLL 
cells) may instruct a gene expression programme promoting CLL maintenance. 
Notwithstanding the presence of AKT kinase activity (AKTS473 and AKTT308 
phosphorylation), a sizeable fraction of FOXO1 was localised in the nuclei of HG-
3 and MEC-1 cells, indicating that nuclear FOXO1 expression paradoxically 
coincides with PI3K-AKT activity. Consistently, a recent study similarly reported 
nuclear FOXO3a expression alongside phosphorylated AKT (AKTS473) in MEC-1 cells 
(501). Although it is unlikely that FOXOs strictly exist as ‘cytoplasmic’ or 
‘nuclear’ (344), these observations raised important points regarding the 
regulation and functional importance of FOXOs in HG-3 and MEC-1 cells. As 
mentioned previously, FOXO activity in the presence of constitutive PI3K-AKT 
signalling has also been reported in other B cell malignancies, such as BL (401) 
and pre-BCR+ BCP-ALL (403), where FOXO activity supported an oncogenic 
phenotype. Nevertheless, without prior characterisation of ‘activating’ FOXO1 




cannot be conclusively resolved (401). However, FOXOs are routinely under the 
influence of different posttranslational and/or posttranscriptional modifications, 
such as JNK-mediated phosphorylation (371) or miRNAs (561), which can promote 
FOXO nuclear localisation and transcriptional activity, respectively (347). 
Furthermore, as mentioned earlier, strict regulation of FOXO1 activity within the 
confines of an established setpoint (403, 506) might permit simultaneous PI3K- 
and FOXO1 activity. 
FOXOs regulate their transcriptional targets in a highly context- and cell type-
specific manner (344, 380, 387, 404, 549). Indeed, FOXO1 activity fulfils many 
distinct functions throughout B cell development (387) and among different B 
cell malignancies (384). Alongside established ‘conserved’ targets (380), one 
might conjecture that FOXOs regulate a unique array of context-dependent 
target genes in CLL. Interestingly, despite similar levels of FOXO1T24 
phosphorylation, the data presented here revealed marked differences in FOXO 
target expression in HG-3 and MEC-1 cells. These findings suggest that HG-3 and 
MEC-1 prognostic might factors influence FOXO activity in a context-dependent 
manner, which may generate distinct FOXO-induced gene signatures on a 
prognostic-level. Other B cell malignancies have demonstrated differences in 
FOXO1 activity among disease- and subtype-specific cell lines, including cHL 
(524), DLBCL (397) and BCP-ALL (403), further indicating that FOXO1 activity is 
probably affected by intrinsic factors such as genomic mutations (562) and 
epigenetic regulation (563). However, since the FOXO transcriptional targets 
were arbitrarily chosen on the basis of prior functional data (344, 348), they 
were not necessarily exclusive to CLL cells. Therefore, it would be interesting to 
perform ChIP-seq binding analysis to uncover direct FOXO targets specifically in 
HG-3 and MEC-1 cells (or primary CLL cells, for that matter). Of note, HG-3 and 
MEC-1 cells are EBV-transformed (431, 432, 564), which has been shown to 
repress FOXO1 activity via Latent Membrane Protein (LMP)-1 and -2A-mediated 
PI3K-AKT activation (565). Unlike endemic BL (566) and EBV+ posttransplant 
lymphoproliferative disorder (PTLD) (567, 568), however, EBV infection is not 
involved in CLL pathogenesis (564). Therefore, while EBV-induced FOXO1 
inactivation might contribute to HG-3 and MEC-1 oncogenesis, one must be 




5.3.2 MEC-1 cells were unaffected by shRNA-mediated FOXO1 
knockdown, suggesting that these cells are largely resilient 
to changes in FOXO1 levels 
In their study, Srinivasan et al. postulated that small changes in FOXO1 levels 
have major effects on mature B cell physiology (275). Largely supporting the 
notion that FOXOs maintain cellular homeostasis within a narrow range (506), 
this view indicated that deviations outside this optimum have deleterious 
consequences for normal (387) and malignant B cells (384). To investigate the 
importance of FOXO1 in CLL maintenance and the functional response to COMBO 
treatment, we adopted FOXO1-targetting shRNA lentiviral vectors to stably 
‘knockdown’ FOXO1 expression in HG-3 and MEC-1 cells. Although MEC-1 cells 
were successfully transduced, several attempts to simultaneously expand 
infected HG-3 cells (including Scr control) were unsuccessful. Going forward, 
protocols for transducing HG-3 cells will need to be optimised to glean 
meaningful comparisons between HG-3 and MEC-1 cells. In pre-BCR- and pre-
BCR+ BCP-ALL cell lines, shRNA-mediated FOXO1 depletion induced G1 cell cycle 
arrest and enhanced caspase-dependent cell death, indicating that BCP-ALL cell 
maintenance is reliant on FOXO1 expression (403). In contrast, BCR-dependent 
DLBCL (DHL4, DHL6, Ly1 and Ly7) and cHL (U-HO1) cell lines were largely 
unaffected by FOXO1 repression (397, 403). In fact, FOXO1 knockdown actually 
enhanced proliferation in another cHL cell line (L428) (403), supporting FOXO1’s 
reported tumour suppressor role in this malignancy (396). Although FOXO1 
depletion modulated transcript abundance of certain FOXO targets (indicating 
perturbed FOXO target regulation), our results demonstrated that shRNA-
mediated FOXO1 knockdown did not affect MEC-1 cell survival, size or 
proliferative capacity. Consistent with the findings observed in DLBCL and cHL 
(U-HO1) cell lines (397, 403), these data suggest that MEC-1 cells are largely 
resilient to changes in FOXO1 expression levels. As functional redundancy exists 
among FOXO transcription factors (404), FOXO1 expression might be superfluous 
in the context of MEC-1 cell maintenance. Here, we demonstrated that FOXO3 
mRNA expression was enhanced following FOXO1 knockdown in MEC-1 cells, 
perhaps indicating the existence of an adaptive mechanism. Whether this finding 
confers functional redundancy among FOXOs in MEC-1 cells remains to be 
elucidated. With experimental hindsight, incubation periods should have been 




evaluate the functional impact of FOXO1 knockdown in MEC-1 cells. For 
example, the doubling time for MEC-1 cells is reportedly ~40 hours (409). In their 
study, Wang et al. assessed the proportion of FOXO1-depleted and scrambled 
control BCP-ALL cell lines on day 3, 6 and 9. Interestingly, the functional effect 
of FOXO1 repression was only apparent after 3 days (403). Taken together, 
although FOXO1 depletion in other B cell malignancies elicit ‘positive’ and 
‘negative’ consequences for cellular function (403), this is not necessarily the 
case in MEC-1 cells. Notwithstanding potential experimental limitations, these 
findings suggest MEC-1 cells may adapt to perturbed FOXO1 levels.  
5.3.3 FOXO1-depleted MEC-1 cells are sensitive to COMBO 
treatment, perhaps suggesting residual FOXO1 is capable of 
mediating treatment response 
ShRNA-mediated FOXO1 repression protected BCR-dependent DLBCL cell lines 
from the cytotoxic and anti-proliferative effect of combined SYK (R406) and AKT 
(MK2206) inhibition (397), indicating that FOXO1 is an effector of truncated BCR 
signalling. Furthermore, pharmacological (PRT318 or LY294002) inactivation of 
pre-BCR signalling or FOXO1-A3 expression resulted in FOXO1-dependent pre-
BCR+ BCP-ALL cell death and reduced proliferation, respectively (402). 
Collectively, these findings suggest that BCR signalling inhibitors unleash 
abnormal levels of FOXO1 activity (straying from the established setpoint) that 
promotes FOXO1-dependent tumour suppressor activity in B cell malignancies. 
Largely corresponding to earlier findings in primary CLL cells, our results 
demonstrated that COMBO treatment inhibited AKT-dependent FOXO1T24 
phosphorylation (HG-3 and MEC-1 cells), augmented FOXO1 nuclear accumulation 
and enhanced FOXO1 DNA-binding activity in MEC-1 cells, suggesting that FOXO1 
mediates the functional response to the COMBO treatment. Interestingly, 
increased FOXO1 activity appeared to be driven predominantly by ibrutinib 
treatment (over that of AZD8055) in MEC-1 cells, perhaps indicative of 
constitutive BTK activation (501) and enhanced BCR signalling capacity via the 
expression of unmutated (94% homology to germline) IGVH (IGHV4-59) genes 
(432, 564). However, shRNA-mediated FOXO1 depletion was unable to rescue 
MEC-1 cells from the pro-apoptotic, cell-contracting and anti-proliferative 
effects of the COMBO treatment. This result was unexpected, especially 




induced FOXO gene targets such as IGFR1, SESN3 and BCL2-L11. Additionally, 
FOXO1 repression diminished COMBO-induced upregulation of BIM (BIMEL, BIML 
and BIMS) and p27KIP1. Thus, FOXO1-depleted MEC-1 cells remained sensitive to 
COMBO treatment, despite aberrant modulation of FOXO targets on a mRNA and 
protein level. This implicated the ‘incomplete’ nature of FOXO1 knockdown as a 
possible explanation for the sensitivity of FOXO1-repressed MEC-1 cells, with 
residual FOXO1 activity being capable of conferring a commensurate response to 
treatment. This is reflected in the ability of FOXO1-depleted cells to enhance 
FOXO1 (mRNA and protein) expression upon COMBO treatment, a potential 
adaptive response that dampens the effect of FOXO1 knockdown. Nevertheless, 
how these findings are resolved amidst the narrative that FOXO elicits 
homeostatic functions within an optimal range remains to be elucidated. Going 
forward, the shRNA constructs and/or protocols for transduction must be 
optimised to improve the levels of FOXO1 knockdown; perhaps combining 
FOXO1-targeting constructs or choosing different constructs targeting multiple 
FOXOs, as described (403). Equally, it would be interesting to adopt CRISPR-Cas9 
technology to achieve full inactivation of FOXO1 (or site-directed mutagenesis 
(401)). Furthermore, a future perspective would be to assess inducible FOXO1-A3 
expression in CLL cells, alongside dominant-negative (DN) FOXO1 (FOXO1-DN) 
constructs, to complement our work on pharmacological-induced FOXO1 
activation.  
5.3.4 Inhibition of FOXO1 activity protects CLL cells from the 
effects of COMBO treatment, indicating FOXO1 mediates the 
functional response to treatment  
Since shRNA-mediated FOXO1 knockdown was only partial, we argued that 
remnants of FOXO1 might have retained the ability to facilitate cellular 
maintenance and induce a proportional response to COMBO treatment. Thus, 
inhibition of FOXO1 transcriptional activity represents an attractive means to 
prevent induction or repression of FOXO target genes. The FOXO1 inhibitor 
AS1842856 has been reported to diminish FOXO1 DNA-binding activity by 
targeted inhibition of ‘active’ FOXO1 (545, 546). In BCP-ALL cells lines (RS4;11 
and UoCB6), transcriptomic analysis uncovered >800 modulated probe sets 
following AS1842856 treatment, with 9 of the top 20 downregulated genes being 




modulated FOXO targets IGFR1, SESN3, BBC3, GADD45A, CDKN1A and CCNG2 in 
CLL cell lines, indicating that FOXO1 activity is repressed. As a next step, it 
would be interesting to assess AS1842856-induced transcriptome changes to 
better understand the FOXO transcriptional landscape in CLL cells. Alongside its 
ability to prevent FOXO1 DNA-binding (545, 546), AS1842856 has been shown to 
sequester FOXO1 in the cytoplasm of hESCs (547). Interestingly, our results 
demonstrated that short-term AS1842856 treatment had no effect on FOXO1 
localisation or COMBO-induced FOXO1 nuclear translocation. Moreover, FOXO1 
DNA-binding activity was largely unaffected by AS1842856 in the presence or 
absence of the COMBO treatment. While these data were surprising, one possible 
explanation was the simultaneous incubation of AS1842856 and the COMBO 
treatment. With hindsight, pre-treating MEC-1 cells with AS1842856 prior to the 
introduction of COMBO might have yielded different results.  
In B cell malignancies, studies adopting AS1842856 to address the functional 
importance of FOXO1 are limited. Interestingly, however, these findings appear 
to highlight FOXO1’s oncogenic potential. Wang et al. showed that AS1842856 
treatment reduced cell growth and survival in BCP-ALL cell lines. Furthermore, 
AS1842856 conferred anti-leukaemia activity in ex vivo patient-derived 
leukaemia cells and in vivo xenograft models (403). In another study, Pyrzynska 
et al. demonstrated that FOXO1 transcriptional activity was implicated in the 
resistance of NHLs to R-CHOP therapy via a mechanism that negatively regulated 
CD20 expression. AS1842856 treatment eliminated FOXO1-mediated CD20 
repression in NHL cell lines (503). At odds with these findings, our results point 
towards a context-dependent tumour suppressor role for FOXO1. Here, we 
showed that AS1842856 treatment essentially rescued CLL cells from the pro-
apoptotic, cell-contracting and anti-proliferative effects of the COMBO 
treatment, indicating that FOXO1 mediates the functional response to 
treatment. Moreover, pharmacological FOXO1 inhibition potentiated CD40L (+IL-
21)-induced CLL cell proliferation, suggesting that FOXO1 operates as a 
‘molecular break’ that regulates CLL proliferative capacity.  
5.3.4.1 Apoptosis 
Whilst largely insensitive to pharmacological FOXO1 inhibition, treatment of HG-




reduction in cell viability. In primary CLL cells, cell viability was initially 
maintained at lower concentrations before decreasing in a dose-dependent 
manner. Notably, calculated EC50 values revealed that primary CLL cells were 
more sensitive to AS1842856 treatment compared to CLL cell lines. However, 
these values far exceeded the IC50 (33 nM) of AS1842856 established in HepG2 
cells (545). Therefore, we cannot exclude potential off-target effects that may 
explain the elevated levels of apoptosis (at higher concentrations). Indeed, 
Nagashima et al. demonstrated that AS1842856 targets other FOXOs (FOXO3 and 
FOXO4) at concentrations exceeding 100 nM. Furthermore, pharmacokinetic 
analysis of AS1842856 revealed a maximum plasma concentration of 300 nM in 
mice (545), indicating that higher concentrations have deleterious off-target 
effects in vivo. Therefore, one should question the biological relevance of 
surpassing these concentrations. In their study, Wang et al. showed that 
AS1842856 induced apoptosis in BCP-ALL cell lines in a time- and dose-
dependent manner (403). On reflection, the impact of AS1842856 on CLL cell 
viability should have been monitored daily for a period up to 96 h. At this point, 
we cannot conclude whether FOXO1 is implicated in the maintenance of CLL 
cells, but this warrants further investigation. On a molecular level, however, 
BCL2-L11 (BIM) expression was unaffected by AS1842856 (30 nM) treatment, 
whereas pro-apoptotic BBC3 (PUMA) transcript abundance was reduced in HG-3 
and MEC-1 cells. These findings echo the modest effects of AS1842856 treatment 
on cell viability and points towards FOXO1 as a tumour suppressor in this 
context.  
In normal and malignant cells, activated FOXOs drive the expression of pro-
apoptotic genes that tip the scales towards cellular apoptosis (344, 346). As 
demonstrated earlier, COMBO treatment augmented FOXO1 DNA-binding 
activity, concomitantly upregulated pro-apoptotic BCL2-L11 expression and 
reduced cell viability. Here, we showed that COMBO-induced cell death was 
seemingly negated in the presence of AS1842856 (30 nM and 100 nM) in MEC-1 
cells, demonstrating that FOXO1 inhibition protected these cells from the pro-
apoptotic effect of COMBO treatment. These findings suggest that FOXO1 
mediates the apoptotic response of COMBO treatment in MEC-1 cells. In the case 
of HG-3 cells, the ability of AS1842856 to prevent COMBO-induced cell death 




be related to its limited efficacy. Nevertheless, enhanced COMBO-induced 
transcript abundance of BCL2-L11 was diminished in the presence of AS1842856 
in MEC-1 cells, indicating that FOXO1-mediated induction of pro-apoptotic BCL2-
L11 contributes to treatment-induced MEC-1 cell death. Importantly, Szydlowski 
et al. similarly showed, albeit by shRNA-mediated FOXO1 knockdown, that 
inhibiting BCR signalling in BCR-dependent DLBCL cell lines resulted in FOXO1-
dependent cell death via a mechanism that involved FOXO1-mediated BCL2-L11 
upregulation (397). 
5.3.4.2 Cell size 
FOXOs have been implicated in the regulation of mTORC1 signalling via induction 
of SESN3, which activates mTORC1-negative regulators TSC1/2 (384, 542). As 
mTORC1 signalling plays a crucial role in the regulation of cell size (442), we 
assessed the impact of pharmacological FOXO1 inhibition on HG-3 and MEC-1 cell 
size. We demonstrated that AS1842856 treatment (100 nM) modestly enhanced 
MEC-1 cell size, which coincided with reduced levels of SESN3 mRNA expression. 
These data indicate that FOXO1 regulates mTORC1 activity, in part, via 
induction of SESN3 in MEC-1 cells. To confirm these findings, the impact of 
AS1842856 treatment on mTORC1 activity (4E-BP1T37/46 and S6S235/236) should be 
assessed. Although AS1842856 (100 nM) marginally enhanced HG-3 cell size, this 
paradoxically corresponded to enhanced levels of SESN3 transcript levels. ‘Basal’ 
SESN3 levels were shown to be higher in HG-3 cells than MEC-1 cells, perhaps 
reflecting reduced mTORC1 activity in HG-3 cells. A mechanism that permits 
SESN3 upregulation upon FOXO1 inhibition remains unknown. In any case, these 
results perhaps underscore a necessity of FOXO1 in mTORC1-dependent MEC-1 
cell size regulation, which largely corresponds to a study demonstrating the 
association between FOXO1 overexpression and reduced cardiomyocyte cell size 
(544).  
Along these lines, enhanced COMBO-induced FOXO1 activity coincided with 
reduced MEC-1 cell size. In search of a tangible link between elevated FOXO1 
activity and MEC-1 cell contraction, we demonstrated that AS1842856 (100 nM) 
treatment marginally rescued the effect of COMBO treatment on MEC-1 cell size. 
Notably, COMBO treatment still significantly reduced cell size in the presence of 




Nevertheless, these findings potentially indicate that FOXO1 contributes to cell 
size regulation independent of mTORC1/2 signalling. Interestingly, Sengupta et 
al. demonstrated that FOXO1-mediated cell size reduction coincided with 
transactivation of autophagy-related genes Gabarapl1 and Atg12 in 
cardiomyocytes (544). Autophagy has been shown to inhibit cell growth (569). As 
FOXOs are known to promote autophagy (570), this ought to be considered as a 
potential response to COMBO treatment-induced FOXO activation in CLL cells. 
Thus, FOXO1 appears to be implicated in cell size regulation via mechanisms 
that involve mTORC1 inhibition and autophagy induction.  
5.3.4.3 Cell cycle progression and proliferation 
Supraphysiological FOXO activation (via PI3K-AKT inhibition or expression of 
constitutively active FOXO-AAA mutants) has been shown to induce cell cycle 
arrest (277, 344, 376, 377, 498). In BCR-dependent DLBCL cell lines DHL4 and 
Ly7, concurrent inhibition of SYK (R406) and AKT (MK2206) synergistically 
reduced proliferation in a FOXO1-dependent manner, inasmuch as FOXO1-
depleted cells were resistant to the cytostatic effect of the combination 
treatment (397). Furthermore, ectopic FOXO1-A3 expression inhibited 
proliferation in cHL cell lines, which correlated with enhanced levels of the cell 
cycle kinase inhibitor CDKN1B (p27KIP1) (396). Collectively, these studies suggest 
that abnormally high levels of FOXO1 activity elicit anti-proliferative tumour 
suppressive functions. Here, our results demonstrated that FOXO1 inhibition 
rescued HG-3 and MEC-1 cells from the anti-proliferative effect of COMBO 
treatment, indicating that enhanced FOXO1 activity mediates treatment 
response. Indeed, AS1842856 diminished COMBO-induced upregulation of FOXO 
target p27KIP1, highlighting a potential FOXO-mediated mechanism for these 
observations. Thus, the anti-proliferative effects of FOXO1 in CLL cell lines 
correlate with the activation of its established tumour suppressor targets. 
Interestingly, FOXO1 inhibition similarly protected MEC-1 cells from the 
cytostatic effect of rapamycin, highlighting the involvement of FOXO1 in the 
functional response to mTORC1 inhibition. Of note, AS1842856 treatment alone 
had no effect on cell cycle regulation or proliferation in HG-3 or MEC-1 cells, 




In CD40L (+IL-21)-stimulated primary CLL cells, AS1842856 (30 nM) shielded 
‘proliferative’ cells from the cytostatic effect of the COMBO treatment, further 
indicating that enhanced FOXO1 activity mediates treatment response. Although 
the regulation of FOXO1 targets was not assessed, earlier experiments revealed 
that COMBO-induced proliferation arrest coincided with p27KIP1 upregulation. 
Therefore, it is interesting to speculate about the modulation of FOXO-induced 
cell cycle kinase inhibitors (e.g. p27KIP1, p21CIP1 and p57KIP2) to delineate FOXO1’s 
tumour suppressor function on a molecular level. Interestingly, pharmacological 
FOXO1 inhibition appeared to potentiate primary CLL cell proliferation, as 
demonstrated by CTV (geometric mean) and absolute cell counts. These findings 
suggest that FOXO1 operates as a ‘molecular break’ that tightly regulates the 
extent of CD40L (+IL-21)-induced CLL proliferation. Consistent with the pro-
proliferative effect of FOXO1 depletion in cHL cell lines (L428) (403), these data 
imply that FOXO1 is a robust tumour suppressor in this context. Going forward, 
FOXO1-targeting shRNA constructs and protocols for transducing primary CLL 
cells must be optimised to complement these findings.  
5.3.5 Summary  
Taken together, these findings demonstrate that FOXO1 activity mediates the 
cytostatic and cytotoxic effects of the COMBO treatment, indicating that FOXO1 
functions as a tumour suppressor in this context. Genetic or pharmacological 
FOXO1 inhibition did not impact HG-3 or MEC-1 cell maintenance, perhaps 
suggesting these cells can withstand reduced FOXO1 levels. However, a surplus 
of nuclear FOXO1 upon COMBO treatment overwhelms the cells and initiates cell 
cycle arrest and apoptosis in a FOXO1-dependent manner (397). These findings 
largely correlate to the notion of the ‘Goldilocks principle’ (403, 506), where 
only optimal (“just right”) FOXO activity supports cellular maintenance (344, 
403). As demonstrated in mature B cells (390), these data likely demonstrate 
that FOXO1 inactivation is an important outcome of CLL-BCR signal transduction 
(downstream of PI3K-AKT signalling) to prevent FOXO1-mediated cell cycle 
arrest and apoptosis. Thus, inhibition of FOXO negative regulators (such as PI3K-
AKT) represent an interesting therapeutic strategy. However, one should be 
cautious of compensatory and/or resistance mechanisms induced by active 
FOXOs. Indeed, studies have shown that FOXOs induce transcription of growth 




signalling. Here, for example, we demonstrated that IGF1R is upregulated upon 
COMBO treatment in a FOXO1-depedent manner. Thus, while FOXO1 activation 
unleashes tumour suppressive functions, this should be complemented by an 
understanding of the transcriptome changes induced by aberrantly enhanced 




6 General Discussion 
6.1 Summary of results 
The data presented in this thesis demonstrates that mTOR is an effector of BCR 
crosslinking in vitro, playing a role in the coordination cellular behaviours 
emanating from BCR engagement (BCR-PI3K-AKT) in CLL cells. mTOR (mTORC1 
and mTORC2) activity was effectively targeted by the ‘second generation’ mTOR 
kinase inhibitor AZD8055 (and its clinical analogue AZD2014), which disabled 
pro-survival feedback loops associated with the selective-mTORC1 inhibitor 
rapamycin. On a molecular level, AZD8055 inhibited mTOR signalling 
downstream of F(ab’)2-mediated BCR ligation and stromal cell (NT-L/CD40L) co-
cultures, highlighting the ability of this compound to disrupt various 
microenvironmental stimuli. On a functional level, AZD8055 elicited potent 
inhibitory effects on CLL growth and proliferation, but only moderately affected 
cell viability in vitro. For these reasons, AZD8055 anti-tumour activity appeared 
to be limited as a monotherapy. A synergistic combination of AZD8055 and the 
BTK inhibitor ibrutinib promoted cell death, augmented cell size contraction and 
arrested proliferation, indicating that simultaneous inhibition of mTOR kinase 
and BTK in CLL cells evokes anti-tumour activity via targeted inhibition of 
multiple oncogenic pathways and at different levels within the same pathway.  
In search of a mechanism of action, we proposed that the combination 
treatment conferred a more robust inhibition of AKT kinase activity, relieving 
negative regulation on tumour suppressive FOXO transcription factors. Our data 
demonstrated that BCR crosslinking negatively regulated FOXO1 (the most 
abundant FOXO in CLL cells) by AKT-dependent FOXO1T24 phosphorylation, 
subsequent nuclear export and reduced DNA-binding activity. Like normal B 
cells, these data suggested that FOXO1 inactivation was an important 
consequence of BCR engagement in CLL cells. For this reason, we hypothesised 
that inhibiting BCR signalling would unleash FOXO1 tumour suppressor activity. 
We showed that elimination of BCR signal transduction, via AZD8055 or ibrutinib 
mono- and combination therapy, re-engaged FOXO1 DNA-binding activity by 
preventing FOXO1 nuclear export, which suggested that FOXO1 was an effector 
of BCR signalling inhibition that mediated treatment response. Through 




contributed to the cytotoxic, cell-contracting and cytostatic effects of the 
combination treatment, indicating that FOXO1 functions as a tumour suppressor 
in this context. Nevertheless, abundant nuclear FOXO1 expression in CLL patient 
LN biopsies points towards a context-dependent homeostatic role for FOXO1 in 
CLL maintenance, which requires further investigation though a comprehensive 
analysis of FOXO1 transcriptional targets in different compartments. In this 
concluding chapter, the implications of these results for prospective pre-clinical 
(translational) investigations and potential clinical studies are examined.  
6.2 mTOR kinase (mTORC1/2) inhibition in CLL: a 
promising target for therapeutic intervention? 
Despite promising results as a monotherapy (and in combination with other 
drugs) in clinical trials of ‘solid’ tumours and blood cancers, AstraZeneca 
discontinued AZD2014 (vistusertib) in November 2018 citing “re-prioritization 
[sic] of the R&D portfolio” (571). As a monotherapy, AZD2014 demonstrated 
anti-cancer effects in ‘solid’ tumours including breast (492) and small cell lung 
cancer (572), whereas a phase II clinical trial comparing AZD2014 and everolimus 
in renal cancer patients was terminated early due to lack of efficacy (573). 
Here, while the cytostatic effect of AZD8055/2014 likely represents a promising 
treatment modality to prevent proliferation-driven clonal evolution in CLL cells, 
the drugs are not particularly cytotoxic. As such, AZD8055/2014 is unlikely to 
eradicate the entirety of leukemic cells. Alongside the potential issues linked to 
the alleviation of adaptive feedback mechanisms, it is increasingly apparent that 
dual mTOR kinase inhibitors require partner drugs as novel combination 
strategies. In agreement with our results assessing the synergistic combination of 
AZD8055/2014 and ibrutinib in CLL cells, in vitro and in vivo pre-clinical studies 
of AZD2014 and acalabrutinib combination in DLBCL have demonstrated 
synergistic growth inhibition (574). As a result, the combination entered phase 
I/II trials in patients with R/R DLBCL (NCT03205046), which remained active 
until the discontinuation of AZD2014. In this section, recent pre-clinical data of 
novel mTOR inhibitors (dual PI3K/mTOR and mTOR/DNA-PK) will be discussed 
and an overview of intriguing treatment strategies combining mTOR inhibitors 




6.2.1 Dual PI3K/mTOR inhibitors in CLL 
The reported drawbacks associated with mTOR kinase inhibitors as 
monotherapies, i.e. diminished feedback inhibition of RTKs sufficient to 
reactivate AKT pro-survival signalling (324), have led to the development of 
novel targeted therapies designed to overcome subsequent activation of PI3K-
AKT signalling (293). The dual PI3K/mTOR inhibitors PF-04691502 (341) and 
SAR245409 (342) have been adopted in CLL pre-clinical investigations. In their 
study, Blunt et al. demonstrated that PF-04691502 prevented AKT reactivation, 
induced caspase-dependent apoptosis irrespective of prognostic features, 
antagonised TME pro-survival signals and inhibited CXCL12-induced chemotaxis. 
Importantly, PF-04691502 was significantly more efficacious in reducing CLL cell 
viability than a synergistic combination of idelalisib and everolimus. In CLL-like 
Eµ-TCL1 mice, PF-04691502 reduced the number of CD5+B220+ leukemic cells in 
the blood, BM and SLOs (341). Along the same lines, Thijssen et al. showed that 
SAR245409 augmented CLL cell death compared to PI3Kδ/α selective inhibitors 
alone, abrogated proliferation and blocked cell adhesion in vitro (342). Phase 1b 
clinical data of SAR245409 (in combination with rituximab or 
rituximab+bendamustine) in R/R patients with B cell malignancies demonstrated 
encouraging clinical activity, with OR rates of 48.6 % (575). Alongside our data 
examining synergy between AZD8055 and ibrutinib (which equally inhibits PI3K-
AKT signalling), these studies collectively indicate that targeted inhibition of 
PI3K and mTOR is a promising therapeutic strategy in CLL (particularly for high-
risk patients) that negates elaborate resistance mechanisms, which ought to be 
investigated further. Therefore, one must speculate on the advantages of such a 
combination alongside the current arsenal of successful combination strategies 
(e.g. ibrutinib and venetoclax (165)). As ibrutinib treatment seemingly enhances 
PI3K-AKT-mTOR signalling (contributing to ibrutinib resistance) in CLL cells (146, 
501), combining ibrutinib with mTOR inhibitors may restrict resistance 
mechanisms that might otherwise lead to disease progression and therapy 
discontinuation. Furthermore, enhanced AKT activity (due to ibrutinib treatment 
and/or resistance) may elevate BCL-xL or MCL-1 expression, limiting the 
effectiveness of venetoclax treatment (or other BH3 mimetics) (216, 278, 462). 
Given the effect of combining AZD8055 with ibrutinib on FOXO1 activity, it is 




expression. Although not conclusively resolved, patients with enhanced FOXO1 
levels may benefit from COMBO-induced FOXO1 tumour suppressor activity.   
Notably, the dual mTOR/DNA-PK inhibitor CC-115 has equally demonstrated pre-
clinical and clinical potency in CLL. DNA-PK is a key regulator of the DNA 
damage repair pathway (343). CC-115 induced apoptosis independently of TP53, 
ATM or NOTCH1 status, inhibited CD40L (+IL-21)-induced proliferation and 
blocked BCR signal transduction (also in idelalisib-resistant patient samples) in 
vitro. In a small cohort (8 patients) of R/R CLL patients, CC-115 similarly showed 
promising clinical efficacy (343).  
6.2.2 mTOR and BCL2 inhibition: a promising combination 
strategy 
In their recent review, Kater and Brown postulated the need to identify a 
partner drug for ibrutinib and discussed the rationale for combining ibrutinib 
with the BCL2 inhibitor venetoclax. The authors highlighted the ability of 
ibrutinib to antagonise chemotaxis towards the CLL-TME, but acknowledged its 
inability to induce robust apoptosis in vitro (576). In pre-clinical studies, ex vivo 
serial samples from ibrutinib-treated CLL patients demonstrated enhanced 
sensitivity to venetoclax treatment via ibrutinib-induced downregulation of MCL-
1 and BCL-xL expression (577). In line with these data, Deng et al. showed that 
BTK inhibition (ibrutinib or acalabrutinib) augmented the cytotoxic effect of 
venetoclax in vitro and ex vivo via BTK inhibitor-induced enhanced 
mitochondrial BCL2 dependence (164). As such, clinical studies are now assessing 
venetoclax combined with ibrutinib in treatment naïve or R/R patients, which 
are ongoing and producing encouraging results (165, 166). Here, we showed that 
AZD8055 treatment inhibited F(ab’)2-induced MCL-1 and CD40L (+IL-4)-induced 
BCL-xL upregulation in primary CLL cells. Encouragingly, our preliminary data 
demonstrates that AZD8055 synergises with venetoclax to enhance apoptosis in 
MEC-1 cells (Smith, unpublished). Interestingly, recent evidence indicates that 
MCL-1- and BCL-xL-dependent resistance to venetoclax can be prevented by 
restricting PI3K-AKT-mTOR activation in DLBCL cell lines (578). The dual mTOR 
kinase inhibitor PQR620 has recently showed anti-tumour activity in a panel of 
56 lymphoma cell lines, and synergised with venetoclax in GCB- and ABC-DLBCL 




with BH3 mimetics in DLBCL (580). Collectively, these data suggest that mTOR 
inhibitors (including dual PI3K/mTOR inhibitors) are promising partner drugs for 
venetoclax and represents a promising treatment modality for CLL patients. As 
such, our preliminary in vitro investigations should be expanded towards further 
in vivo studies.  
6.3 mTOR kinase and CLL cell migration 
A common thread that entwines BCR kinase inhibitors is the ability to antagonize 
CLL cell chemotaxis towards secreted chemokine gradients emanating from the 
CLL-TME (45). In a clinical setting, this manifests as a redistribution of CLL cells 
from the tissues to the PB compartment (124). Recently, Holroyd et al. expertly 
reviewed the role of mTOR signalling in the regulation of cellular motility, which 
emphasised CLL as an archetypal model for migration studies (333). Cell 
migration is orchestrated, in part, by the coordinated activities of mTORC1 and 
mTORC2, which regulate cellular adhesion (581) and actin cytoskeleton 
reorganisation via biosynthesis/activity of small Rho GTPases (305, 582-584). In 
clinical trial, the mTORC1-selective inhibitor everolimus promoted CLL cell 
redistribution from the lymphoid organs to the PB compartment (339), 
suggesting mTOR inhibition abrogates CLL cell infiltration into the tissues. Our 
group has generated interesting preliminary data that demonstrates the ability 
of AZD8055 to block CLL cell pseudoemperipolesis, reduce GTPase activity, 
overcome CXCL12-induced chemotaxis and diminish actin polymerisation 
(Holroyd, unpublished). In line with these data, AZD8055 reduced the migratory 
capacity of breast cancer cell lines (322). Furthermore, the PI3K/mTOR 
inhibitors PF-04691502 and SAR245409 inhibited CXCL12-induced CLL cell 
chemotaxis, which, in the case of SAR245409, had a greater anti-migratory 
effect than idelalisib alone (341, 342). Collectively, these studies demonstrate 
that mTOR plays a prominent role in the migratory potential of CLL cells, which 
can be targeted by mTOR inhibitors. Holroyd’s data examining the effect of 
AZD8055 on CLL cell migration (233) is important as it aligns with the effect of 
everolimus (339) and other BCR-targeted therapies in vivo and in vitro (126-130, 
139). This is a key point because CLL cell migration towards- and localisation 
within the CLL-TME precedes the ability of CLL cells to proliferate. Furthermore, 
treatment-induced redistribution of CLL cells from the tissues to the PB 




niche. As such, inhibitors that negate cell motility and homing represent an 
attractive therapeutic strategy, particularly in combination with cytotoxic 
agents such as venetoclax (164). Clearly, the data presented within this thesis 
only scratch the surface of mTOR’s functional importance (and consequences of 
mTOR inhibition therein) for CLL pathogenesis. As mTOR signalling controls 
multiple functional behaviours, further pharmacological in vitro and in vivo 
studies are needed to elucidate mTOR’s effects on CLL cells.  
6.4 Reengaging tumour suppressor activity in CLL 
In their study, Ventura et al. demonstrated that genetically restoring p53 
function in lymphoma and sarcoma mouse models was capable of nullifying 
cancer cell growth (585), indicating that reactivation of tumour suppressors 
might represent a promising therapeutic strategy in human cancers (586). 
However, these treatments have not been forthcoming, owing primarily to the 
dearth of strategies to reengage tumour suppressors that have been genetically 
compromised (such as TP53 and ATM in subsets of CLL patients) (586). This being 
said, tumour suppressors need not be genetically inactivated to contribute to 
tumorigenesis (587). As postulated by Berger et al., functional inhibition of 
otherwise ‘genetically intact’ tumour suppressors via post-transcriptional and 
post-translational modifications similarly facilitate cancer progression in certain 
contexts (588). Indeed, FOXO transcription factors are seldom mutated in a way 
that impedes functionality (344), rather, they are deemed inoperable via 
negative regulation by overactive PI3K-AKT signalling (347). This has shifted the 
focus towards identifying and therapeutically targeting signalling networks 
and/or mechanisms that regulate tumour suppressor localisation, stability and 
activity (586). In this section, we summarise studies that aim to reactivate 
tumour suppressors in CLL and highlight potential druggable targets to unleash 
FOXO function. The roles of tumour suppressors in CLL was recently reviewed 
(586, 587).  
6.4.1 Reactivating PTEN function: USP7 inhibition  
As mentioned earlier, studies have demonstrated that the tumour suppressor 
PTEN, which negatively regulates PI3K-AKT signal transduction, is functionally 




modifications (288-290). More recently, Carra et al. demonstrated that PTEN 
tumour suppressor activity was negatively regulated by aberrant upregulation of 
the deubiquitinase USP7. Targeted inhibition of USP7 using the small-molecule 
inhibitor P5091 induced growth inhibition and apoptosis in MEC-1 cells (and 
apoptosis in primary CLL cells). Interestingly, PTEN was predominantly localised 
in the cytoplasm of CLL cells, whereas normal B cells displayed a ‘diffuse 
pattern’ throughout the cellular compartments. On a mechanistic level, P5091 
disrupted the USP7-PTEN network, which promoted PTEN stabilisation and 
nuclear localisation in CLL cells, suggesting USP7 overexpression promoted 
aberrant PTEN localisation. To corroborate this, forced nuclear expression of 
PTEN induced apoptosis and cell cycle arrest in MEC-1 cells, akin to the effects 
of USP7 inhibition. This indicated that nuclear PTEN exerts tumour suppressive 
functions (292). Largely aligning with our data on FOXO1, reactivation of tumour 
suppressors (via pharmacological inhibition of negative regulators) exerts anti-
cancer properties in CLL cells. Importantly, the functional consequences of USP7 
inhibition were independent of TP53 aberrations, suggesting reengagement of 
PTEN activity can fulfil tumour suppressive functions in patients with unmet 
clinical needs (288, 292). Although FOXO1 activity was not assessed on the basis 
of TP53 status in primary CLL cells, our results demonstrated that COMBO-
induced FOXO1 activity promoted growth arrest and apoptosis in TP53-deleted 
MEC-1 cells. Interestingly, USP7 has been shown to inactivate FOXOs via 
deubiquitination and subsequent nuclear export in response to oxidative stress 
(589), highlighting that P5091 may also promote FOXO nuclear localisation in 
CLL. These studies highlight the need for a more detailed analysis of 
posttranslational FOXO modifications (phosphorylation, acetylation, methylation 
and ubiquitination) in a context-dependent and temporal-specific manner, 
particularly downstream of microenvironmental stimuli. Nevertheless, these 
findings demonstrate that reactivation of tumour suppressors might represent a 
promising treatment strategy in CLL.  
On a related note, studies have also investigated the tumour suppressive 
properties of the phosphatase SHIP1. SHIP1 dampens BCR ligation-induced PI3K-
AKT signalling via dephosphorylation of PIP3 (590). Recently, Lemm et al. 
showed that pharmacological activation of SHIP1 using AQX-435 induced 




microenvironment stimuli in vitro. Furthermore, combining AQX-435 with 
ibrutinib further downregulated PI3K-AKT signalling (591). Paradoxically, 
unpublished data has shown that pharmacological inhibition of SHIP1 using 3-a-
Aminocholestane (3AC) induced CLL cell death via BCR overactivation (592). 
Collectively, these findings indicate that SHIP1 activity, akin to FOXO1 (408), is 
tightly regulated within a narrow range for optimal cellular maintenance. 
Therefore, a better understanding of tumour suppressor regulation and/or 
activity is necessary to harness tumour suppressors as mediators of novel 
targeted therapy in CLL. 
6.4.2 Inhibition of FOXO negative regulators: ERK, CDK2 and CK1  
Although AKT-dependent FOXO phosphorylation is perhaps the most prominent 
posttranslational modification affecting FOXO activity and subcellular 
localisation (345), FOXO transcription factors are also negatively regulated by 
MEK1/2-ERK (366, 367), CDK2 (368) and CK1 (369, 370) pathways. ERK-
dependent inactivation of FOXO3a (via phosphorylation at Ser294, Ser344 and 
Ser425 residues) resulted in its nuclear exclusion and MDM2-mediated 
degradation, which enhanced proliferation and tumorigenesis in a mouse model 
of breast cancer (366). In CLL, inhibition of MEK1/2 using binimetinib diminished 
ERK1/2 activity and overcame in vitro TME stimuli (IgM, SDF-1α and CD40L co-
cultures) to induce apoptosis (593, 594). Although the impact of binimetinib on 
FOXO activity was not assessed, subsequent investigations (including our group’s 
ongoing study of the ERK1/2 inhibitor AZ6197 in CLL) should address the 
functional consequence of MEK1/2 and ERK1/2 inhibition on FOXO dynamics. In 
their study, Huang et al. demonstrated that CDK2 phosphorylated FOXO1 at 
Ser249 (FOXO1S249), which promoted its cytoplasmic translocation and 
inactivation. Upon DNA damage, CDK2-dependent FOXO1S249 phosphorylation is 
diminished. Importantly, FOXO1 knockdown interfered with DNA damage-
induced apoptosis irrespective of cellular p53 status. Thus, CDK2 and FOXO1 
regulated the apoptotic DNA damage response (368). The CDK2 inhibitor 
roscovitine induced caspase-dependent apoptosis in CLL cells (595), while our 
group demonstrated that CDK2/7/9 inhibitor CR8 overcame in vitro TME stimuli 
to promote apoptosis, prevent CLL cell proliferation and inhibit NF-κB signalling 
(596). The CDK2/9 inhibitor CYC065 has recently entered phase I clinical trials in 




of FOXO1 activity in response to CDK2 inhibitors warrants further investigation. 
Finally, CK1-dependent phosphorylation of FOXO1 at Ser322 facilitated FOXO1 
nuclear export (369, 370). CK1 has emerged as a novel therapeutic target in CLL. 
In preclinical studies, the CK1 inhibitor PF670462 inhibited TME interactions 
(CXCL12/CCL19-induced chemotaxis and stromal cell communication), delayed 
CLL-like Eµ-TCL1 leukaemia development and synergised with ibrutinib to 
augment inhibition of chemotaxis (598). Thus, it is interesting to speculate about 
the role of FOXO1 following CK1 inhibition, particularly in combination with 
ibrutinib. 
6.4.3 SINE inhibitors: preventing FOXO nuclear export?  
In ‘normal’ cells, the nuclear export protein exportin 1 (XPO1), otherwise known 
as chromosomal region maintenance 1 (CRM1), plays an important homeostatic 
role mediating nuclear-to-cytoplasmic shuttling (and inactivation) of tumour 
suppressors including p53 and FOXO (599). XPO1 overactivation is frequently 
observed in cancer, which contributes towards the aberrant cytoplasmic 
localisation of tumour suppressor molecules. Deregulation of XPO1 is typically 
associated with poor prognosis and treatment resistance (600-603). In CLL, XPO1 
is overexpressed (604), recurrently mutated (605) and plays a key role in CLL 
drug resistance linked with ‘gain of short arm chromosome 2’ (2p+) cytogenetic 
aberrations (606). As such, XPO1 has emerged as a novel target for therapeutic 
exploitation using selective inhibitors of nuclear export (SINE) compounds (607). 
In their study, Lapalombella et al. demonstrated that the small-molecule SINE 
KPT-185 inhibited XPO1-cargo complexes, induced apoptosis and, importantly, 
prevented nuclear export of FOXO3a in CLL cells (604). Although the functional 
importance of treatment-induced nuclear FOXO3a was not assessed, one can 
speculate about the tumour suppressor activity of FOXOs in this scenario. 
Interestingly, Corno et al. showed that FOXO1 knockdown reduced the sensitivity 
of ovarian cancer cells to the XPO1 inhibitor selinexor (KTP-330) (608), 
demonstrating that SINEs promote cytotoxicity, in part, via retention of nuclear 
FOXO activity. Preclinical studies further demonstrated that combining selinexor 
with ibrutinib synergistically enhanced cytotoxicity in CLL cells (609). This 
combination subsequently entered in phase I clinical trials (NCT02303392) in R/R 
CLL patients, for which FOXO localisation was a study outcome (610). In 2017, 




investigator’s brochure’ (611). Nevertheless, the effect of selinexor on FOXO1 
subcellular localisation and activity in CLL warrants further investigation.  
6.5 FOXO1 as a prognostic/predictive biomarker in CLL 
The advent of targeted therapy has accelerated the ever-growing need to 
investigate novel prognostic/predictive biomarkers to identify CLL patients in 
need of therapy (including the type of treatment) and/or at risk of disease 
progression (612). Stratification of CLL patient LN biopsies into ‘indolent’ or 
‘progressive’ disease revealed that FOXO1 expression was significantly higher in 
‘progressive’ CLL patients compared to ‘indolent’ patients. Although the 
functional and/or pathological relevance remains unknown, it is possible that 
FOXO1 expression levels may represent a novel prognostic and/or predictive 
biomarker in CLL. These observations appear to be specific for histological 
specimens derived from the LN, as stratification of PB-derived CLL cells revealed 
no significant difference between favourable (no del(11q)/del(17p)) and poor 
prognostic (del(11q)/del(17p)) patients. While these findings were promising, 
Hornsveld et al. proposed that one must be careful of interpreting results from 
histopathological studies (344). Indeed, studies assessing FOXO expression levels 
as a prognostic indicator have generated conflicting results (344). For example, 
previous reports have correlated high FOXO3 expression levels to poor prognosis 
in AML and glioblastoma (405, 406), whereas another study observed a link 
between low FOXO3 and poor prognosis in colorectal cancer (616). Although this 
may represent a context-specific effect, interpreting correlations between 
FOXO1 expression levels and CLL disease progression requires further attention 
to glean meaningful insights (344). Equally, as mentioned earlier, FOXO1 activity 
(FOXO1T24), subcellular localisation and/or transcriptional output may also offer 
prognostic insights into treatment response/relapse (specifically BCR signalling 
inhibitors) (344, 407, 613, 617), which similarly requires further investigation.  
6.6 Concluding remarks 
To those navigating the PhD journey (or seasoned professionals alike), I offer you 
this thesis in the hope it provides inspiration and/or the catalyst for exciting 
new avenues of research. This thesis has raised a number of important 




signalling in CLL pathogenesis, 2) the identification of rational AZD8055/2014 
drug combinations and 3) the role of FOXOs in CLL disease maintenance, 
prognosis and therapy response, which I have attempted to highlight throughout 
this thesis. Further investigation into these unknowns may uncover exciting data 
with the potential to form the basis of future pre-clinical investigations and CLL 
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